<?xml version="1.0" encoding="UTF-8"?><subLeg xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xml.gov.hk/schemas/hklm/1.0 https://www.elegislation.gov.hk/schemas/hklm.xsd" xml:lang="en"><meta><docName>Cap. 138 sub. leg. A</docName><docType>cap</docType><docNumber>138A</docNumber><docStatus>In effect</docStatus><dc:identifier>/hk/cap138A!en</dc:identifier><dc:date>2025-10-17</dc:date><dc:subject>legislation</dc:subject><dc:language>en</dc:language><dc:publisher>DoJ</dc:publisher><dc:rights>the Government of the Hong Kong Special Administrative Region</dc:rights></meta><main xml:lang="en" xsi:schemaLocation="http://www.xml.gov.hk/schemas/hklm/1.0 https://www.elegislation.gov.hk/schemas/hklm.xsd"><docTitle id="ID_1438402706316_001" name="shortTitle" reason="inEffect" status="operational" temporalId="shortTitle" startPeriod="2015-11-12">Pharmacy and
            Poisons
            Regulations</docTitle><enactingFormula role="empoweringSection">(<ref href="/hk/cap138/s29">Cap. 138, section
                29</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker></enactingFormula><commencementNote>[1 July
                1978]<sourceNote class="font_size_10"> <ref href="/hk/1978/ln145">L.N. 145 of 1978</ref></sourceNote></commencementNote><sourceNote>(Format changes—<ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote><part id="ID_1438402706316_003" name="P1" reason="inEffect" startPeriod="2015-11-12" status="operational" temporalId="P1"><num value="1">Part
            1</num><heading>Preliminary</heading><section id="ID_1438402706331_001" name="s1" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s1"><num value="1">1.</num><heading>Citation</heading><content>These regulations may be cited as the <shortTitle>Pharmacy and Poisons Regulations</shortTitle>.</content></section><section id="ID_1438402706347_001" name="s2" reason="inEffect" role="regulation" startPeriod="2021-08-01" status="operational" temporalId="s2"><num value="2">2.</num><heading>Interpretation</heading><subsection id="ID_1438411267920_011" name="1" temporalId="s2_1"><num value="1">(1)</num><leadIn>In these regulations, unless the context otherwise requires—</leadIn><def name="AntimonialPoisons"><term>antimonial
                    poisons</term>
                    (<term xml:lang="zh-Hant-HK">含銻毒藥</term>) means organic and inorganic compounds
                of antimony;</def><def name="ArsenicalPoisons"><term>arsenical
                    poisons</term>
                    (<term xml:lang="zh-Hant-HK">含砷毒藥</term>) means organic and inorganic compounds
                of arsenic;</def><def name="AuthorizedPerson"><term>authorized person</term> (<term xml:lang="zh-Hant-HK">獲授權人</term>) means a person whose name is entered in the register of authorized
                    persons;<inline class="width_3"> </inline><sourceNote>(<ref href="/hk/2015/2">2
                        of 2015 s. 32</ref>)</sourceNote></def><def name="BritishPharmaceuticalCodex,BritishPharmacopoeia,BritishNationalFormulary,BritishVeterinaryCodex"><term>British
                    Pharmaceutical
                Codex</term>
                    (<term xml:lang="zh-Hant-HK">英國藥學藥典</term>),
                    <term>British
                    Pharmacopoeia</term>
                    (<term xml:lang="zh-Hant-HK">英國藥典</term>),
                    <term>British
                    National
                Formulary</term>
                    (<term xml:lang="zh-Hant-HK">英國國家處方集</term>) and
                    <term>British
                    Veterinary
                Codex</term>
                    (<term xml:lang="zh-Hant-HK">英國獸醫藥方集</term>) include the supplements
                thereto;</def><def name="ExpiryDate"><term>expiry date</term> (<term xml:lang="zh-Hant-HK">使用期限</term>)—see paragraph (1A); <sourceNote>(<ref href="hk/2020/19">19 of 2020 s. 5</ref>)</sourceNote></def><def name="Food"><term>food</term>
                    (<term xml:lang="zh-Hant-HK">食物</term>) includes a beverage;</def><def name="GMPGuide"><term>GMP Guide</term> (《<term xml:lang="zh-Hant-HK">指引</term>》)
                means the Good Manufacturing Practice Guide issued under <ref>regulation 28A</ref>
                as revised from time to time under that regulation;
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 32</ref>)</sourceNote></def><def name="MedicineForTheInternalTreatmentOfHumanAndAnimalAilments"><term>medicine
                    for the internal treatment of human and animal
                ailments</term>
                    (<term xml:lang="zh-Hant-HK">用於治療人類及動物病患的內服藥物</term>) includes any medicine to
                be administered by injection, but does not include any mouth-wash, eye-drops,
                eye-lotion, ear-drops, nasal drops, douche or similar article;</def><def name="RegisterOfAuthorizedPersons"><term>register of authorized persons</term>
                    (<term xml:lang="zh-Hant-HK">獲授權人名冊</term>) means the register of authorized
                persons kept under <ref>regulation 30B</ref>;
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 32</ref>)</sourceNote></def><def name="SpecifiedForm"><term>specified form</term> (<term xml:lang="zh-Hant-HK">指明格式</term>), in relation to a purpose under these regulations, means the form
                specified for that purpose under <ref>regulation 38B</ref>;
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 32</ref>)</sourceNote></def><def name="Tribunal"><term>Tribunal</term>
                    (<term xml:lang="zh-Hant-HK">審裁處</term>) means the Pharmacy and Poisons Appeal
                Tribunal established by <ref>section 30</ref> of the Ordinance;
                <sourceNote>(<ref href="/hk/1980/ln369">L.N. 369 of 1980</ref>)</sourceNote></def><def name="VeterinaryInstitution"><term>veterinary
                    institution</term>
                    (<term xml:lang="zh-Hant-HK">獸醫機構</term>) means a veterinary hospital,
                veterinary clinic or other premises where sick animals are treated.</def></subsection><subsection id="ID_1626054122911_001" name="1A" temporalId="s2_1A"><num value="1A">(1A)</num><leadIn>For the purposes of these regulations, the expiry date of a pharmaceutical
                product is the date determined by the manufacturer of the product—</leadIn><paragraph id="ID_1626054122912_002" name="a" temporalId="s2_1A_a"><num value="a">(a)</num><content>on the basis of the product’s specifications; and</content></paragraph><paragraph id="ID_1626054122913_003" name="b" temporalId="s2_1A_b"><num value="b">(b)</num><content>on the assumption that the product is stored under conditions suitable to
                    it,</content></paragraph><continued>as the date after which the product should not be used. <sourceNote>(<ref href="hk/2020/19">19 of 2020 s. 5</ref>)</sourceNote></continued></subsection><subsection id="ID_1438411267935_053" name="2" temporalId="s2_2"><num value="2">(2)</num><content>In these regulations any reference to an alkaloid shall include a reference to
                any salt of that alkaloid, and, in a case where the esters of an alkaloid are
                included in the Poisons List by virtue of the words “its esters”, to any esters of
                that alkaloid.</content></subsection><subsection id="ID_1438411267951_005" name="3" temporalId="s2_3"><num value="3">(3)</num><leadIn>Any reference in the <ref>Schedules</ref> to these regulations to the percentage
                of a poison contained in any substance or preparation shall, unless otherwise
                expressly provided, be construed in the following manner, that is to say, a
                reference to a substance or preparation containing 1 per cent of any poison
                means—</leadIn><paragraph id="ID_1438411267951_013" name="a" temporalId="s2_3_a"><num value="a">(a)</num><content>in the case of a solid, that 1
                    gram
                    of the poison is contained in every 100
                    grams
                    of the substance or preparation;
                    <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                    2020</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411267951_021" name="b" temporalId="s2_3_b"><num value="b">(b)</num><content>in the case of a liquid, that 1 millilitre of the poison, or, if the poison
                    itself is a solid, 1
                    gram
                    of the poison, is contained in every 100 millilitres of the substance or preparation,
                    <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                    2020</ref>)</sourceNote></content></paragraph><continued>and so in proportion for any greater or less percentage.</continued></subsection><subsection id="ID_1438411267951_034" name="4" temporalId="s2_4"><num value="4">(4)</num><content>Substances listed in Divisions A in the <ref>Schedules</ref> to these
                regulations are those whose uses are essentially medicinal, whilst substances listed
                in Divisions B are not normally used medicinally.
                <sourceNote>(<ref href="/hk/2007/ln41">L.N. 41 of 2007</ref>)</sourceNote></content></subsection><subsection id="ID_1438411267951_042" name="5" temporalId="s2_5"><num value="5">(5)</num><content>Where in these regulations reference is made to a numbered section the
                reference shall be a reference to that section of the Ordinance.
                </content></subsection><subsection id="ID_1438411267966_005" name="6" temporalId="s2_6"><num value="6">(6)</num><def name="TheCommittee">Where functions are conferred on a committee by any provision
                of these regulations, references in such provision to “<term class="old_format">the
                    Committee</term>” shall be construed as references to the executive committee
                established under <ref>section 4A</ref> of the Ordinance for the purpose of
                performing such functions.
                <sourceNote>(<ref href="/hk/1980/ln369">L.N. 369 of 1980</ref>)</sourceNote></def></subsection></section><section id="ID_1438402706363_002" name="s2A" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s2A"><num value="2A">2A.</num><heading>Poisons List</heading><content>The Poisons List is set out in <ref>Schedule 10</ref>.<br></br></content><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 33</ref>)</sourceNote></section><section id="ID_1438402706378_001" name="s3" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s3"><num value="3">3.</num><heading>Application of <ref>section 22</ref> restricted to
                                <ref>Schedule
                                1</ref></heading><sourceNote>(<ref href="hk/2020/er5">E.R. 5 of 2020</ref>)</sourceNote><content><ref>Section 22</ref> shall only apply to those poisons included in
                                <ref>Part
                                1</ref>
                        of the Poisons List which are also included in
                                <ref>Schedule
                                1</ref> but not included in
                                <ref>Schedule
                                3</ref>.</content><sourceNote>(<ref href="/hk/1999/ln202">L.N. 202 of 1999</ref>; <ref href="/hk/2015/2">2 of 2015 s. 34</ref>; <ref href="hk/2015/er3">E.R. 3 of 2015</ref>; <ref href="hk/2020/er5">E.R. 5 of
                        2020</ref>)</sourceNote></section><section id="ID_1438402706378_003" name="s4" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s4"><num value="4">4.</num><heading>Extension of labelling provisions and relaxation with respect to poisons in
                <ref>Schedule
                6</ref></heading><sourceNote>(<ref href="hk/2020/er5">E.R. 5 of 2020</ref>)</sourceNote><subsection id="ID_1438411268044_004" name="1" temporalId="s4_1"><num value="1">(1)</num><content>Subject to paragraph (2), the provisions of <ref>section 27</ref> and
                    <ref>regulations 12 to 17</ref> (which provisions relate to the labelling of
                poisons) shall apply to sales exempted by <ref>section 32</ref>, and shall also
                apply to the supply of poisons (otherwise than on sale) and references in those
                provisions to the sale and the seller of poisons shall be deemed to refer to the
                supply and the supplier of poisons respectively.
                </content></subsection><subsection id="ID_1438411268044_012" name="2" temporalId="s4_2"><num value="2">(2)</num><leadIn>In the case of the sale or supply of any of the poisons included in
                    <ref>Schedule
                    6</ref> to a person who—
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of 2020</ref>)</sourceNote></leadIn><paragraph id="ID_1438411268044_020" name="a" temporalId="s4_2_a"><num value="a">(a)</num><content>carries on a business in the course of which poisons are regularly sold by
                    way of wholesale dealing or are regularly used in the manufacture of other
                    articles; and</content></paragraph><paragraph id="ID_1438411268060_006" name="b" temporalId="s4_2_b"><num value="b">(b)</num><content>requires the poison for the purpose of that business,</content></paragraph><continued>if the outside of the package in which the poison is sold or supplied is
                labelled conspicuously with words indicating the dangerous properties of the poison,
                it shall be necessary to comply only with <ref>regulation 15</ref> and <ref>section
                    27(a)</ref> and <ref>section 27(d)</ref> (as modified by <ref>regulation
                    17</ref>).</continued></subsection><sourceNote>(<ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section><section id="ID_1438402706394_002" name="s5" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s5"><num value="5">5.</num><heading>Extension of <ref>section 22</ref> to sales wholesale etc. and relaxation of the
            section</heading><subsection id="ID_1438411268076_019" name="1" temporalId="s5_1"><num value="1">(1)</num><content>
                <leadIn><ref>Section 22</ref> shall apply to sales exempted by <ref>section
                    32</ref>, except sales of poisons to be exported to purchasers outside Hong
                    Kong, and shall also apply to the supply in the form of a commercial sample,
                    otherwise than on sale, of any substance included in
                        <ref>Schedule
                        1</ref> in like manner as if references in <ref>section
                        22</ref> to the sale and seller of poisons respectively included references
                    to the supply and the supplier of poisons in the form of commercial samples:
                    <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of 2020</ref>)</sourceNote></leadIn>
                
                
                <proviso name="proviso" temporalId="s5_1_proviso">
                    <leadIn>Provided that <ref>section 22</ref> shall not apply to the sale or
                        supply of any article by the licensed manufacturer thereof or by a person
                        carrying on a business in the course of which poisons are regularly sold by
                        way of wholesale dealing, if—  <sourceNote>(<ref href="/hk/2015/2">2 of 2015
                                s. 35</ref>)</sourceNote></leadIn>
                    
                    
                    <paragraph id="ID_1438411268091_012" name="a" temporalId="s5_1_a"><num value="a">(a)</num><content>the article is sold or supplied to a person carrying on a business
                            in the course of which poisons are regularly sold or are regularly used
                            in the manufacture of other articles; and</content></paragraph>
                    <paragraph id="ID_1438411268091_020" name="b" temporalId="s5_1_b"><num value="b">(b)</num><content>the seller or supplier is reasonably satisfied that the purchaser
                            requires the article for the purpose of that business.</content></paragraph>
                </proviso>
            </content></subsection><subsection id="ID_1438411268091_027" name="2" temporalId="s5_2"><num value="2">(2)</num><content><ref>Section 22(1)</ref> shall, in its application to sales exempted by
                    <ref>section 32</ref> and to the supply in the form of commercial samples of
                substances included in
                    <ref>Schedule
                    1</ref>, be deemed to be satisfied if the person to whom the
                poison or sample is sold or supplied is known by the person in charge of the
                department of the business through which the sale or supply is effected to be a
                person to whom the poison or sample may properly be sold or supplied.
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of 2020</ref>)</sourceNote></content></subsection><subsection id="ID_1438411268107_005" name="3" temporalId="s5_3"><num value="3">(3)</num><leadIn>Subject to paragraph (4), so much of <ref>section 22(3)(b)</ref> as requires an
                entry in the poisons book to be signed by the purchaser of a poison shall not, as
                respects the sale of a poison to a person for the purpose of his trade, business or
                profession, apply if the following requirements are satisfied—</leadIn><paragraph id="ID_1438411268107_013" name="a" temporalId="s5_3_a"><num value="a">(a)</num><content>the seller shall obtain before the completion of the sale an order in
                    writing signed by the purchaser stating his name and address, trade, business or
                    profession, the name and quantity of the article to be purchased, and the
                    purpose for which it is required;</content></paragraph><paragraph id="ID_1438411268107_021" name="b" temporalId="s5_3_b"><num value="b">(b)</num><content>the seller shall be reasonably satisfied that the signature is that of the
                    person purporting to have signed the order, and that that person carries on the
                    trade, business or profession stated in the order, being one in which the poison
                    to be purchased is used; and</content></paragraph><paragraph id="ID_1438411268122_006" name="c" temporalId="s5_3_c"><num value="c">(c)</num><content>if the article sold is sent by post, it shall be sent by registered
                    post.</content></paragraph></subsection><subsection id="ID_1438411268122_013" name="4" temporalId="s5_4"><num value="4">(4)</num><content>Where a person represents that he urgently requires a poison for the purpose of
                his trade, business or profession, the seller may, if he is reasonably satisfied
                that the person so requires the poison and is, by reason of some emergency, unable
                before delivery either to furnish to the seller an order in writing duly signed or
                to attend and sign the entry in the book, deliver the poison to the purchaser on an
                undertaking by the purchaser to furnish such an order within 48 hours next
                following.</content></subsection><subsection id="ID_1438411268138_005" name="5" temporalId="s5_5"><num value="5">(5)</num><content>Any purchaser by whom an undertaking under paragraph (4) has been given who
                fails to deliver to the seller a signed order in accordance with the undertaking, or
                any person who for the purpose of obtaining delivery of any poison makes a statement
                which is to his knowledge false in any material particular shall be guilty of an
                offence and shall be liable on conviction to a fine
                at
                level 3 and to imprisonment for 12 months.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 35</ref>)</sourceNote></content></subsection><subsection id="ID_1438411268138_013" name="6" temporalId="s5_6"><num value="6">(6)</num><content>In the case of a sale or the supplying of a poison included in
                    <ref>Schedule
                    1</ref> to an institution such of the provisions of this
                regulation as require the purchaser to state his trade, business or profession and
                the seller to be satisfied with respect thereto shall not apply and for the
                reference in paragraph (4) to the purposes of the purchaser’s trade, business or
                profession there shall be substituted in the case of any such sale a reference to
                the name of the institution and the full name and rank or position held at the
                institution of the person making the order.
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of 2020</ref>)</sourceNote></content></subsection><sourceNote>(<ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section><section id="ID_1438402706409_001" name="s6" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s6"><num value="6">6.</num><heading>Relaxation of <ref>section 28(3)</ref> in the case of certain medicines</heading><leadIn>The requirements of <ref>section 28(3)</ref> (which requires particulars of
            medicines supplied or dispensed under that section to be entered in a book) shall be
            satisfied in respect of medicines included in
                <ref>Schedule
                1</ref>, but need not be satisfied in respect of other medicines
            which are supplied by—
            <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of 2020</ref>)</sourceNote></leadIn><paragraph id="ID_1438411268200_012" name="a" temporalId="s6_a"><num value="a">(a)</num><content>a registered medical practitioner for the purposes of medical treatment;
                or</content></paragraph><paragraph id="ID_1438411268200_020" name="b" temporalId="s6_b"><num value="b">(b)</num><content>an authorized seller of poisons on and in accordance with a prescription given
                by a registered medical practitioner.</content></paragraph><sourceNote>(<ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section><section id="ID_1438402706409_003" name="s7" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s7"><num value="7">7.</num><heading>Exemption from the provisions relating solely to
                <ref>Schedule
                1</ref></heading><sourceNote>(<ref href="hk/2020/er5">E.R. 5 of 2020</ref>)</sourceNote><leadIn>The provisions of these regulations and of the Ordinance (as modified by these
            regulations) which apply solely to the substances in
                <ref>Schedule
                1</ref> shall not apply to—
            <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of 2020</ref>)</sourceNote></leadIn><paragraph id="ID_1438411268216_012" name="a" temporalId="s7_a"><num value="a">(a)</num><content>machine-spread plasters;</content></paragraph><paragraph id="ID_1438411268216_020" name="b" temporalId="s7_b"><num value="b">(b)</num><content>surgical
                dressings;
                or</content></paragraph><paragraph id="ID_1438411268216_028" name="c" temporalId="s7_c"><num value="c">(c)</num><sourceNote>(Repealed <ref href="/hk/1995/ln262">L.N. 262 of 1995</ref>)</sourceNote></paragraph><paragraph id="ID_1438411268216_036" name="d" temporalId="s7_d"><num value="d">(d)</num><content>corn paints in which the only poison is a poison included in the Poisons List
                under the
                item
                “Cannabis”.</content></paragraph><sourceNote>(<ref href="hk/2015/er3">E.R. 3 of
            2015</ref>; <ref href="hk/2020/er5">E.R. 5 of
            2020</ref>)</sourceNote></section><section id="ID_1438402706425_002" name="s8" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s8"><num value="8">8.</num><heading>Complete exemption for articles and substances in
                <ref>Schedule
                2</ref></heading><sourceNote>(<ref href="hk/2020/er5">E.R. 5 of 2020</ref>)</sourceNote><subsection id="ID_1438411268232_042" name="1" temporalId="s8_1"><num value="1">(1)</num><leadIn>Subject to paragraph (2), nothing in the Ordinance or these regulations shall
                apply—</leadIn><paragraph id="ID_1438411268232_050" name="a" temporalId="s8_1_a"><num value="a">(a)</num><content>to any article in Group I of
                        <ref>Schedule
                        2</ref>; or</content></paragraph><paragraph id="ID_1438411268232_058" name="b" temporalId="s8_1_b"><num value="b">(b)</num><content>to any of the articles or substances specified in the second column of
                    Group II of
                        <ref>Schedule
                        2</ref> opposite the description of the poison specified
                    in the first column thereof.
                    <sourceNote>(<ref href="/hk/1987/ln85">L.N. 85 of
                        1987</ref>; <ref href="hk/2020/er5">E.R. 5 of
                        2020</ref>)</sourceNote></content></paragraph></subsection><subsection id="ID_1438411268247_004" name="2" temporalId="s8_2"><num value="2">(2)</num><content>Notwithstanding paragraph <ref>(1)(b)</ref>,
                    <ref>Parts
                    6</ref>,
                    <ref>7</ref>, <ref>8</ref>, <ref>9</ref> and
                <ref>10</ref>
                of these regulations shall apply to every article or substance referred to in that
                paragraph, that is a pharmaceutical product within the meaning of the Ordinance.
                <sourceNote>(<ref href="/hk/1987/ln85">L.N. 85 of 1987</ref>; <ref href="/hk/2015/2">2 of 2015
                        s. 36</ref>)</sourceNote></content></subsection><sourceNote>(<ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section></part><part id="ID_1438402706441_001" name="P2" reason="inEffect" startPeriod="2015-11-12" status="operational" temporalId="P2"><num value="2">Part
            2</num><heading>Additional
            Restrictions on the Sale of
            Poisons</heading><section id="ID_1438402706441_003" name="s9" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s9"><num value="9">9.</num><heading>Additional restriction of sale of poisons in
                <ref>Schedule
                3</ref></heading><sourceNote>(<ref href="hk/2020/er5">E.R. 5 of 2020</ref>)</sourceNote><subsection id="ID_1438411268263_004" name="1" temporalId="s9_1"><num value="1">(1)</num><content>No person shall sell any poison included in
                    <ref>Schedule
                    3</ref>, except on and in accordance with a prescription given
                by a registered medical practitioner, registered dentist or registered veterinary surgeon.
                <sourceNote>(<ref href="/hk/1997/ln614">L.N. 614 of
                    1997</ref>; <ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></content></subsection><subsection id="ID_1438411268278_005" name="2" temporalId="s9_2"><num value="2">(2)</num><content>This regulation shall apply to the sale of any such poison, including a
                medicine exempted by <ref>section 28</ref>, but shall not apply to any sale exempted
                by <ref>section 32</ref>.</content></subsection><subsection id="ID_1438411268278_013" name="3" temporalId="s9_3"><num value="3">(3)</num><leadIn>For the purposes of this regulation a prescription shall—</leadIn><paragraph id="ID_1438411268278_021" name="a" temporalId="s9_3_a"><num value="a">(a)</num><content>be in writing and be signed by the person giving it with his usual
                    signature and be dated by him;</content></paragraph><paragraph id="ID_1438411268278_029" name="b" temporalId="s9_3_b"><num value="b">(b)</num><content>specify the address of the person giving it;</content></paragraph><paragraph id="ID_1438411268278_037" name="c" temporalId="s9_3_c"><num value="c">(c)</num><content>specify the name and address of the person for whose treatment it is given
                    or, if the prescription is given by a registered veterinary surgeon, of the
                    person to whom the medicine is to be delivered;
                    <sourceNote>(<ref href="/hk/1997/ln614">L.N. 614 of 1997</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411268278_045" name="d" temporalId="s9_3_d"><num value="d">(d)</num><content>have written thereon, if given by a dentist, the words “For dental
                    treatment only 祇限牙科醫療用”, or, if given by a registered veterinary surgeon, the
                    words “For animal treatment only 祇限醫治禽畜用”; and
                    <sourceNote>(<ref href="/hk/1997/ln614">L.N. 614 of 1997</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411268278_053" name="e" temporalId="s9_3_e"><num value="e">(e)</num><content>indicate the total amount of the medicine to be supplied and the dose to be
                    taken or administered.</content></paragraph></subsection><subsection id="ID_1438411268294_005" name="4" temporalId="s9_4"><num value="4">(4)</num><leadIn>The person dispensing the prescription shall comply with the following
                requirements—</leadIn><paragraph id="ID_1438411268294_013" name="a" temporalId="s9_4_a"><num value="a">(a)</num><leadIn>the prescription shall not be dispensed more than once unless the prescriber
                    has directed either—</leadIn><subparagraph id="ID_1438411268294_021" name="i" temporalId="s9_4_a_i"><num value="i">(i)</num><content>that it may be dispensed a stated number of times; or</content></subparagraph><subparagraph id="ID_1438411268294_029" name="ii" temporalId="s9_4_a_ii"><num value="ii">(ii)</num><content>that it may be dispensed at stated intervals;</content></subparagraph></paragraph><paragraph id="ID_1438411268294_036" name="b" temporalId="s9_4_b"><num value="b">(b)</num><content>if the prescription contains a direction that it may be dispensed a stated
                    number of times or at stated intervals, it shall not be dispensed otherwise than
                    in accordance with the direction;</content></paragraph><paragraph id="ID_1438411268294_044" name="c" temporalId="s9_4_c"><num value="c">(c)</num><content>at the time of dispensing there shall be noted on the prescription above
                    the signature of the prescriber the name and address of the seller and the date
                    on which the prescription is dispensed; and</content></paragraph><paragraph id="ID_1438411268294_052" name="d" temporalId="s9_4_d"><num value="d">(d)</num><content>except in the case of a prescription which may be dispensed again, the
                    prescription shall, for a period of 2 years, be retained and kept on the
                    premises on which it was dispensed in such manner as to be readily available for
                    inspection.</content></paragraph></subsection><sourceNote>(<ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section><section id="ID_1438402706456_001" name="s10" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s10"><num value="10">10.</num><heading>Restriction of sales by listed sellers of poisons</heading><content>No listed seller of poisons shall sell any poison other than a solution of ammonia, hydrochloric acid, nitric acid, potassium quadroxalate or sulphuric acid, except in a closed container as closed by the manufacturer or other person from whom the poison was obtained.</content></section><section id="ID_1438402706456_003" name="s10A" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s10A"><num value="10A">10A.</num><heading>Prohibition on dispensing of prescriptions by listed sellers of poisons</heading><content>No listed seller of poisons shall dispense any prescription for medicine.</content><sourceNote>(<ref href="/hk/1987/ln85">L.N. 85 of 1987</ref>)</sourceNote></section><section id="ID_1438402706472_001" name="s11" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s11"><num value="11">11.</num><heading>Restriction of sale of strychnine</heading><subsection id="ID_1438411268356_018" name="1" temporalId="s11_1"><num value="1">(1)</num><content>No person shall sell or supply strychnine except as an ingredient in a medicine.</content></subsection><subsection id="ID_1438411268356_026" name="2" temporalId="s11_2"><num value="2">(2)</num><leadIn>This regulation shall extend to transactions exempted by <ref>section 32</ref>, but shall not apply to the sale of strychnine—</leadIn><paragraph id="ID_1438411268372_005" name="a" temporalId="s11_2_a"><num value="a">(a)</num><content>by way of wholesale dealing;</content></paragraph><paragraph id="ID_1438411268372_013" name="b" temporalId="s11_2_b"><num value="b">(b)</num><content>to be exported to purchasers outside Hong Kong;</content></paragraph><paragraph id="ID_1438411268372_021" name="c" temporalId="s11_2_c"><num value="c">(c)</num><content>for the purpose of being compounded in medicines prescribed or administered
                    by a registered medical practitioner or registered veterinary surgeon; or
                    <sourceNote>(<ref href="/hk/1997/ln614">L.N. 614 of 1997</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411268372_029" name="d" temporalId="s11_2_d"><num value="d">(d)</num><content>to a person or institution concerned with education, scientific research or chemical analysis, for the purpose of that education, research or analysis.</content></paragraph></subsection></section></part><part id="ID_1438402706472_003" name="P3" reason="inEffect" startPeriod="2015-11-12" status="operational" temporalId="P3"><num value="3">Part
            3</num><heading>Supplementary
            Provisions with respect to Labelling and Containers of
            Poisons</heading><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 73</ref>)</sourceNote><section id="ID_1438402706487_002" name="s12" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s12"><num value="12">12.</num><heading>Manner of labelling containers</heading><subsection id="ID_1438411268403_011" name="1" temporalId="s12_1"><num value="1">(1)</num><content>Subject to paragraphs (2) and (3), the particulars with which the container of a poison is required to be labelled under <ref>section 27</ref> and under these regulations, shall appear in a conspicuous position on the container in which the poison is sold and on every box or other covering of whatever nature enclosing the container, and the particulars shall be clearly and distinctly set out and not in any way obscured or obliterated.</content></subsection><subsection id="ID_1438411268419_005" name="2" temporalId="s12_2"><num value="2">(2)</num><content>Where the poison is contained in a cachet or similar article it shall not be necessary to label the article itself, if every box or other covering in which the article is enclosed is labelled in accordance with paragraph (1).</content></subsection><subsection id="ID_1438411268419_013" name="3" temporalId="s12_3"><num value="3">(3)</num><content>Nothing in <ref>section 27</ref> or in this regulation or <ref>regulations 13
                    to 17</ref> shall be deemed to require the labelling of any transparent cover or
                any wrapper, hamper, packing case, crate or other covering used solely for the
                purposes of transport or delivery.
                </content></subsection></section><section id="ID_1438402706503_002" name="s13" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s13"><num value="13">13.</num><heading>Labelling of name of poison</heading><subsection id="ID_1438411268434_027" name="1" temporalId="s13_1"><num value="1">(1)</num><content>
                <leadIn>For the purposes of <ref>section 27(a)</ref> and <ref>regulation
                        22(3)(a)</ref>, the name of a poison shall be the term under which it is
                    included in the Poisons List:</leadIn>
                
                <marker role="blank-line"></marker>
                
                <proviso name="proviso" temporalId="s13_1_proviso">
                    <leadIn>Provided that, where the term describes a group of poisons and not the
                        poison specifically, the name of the poison shall
                        be—<marker role="blank-line"></marker></leadIn>
                    <paragraph id="ID_1438411268434_042" name="a" temporalId="s13_1_a"><num value="a">(a)</num><content>if the poison is the subject of a monograph in either the British
                            Pharmacopoeia, the British Pharmaceutical Codex or the British
                            Veterinary Codex, one of the names or synonyms or abbreviated names set
                            out at the head of the monograph; or</content></paragraph>
                    <paragraph id="ID_1438411268450_006" name="b" temporalId="s13_1_b"><num value="b">(b)</num><content>in any other case, the accepted scientific name or the name
                            descriptive of the true nature and origin of the poison.</content></paragraph>
                </proviso>
            </content></subsection><subsection id="ID_1438411268450_013" name="2" temporalId="s13_2"><num value="2">(2)</num><leadIn>For the purposes of the proviso to paragraph (1), where—</leadIn><paragraph id="ID_1438411268450_021" name="a" temporalId="s13_2_a"><num value="a">(a)</num><content>a substance is the subject of a monograph in the British Pharmacopoeia, the British Pharmaceutical Codex or the British Veterinary Codex, or any dilution, concentration or admixture of such substance; or</content></paragraph><paragraph id="ID_1438411268450_029" name="b" temporalId="s13_2_b"><num value="b">(b)</num><content>a preparation is contained in the British Pharmacopoeia, the British Pharmaceutical Codex, the British National Formulary or the British Veterinary Codex, or any dilution, concentration or admixture of such preparation; or</content></paragraph><paragraph id="ID_1438411268450_037" name="c" temporalId="s13_2_c"><num value="c">(c)</num><content>a surgical dressing of a type for which a standard is prescribed in the British Pharmaceutical Codex,</content></paragraph><continued>it shall be sufficient to state the name, synonym or abbreviated name used to describe
                the substance, preparation or surgical dressing with the addition of the letters
                B.P., B.P.C., B.N.F. or B. Vet.
                C., as the case may be.</continued></subsection></section><section id="ID_1438402706519_001" name="s14" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s14"><num value="14">14.</num><heading>Labelling of particulars as to proportions of the poison</heading><leadIn>For the purpose of <ref>section 27(b)</ref> (which requires preparation containing
            poisons to be labelled with particulars as to the proportion of each poison
            therein)—</leadIn><paragraph id="ID_1438411268481_012" name="a" temporalId="s14_a"><num value="a">(a)</num><content>in the case of a preparation containing a poison specified in the first column
                of
                    <ref>Schedule
                    4</ref>, it shall be sufficient to state on the label the
                particulars specified in the second column of that <ref>Schedule</ref> against the
                description of the poison;
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411268481_020" name="b" temporalId="s14_b"><num value="b">(b)</num><content>in the case of a substance, preparation or surgical dressing which is named in
                accordance with <ref>regulation 13(2)</ref>, it shall not be necessary to state on
                the label the proportion of the poison contained in the substance, preparation or
                surgical dressing, and in the case of any dilution, concentration or admixture of
                such substance or preparation it shall be sufficient to state the proportion which
                the substance or preparation bears to the total ingredients of that dilution,
                concentration or admixture;</content></paragraph><paragraph id="ID_1438411268497_006" name="c" temporalId="s14_c"><num value="c">(c)</num><content>where the poison is in tablets, pills, cachets, capsules, lozenges or similar
                articles, it shall be sufficient to state on the label of the box or other covering
                in which the articles are enclosed the number of the articles and the amount of the
                poison, or in the case of a preparation or substance mentioned in
                subparagraph
                (b), the amount of the preparation or substance, contained in each article;
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411268512_006" name="d" temporalId="s14_d"><num value="d">(d)</num><content>where the poison is in ampoules it shall be sufficient to show the name of the
                poison contained in it together with, either its concentration (if in solution or in
                emulsified form), or the quantity (if in solid form); and</content></paragraph><paragraph id="ID_1438411268512_014" name="e" temporalId="s14_e"><num value="e">(e)</num><content>where any proportion is stated as a percentage, the statement shall indicate
                whether the percentage is calculated on the basis of weight in weight, weight in
                volume, or volume in volume.</content></paragraph><sourceNote>(<ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section><section id="ID_1438402706519_003" name="s15" temporalId="s15" startPeriod="2016-10-20" status="operational" reason="inEffect"><num value="15">15.</num><heading>Poisons to be labelled “Poison 毒藥” or other bilingual text specified in
                <ref>Schedule
                5</ref> etc.</heading><sourceNote>(<ref href="hk/2016/er1">E.R. 1 of
                2016</ref>)</sourceNote><subsection id="ID_1469686805944_001" name="1" temporalId="s15_1"><num value="1">(1)</num><content>For the purposes of <ref>section 27(c)</ref>, a container of a medicine must be
                labelled in clear print with the text in both English and Chinese as specified in
                    <ref>Schedule
                    5</ref> in respect of the medicine or the class to which the
                medicine belongs.</content></subsection><subsection id="ID_1469686805944_002" name="2" temporalId="s15_2"><num value="2">(2)</num><leadIn>For the purposes of <ref>section 27(ca)</ref>, a container of a substance or
                mixture of substances that is not a medicine must be labelled with the following
                text in clear print—</leadIn><paragraph id="ID_1469686805944_003" name="a" temporalId="s15_2_a"><num value="a">(a)</num><content>the text in both English and Chinese as specified in
                        <ref>Schedule
                        5</ref> in respect of the substance or mixture or the
                    class to which the substance or mixture belongs; or</content></paragraph><paragraph id="ID_1469686805959_004" name="b" temporalId="s15_2_b"><num value="b">(b)</num><content>if no text is so specified, “Poison 毒藥”.</content></paragraph></subsection><subsection id="ID_1469686805959_005" name="3" temporalId="s15_3"><num value="3">(3)</num><content>The text referred to in paragraph (1) or (2) must not be modified in meaning by
                the addition of any other texts or marks.</content></subsection><sourceNote>(<ref href="hk/2015/2">2 of 2015 s.
            37</ref>; <ref href="hk/2016/er1">E.R. 1 of 2016</ref>)</sourceNote></section><section id="ID_1438402706534_002" name="s16" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s16"><num value="16">16.</num><heading>Special precautions in the case of certain articles</heading><subsection id="ID_1438411268575_027" name="1" temporalId="s16_1"><num value="1">(1)</num><leadIn>No person shall sell or supply any poison—</leadIn><paragraph id="ID_1438411268575_035" name="a" temporalId="s16_1_a"><num value="a">(a)</num><content>in the case of a liquid other than a medicine, in a container of a capacity
                    of not more than 2 litres, unless the container is labelled with the words “Not
                    to be taken 忌食”; and
                    <sourceNote>(<ref href="/hk/1982/ln22">L.N. 22 of
                    1982</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411268575_043" name="b" temporalId="s16_1_b"><num value="b">(b)</num><content>in the case of an embrocation, liniment, lotion, liquid antiseptic, or
                    other liquid medicine for external application, unless the container is labelled
                    with the type of preparation and the words “For external use only 祇供外用”.
                    <sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>)</sourceNote></content></paragraph></subsection><subsection id="ID_1438411268590_005" name="2" temporalId="s16_2"><num value="2">(2)</num><content>No person shall sell or supply any compressed hydrocyanic acid, unless the
                container thereof is labelled with the words “Warning. This container holds
                poisonous gas and should only be opened and used by persons having expert knowledge
                of the precautions to be taken in its use. 警告：此容器內載毒氣，祇限由具有專門知識而在使用上知所提防之人士開啟及使用。”.
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></content></subsection><subsection id="ID_1438411268590_013" name="3" temporalId="s16_3"><num value="3">(3)</num><content>This regulation shall be in addition to the other requirements of the Ordinance
                and of these regulations with respect to labelling and shall apply to the
                transactions referred to in <ref>sections 28</ref> and <ref>32</ref>, but shall not
                apply to the sale or supply of poisons to be exported to purchasers outside Hong
                Kong.</content></subsection></section><section id="ID_1438402706550_001" name="s17" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s17"><num value="17">17.</num><heading>Name of seller and address of premises</heading><subsection id="ID_1438411268637_004" name="1" temporalId="s17_1"><num value="1">(1)</num><leadIn><ref>Section 27(d)</ref> (which requires the container of a poison to be
                labelled with the name of the seller and the address of the premises on which it was
                sold) shall apply to the transactions referred to in <ref>section 32</ref>, but
                shall not apply—</leadIn><paragraph id="ID_1438411268637_012" name="a" temporalId="s17_1_a"><num value="a">(a)</num><content>in the case of an article sold for the purpose of being sold again in the
                    same container; or</content></paragraph><paragraph id="ID_1438411268637_020" name="b" temporalId="s17_1_b"><num value="b">(b)</num><content>to poisons to be exported to purchasers outside Hong Kong.</content></paragraph></subsection><subsection id="ID_1438411268637_027" name="2" temporalId="s17_2"><num value="2">(2)</num><content>The requirements of <ref>section 27(d)</ref> shall be deemed to be satisfied,
                in the case of a poison supplied from a warehouse or depot, if the container of the
                poison is labelled with the address of the supplier’s principal place of
                business.</content></subsection><subsection id="ID_1438411268637_035" name="3" temporalId="s17_3"><num value="3">(3)</num><content>Where any poison (other than a substance included in
                    <ref>Schedule
                    1</ref>) is sold in a container and outer covering, being the
                container and covering in which it was obtained by the seller, it shall be
                sufficient if the name of the seller and the address of the premises on which it was
                sold appear only on the outer covering.
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></content></subsection><subsection id="ID_1438411268653_005" name="4" temporalId="s17_4"><num value="4">(4)</num><content>Where the names of more than one person or more than one address appear on any
                label, there shall also be words on the label indicating clearly which person is the
                seller and at which of the addresses the poison was sold.</content></subsection><sourceNote>(<ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section><section id="ID_1438402706550_003" name="s18" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s18"><num value="18">18.</num><heading>Form of containers of
            poisons</heading><sourceNote class="align_right">(<ref href="/hk/2015/2">2 of 2015 s. 73</ref>)</sourceNote><subsection id="ID_1438411268668_028" name="1" temporalId="s18_1"><num value="1">(1)</num><leadIn>No person shall sell, whether wholesale or retail, or supply any poison
                unless—</leadIn><paragraph id="ID_1438411268668_036" name="a" temporalId="s18_1_a"><num value="a">(a)</num><content>it is contained in a container impervious to the poison and sufficiently
                    stout to prevent leakage arising from the ordinary risks of handling and
                    transport; and</content></paragraph><paragraph id="ID_1438411268668_044" name="b" temporalId="s18_1_b"><num value="b">(b)</num><content>in the case of a liquid contained in a glass bottle or plastic container
                    containing not more than 2 litres, not being a medicine made up ready to be
                    taken for the internal treatment of human or animal ailments, the outer surface
                    of the bottle or container is fluted vertically with ribs or grooves
                    recognizable by touch.
                    <sourceNote>(<ref href="/hk/1982/ln22">L.N. 22 of 1982</ref>)</sourceNote></content></paragraph></subsection><subsection id="ID_1438411268684_005" name="2" temporalId="s18_2"><num value="2">(2)</num><content>Paragraph <ref>(1)(a)</ref> shall apply to the transactions referred to in
                    <ref>section 28</ref>, and paragraph <ref>(1)(b)</ref> shall apply to the
                transactions exempted by <ref>section 32</ref> but shall not apply to the sale or
                supply of poisons to be exported to purchasers outside Hong Kong.</content></subsection></section></part><part id="ID_1438402706565_002" name="P4" reason="inEffect" startPeriod="2015-11-12" status="operational" temporalId="P4"><num value="4">Part
            4</num><heading>Storage
            and Transport of Poisons</heading><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 73</ref>)</sourceNote><section id="ID_1438402706581_001" name="s19" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s19"><num value="19">19.</num><heading>Storage of poisons</heading><subsection id="ID_1438411268731_011" name="1" temporalId="s19_1"><num value="1">(1)</num><content>No person shall store any poison except in a container impervious to the poison
                and sufficiently stout to prevent leakage from the container arising from the
                ordinary risks of handling.</content></subsection><subsection id="ID_1438411268731_019" name="2" temporalId="s19_2"><num value="2">(2)</num><leadIn>No person shall store any poison included in Part
                1
                of the Poisons List in any retail shop or premises used in
                connexion
                therewith unless the substance is
                        stored— <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 38</ref>)</sourceNote></leadIn><paragraph id="ID_1438411268731_027" name="a" temporalId="s19_2_a"><num value="a">(a)</num><content>in a receptacle reserved solely for the storage of poisons, which
                    receptacle shall be locked with an adequate lock the key for which shall be
                    retained by the registered pharmacist; and
                    <sourceNote>(<ref href="/hk/1989/ln197">L.N. 197 of 1989</ref>; <ref href="/hk/1995/ln366">L.N. 366 of 1995</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411268731_035" name="b" temporalId="s19_2_b"><num value="b">(b)</num><content>in a part of the premises to which customers are not permitted to have
                    access and which is partitioned off or otherwise separated from the remainder of
                    the premises.</content></paragraph></subsection><subsection id="ID_1438411268746_005" name="3" temporalId="s19_3"><num value="3">(3)</num><content>No food shall be stored in the part of the premises where such poison is stored.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 38</ref>)</sourceNote></content></subsection><sourceNote>(<ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section><section id="ID_1438402706581_003" name="s20" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s20"><num value="20">20.</num><heading>Transport of poisons</heading><content>No person shall consign any poison for transport unless it is sufficiently stoutly packed to avoid leakage arising from the ordinary risks of handling and transport.</content></section><section id="ID_1438402706612_001" name="s21" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s21"><num value="21">21.</num><heading>Special provisions with respect to the transport of poisons in
                <ref>Schedule
                7</ref></heading><sourceNote>(<ref href="hk/2020/er5">E.R. 5 of 2020</ref>)</sourceNote><subsection id="ID_1438411268778_011" name="1" temporalId="s21_1"><num value="1">(1)</num><content>No person shall consign for transport by carrier any poison included in
                    <ref>Schedule
                    7</ref> unless the outside of the package containing the
                article is labelled conspicuously with the name or description of the poison as set
                forth in that <ref>Schedule</ref> and a notice indicating that it is to be kept
                separate from food and from empty containers in which food has been
                contained.</content></subsection><subsection id="ID_1438411268793_005" name="2" temporalId="s21_2"><num value="2">(2)</num><content>No person shall knowingly transport any poison included in
                    <ref>Schedule
                    7</ref>, either on his own behalf or for another person, in
                any vehicle in which food is being transported, unless the food is carried in a part
                of the vehicle effectively separated from that containing the poison, or is
                otherwise adequately protected from the risk of contamination.</content></subsection><subsection id="ID_1438411268793_013" name="3" temporalId="s21_3"><num value="3">(3)</num><content>This regulation shall not apply to medicines.</content></subsection><sourceNote>(<ref href="hk/2015/er3">E.R. 3 of
            2015</ref>; <ref href="hk/2020/er5">E.R. 5 of
            2020</ref>)</sourceNote></section></part><part id="ID_1438402706612_003" name="P5" reason="inEffect" startPeriod="2015-11-12" status="operational" temporalId="P5"><num value="5">Part
            5</num><heading>Special
            Provisions with respect to Institutions</heading><section id="ID_1438402706628_002" name="s22" reason="inEffect" role="regulation" startPeriod="2021-08-01" status="operational" temporalId="s22"><num value="22">22.</num><heading>Supply of medicines to out-patients from certain institutions, etc.</heading><subsection id="ID_1438411268824_004" name="1" temporalId="s22_1"><num value="1">(1)</num><leadIn>Nothing in the Ordinance or in these regulations, except <ref>regulation
                    16</ref>,
                this Part and
                    <ref>Part 7</ref>,
                applies
                with respect to—  <sourceNote>(<ref href="/hk/1995/ln262">L.N. 262 of
                    1995</ref>; <ref href="hk/2020/19">19 of 2020 s. 6</ref>)</sourceNote></leadIn><paragraph id="ID_1438411268824_012" name="a" temporalId="s22_1_a"><num value="a">(a)</num><content>any medicine dispensed in an institution where the dispensing is under the
                    supervision of a registered pharmacist or other person as may be approved by the
                    Director of Health; or
                    <sourceNote>(<ref href="/hk/1989/ln76">L.N. 76 of 1989</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411268824_020" name="b" temporalId="s22_1_b"><num value="b">(b)</num><content>any medicine for the treatment of animals supplied from a veterinary
                    institution which is under the superintendence of a registered veterinary surgeon,
                    <sourceNote>(<ref href="/hk/1997/ln614">L.N. 614 of 1997</ref>)</sourceNote></content></paragraph><continued>if the requirements of this regulation are satisfied in relation
                thereto.</continued></subsection><subsection id="ID_1438411268824_033" name="2" temporalId="s22_2"><num value="2">(2)</num><content>The medicine shall not be supplied except by, or on and in accordance with a
                prescription of, a duly registered medical practitioner for the purposes of medical
                treatment, or a registered dentist for the purposes of dental treatment, or a
                registered veterinary surgeon for the purposes of animal treatment.
                <sourceNote>(<ref href="/hk/1997/ln614">L.N. 614 of 1997</ref>)</sourceNote></content></subsection><subsection id="ID_1438411268840_005" name="3" temporalId="s22_3"><num value="3">(3)</num><leadIn>In a case where a substance included in
                    <ref>Schedule
                    1</ref> is supplied, a record shall be kept on the premises in
                such a way that there can readily be traced at any time during a period of 2 years
                after the date on which the substance was supplied the following particulars—
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></leadIn><paragraph id="ID_1438411268840_013" name="a" temporalId="s22_3_a"><num value="a">(a)</num><content>the name and quantity of the poison supplied;</content></paragraph><paragraph id="ID_1438411268840_021" name="b" temporalId="s22_3_b"><num value="b">(b)</num><content>the date on which the poison was supplied;</content></paragraph><paragraph id="ID_1438411268840_029" name="c" temporalId="s22_3_c"><num value="c">(c)</num><content>the name and address of the person to whom the poison was supplied;
                    and</content></paragraph><paragraph id="ID_1438411268840_037" name="d" temporalId="s22_3_d"><num value="d">(d)</num><content>the name of the person who supplied the poison or who gave the prescription
                    upon which it was supplied.</content></paragraph></subsection><subsection id="ID_1438411268840_044" name="4" temporalId="s22_4"><num value="4">(4)</num><leadIn>The container of the medicine shall be labelled—</leadIn><paragraph id="ID_1438411268840_052" name="a" temporalId="s22_4_a"><num value="a">(a)</num><content>with a designation sufficient to identify the institution or veterinary
                    institution from which it was supplied; and
                    <sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>; <ref href="/hk/2015/2">2
                            of 2015 s. 39</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411268856_006" name="b" temporalId="s22_4_b"><num value="b">(b)</num><sourceNote>(Repealed <ref href="/hk/2015/2">2 of 2015 s. 39</ref>)</sourceNote></paragraph><paragraph id="ID_1438411268856_014" name="c" temporalId="s22_4_c"><num value="c">(c)</num><content>in the case of a poison supplied from a veterinary institution, with the
                    words “For animal treatment only 祇限醫治禽畜用”.</content></paragraph></subsection><subsection id="ID_1438411268856_021" name="5" temporalId="s22_5"><num value="5">(5)</num><content>The medicine shall be clearly labelled with instructions for use in either
                English or Chinese.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 39</ref>)</sourceNote></content></subsection><subsection id="ID_1438411268856_029" name="6" temporalId="s22_6"><num value="6">(6)</num><content>In the case of a medicine to which <ref>regulation 16</ref> applies the
                requirements of that regulation shall be satisfied in addition to the requirements
                of this regulation.</content></subsection><sourceNote>(<ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section><section id="ID_1438402706628_004" name="s23" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s23"><num value="23">23.</num><heading>Supply of medicines for use in institutions, etc.</heading><subsection id="ID_1438411268887_020" name="1" temporalId="s23_1"><num value="1">(1)</num><content>In any institution in which medicines are dispensed in a dispensing or
                pharmaceutical department in charge of a registered pharmacist or any other person
                approved by the Director of Health for that purpose, no medicine containing a poison
                shall be supplied from that department, except in cases of emergency, for use in the
                wards, operating theatres or other sections of the institution, except in accordance
                with paragraphs (2) and (3).
                <sourceNote>(<ref href="/hk/1989/ln76">L.N. 76 of 1989</ref>)</sourceNote></content></subsection><subsection id="ID_1438411268902_005" name="2" temporalId="s23_2"><num value="2">(2)</num><content>Subject to paragraph (4), the medicines shall not be supplied except upon a written order signed by a duly registered medical practitioner, registered dentist, or by a person authorized to be in charge of a ward, theatre or other section of the institution.</content></subsection><subsection id="ID_1438411268902_013" name="3" temporalId="s23_3"><num value="3">(3)</num><content>The container of the medicine shall be labelled with words describing its contents.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 40</ref>)</sourceNote></content></subsection><subsection id="ID_1438411268902_021" name="4" temporalId="s23_4"><num value="4">(4)</num><content>In the case of an emergency, a medicine containing a poison may be supplied without a written order if the person ordering the medicine undertakes to furnish a written order in respect of that medicine within the next 24 hours.</content></subsection></section><section id="ID_1438402706643_002" name="s24" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s24"><num value="24">24.</num><heading>Storage of poisons in institutions</heading><subsection id="ID_1438411268934_004" name="1" temporalId="s24_1"><num value="1">(1)</num><content>In any institution in which medicines are dispensed in a dispensing or
                pharmaceutical department in the charge of a person appointed for the purpose, all
                poisons other than those issued for use within the institution shall be stored in
                that department.</content></subsection><subsection id="ID_1438411268934_012" name="2" temporalId="s24_2"><num value="2">(2)</num><leadIn>In any institution to which paragraph (1) does not apply all poisons other than
                those issued for use within the institution shall be stored—</leadIn><paragraph id="ID_1438411268934_020" name="a" temporalId="s24_2_a"><num value="a">(a)</num><content>in the charge of a person appointed for the purpose by the governing body
                    or person in control of the institution; and</content></paragraph><paragraph id="ID_1438411268934_028" name="b" temporalId="s24_2_b"><num value="b">(b)</num><content>in the case of substances included in
                        <ref>Schedule
                        1</ref> either in a cupboard or drawer, or on a shelf,
                    reserved for the storage of poisons.
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s.
                        41</ref>; <ref href="hk/2020/er5">E.R. 5 of
                        2020</ref>)</sourceNote></content></paragraph></subsection><subsection id="ID_1438411268934_035" name="3...4" temporalId="s24_3...4"><num value="3...4">(3)-(4)</num><sourceNote>(Repealed <ref href="/hk/2015/2">2 of 2015 s.
                41</ref>)<marker role="section-break"></marker></sourceNote></subsection><subsection id="ID_1438411268934_043" name="5" temporalId="s24_5"><num value="5">(5)</num><content>All places in which poisons are required by this regulation to be stored shall
                be inspected at regular intervals of time not exceeding three months by a registered
                pharmacist or registered medical practitioner appointed for the purpose by the
                governing body of the institution and a record of all inspections shall be made in a
                book kept at the institution.</content></subsection><sourceNote>(<ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section></part><part id="ID_1438402706659_001" name="P5A" reason="inEffect" startPeriod="2015-11-12" status="operational" temporalId="P5A"><num value="5A">Part
                        5A</num><heading>Listed
                        Sellers of Poisons</heading><section id="ID_1438402706659_003" name="s24A" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s24A"><num value="24A">24A.</num><heading>Applications to be entered on list under <ref>section 25</ref></heading><subsection id="ID_1438411268980_004" name="1" temporalId="s24A_1"><num value="1">(1)</num><content>Any application under <ref>section 25(1)</ref> shall be made in writing to the
                Committee and shall be accompanied by the fee specified in
                    <ref>Schedule
                    9</ref>.
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></content></subsection><subsection id="ID_1438411268980_012" name="2" temporalId="s24A_2"><num value="2">(2)</num><content>
                <leadIn>The Committee may grant or refuse any application under this regulation and
                    shall notify the applicant of its decision:</leadIn>
                <proviso name="proviso" temporalId="s24A_2_proviso">Provided that if the Committee
                    intends to refuse an application the Committee shall first notify the applicant
                    and the applicant may, not later than 14 days after the date of such
                    notification, submit representations in writing to the Committee in support of
                    his application.</proviso>
            </content></subsection><subsection id="ID_1438411268980_026" name="3" temporalId="s24A_3"><num value="3">(3)</num><content>Where the Committee grants an application under this regulation the Committee
                shall notify the Board of its decision and shall state whether the applicant has
                paid the prescribed fee.</content></subsection><subsection id="ID_1438411268980_034" name="4" temporalId="s24A_4"><num value="4">(4)</num><content>Any applicant aggrieved by a decision made in respect of the applicant under
                this regulation may, in the prescribed manner, appeal to the Tribunal against that decision.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s.
                42</ref>)</sourceNote></content></subsection><sourceNote>(Part 5A added <ref href="/hk/1980/ln369">L.N. 369 of
            1980</ref>; <ref href="hk/2015/er3">E.R. 3 of
            2015</ref>)</sourceNote></section></part><part id="ID_1438402706690_001" name="P5B" reason="inEffect" startPeriod="2015-11-12" status="operational" temporalId="P5B"><num value="5B">Part
            5B</num><heading>Registration
            of Premises of Authorized Sellers of Poisons</heading><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 73</ref>)</sourceNote><section id="ID_1438402706690_003" name="s24B" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s24B"><num value="24B">24B.</num><heading>Applications to register premises under <ref>section 13</ref></heading><leadIn>An application to register premises under <ref>section 13</ref> shall be—</leadIn><paragraph id="ID_1438411269074_012" name="a" temporalId="s24B_a"><num value="a">(a)</num><sourceNote>(Repealed <ref href="/hk/2015/2">2 of 2015 s. 43</ref>)</sourceNote></paragraph><paragraph id="ID_1438411269074_020" name="b" temporalId="s24B_b"><num value="b">(b)</num><content>submitted together with a copy of the certificate of registration of the
                registered pharmacist by whom or in whose presence and under whose supervision the
                actual sale of poisons will be conducted under <ref>section 11(1)</ref> of the Ordinance.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 43</ref>)</sourceNote></content></paragraph><sourceNote>(<ref href="/hk/1987/ln85">L.N. 85 of 1987</ref>)</sourceNote></section><section id="ID_1438402706737_001" name="s24C" reason="repealed" role="regulation" startPeriod="2015-02-06" status="repealed" temporalId="s24C"><num value="24C">24C.</num><sourceNote>(Repealed <ref href="/hk/2015/2">2 of 2015 s. 44</ref>)</sourceNote></section></part><part id="ID_1438402706924_001" name="P6" reason="inEffect" startPeriod="2015-11-12" status="operational" temporalId="P6"><num value="6">Part
            6</num><heading>Wholesale
            Dealing in Poisons and Pharmaceutical Products</heading><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 73</ref>)</sourceNote><section id="ID_1438402707080_002" name="s25" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s25"><num value="25">25.</num><heading>Sale and supply of poisons or pharmaceutical products wholesale</heading><leadIn>A person must not, by way of wholesale dealing, sell or supply at or from any premises a pharmaceutical product, or a substance or article consisting of or containing any poison, unless the person—</leadIn><paragraph id="ID_1438411269121_033" name="a" temporalId="s25_a"><num value="a">(a)</num><content>holds a wholesale dealer licence issued to the person by the Committee in respect of those premises;</content></paragraph><paragraph id="ID_1438411269121_041" name="b" temporalId="s25_b"><num value="b">(b)</num><content>is an authorized seller of poisons; or</content></paragraph><paragraph id="ID_1438411269121_049" name="c" temporalId="s25_c"><num value="c">(c)</num><content>is a licensed manufacturer selling or supplying only pharmaceutical products manufactured by the licensed manufacturer.</content><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 45</ref>)</sourceNote></paragraph></section><section id="ID_1438402707111_001" name="s26" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s26"><num value="26">26.</num><heading>Pharmacy and Poisons (Wholesale Licences) Committee</heading><subsection id="ID_1438411269136_041" name="1" temporalId="s26_1"><num value="1">(1)</num><content>There shall be for the purposes of this Part a Committee to be called the
                Pharmacy and Poisons (Wholesale Licences) Committee.</content></subsection><subsection id="ID_1438411269152_005" name="2" temporalId="s26_2"><num value="2">(2)</num><sourceNote>(Repealed <ref href="/hk/1980/ln369">L.N. 369 of 1980</ref>)</sourceNote></subsection><subsection id="ID_1438411269152_013" name="3" temporalId="s26_3"><num value="3">(3)</num><content>The Committee may, subject to any conditions it thinks fit to impose, issue a
                wholesale dealer licence on payment of the fee prescribed in
                    <ref>Schedule
                    9</ref>.
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></content></subsection><subsection id="ID_1438411269152_021" name="4" temporalId="s26_4"><num value="4">(4)</num><content>The issue of a wholesale dealer licence shall be at the discretion of the
                Committee and shall be in the specified
                form.</content></subsection><subsection id="ID_1438411269152_029" name="5" temporalId="s26_5"><num value="5">(5)</num><leadIn>In any of the circumstances specified in paragraph (5A), the Committee
                may—</leadIn><paragraph id="ID_1438411269152_037" name="a" temporalId="s26_5_a"><num value="a">(a)</num><content>revoke a wholesale dealer licence or suspend it for a period it thinks
                    fit;</content></paragraph><paragraph id="ID_1438411269152_045" name="b" temporalId="s26_5_b"><num value="b">(b)</num><content>issue a warning letter to the licensed wholesale dealer; or</content></paragraph><paragraph id="ID_1438411269152_053" name="c" temporalId="s26_5_c"><num value="c">(c)</num><content>vary a condition of the licence imposed under paragraph (3).
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 46</ref>)</sourceNote></content></paragraph></subsection><subsection id="ID_1438411269152_060" name="5A" temporalId="s26_5A"><num value="5A">(5A)</num><leadIn>The circumstances are—</leadIn><paragraph id="ID_1438411269152_068" name="a" temporalId="s26_5A_a"><num value="a">(a)</num><leadIn>that, in the Committee’s opinion, the licensed wholesale dealer has
                    contravened—</leadIn><subparagraph id="ID_1438411269152_076" name="i" temporalId="s26_5A_a_i"><num value="i">(i)</num><content>a condition of the licence; or</content></subparagraph><subparagraph id="ID_1438411269152_084" name="ii" temporalId="s26_5A_a_ii"><num value="ii">(ii)</num><content>any of these regulations or a code of practice applicable to the
                        licensed wholesale dealer; or</content></subparagraph></paragraph><paragraph id="ID_1438411269168_006" name="b" temporalId="s26_5A_b"><num value="b">(b)</num><leadIn>that the licensed wholesale dealer has been convicted of—</leadIn><subparagraph id="ID_1438411269168_014" name="i" temporalId="s26_5A_b_i"><num value="i">(i)</num><content>an offence under the Ordinance or any of the regulations made under
                            <ref>section 29</ref>, the Dangerous Drugs Ordinance (<ref href="/hk/cap134">Cap. 134</ref>), the Antibiotics Ordinance (<ref href="/hk/cap137">Cap. 137</ref>) or the Undesirable Medical
                        Advertisements Ordinance (<ref href="/hk/cap231">Cap. 231</ref>);
                        or</content></subparagraph><subparagraph id="ID_1438411269168_022" name="ii" temporalId="s26_5A_b_ii"><num value="ii">(ii)</num><content>an offence under <ref>section 6C</ref> or <ref>6D</ref> of the Import
                        and Export Ordinance (<ref href="/hk/cap60">Cap. 60</ref>), <ref>section
                            52</ref>, <ref>54</ref> or <ref>61</ref> of the Public Health and
                        Municipal Services Ordinance (<ref href="/hk/cap132">Cap. 132</ref>) or
                            <ref>section 7</ref>, <ref>7A</ref> or <ref>9</ref> of the Trade
                        Descriptions Ordinance (<ref href="/hk/cap362">Cap. 362</ref>).
                        <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 46</ref>)</sourceNote></content></subparagraph></paragraph></subsection><subsection id="ID_1438411269168_028" name="5B" temporalId="s26_5B"><num value="5B">(5B)</num><def name="SuspensionPeriod">The Committee may, subject to any conditions it thinks fit
                to impose, suspend for a period not exceeding 3 years (<term>suspension
                    period</term>) the operation of a decision made under paragraph
                    <ref>(5)(a)</ref> so that the decision takes effect only if a condition so
                imposed is contravened during the suspension period, and in the case of such a
                contravention, the decision takes effect on the date specified by the Committee
                having regard to all the circumstances of the case.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 46</ref>)</sourceNote></def></subsection><subsection id="ID_1438411269183_004" name="6" temporalId="s26_6"><num value="6">(6)</num><content>Any applicant or licensed wholesale dealer aggrieved by a decision of the
                Committee under this regulation may, in the prescribed manner, appeal to the
                Tribunal against that decision.
                <sourceNote>(<ref href="/hk/1980/ln369">L.N. 369 of
                    1980</ref>)</sourceNote></content></subsection><subsection id="ID_1438411269183_012" name="7" temporalId="s26_7"><num value="7">(7)</num><sourceNote>(Repealed <ref href="/hk/1980/ln369">L.N. 369 of 1980</ref>)</sourceNote></subsection><subsection id="ID_1438411269183_020" name="8" temporalId="s26_8"><num value="8">(8)</num><leadIn>An applicant for a wholesale dealer
                        licence— <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 46</ref>)</sourceNote></leadIn><paragraph id="ID_1438411269183_028" name="a" temporalId="s26_8_a"><num value="a">(a)</num><content>shall nominate in writing a responsible person to be in charge of the
                    poisons or pharmaceutical products; and</content></paragraph><paragraph id="ID_1438411269183_036" name="b" temporalId="s26_8_b"><num value="b">(b)</num><content>may nominate in writing one or more deputies to act during the temporary
                    absence of the responsible
                    person.</content></paragraph></subsection><subsection id="ID_1438411269199_005" name="9" temporalId="s26_9"><num value="9">(9)</num><content>An applicant shall at the time of his application submit to the Secretary the
                name of the person so nominated and of any deputy, and shall advise the Secretary of
                any change within 7 days of its
                occurrence.</content></subsection><subsection id="ID_1438411269199_013" name="10" temporalId="s26_10"><num value="10">(10)</num><leadIn>If—</leadIn><paragraph id="ID_1438411269199_021" name="a" temporalId="s26_10_a"><num value="a">(a)</num><def name="AmendingOrdinance">a person was issued with a wholesale poisons licence
                    under this regulation, as in force before the commencement
                    date*
                    of the Pharmacy and Poisons (Amendment) Ordinance 2015 (<ref href="/hk/2015/2">2
                        of 2015</ref>)
                    (<term>amending Ordinance</term>); and</def></paragraph><paragraph id="ID_1438411269199_028" name="b" temporalId="s26_10_b"><num value="b">(b)</num><content>that licence was in force immediately before that date,</content></paragraph><continued>then, for the remainder of the period for which that licence would have
                continued to be valid had <ref>section 46</ref> of the amending Ordinance not been
                enacted, the person is to be regarded as a licensed wholesale dealer, and the
                Ordinance and regulations made under <ref>section 29</ref> apply to the person accordingly.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 46</ref>)</sourceNote></continued><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s.
                46</ref>; <ref href="hk/2015/er3">E.R. 3 of
                2015</ref>)</sourceNote></subsection><editorialNote type="footnote" id="ID_1596599359485_001">
            <content>Editorial Note:</content>
            <content><inline class="force_orig_font">*</inline> Commencement Date: 6 February
                2015.</content>
        </editorialNote></section><section id="ID_1438402707143_001" name="s27" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s27"><num value="27">27.</num><heading>Sales of poisons by licensed wholesale dealers or licensed
            manufacturers</heading><sourceNote class="align_right">(<ref href="/hk/2015/2">2 of 2015 s. 47</ref>)</sourceNote><leadIn>A licensed wholesale dealer or licensed manufacturer must not sell or supply a
            poison to any person other than the following—  <sourceNote>(<ref href="/hk/2015/2">2 of
                    2015 s. 47</ref>)</sourceNote></leadIn><paragraph id="ID_1438411269246_048" name="a" temporalId="s27_a"><num value="a">(a)</num><content>a licensed wholesale dealer;
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 47</ref>)</sourceNote></content></paragraph><paragraph id="ID_1453948071882_001" name="ab" temporalId="s27_ab"><num value="ab">(ab)</num><content>a licensed manufacturer;
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 47</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411269261_015" name="b" temporalId="s27_ab_b"><num value="b">(b)</num><content>an authorized seller of poisons;</content></paragraph><paragraph id="ID_1438411269261_023" name="c" temporalId="s27_ab_c"><num value="c">(c)</num><content>a registered pharmacist;</content></paragraph><paragraph id="ID_1438411269261_031" name="d" temporalId="s27_ab_d"><num value="d">(d)</num><content>a registered medical practitioner, a registered dentist or a registered
                veterinary surgeon;
                <sourceNote>(<ref href="/hk/1997/ln614">L.N. 614 of 1997</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411269261_039" name="e" temporalId="s27_ab_e"><num value="e">(e)</num><content>persons who require the poison for the purpose of their trade or
                business;</content></paragraph><paragraph id="ID_1438411269261_047" name="f" temporalId="s27_ab_f"><num value="f">(f)</num><content>a Government department or public officer requiring the article for the
                purposes of the public service;</content></paragraph><paragraph id="ID_1438411269261_055" name="g" temporalId="s27_ab_g"><num value="g">(g)</num><content>a person or an establishment concerned with education or scientific research,
                if the article is required for the purposes of such education or research;</content></paragraph><paragraph id="ID_1438411269261_063" name="h" temporalId="s27_ab_h"><num value="h">(h)</num><content>an institution;</content></paragraph><paragraph id="ID_1438411269261_071" name="i" temporalId="s27_ab_i"><num value="i">(i)</num><content>purchasers outside Hong Kong; or</content></paragraph><paragraph id="ID_1438411269261_078" name="j" temporalId="s27_j"><num value="j">(j)</num><content>a listed seller of poisons, if the poison is included in the classes of poisons
                in Part
                2
                of the Poisons List that the listed seller is licensed to sell.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 47</ref>)</sourceNote></content></paragraph><sourceNote>(<ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section><section id="ID_1438402707143_003" name="s28" reason="inEffect" role="regulation" startPeriod="2021-08-01" status="operational" temporalId="s28"><num value="28">28.</num><heading>Records to be kept by licensed wholesale dealers or licensed
            manufacturers</heading><sourceNote class="align_right">(<ref href="/hk/2015/2">2 of 2015 s. 48</ref>)</sourceNote><subsection id="ID_1438411269308_004" name="1" temporalId="s28_1"><num value="1">(1)</num><leadIn>A licensed wholesale dealer or licensed manufacturer must record the following
                particulars for each transaction by which any poison included in Part
                1
                of the Poisons List or any pharmaceutical product is acquired by him whether by way
                of import, purchase, gift or
                        otherwise— <sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>; <ref href="/hk/2015/2">2 of 2015 s. 48</ref>)</sourceNote></leadIn><paragraph id="ID_1438411269308_012" name="a" temporalId="s28_1_a"><num value="a">(a)</num><content>the date of the transaction;</content></paragraph><paragraph id="ID_1438411269308_020" name="b" temporalId="s28_1_b"><num value="b">(b)</num><content>the name of the supplier;</content></paragraph><paragraph id="ID_1438411269308_028" name="c" temporalId="s28_1_c"><num value="c">(c)</num><content>the name of the poison or pharmaceutical product;</content></paragraph><paragraph id="ID_1438411269308_036" name="ca" temporalId="s28_1_ca"><num value="ca">(ca)</num><content>the batch number, pack size and unit of quantity of the poison or
                    pharmaceutical product;
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 48</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411269308_044" name="d" temporalId="s28_1_d"><num value="d">(d)</num><content>the total quantity of the poison or pharmaceutical product;</content></paragraph><paragraph id="ID_1438411269324_006" name="e" temporalId="s28_1_e"><num value="e">(e)</num><content>the nature of the transaction; and</content></paragraph><paragraph id="ID_1438411269324_014" name="f" temporalId="s28_1_f"><num value="f">(f)</num><content>a reference to the invoice or other documents supporting the
                    transaction.</content></paragraph></subsection><subsection id="ID_1453949748210_001" name="2" temporalId="s28_2"><num value="2">(2)</num><leadIn>A licensed wholesale dealer or licensed manufacturer must record the following
                particulars for each transaction by which any poison included in Part
                1
                of the Poisons List or any pharmaceutical product is disposed of, whether the
                disposition is by way of export, sale, gift or otherwise—  <sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>; <ref href="/hk/2015/2">2 of
                        2015 s. 48</ref>)</sourceNote></leadIn><paragraph id="ID_1438411269324_029" name="a" temporalId="s28_2_a"><num value="a">(a)</num><content>the date of the transaction;</content></paragraph><paragraph id="ID_1438411269324_037" name="b" temporalId="s28_2_b"><num value="b">(b)</num><content>the nature of the transaction;</content></paragraph><paragraph id="ID_1438411269324_045" name="c" temporalId="s28_2_c"><num value="c">(c)</num><content>the name of the person to whom the poison or pharmaceutical product is
                    supplied;</content></paragraph><paragraph id="ID_1626141999052_001" name="ca" temporalId="s28_2_ca"><num value="ca">(ca)</num><content>for an advanced therapy product supplied for use by a registered medical
                    practitioner or registered dentist—the name and address of the practitioner or
                    dentist; <sourceNote>(<ref href="hk/2020/19">19 of 2020 s. 7</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411269324_053" name="d" temporalId="s28_2_d"><num value="d">(d)</num><content>the total quantity of the poison or pharmaceutical product;</content></paragraph><paragraph id="ID_1438411269324_061" name="e" temporalId="s28_2_e"><num value="e">(e)</num><content>a reference to the invoice or other documents supporting the
                    transaction;</content></paragraph><paragraph id="ID_1438411269324_069" name="f" temporalId="s28_2_f"><num value="f">(f)</num><content>the name of the poison or pharmaceutical product;</content></paragraph><paragraph id="ID_1438411269324_077" name="fa" temporalId="s28_2_fa"><num value="fa">(fa)</num><content>the batch number, pack size and unit of quantity of the poison or
                    pharmaceutical product;
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 48</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411269324_085" name="g" temporalId="s28_2_g"><num value="g">(g)</num><content>the balance of the poison or pharmaceutical product remaining in his
                    possession after the transaction.</content></paragraph></subsection><subsection id="ID_1438411269324_093" name="3" temporalId="s28_3"><num value="3">(3)</num><content>For each poison in Part
                1
                of the Poisons List or pharmaceutical product there shall be a separate entry in the
                records and all transactions involving that poison or pharmaceutical product shall
                be entered in a part of the records reserved for that poison or pharmaceutical
                product.</content></subsection><subsection id="ID_1438411269339_006" name="4" temporalId="s28_4"><num value="4">(4)</num><content>Unless the Committee approves another system of recording, all records of
                transactions must be in the specified form.</content></subsection><subsection id="ID_1438411269339_014" name="5" temporalId="s28_5"><num value="5">(5)</num><content>Every transaction to which these regulations relate shall be recorded within 72
                hours after the time it took place.</content></subsection><subsection id="ID_1438411269339_022" name="6" temporalId="s28_6"><num value="6">(6)</num><content>Records of sales or supplies maintained under this regulation shall be
                supported by documents signed by the purchaser.</content></subsection><subsection id="ID_1438411269339_030" name="7" temporalId="s28_7"><num value="7">(7)</num><content>In the case of an import or export transaction, the licensed wholesale dealer
                or licensed manufacturer must retain all shipping and other documents supporting the transaction.
                <sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of
                1978</ref>)</sourceNote></content></subsection><subsection id="ID_1438411269339_037" name="8" temporalId="s28_8"><num value="8">(8)</num><content>A licensed wholesale dealer must set up and maintain a system of control that
                will enable the rapid and, so far as practicable, complete recall of any lot or
                batch of a pharmaceutical substance or product from sale to the public in the event
                of the pharmaceutical substance or product being found to be dangerous or injurious
                to health.
                <sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of
                1978</ref>)</sourceNote></content></subsection><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s.
            48</ref>; <ref href="hk/2015/er3">E.R. 3 of
            2015</ref>)</sourceNote></section></part><part id="ID_1438402707158_002" name="P7" reason="inEffect" startPeriod="2015-11-12" status="operational" temporalId="P7"><num value="7">Part
            7</num><heading>Manufacture
            of Pharmaceutical Products</heading><sourceNote class="align_right">(<ref href="/hk/2015/2">2 of 2015 s. 73</ref>)</sourceNote><section id="ID_1438402707174_002" name="s28A" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s28A"><num value="28A">28A.</num><heading>Good Manufacturing Practice Guide</heading><subsection id="ID_1438411269402_039" name="1" temporalId="s28A_1"><num value="1">(1)</num><content>The Board may issue a Good Manufacturing Practice Guide providing for the principles and guidelines of good manufacturing practice in respect of pharmaceutical products.</content></subsection><subsection id="ID_1438411269417_005" name="2" temporalId="s28A_2"><num value="2">(2)</num><leadIn>The GMP Guide—</leadIn><paragraph id="ID_1438411269417_013" name="a" temporalId="s28A_2_a"><num value="a">(a)</num><content>may consist of a code, standard, rule, specification or any other documentary form of practical guidance prepared by the Board or any other body or authority; and</content></paragraph><paragraph id="ID_1438411269417_021" name="b" temporalId="s28A_2_b"><num value="b">(b)</num><content>may apply, incorporate or refer to a document that has been formulated or published by a body or authority either as in force at the time when the document is so applied, incorporated or referred to or as amended, formulated or published from time to time.</content></paragraph></subsection><subsection id="ID_1438411269417_028" name="3" temporalId="s28A_3"><num value="3">(3)</num><leadIn>If the GMP Guide is issued, the Board must by notice published in the Gazette—</leadIn><paragraph id="ID_1438411269417_036" name="a" temporalId="s28A_3_a"><num value="a">(a)</num><content>identify the Guide; and</content></paragraph><paragraph id="ID_1438411269417_044" name="b" temporalId="s28A_3_b"><num value="b">(b)</num><content>specify the date on which the Guide is to take effect.</content></paragraph></subsection><subsection id="ID_1438411269417_051" name="4" temporalId="s28A_4"><num value="4">(4)</num><content>The Board may from time to time revise the whole or any part of the GMP Guide.</content></subsection><subsection id="ID_1438411269417_059" name="5" temporalId="s28A_5"><num value="5">(5)</num><leadIn>If the GMP Guide is revised, the Board must by notice published in the Gazette—</leadIn><paragraph id="ID_1438411269417_067" name="a" temporalId="s28A_5_a"><num value="a">(a)</num><content>identify the Guide or part revised; and</content></paragraph><paragraph id="ID_1438411269417_075" name="b" temporalId="s28A_5_b"><num value="b">(b)</num><content>specify the date on which the revision is to take effect.</content></paragraph></subsection><subsection id="ID_1438411269433_005" name="6" temporalId="s28A_6"><num value="6">(6)</num><leadIn>The Board must make a copy of the GMP Guide available for inspection by the public free of charge—</leadIn><paragraph id="ID_1438411269433_013" name="a" temporalId="s28A_6_a"><num value="a">(a)</num><content>at the office of the Secretary during normal office hours; and</content></paragraph><paragraph id="ID_1438411269433_021" name="b" temporalId="s28A_6_b"><num value="b">(b)</num><content>in any other manner the Board thinks fit.</content></paragraph></subsection><subsection id="ID_1438411269433_028" name="7" temporalId="s28A_7"><num value="7">(7)</num><content>The GMP Guide, and a notice published under paragraph (3) or (5), are not subsidiary legislation.</content><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 49</ref>)</sourceNote></subsection></section><section id="ID_1438402707236_001" name="s29" reason="inEffect" role="regulation" startPeriod="2021-08-01" status="operational" temporalId="s29"><num value="29">29.</num><heading>Licensing of manufacturers</heading><subsection id="ID_1453952351181_001" name="1" temporalId="s29_1"><num value="1">(1)</num><content>A person must not manufacture any pharmaceutical product on any premises unless
                he is the holder of a licence to manufacture pharmaceutical products on those
                premises.</content></subsection><subsection id="ID_1438411269464_013" name="1A" temporalId="s29_1A"><num value="1A">(1A)</num><leadIn>For the purposes of paragraph (1), a person is not regarded as manufacturing a
                pharmaceutical product only by affixing to the container of the product a
                label—</leadIn><paragraph id="ID_1438411269464_021" name="a" temporalId="s29_1A_a"><num value="a">(a)</num><leadIn>that does not state any of the following particulars—</leadIn><subparagraph id="ID_1438411269464_028" name="i" role="subSubParagraph" temporalId="s29_1A_a_i"><num value="i">(i)</num><content>particulars mentioned in <ref>regulation 31(1)(a)</ref>, (b),
                        (e),
                        (f)
                        or (g);
                        <sourceNote>(<ref href="hk/2020/19">19 of 2020 s. 8</ref>)</sourceNote></content></subparagraph><subparagraph id="ID_1438411269464_036" name="ii" role="subSubParagraph" temporalId="s29_1A_a_ii"><num value="ii">(ii)</num><content>particulars regarding the dosage, route or frequency of administration
                        of the product;</content></subparagraph><subparagraph id="ID_1438411269464_044" name="iii" role="subSubParagraph" temporalId="s29_1A_a_iii"><num value="iii">(iii)</num><content>the name of the product; and</content></subparagraph></paragraph><paragraph id="ID_1438411269464_052" name="b" temporalId="s29_1A_b"><num value="b">(b)</num><leadIn>that does not obscure, change or obliterate any of the following particulars
                    labelled on the container—</leadIn><subparagraph id="ID_1438411269464_059" name="i" role="subSubParagraph" temporalId="s29_1A_b_i"><num value="i">(i)</num><content>particulars mentioned in subparagraph (a);</content></subparagraph><subparagraph id="ID_1438411269464_067" name="ii" role="subSubParagraph" temporalId="s29_1A_b_ii"><num value="ii">(ii)</num><content>particulars mentioned in <ref>regulation 31(1)(c)</ref>.
                        <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 50</ref>)</sourceNote></content></subparagraph></paragraph></subsection><subsection id="ID_1438411269464_073" name="2" temporalId="s29_2"><num value="2">(2)</num><sourceNote>(Repealed <ref href="/hk/2015/2">2 of 2015 s. 50</ref>)</sourceNote></subsection><subsection id="ID_1453952351228_002" name="3" temporalId="s29_3"><num value="3">(3)</num><content>The Committee may, subject to any conditions it thinks fit to impose, issue a
                licence to manufacture pharmaceutical products in the specified form on payment of
                the fee prescribed in
                    <ref>Schedule
                    9</ref>.
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></content></subsection><subsection id="ID_1438411269480_006" name="4" temporalId="s29_4"><num value="4">(4)</num><leadIn>In any of the circumstances specified in paragraph (4A), the Committee
                may—</leadIn><paragraph id="ID_1438411269480_014" name="a" temporalId="s29_4_a"><num value="a">(a)</num><content>revoke a licence to manufacture pharmaceutical products or suspend it for a
                    period it thinks fit;</content></paragraph><paragraph id="ID_1438411269480_022" name="b" temporalId="s29_4_b"><num value="b">(b)</num><content>issue a warning letter to the licensed manufacturer; or</content></paragraph><paragraph id="ID_1438411269480_030" name="c" temporalId="s29_4_c"><num value="c">(c)</num><content>vary a condition of the licence imposed under paragraph (3).
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 50</ref>)</sourceNote></content></paragraph></subsection><subsection id="ID_1438411269480_037" name="4A" temporalId="s29_4A"><num value="4A">(4A)</num><leadIn>The circumstances are—</leadIn><paragraph id="ID_1438411269480_045" name="a" temporalId="s29_4A_a"><num value="a">(a)</num><leadIn>that, in the Committee’s opinion, the licensed manufacturer has
                    contravened—</leadIn><subparagraph id="ID_1438411269480_052" name="i" role="subSubParagraph" temporalId="s29_4A_a_i"><num value="i">(i)</num><content>a condition of the licence or any of these regulations; or </content></subparagraph><subparagraph id="ID_1438411269480_060" name="ii" role="subSubParagraph" temporalId="s29_4A_a_ii"><num value="ii">(ii)</num><content>a code of practice applicable to the licensed manufacturer or the GMP
                        Guide; or</content></subparagraph></paragraph><paragraph id="ID_1438411269480_068" name="b" temporalId="s29_4A_b"><num value="b">(b)</num><leadIn>that the licensed manufacturer has been convicted of—</leadIn><subparagraph id="ID_1438411269480_075" name="i" role="subSubParagraph" temporalId="s29_4A_b_i"><num value="i">(i)</num><content>an offence under the Ordinance or any of the regulations made under
                            <ref>section 29</ref>, the Dangerous Drugs Ordinance (<ref href="/hk/cap134">Cap. 134</ref>), the Antibiotics Ordinance (<ref href="/hk/cap137">Cap. 137</ref>) or the Undesirable Medical
                        Advertisements Ordinance (<ref href="/hk/cap231">Cap. 231</ref>);
                        or</content></subparagraph><subparagraph id="ID_1438411269495_007" name="ii" role="subSubParagraph" temporalId="s29_4A_b_ii"><num value="ii">(ii)</num><content>an offence under <ref>section 6C</ref> or <ref>6D</ref> of the Import
                        and Export Ordinance (<ref href="/hk/cap60">Cap. 60</ref>), <ref>section
                            52</ref>, <ref>54</ref> or <ref>61</ref> of the Public Health and
                        Municipal Services Ordinance (<ref href="/hk/cap132">Cap. 132</ref>) or
                            <ref>section 7</ref>, <ref>7A</ref> or <ref>9</ref> of the Trade
                        Descriptions Ordinance (<ref href="/hk/cap362">Cap. 362</ref>).
                        <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 50</ref>)</sourceNote></content></subparagraph></paragraph></subsection><subsection id="ID_1438411269495_014" name="4B" temporalId="s29_4B"><num value="4B">(4B)</num><def name="SuspensionPeriod">The Committee may, subject to any conditions it thinks fit
                to impose, suspend for a period not exceeding 3 years (<term>suspension
                    period</term>) the operation of a decision made under paragraph
                    <ref>(4)(a)</ref> so that the decision takes effect only if a condition so
                imposed is contravened during the suspension period, and in the case of such a
                contravention, the decision takes effect on the date specified by the Committee
                having regard to all the circumstances of the case.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 50</ref>)</sourceNote></def></subsection><subsection id="ID_1438411269511_004" name="5" temporalId="s29_5"><num value="5">(5)</num><leadIn>For the purpose of certifying that a manufacturer is licensed under this
                regulation, the Committee, subject to any conditions it may impose and to the
                payment of the fee prescribed in
                    <ref>Schedule
                    9</ref>, may issue to the manufacturer—
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></leadIn><paragraph id="ID_1453952351322_003" name="a" temporalId="s29_5_a"><num value="a">(a)</num><content>a certificate for manufacture; or</content></paragraph><paragraph class="tied-tag-subparagraph-paragraph" id="ID_1438411269511_021" name="b" temporalId="s29_5_b"><num value="b">(b)</num><content>an interim-certificate for manufacture,</content></paragraph><continued>in the specified
                forms.</continued></subsection><subsection id="ID_1438411269511_033" name="6" temporalId="s29_6"><num value="6">(6)</num><leadIn>For the purpose of exporting pharmaceutical products manufactured by a licensed
                manufacturer, the Committee may, subject to any conditions it may impose and to the
                payment of the fee prescribed in
                    <ref>Schedule
                    9</ref>, issue to the
                        manufacturer— <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s.
                    50</ref>; <ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></leadIn><paragraph id="ID_1453952351337_004" name="a" temporalId="s29_6_a"><num value="a">(a)</num><content>a free sale certificate of pharmaceutical product; or</content></paragraph><paragraph class="tied-tag-subparagraph-paragraph" id="ID_1438411269511_050" name="b" temporalId="s29_6_b"><num value="b">(b)</num><content>a certificate of pharmaceutical product,</content></paragraph><continued>in the specified forms.
                <sourceNote>(<ref href="/hk/1991/ln449">L.N. 449 of 1991</ref>)</sourceNote></continued></subsection><subsection id="ID_1438411269511_062" name="7" temporalId="s29_7"><num value="7">(7)</num><content>Any applicant or licensed manufacturer aggrieved by a decision of the Committee
                under this regulation may, in the prescribed manner, appeal to the Tribunal against
                that decision.
                <sourceNote>(<ref href="/hk/1980/ln369">L.N. 369 of 1980</ref>)</sourceNote></content></subsection><sourceNote>(<ref href="/hk/1980/ln369">L.N. 369 of 1980</ref>; <ref href="/hk/2015/2">2 of
                2015 s.
            50</ref>; <ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section><section id="ID_1438402707252_002" name="s30" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s30"><num value="30">30.</num><heading>Manufacture to be under supervision of a registered pharmacist</heading><subsection id="ID_1438411269573_004" name="1" temporalId="s30_1"><num value="1">(1)</num><leadIn>In all premises in which pharmaceutical products are manufactured such products shall be manufactured by or under the supervision of—</leadIn><paragraph id="ID_1438411269573_012" name="a" temporalId="s30_1_a"><num value="a">(a)</num><content>a registered pharmacist; or
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 51</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411269573_020" name="b" temporalId="s30_1_b"><num value="b">(b)</num><sourceNote>(Repealed <ref href="/hk/2015/2">2 of 2015 s. 51</ref>)</sourceNote></paragraph><paragraph id="ID_1438411269573_028" name="c" temporalId="s30_1_c"><num value="c">(c)</num><content>a person having such other qualifications or sufficient experience as may be approved by the Board.</content></paragraph></subsection><subsection id="ID_1438411269573_035" name="2" temporalId="s30_2"><num value="2">(2)</num><def name="Supervision">For the purposes of paragraph (1),
                    <term>supervision</term>
                    (<term xml:lang="zh-Hant-HK">監督</term>) means the exercise by any of the persons
                referred to in paragraph (1) of control over the process of manufacture and of the
                persons engaged therein.
                <sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>)</sourceNote></def></subsection></section><section id="ID_1438402707267_002" name="s30A" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s30A"><num value="30A">30A.</num><heading>Authorized person to certify compliance with GMP Guide etc.</heading><subsection id="ID_1438411269604_004" name="1" temporalId="s30A_1"><num value="1">(1)</num><content>A licensed manufacturer must ensure that at least one authorized person is
                employed to be responsible for carrying out, in relation to the pharmaceutical
                products manufactured under the licence, the duties specified in paragraph
                (2).</content></subsection><subsection id="ID_1438411269604_012" name="2" temporalId="s30A_2"><num value="2">(2)</num><leadIn>An authorized person is responsible for ensuring and certifying that—</leadIn><paragraph id="ID_1438411269604_020" name="a" temporalId="s30A_2_a"><num value="a">(a)</num><content>each batch of the pharmaceutical products has been manufactured and checked
                    in accordance with the GMP Guide; and</content></paragraph><paragraph id="ID_1438411269604_028" name="b" temporalId="s30A_2_b"><num value="b">(b)</num><content>the registrable particulars of each batch of the pharmaceutical products
                    correspond exactly with the registered particulars of the products.</content></paragraph></subsection><subsection id="ID_1438411269604_035" name="3" temporalId="s30A_3"><num value="3">(3)</num><leadIn>In this regulation—</leadIn><def name="RegisteredParticulars"><term>registered particulars</term> (<term xml:lang="zh-Hant-HK">註冊詳情</term>) has the meaning given by <ref>regulation
                    35A</ref>;</def><def name="RegistrableParticulars"><term>registrable particulars</term> (<term xml:lang="zh-Hant-HK">須註冊詳情</term>) has the meaning given by <ref>regulation
                    35A</ref>.</def></subsection><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 52</ref>)</sourceNote></section><section id="ID_1438402707283_001" name="s30B" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s30B"><num value="30B">30B.</num><heading>Register of authorized persons</heading><subsection id="ID_1438411269636_004" name="1" temporalId="s30B_1"><num value="1">(1)</num><content>The Board must cause the Secretary to keep a register of authorized persons for the purposes of these regulations.</content></subsection><subsection id="ID_1438411269636_012" name="2" temporalId="s30B_2"><num value="2">(2)</num><content>The register may be kept in a form the Board thinks fit.</content></subsection><subsection id="ID_1438411269636_020" name="3" temporalId="s30B_3"><num value="3">(3)</num><leadIn>The register must contain, for each person who is registered as an authorized person under this Part—</leadIn><paragraph id="ID_1438411269636_028" name="a" temporalId="s30B_3_a"><num value="a">(a)</num><content>the name and address of the person; and</content></paragraph><paragraph id="ID_1438411269636_036" name="b" temporalId="s30B_3_b"><num value="b">(b)</num><content>any other particulars of the person the Board thinks fit.</content></paragraph></subsection><subsection id="ID_1438411269636_043" name="4" temporalId="s30B_4"><num value="4">(4)</num><content>The Board may amend the register as to the name, address or any other particulars relating to an authorized person whose name appears in the register on being satisfied that the amendment is necessary for preserving the accuracy of the register.</content></subsection><subsection id="ID_1438411269636_051" name="5" temporalId="s30B_5"><num value="5">(5)</num><leadIn>The Secretary must make the register available for inspection by the public free of charge at the office of the Secretary during normal office hours, and in any other manner the Secretary thinks fit, so as to enable a member of the public—</leadIn><paragraph id="ID_1438411269651_005" name="a" temporalId="s30B_5_a"><num value="a">(a)</num><content>to ascertain whether a person is an authorized person; and</content></paragraph><paragraph id="ID_1438411269651_013" name="b" temporalId="s30B_5_b"><num value="b">(b)</num><content>to ascertain the particulars of the registration of the person.</content><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 52</ref>)</sourceNote></paragraph></subsection></section><section id="ID_1438402707283_003" name="s30C" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s30C"><num value="30C">30C.</num><heading>Application for registration as authorized person</heading><subsection id="ID_1438411269667_034" name="1" temporalId="s30C_1"><num value="1">(1)</num><content>A person who satisfies the requirements specified in paragraph (2) may apply to the Committee for registration as an authorized person.</content></subsection><subsection id="ID_1438411269667_042" name="2" temporalId="s30C_2"><num value="2">(2)</num><leadIn>The requirements are that—</leadIn><paragraph id="ID_1438411269667_050" name="a" temporalId="s30C_2_a"><num value="a">(a)</num><leadIn>the person—</leadIn><subparagraph id="ID_1438411269667_058" name="i" temporalId="s30C_2_a_i"><num value="i">(i)</num><content>is a registered pharmacist; or</content></subparagraph><subparagraph id="ID_1438411269667_066" name="ii" temporalId="s30C_2_a_ii"><num value="ii">(ii)</num><content>holds a qualification awarded on completion of a course recognized by the Committee; and</content></subparagraph></paragraph><paragraph id="ID_1438411269667_073" name="b" temporalId="s30C_2_b"><num value="b">(b)</num><leadIn>the person—</leadIn><subparagraph id="ID_1438411269682_006" name="i" temporalId="s30C_2_b_i"><num value="i">(i)</num><content>has at least 3 years’ relevant experience in Hong Kong or a place outside Hong Kong in manufacturing pharmaceutical products in accordance with the GMP Guide or a document similar or equivalent to that Guide issued or adopted by a competent authority of a place outside Hong Kong; or</content></subparagraph><subparagraph id="ID_1438411269682_014" name="ii" temporalId="s30C_2_b_ii"><num value="ii">(ii)</num><content>meets any other criteria that the Committee may specify.</content></subparagraph></paragraph></subsection><subsection id="ID_1438411269682_020" name="3" temporalId="s30C_3"><num value="3">(3)</num><content>The application must be in the specified form.</content></subsection><subsection id="ID_1438411269682_028" name="4" temporalId="s30C_4"><num value="4">(4)</num><content>The Committee may require the applicant to provide any information or document that the Committee considers reasonably necessary for determining the application.</content><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 52</ref>)</sourceNote></subsection></section><section id="ID_1438402707299_002" name="s30D" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s30D"><num value="30D">30D.</num><heading>Registration as authorized person</heading><subsection id="ID_1438411269714_004" name="1" temporalId="s30D_1"><num value="1">(1)</num><content>The Committee must decide whether to grant or refuse an application for
                registration made under <ref>regulation 30C</ref>.</content></subsection><subsection id="ID_1438411269714_012" name="2" temporalId="s30D_2"><num value="2">(2)</num><content>The Committee may grant an application on being satisfied that the applicant is
                a fit and proper person to be registered as an authorized person.</content></subsection><subsection id="ID_1438411269714_020" name="3" temporalId="s30D_3"><num value="3">(3)</num><content>A registration under this regulation is subject to any conditions the Committee
                thinks fit to impose.</content></subsection><subsection id="ID_1438411269714_028" name="4" temporalId="s30D_4"><num value="4">(4)</num><content>On registration, the Committee must issue to the applicant a certificate of
                registration in the specified form on payment of the fee prescribed in
                    <ref>Schedule
                    9</ref>.
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></content></subsection><subsection id="ID_1438411269714_036" name="5" temporalId="s30D_5"><num value="5">(5)</num><content>Subject to <ref>regulation 30F</ref>, a registration has effect from the date
                on which the certificate of registration is issued until the end of the year in
                which the date falls.</content></subsection><subsection id="ID_1438411269714_044" name="6" temporalId="s30D_6"><num value="6">(6)</num><content>An applicant aggrieved by a decision made in respect of the applicant under
                this regulation may, in the prescribed manner, appeal to the Tribunal against that
                decision.</content></subsection><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 52</ref>; <ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section><section id="ID_1438402707299_004" name="s30E" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s30E"><num value="30E">30E.</num><heading>Renewal of registration of authorized person</heading><subsection id="ID_1438411269745_051" name="1" temporalId="s30E_1"><num value="1">(1)</num><content>The Committee may, on an application, renew the registration of an authorized
                person.</content></subsection><subsection id="ID_1438411269745_059" name="2" temporalId="s30E_2"><num value="2">(2)</num><content>An application for renewal of registration must be in the specified
                form.</content></subsection><subsection id="ID_1438411269745_067" name="3" temporalId="s30E_3"><num value="3">(3)</num><content>The Committee may require the applicant to provide any information or document
                that the Committee considers reasonably necessary for determining the
                application.</content></subsection><subsection id="ID_1438411269760_005" name="4" temporalId="s30E_4"><num value="4">(4)</num><content>A registration renewed under this regulation is subject to any conditions the
                Committee thinks fit to impose.</content></subsection><subsection id="ID_1438411269760_013" name="5" temporalId="s30E_5"><num value="5">(5)</num><content>On renewal of registration, the Committee must issue to the applicant a renewed
                certificate of registration in the specified form on payment of the fee prescribed
                in
                    <ref>Schedule
                    9</ref>.
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></content></subsection><subsection id="ID_1438411269760_021" name="6" temporalId="s30E_6"><num value="6">(6)</num><content>Subject to <ref>regulation 30F</ref>, a renewed registration has effect from
                the date on which the renewed certificate of registration is issued until the end of
                the year in which the date falls.</content></subsection><subsection id="ID_1438411269760_029" name="7" temporalId="s30E_7"><num value="7">(7)</num><content>An applicant aggrieved by a decision made in respect of the applicant under
                this regulation may, in the prescribed manner, appeal to the Tribunal against that
                decision.</content></subsection><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 52</ref>; <ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section><section id="ID_1438402707314_002" name="s30F" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s30F"><num value="30F">30F.</num><heading>Cancellation or suspension etc. of registration as authorized person</heading><subsection id="ID_1438411269792_004" name="1" temporalId="s30F_1"><num value="1">(1)</num><leadIn>The Committee may exercise any one or more of the following powers in any of the circumstances specified in paragraph (2) in respect of a person registered as an authorized person under this Part—</leadIn><paragraph id="ID_1438411269792_012" name="a" temporalId="s30F_1_a"><num value="a">(a)</num><content>cancel the registration;</content></paragraph><paragraph id="ID_1438411269792_020" name="b" temporalId="s30F_1_b"><num value="b">(b)</num><content>suspend the registration for a period specified by the Committee;</content></paragraph><paragraph id="ID_1438411269792_028" name="c" temporalId="s30F_1_c"><num value="c">(c)</num><content>issue a warning letter to the person;</content></paragraph><paragraph id="ID_1438411269792_036" name="d" temporalId="s30F_1_d"><num value="d">(d)</num><content>vary a condition of the registration imposed under <ref>regulation 30D(3)</ref> or <ref>30E(4)</ref>.</content></paragraph></subsection><subsection id="ID_1438411269792_043" name="2" temporalId="s30F_2"><num value="2">(2)</num><leadIn>The circumstances are—</leadIn><paragraph id="ID_1438411269792_051" name="a" temporalId="s30F_2_a"><num value="a">(a)</num><content>that the Committee is satisfied that the person is no longer a fit and proper person to be registered as an authorized person;</content></paragraph><paragraph id="ID_1438411269792_059" name="b" temporalId="s30F_2_b"><num value="b">(b)</num><leadIn>that in the Committee’s opinion, the person has contravened—</leadIn><subparagraph id="ID_1438411269792_067" name="i" temporalId="s30F_2_b_i"><num value="i">(i)</num><content>a condition of the registration; or</content></subparagraph><subparagraph id="ID_1438411269792_075" name="ii" temporalId="s30F_2_b_ii"><num value="ii">(ii)</num><content>any of these regulations or a code of practice applicable to the person as an authorized person; or</content></subparagraph></paragraph><paragraph id="ID_1438411269792_082" name="c" temporalId="s30F_2_c"><num value="c">(c)</num><leadIn>that the person has been convicted of—</leadIn><subparagraph id="ID_1438411269792_090" name="i" temporalId="s30F_2_c_i"><num value="i">(i)</num><content>an offence under the Ordinance or any of the regulations made under <ref>section 29</ref>, the Dangerous Drugs Ordinance (<ref href="/hk/cap134">Cap. 134</ref>), the Antibiotics Ordinance (<ref href="/hk/cap137">Cap. 137</ref>) or the Undesirable Medical Advertisements Ordinance (<ref href="/hk/cap231">Cap. 231</ref>); or</content></subparagraph><subparagraph id="ID_1438411269807_007" name="ii" temporalId="s30F_2_c_ii"><num value="ii">(ii)</num><content>an offence under <ref>section 52</ref>, <ref>54</ref> or <ref>61</ref> of the Public Health and Municipal Services Ordinance (<ref href="/hk/cap132">Cap. 132</ref>) or <ref>section 7</ref>, <ref>7A</ref> or <ref>9</ref> of the Trade Descriptions Ordinance (<ref href="/hk/cap362">Cap. 362</ref>).</content></subparagraph></paragraph></subsection><subsection id="ID_1438411269807_013" name="3" temporalId="s30F_3"><num value="3">(3)</num><def name="SuspensionPeriod">The Committee may, subject to any conditions it thinks fit to impose, suspend for a period not exceeding 3 years (<term>suspension period</term>) the operation of a decision made under paragraph <ref>(1)(a)</ref> or (b) so that the decision takes effect only if a condition so imposed is contravened during the suspension period, and in the case of such a contravention, the decision takes effect on the date specified by the Committee having regard to all the circumstances of the case.</def></subsection><subsection id="ID_1438411269823_004" name="4" temporalId="s30F_4"><num value="4">(4)</num><leadIn>The Committee must cause the Secretary to—</leadIn><paragraph id="ID_1438411269823_012" name="a" temporalId="s30F_4_a"><num value="a">(a)</num><content>as soon as practicable after cancelling a person’s registration under paragraph <ref>(1)(a)</ref>, remove the entries relating to the person from the register of authorized persons; or</content></paragraph><paragraph id="ID_1438411269823_020" name="b" temporalId="s30F_4_b"><num value="b">(b)</num><content>as soon as practicable after suspending a person’s registration under paragraph <ref>(1)(b)</ref>, remove the entries relating to the person from the register of authorized persons, and restore those entries to the register as soon as practicable after the period of suspension expires.</content></paragraph></subsection><subsection id="ID_1438411269823_027" name="5" temporalId="s30F_5"><num value="5">(5)</num><content>A person whose registration as an authorized person is cancelled must immediately return to the Committee the certificate of registration or renewed certificate of registration issued to the person under <ref>regulation 30D</ref> or <ref>30E</ref>.</content></subsection><subsection id="ID_1438411269823_035" name="6" temporalId="s30F_6"><num value="6">(6)</num><content>A person mentioned in paragraph (1) who is aggrieved by a decision made in respect of the person under this regulation may, in the prescribed manner, appeal to the Tribunal against that decision.</content><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 52</ref>)</sourceNote></subsection></section><section id="ID_1438402707330_002" name="s31" reason="inEffect" role="regulation" startPeriod="2021-08-01" status="operational" temporalId="s31"><num value="31">31.</num><heading>Labelling by licensed
            manufacturers</heading><sourceNote class="align_right">(<ref href="/hk/2015/2">2 of 2015 s. 53</ref>)</sourceNote><subsection id="ID_1453961673827_001" name="1" temporalId="s31_1"><num value="1">(1)</num><leadIn>Subject to paragraph (4), a licensed manufacturer shall label or cause to be
                labelled the container of each pharmaceutical product, with the following
                        particulars— <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 53</ref>)</sourceNote></leadIn><paragraph id="ID_1438411269870_027" name="a" temporalId="s31_1_a"><num value="a">(a)</num><leadIn>the appropriate designation of—</leadIn><subparagraph id="ID_1438411269870_035" name="i" temporalId="s31_1_a_i"><num value="i">(i)</num><content>the substance or substances from which the pharmaceutical product was
                        manufactured;</content></subparagraph><subparagraph id="ID_1438411269870_043" name="ii" temporalId="s31_1_a_ii"><num value="ii">(ii)</num><content>each of the active constituents of the product; or</content></subparagraph><subparagraph id="ID_1438411269885_007" name="iii" temporalId="s31_1_a_iii"><num value="iii">(iii)</num><content>each of the ingredients from which the product was
                        compounded;</content></subparagraph></paragraph><paragraph id="ID_1438411269885_014" name="b" temporalId="s31_1_b"><num value="b">(b)</num><content>in the case where the appropriate designation of each of the active
                    constituents or ingredients of a product is given, the appropriate quantitative
                    particulars of those constituents or ingredients;</content></paragraph><paragraph id="ID_1438411269885_022" name="c" temporalId="s31_1_c"><num value="c">(c)</num><content>the name and address of the manufacturer;
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 53</ref>)</sourceNote></content></paragraph><paragraph id="ID_1626055814893_001" name="d" temporalId="s31_1_d"><num value="d">(d)</num><content>for a pharmaceutical product registered under <ref>regulation 36</ref>—the
                    number of the registration certificate issued under <ref>regulation 36(5)</ref>;
                        <sourceNote>(<ref href="hk/2020/19">19 of 2020 s. 9</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411269885_037" name="e" temporalId="s31_1_e"><num value="e">(e)</num><content>the batch number of the pharmaceutical product;
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s.
                        53</ref>; <ref href="hk/2020/19">19 of 2020 s. 9</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411269885_045" name="f" temporalId="s31_1_f"><num value="f">(f)</num><content>the expiry date of the pharmaceutical product;
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s.
                        53</ref>; <ref href="hk/2020/19">19 of 2020 s. 9</ref>)</sourceNote></content></paragraph><paragraph id="ID_1626055815155_002" name="g" temporalId="s31_1_g"><num value="g">(g)</num><leadIn>for an advanced therapy product—</leadIn><subparagraph id="ID_1626055815156_003" name="1" temporalId="s31_1_g_1"><num value="1">(i)</num><content>the product code, and the unique donation identifier, assigned in
                        accordance with the codes of practice issued by the Board; and</content></subparagraph><subparagraph id="ID_1626055815157_004" name="2" temporalId="s31_1_g_2"><num value="2">(ii)</num><leadIn>if the product is for autologous use only—</leadIn><subparagraph role="subSubparagraph" id="ID_1626055815157_005" name="A" temporalId="s31_1_g_2_A"><num value="A">(A)</num><content>the unique recipient identifier assigned in accordance with the
                            codes of practice issued by the Board; and</content></subparagraph><subparagraph role="subSubparagraph" id="ID_1626055815158_006" name="B" temporalId="s31_1_g_2_B"><num value="B">(B)</num><content>the English words “For autologous use only” or the Chinese
                            characters “只供自體使用”. <sourceNote>(<ref href="hk/2020/19">19 of 2020 s. 9</ref>)</sourceNote></content></subparagraph></subparagraph></paragraph></subsection><subsection id="ID_1453961673999_002" name="2" temporalId="s31_2"><num value="2">(2)</num><leadIn>For the purposes of paragraph (1)—</leadIn><paragraph id="ID_1438411269885_061" name="a" temporalId="s31_2_a"><num value="a">(a)</num><def name="AppropriateDesignation">
                    
                    
                    
                    <leadIn>the expression
                            <term>appropriate
                            designation</term>
                            (<term xml:lang="zh-Hant-HK">適當稱號</term>), in relation to a substance,
                        constituent or ingredient, means—</leadIn>
                    <subparagraph id="ID_1438411269885_069" name="i" temporalId="s31_2_a_i"><num value="i">(i)</num><content>in the case of a poison included in the Poisons List, the name with
                            which the container of the poison is for the time being required to be
                            labelled in accordance with <ref>regulation 13</ref>;</content></subparagraph>
                    <subparagraph id="ID_1438411269901_007" name="ii" temporalId="s31_2_a_ii"><num value="ii">(ii)</num><content>in the case where a substance, constituent or ingredient is not a
                            poison and is described in any of the monographs contained in the
                            edition of the British
                            Pharmacopoeia,
                            the British Pharmaceutical Codex or the British Veterinary Codex which
                            was last published before the date on which the article was sold or
                            supplied, the description set out at the head of that monograph;
                            and</content></subparagraph>
                    
                    
                    
                    <subparagraph id="ID_1438411269901_015" name="iii" temporalId="s31_2_a_iii"><num value="iii">(iii)</num><content>in any other case the accepted scientific name or the name
                            descriptive of the true nature and origin of the substance, constituent
                            or ingredient;</content></subparagraph>
                    
                    
                    
                </def></paragraph><paragraph id="ID_1438411269901_022" name="b" temporalId="s31_2_b"><num value="b">(b)</num><def name="AppropriateQuantitativeParticulars">
                    
                    
                    
                    <leadIn>the expression
                            <term>appropriate
                            quantitative
                        particulars</term>
                            (<term xml:lang="zh-Hant-HK">適當數量詳情</term>), in relation to the active
                        constituent or ingredient of a pharmaceutical product, means—</leadIn>
                    
                    
                    
                    <subparagraph id="ID_1438411269901_030" name="i" temporalId="s31_2_b_i"><num value="i">(i)</num><content>the percentage or quantity of that constituent or ingredient
                            contained in the pharmaceutical product sold or supplied; or</content></subparagraph>
                    
                    
                    
                    <subparagraph id="ID_1438411269901_038" name="ii" temporalId="s31_2_b_ii"><num value="ii">(ii)</num><content>in the case of a pharmaceutical product which is in pill, capsule,
                            tablet or similar article, either the percentage or quantity of the
                            substance or substances comprising or forming part of the pills,
                            capsules, tablets or similar articles, or the quantity of each
                            constituent or ingredient in each pill, capsule, tablet or article;
                            <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 53</ref>)</sourceNote></content></subparagraph>
                    
                    
                    
                </def></paragraph><paragraph id="ID_1438411269916_005" name="c" temporalId="s31_2_c"><num value="c">(c)</num><def name="BatchNumber">
                    
                    
                    
                    <leadIn><term>batch number</term> (<term xml:lang="zh-Hant-HK">批次編號</term>), in
                        relation to a pharmaceutical product, means a unique combination of numbers,
                        letters or other symbols from which—</leadIn>
                    
                    
                    
                    <subparagraph id="ID_1438411269916_013" name="i" temporalId="s31_2_c_i"><num value="i">(i)</num><content>the batch or lot to which the product belongs can be identified;
                            and</content></subparagraph>
                    
                    
                    <subparagraph id="ID_1438411269916_021" name="ii" temporalId="s31_2_c_ii"><num value="ii">(ii)</num><content>the production and distribution history of the product can be determined.
                            <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s.
                                53</ref>; <ref href="hk/2020/19">19 of 2020 s. 9</ref>)</sourceNote></content></subparagraph>
                    
                    
                    
                </def></paragraph><paragraph id="ID_1438411269916_028" name="d" temporalId="s31_2_d"><num value="d">(d)</num><sourceNote>(Repealed <ref href="hk/2020/19">19 of 2020 s. 9</ref>)</sourceNote></paragraph></subsection><subsection id="ID_1438411269916_035" name="3" temporalId="s31_3"><num value="3">(3)</num><content>For the purposes of paragraph (1) the container to be labelled shall, where the
                pharmaceutical product is packed by the manufacturer in more than one container, be
                the container which is likely to be sold or distributed to the ultimate user of the
                product.</content></subsection><subsection id="ID_1438411269932_005" name="4" temporalId="s31_4"><num value="4">(4)</num><leadIn>In the case of a pharmaceutical product intended for export it shall be a
                sufficient compliance with this regulation if the container of the product is
                labelled with the following particulars—</leadIn><paragraph id="ID_1438411269932_013" name="a" temporalId="s31_4_a"><num value="a">(a)</num><content>the name and address of the manufacturer; and</content></paragraph><paragraph id="ID_1438411269932_021" name="b" temporalId="s31_4_b"><num value="b">(b)</num><content>such other details as the importing country may require.
                    <sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>)</sourceNote></content></paragraph></subsection></section><section id="ID_1438402707345_002" name="s32" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s32"><num value="32">32.</num><heading>Manufacturing workers not to infect products</heading><content>A licensed manufacturer must take adequate steps to ensure that every person
            engaged in the manufacturing of pharmaceutical products does not contaminate or infect
            such
            products.</content><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 54</ref>)</sourceNote></section><section id="ID_1438402707361_002" name="s33" reason="inEffect" role="regulation" startPeriod="2021-08-01" status="operational" temporalId="s33"><num value="33">33.</num><heading>Duties of licensed manufacturers regarding identity, purity, safety,
            etc.</heading><sourceNote class="align_right">(<ref href="/hk/2015/2">2 of 2015 s. 55</ref>)</sourceNote><subsection id="ID_1438411269994_018" name="1" temporalId="s33_1"><num value="1">(1)</num><content>Subject to paragraph (1A), a licensed manufacturer must test each lot or batch
                of raw or bulk material intended to be used in the manufacture of pharmaceutical
                products to ensure identity and purity.
                <sourceNote>(<ref href="hk/1978/ln137">L.N. 137 of
                1978</ref>)</sourceNote></content></subsection><subsection id="ID_1438411269994_026" name="1A" temporalId="s33_1A"><num value="1A">(1A)</num><content>Raw or bulk material the identity and purity of which the manufacturer thereof
                has certified by a certificate of analysis does not require a test by a licensed
                manufacturer under paragraph (1).
                <sourceNote>(<ref href="hk/1978/ln137">L.N. 137 of
                1978</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270010_005" name="2" temporalId="s33_2"><num value="2">(2)</num><content>A licensed manufacturer must ensure that the registrable particulars of each
                batch of pharmaceutical products in a finished form correspond exactly with the
                registered particulars of the products.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 55</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270010_013" name="3" temporalId="s33_3"><num value="3">(3)</num><content>Every parenteral product shall be manufactured in accordance with the method of
                preparation of injections laid down by the British Pharmacopoeia or other
                Pharmacopoeia with which the particular product is intended to comply.</content></subsection><subsection id="ID_1438411270010_021" name="4" temporalId="s33_4"><num value="4">(4)</num><content>Unless paragraph
                (4B) or
                (4D) applies, a licensed manufacturer must retain a control sample
                of each batch of finished products under conditions of storage suitable to that
                product for a period of not less than 1 year after the expiry date of the product.
                <sourceNote>(<ref href="hk/1978/ln137">L.N. 137 of
                    1978</ref>; <ref href="hk/2020/19">19 of 2020 s. 10</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270010_029" name="4A" temporalId="s33_4A"><num value="4A">(4A)</num><leadIn>Paragraph (4B) applies to a licensed manufacturer in respect of a batch of
                pharmaceutical products if all of the following conditions are satisfied—</leadIn><paragraph id="ID_1438411270026_005" name="a" temporalId="s33_4A_a"><num value="a">(a)</num><content>the products are enclosed in a primary container in which the products are
                    to be sold or supplied;</content></paragraph><paragraph id="ID_1438411270026_013" name="b" temporalId="s33_4A_b"><num value="b">(b)</num><leadIn>the process of manufacture that the manufacturer carries out, in respect of
                    the products, only involves one or more of the following—</leadIn><subparagraph id="ID_1438411270026_021" name="i" temporalId="s33_4A_b_i"><num value="i">(i)</num><content>adding a package insert;</content></subparagraph><subparagraph id="ID_1438411270026_029" name="ii" temporalId="s33_4A_b_ii"><num value="ii">(ii)</num><content>replacing a package insert;</content></subparagraph><subparagraph id="ID_1438411270026_037" name="iii" temporalId="s33_4A_b_iii"><num value="iii">(iii)</num><leadIn>(if the products are intended for export) affixing a label to any
                        labelled container of the products, and the label does not obscure, change
                        or obliterate any of the following particulars appearing on that labelled
                        container—</leadIn><subparagraph id="ID_1438411270026_044" name="A" role="subSubParagraph" temporalId="s33_4A_b_iii_A"><num value="A">(A)</num><content>particulars required to be labelled under <ref>regulation
                                31(4)</ref>;</content></subparagraph><subparagraph id="ID_1438411270026_052" name="B" role="subSubParagraph" temporalId="s33_4A_b_iii_B"><num value="B">(B)</num><content>the name of the products;</content></subparagraph><subparagraph id="ID_1438411270026_060" name="C" role="subSubParagraph" temporalId="s33_4A_b_iii_C"><num value="C">(C)</num><content>the batch number of the products;</content></subparagraph><subparagraph id="ID_1438411270026_068" name="D" role="subSubParagraph" temporalId="s33_4A_b_iii_D"><num value="D">(D)</num><content>the expiry date of the products;</content></subparagraph></subparagraph><subparagraph id="ID_1438411270026_076" name="iv" temporalId="s33_4A_b_iv"><num value="iv">(iv)</num><leadIn>(if the products are not intended for export) affixing a label to any
                        labelled container of the products, and the label does not obscure, change
                        or obliterate any of the following particulars appearing on that labelled
                        container—</leadIn><subparagraph id="ID_1438411270026_083" name="A" role="subSubParagraph" temporalId="s33_4A_b_iv_A"><num value="A">(A)</num><content>the registered particulars of the products;</content></subparagraph><subparagraph id="ID_1438411270026_091" name="B" role="subSubParagraph" temporalId="s33_4A_b_iv_B"><num value="B">(B)</num><content>the batch number of the products;</content></subparagraph><subparagraph id="ID_1438411270026_099" name="C" role="subSubParagraph" temporalId="s33_4A_b_iv_C"><num value="C">(C)</num><content>the expiry date of the products;</content></subparagraph></subparagraph></paragraph><paragraph id="ID_1438411270041_006" name="c" temporalId="s33_4A_c"><num value="c">(c)</num><content>throughout the process of manufacture, the primary container remains closed.
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 55</ref>)</sourceNote></content></paragraph></subsection><subsection id="ID_1438411270041_013" name="4B" temporalId="s33_4B"><num value="4B">(4B)</num><leadIn>The manufacturer is only required to retain a sample of the following of the
                batch of finished products for a period of not less than 1 year after the expiry
                date of the products—</leadIn><paragraph id="ID_1438411270041_021" name="a" temporalId="s33_4B_a"><num value="a">(a)</num><content>if paragraph <ref>(4A)(b)(i)</ref> applies, the package insert
                    added;</content></paragraph><paragraph id="ID_1438411270041_029" name="b" temporalId="s33_4B_b"><num value="b">(b)</num><content>if paragraph <ref>(4A)(b)(ii)</ref> applies, the replacing package
                    insert;</content></paragraph><paragraph id="ID_1438411270041_037" name="c" temporalId="s33_4B_c"><num value="c">(c)</num><content>if paragraph <ref>(4A)(b)(iii)</ref> or (iv) applies, the label affixed.
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 55</ref>)</sourceNote></content></paragraph></subsection><subsection id="ID_1626159975439_001" name="4C" temporalId="s33_4C"><num value="4C">(4C)</num><content>Paragraph (4D) applies to a licensed manufacturer of an advanced therapy
                product containing or consisting of cells or tissues. <sourceNote>(<ref href="hk/2020/19">19 of 2020 s. 10</ref>)</sourceNote></content></subsection><subsection id="ID_1626159975441_002" name="4D" temporalId="s33_4D"><num value="4D">(4D)</num><content>The manufacturer is only required to keep photographs that clearly present the
                particulars mentioned in <ref>regulation 31(1)</ref> of each batch of finished
                products for a period of not less than 1 year after the expiry date of the products.
                    <sourceNote>(<ref href="hk/2020/19">19 of 2020 s. 10</ref>)</sourceNote></content></subsection><subsection id="ID_1453963546020_001" name="5" temporalId="s33_5"><num value="5">(5)</num><content>A licensed manufacturer must set up and maintain a system of control that will
                enable the rapid and, so far as practicable, complete recall of any lot or batch of
                a pharmaceutical substance or product from sale to the public in the event of the
                pharmaceutical substance or product being found to be dangerous or injurious to health.
                <sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>)</sourceNote></content></subsection><subsection id="ID_1453963546051_002" name="6" temporalId="s33_6"><num value="6">(6)</num><content>Despite paragraphs (4),
                <ref>(4B)(c)</ref>
                and
                <ref>(4D)</ref>,
                a licensed manufacturer is not required to comply with paragraph (4),
                <ref>(4B)(c)</ref>
                or
                    <ref>(4D)</ref>
                (as
                applicable) in respect of a batch of pharmaceutical products if the manufacturer is
                not regarded as manufacturing the products for the purposes of <ref>regulation
                    29(1)</ref>.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s.
                    55</ref>; <ref href="hk/2020/19">19 of 2020 s. 10</ref>)</sourceNote></content></subsection><subsection id="ID_1453963546083_003" name="7" temporalId="s33_7"><num value="7">(7)</num><leadIn>In this regulation—</leadIn><def name="BatchNumber"><term>batch number</term> (<term xml:lang="zh-Hant-HK">批次編號</term>) has the meaning given by <ref>regulation 31(2)(c)</ref>;</def><def name="LabelledContainer">
                <leadIn><term>labelled container</term> (<term xml:lang="zh-Hant-HK">帶標籤容器</term>),
                    for a pharmaceutical product, means a container of the product on which the
                    following particulars appear—</leadIn>
                <paragraph id="ID_1438411270057_033" name="a" temporalId="s33_7_a"><num value="a">(a)</num><content>the name of the product;</content></paragraph>
                <paragraph id="ID_1438411270057_041" name="b" temporalId="s33_7_b"><num value="b">(b)</num><content>the batch number of the product;</content></paragraph>
                <paragraph id="ID_1438411270057_049" name="c" temporalId="s33_7_c"><num value="c">(c)</num><content>the expiry date of the product;</content></paragraph>
            </def><def name="PackageInsert"><term>package insert</term> (<term xml:lang="zh-Hant-HK">包裝附頁</term>) has the meaning given by <ref>regulation 36(3A)</ref>;</def><def name="PrimaryContainer"><term>primary container</term> (<term xml:lang="zh-Hant-HK">最內層容器</term>), for a pharmaceutical product, means the container that is in
                direct contact with the product;</def><def name="RegisteredParticulars"><term>registered particulars</term> (<term xml:lang="zh-Hant-HK">註冊詳情</term>) has the meaning given by <ref>regulation
                    35A</ref>;</def><def name="RegistrableParticulars"><term>registrable particulars</term> (<term xml:lang="zh-Hant-HK">須註冊詳情</term>) has the meaning given by <ref>regulation
                    35A</ref>.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 55</ref>)</sourceNote></def></subsection><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s.
            55</ref>; <ref href="hk/2020/19">19 of 2020 s. 10</ref>)</sourceNote></section><section id="ID_1438402707377_001" name="s34" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s34"><num value="34">34.</num><heading>Licensed manufacturer’s
            premises</heading><sourceNote class="align_right">(<ref href="/hk/2015/2">2 of 2015 s. 56</ref>)</sourceNote><subsection id="ID_1438411270135_004" name="1" temporalId="s34_1"><num value="1">(1)</num><leadIn>No pharmaceutical product shall be manufactured unless the premises and the
                fittings and machinery therein used in the manufacturing of such product are of such
                construction, materials and finish as
                        to— <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 56</ref>)</sourceNote></leadIn><paragraph id="ID_1438411270135_012" name="a" temporalId="s34_1_a"><num value="a">(a)</num><content>permit the ready and efficient cleaning of all surfaces; and</content></paragraph><paragraph id="ID_1438411270135_020" name="b" temporalId="s34_1_b"><num value="b">(b)</num><content>avoid the contamination of the product during manufacture.
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 56</ref>)</sourceNote></content></paragraph></subsection><subsection id="ID_1438411270135_027" name="2" temporalId="s34_2"><num value="2">(2)</num><leadIn>All premises used in the manufacturing, testing and despatch of pharmaceutical
                products shall
                        be— <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 56</ref>)</sourceNote></leadIn><paragraph id="ID_1438411270135_035" name="a" temporalId="s34_2_a"><num value="a">(a)</num><content>suitable for the purpose; and</content></paragraph><paragraph id="ID_1438411270135_043" name="b" temporalId="s34_2_b"><num value="b">(b)</num><content>maintained in a clean and orderly condition.</content></paragraph></subsection><subsection id="ID_1438411270135_050" name="3" temporalId="s34_3"><num value="3">(3)</num><content>The temperature and humidity of the premises shall be controlled as appropriate
                to the manufacture of the product or the process being carried out
                therein.</content></subsection><subsection id="ID_1438411270150_006" name="4" temporalId="s34_4"><num value="4">(4)</num><content>All parenteral products shall be manufactured and put into containers in an
                enclosed area in which aseptic conditions can be maintained.</content></subsection><subsection id="ID_1438411270150_014" name="5" temporalId="s34_5"><num value="5">(5)</num><content>The enclosed area referred to in paragraph (4) shall be separate from the areas
                used for the manufacture of other pharmaceutical products.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 56</ref>)</sourceNote></content></subsection></section><section id="ID_1438402707392_001" name="s35" reason="inEffect" role="regulation" startPeriod="2021-08-01" status="operational" temporalId="s35"><num value="35">35.</num><heading>Records to be kept by licensed
            manufacturers</heading><sourceNote class="align_right">(<ref href="/hk/2015/2">2 of 2015 s. 57</ref>)</sourceNote><subsection id="ID_1438411270182_004" name="1" temporalId="s35_1"><num value="1">(1)</num><leadIn>A licensed manufacturer must maintain adequate records in respect of each
                pharmaceutical product prepared by him,
                        showing— <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 57</ref>)</sourceNote></leadIn><paragraph id="ID_1438411270182_012" name="a" temporalId="s35_1_a"><num value="a">(a)</num><content>the quantities of all substances used in the manufacture of the
                    product;</content></paragraph><paragraph id="ID_1438411270182_020" name="b" temporalId="s35_1_b"><num value="b">(b)</num><content>the quantity of the product manufactured;</content></paragraph><paragraph id="ID_1438411270182_028" name="c" temporalId="s35_1_c"><num value="c">(c)</num><content>the name and the address of the person to whom the pharmaceutical product
                    was sold or supplied;</content></paragraph><paragraph id="ID_1626142049491_001" name="ca" temporalId="s35_1_ca"><num value="ca">(ca)</num><content>for an advanced therapy product sold or supplied for use by a registered
                    medical practitioner or registered dentist—the name and address of the
                    practitioner or dentist; <sourceNote>(<ref href="hk/2020/19">19 of 2020 s. 11</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411270182_036" name="d" temporalId="s35_1_d"><num value="d">(d)</num><content>the nature and results of tests made on each lot or batch of raw or bulk
                    materials used in the product;</content></paragraph><paragraph id="ID_1438411270182_044" name="e" temporalId="s35_1_e"><num value="e">(e)</num><content>the nature and results of tests made on each batch of finished
                    product;</content></paragraph><paragraph id="ID_1438411270182_052" name="f" temporalId="s35_1_f"><num value="f">(f)</num><content>any complaints received relating to the product and the action taken
                    on
                    the complaints by the manufacturer; </content></paragraph><paragraph id="ID_1438411270197_006" name="g" temporalId="s35_1_g"><num value="g">(g)</num><content>the nature and result of any tests made on the samples
                    retained; and
                    <sourceNote>(<ref href="/hk/1975/ln228">L.N. 228 of 1975</ref>)</sourceNote></content></paragraph><paragraph id="ID_1626142049595_002" name="h" temporalId="s35_1_h"><num value="h">(h)</num><leadIn>for an advanced therapy product containing or consisting of cells or
                    tissues—</leadIn><subparagraph id="ID_1626142049597_003" name="1" temporalId="s35_1_h_1"><num value="1">(i)</num><content>the name and address of the person from whom the cells or tissues used
                        for the preparation of the product were obtained; and</content></subparagraph><subparagraph id="ID_1626142049598_004" name="2" temporalId="s35_1_h_2"><num value="2">(ii)</num><content>the unique donation identifier assigned in accordance with the codes of
                        practice issued by the Board. <sourceNote>(<ref href="hk/2020/19">19 of 2020 s. 11</ref>)</sourceNote></content></subparagraph></paragraph></subsection><subsection id="ID_1438411270197_013" name="2" temporalId="s35_2"><num value="2">(2)</num><content>A record showing the matters mentioned in paragraph <ref>(1)(a)</ref>, (b),
                (d),
                (e),
                (g) or
                (h) must be completed when the manufacturing process or test
                concerned is being carried out.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 57</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270197_021" name="3" temporalId="s35_3"><num value="3">(3)</num><content>A record showing the matters mentioned in paragraph
                <ref>(1)(c)</ref>
                or (ca) must be completed within 72 hours after the transaction
                concerned takes place.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 57</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270197_029" name="4" temporalId="s35_4"><num value="4">(4)</num><leadIn>For the purposes of paragraph <ref>(1)(f)</ref>—</leadIn><paragraph id="ID_1438411270197_037" name="a" temporalId="s35_4_a"><num value="a">(a)</num><content>a record showing a complaint must be completed within 72 hours after the
                    complaint is received by the licensed manufacturer;
                    and</content></paragraph><paragraph id="ID_1438411270197_045" name="b" temporalId="s35_4_b"><num value="b">(b)</num><content>a record showing an action taken in respect of a complaint must be
                    completed within 72 hours after the action is taken.
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 57</ref>)</sourceNote></content></paragraph></subsection><sourceNote>(<ref href="hk/2020/19">19 of 2020 s. 11</ref>)</sourceNote></section></part><part id="ID_1438402707392_003" name="P8" reason="inEffect" startPeriod="2015-11-12" status="operational" temporalId="P8"><num value="8">Part
            8</num><heading>Registration
            of Pharmaceutical Products and Substances</heading><section id="ID_1438402707408_002" name="s35A" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s35A"><num value="35A">35A.</num><heading>Interpretation (Part
            8)</heading><leadIn>In this Part, unless the context otherwise requires—</leadIn><def name="AdditionalParticulars"><term>additional
                particulars</term>
                (<term xml:lang="zh-Hant-HK">附加詳情</term>), in relation to a pharmaceutical product
            or substance registered before the commencement date, means those registrable
            particulars of the product or substance not referred to in the repealed <ref>regulation
                36(3)</ref>;</def><def name="CommencementDate"><term>commencement
                date</term>
                (<term xml:lang="zh-Hant-HK">生效日期</term>) means the commencement date* of
                <ref>section 4</ref> of the Pharmacy and Poisons (Amendment) (No. 2)
            Regulation 1995 
            (<ref href="/hk/1995/ln366">L.N. 366 of
            1995</ref>);</def><def name="RegisteredParticulars">
            <leadIn><term>registered
                    particulars</term>
                    (<term xml:lang="zh-Hant-HK">註冊詳情</term>) means—</leadIn>
            <paragraph id="ID_1438411270244_033" name="a" temporalId="s35A_a"><num value="a">(a)</num><leadIn>in relation to a pharmaceutical product or substance registered before the
                    commencement date—</leadIn><subparagraph id="ID_1438411270244_041" name="i" temporalId="s35A_a_i"><num value="i">(i)</num><content>such of its particulars as are registered under the repealed
                            <ref>regulation 36(3)</ref>; and</content></subparagraph><subparagraph id="ID_1438411270244_049" name="ii" temporalId="s35A_a_ii"><num value="ii">(ii)</num><content>its additional particulars as contained in or ascertainable from the
                        application form, the relevant literature and supporting documents (if any)
                        submitted to the Committee for the purpose of the registration of the
                        product or substance, or as contained in or ascertainable from the specimen
                        sales packs or samples (or prototypes of the packs and proposed wordings of
                        the labels) made available for inspection by the Committee for the purpose
                        of the registration of the product or substance;</content></subparagraph></paragraph>
            <paragraph id="ID_1438411270260_006" name="b" temporalId="s35A_b"><num value="b">(b)</num><content>in relation to a pharmaceutical product or substance registered on or after
                    the commencement date, its registrable particulars as registered under
                        <ref>regulation 36(3)</ref>, or</content></paragraph>
            <continued>in either case, where from time to time any subsequent approval has been
                given by the Board or the Committee to change any of the registrable particulars of
                the product or substance as from a certain date, then as from that date, its said
                particulars changed in accordance with such approval;</continued>
        </def><def name="RegisteredProductOrSubstance"><term>registered
                product or
            substance</term>
                (<term xml:lang="zh-Hant-HK">註冊製品或物質</term>) means any pharmaceutical product or
            substance which is the subject of a valid registration certificate issued under
                <ref>regulation 36(5)</ref>;</def><def name="RegistrableParticulars"><term>registrable
                particulars</term>
                (<term xml:lang="zh-Hant-HK">須註冊詳情</term>), in relation to a pharmaceutical
            substance, means the particulars referred to in <ref>regulation 36(3)(a)</ref>, and, in
            relation to a pharmaceutical product, means all of the particulars referred to in
                <ref>regulation 36(3)(a)</ref> and (b);</def><def name="RepealedRegulation363"><term>repealed
                    <ref>regulation
            36(3)</ref></term>
                (<term xml:lang="zh-Hant-HK">已廢除的<ref>第36(3)條</ref></term>) means the
                <ref>regulation 36(3)</ref> which was in force immediately before the commencement
            date.</def><sourceNote>(<ref href="/hk/1995/ln366">L.N. 366 of
            1995</ref>; <ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote><editorialNote type="footnote" id="ID_1596601226460_001">
            <content>Editorial Note:</content>
            <content><inline class="force_orig_font">*</inline>
                Commencement
                date:
                28
                July 1995.</content>
        </editorialNote></section><section id="ID_1438402707423_001" name="s36" reason="inEffect" role="regulation" startPeriod="2021-08-01" status="operational" temporalId="s36"><num value="36">36.</num><heading>Registration of pharmaceutical products and substances</heading><subsection id="ID_1438411270306_053" name="1" temporalId="s36_1"><num value="1">(1)</num><leadIn>Subject to paragraphs (1A), (1B) and (1C), no person shall sell, offer for sale
                or distribute or possess for the purposes of sale, distribution or other use any
                pharmaceutical product or substance unless the product or substance is registered
                with the
                        Board— <sourceNote>(<ref href="/hk/1987/ln85">L.N. 85 of 1987</ref>; <ref href="/hk/1995/ln366">L.N.
                        366 of 1995</ref>)</sourceNote></leadIn><paragraph id="ID_1438411270322_005" name="a" temporalId="s36_1_a"><num value="a">(a)</num><content>by the licensed manufacturer, or a licensed wholesale dealer who has
                    entered into a contract with the licensed manufacturer under which the licensed
                    manufacturer is required to manufacture the pharmaceutical product or substance,
                    if the pharmaceutical product or substance is manufactured in Hong
                    Kong;</content></paragraph><paragraph id="ID_1438411270322_013" name="b" temporalId="s36_1_b"><num value="b">(b)</num><content>by a person referred to in <ref>section 28A(1)</ref> or (3) who imports the
                    pharmaceutical product or substance into Hong Kong, if the pharmaceutical
                    product or substance is manufactured outside Hong Kong; or</content></paragraph><paragraph id="ID_1438411270322_021" name="c" temporalId="s36_1_c"><num value="c">(c)</num><content>by the local branch, subsidiary, representative, agent or distributor of a
                    manufacturer outside Hong Kong.
                    <sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>; <ref href="/hk/1998/23">23
                            of 1998 s. 2</ref>; <ref href="/hk/2015/2">2 of 2015 s.
                        58</ref>)</sourceNote></content></paragraph></subsection><subsection id="ID_1453965234592_001" name="1A" temporalId="s36_1A"><num value="1A">(1A)</num><leadIn>Nothing in paragraph (1) shall apply in the case of possession or use where the
                pharmaceutical product or substance—</leadIn><paragraph id="ID_1453965234592_002" name="a" temporalId="s36_1A_a"><num value="a">(a)</num><leadIn>has been imported into Hong Kong—</leadIn><subparagraph id="ID_1438411270322_044" name="i" temporalId="s36_1A_a_i"><num value="i">(i)</num><content>to be exported outside Hong Kong; or
                        <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 58</ref>)</sourceNote></content></subparagraph><subparagraph id="ID_1453965234623_003" name="ii" temporalId="s36_1A_a_ii"><num value="ii">(ii)</num><content>by a licensed manufacturer for the purpose of manufacture or the
                        compounding of pharmaceutical preparations;
                        <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 58</ref>)</sourceNote></content></subparagraph><subparagraph id="ID_1438411270338_015" name="iii" temporalId="s36_1A_a_iii"><num value="iii">(iii)</num><sourceNote>(Repealed <ref href="/hk/2015/2">2 of 2015 s. 58</ref>)</sourceNote></subparagraph></paragraph><paragraph id="ID_1453965234686_004" name="ab" temporalId="s36_1A_ab"><num value="ab">(ab)</num><content>is possessed or is to be used for the purpose of treatment by a registered
                    medical practitioner or a registered dentist of a particular patient or for the
                    purpose of treatment by a registered veterinary surgeon of a particular animal;
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 58</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411270338_030" name="b" temporalId="s36_1A_b"><num value="b">(b)</num><content>has been manufactured in Hong Kong to be exported outside Hong Kong;
                    <sourceNote>(<ref href="/hk/1987/ln85">L.N. 85 of 1987</ref>; <ref href="/hk/2015/2">2 of
                            2015 s. 58</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411270338_037" name="c" temporalId="s36_1A_c"><num value="c">(c)</num><content>is to be administered for the purposes of a clinical trial that is to be
                    conducted in accordance with a clinical trial certificate issued under
                        <ref>regulation 36B(3)</ref>; or
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 58</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411270338_045" name="d" temporalId="s36_1A_d"><num value="d">(d)</num><content>is to be administered for the purposes of a medicinal test that is to be
                    conducted in accordance with a medicinal test certificate issued under
                        <ref>regulation 36B(3)</ref>.
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 58</ref>)</sourceNote></content></paragraph></subsection><subsection id="ID_1438411270353_005" name="1B" temporalId="s36_1B"><num value="1B">(1B)</num><content>For the avoidance of any doubt, a pharmaceutical product or substance is
                registered with the Board, for the purposes of paragraph (1), if and only if its
                registrable particulars are those which correspond exactly with the registered
                particulars of a registered product or substance.
                <sourceNote>(<ref href="/hk/1995/ln366">L.N. 366 of 1995</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270353_013" name="1C" temporalId="s36_1C"><num value="1C">(1C)</num><content>It shall be a defence to a charge against any person for contravening paragraph
                (1) if the person proves that he did not know and could not with reasonable
                diligence have discovered that the product or substance was not registered with the Board.
                <sourceNote>(<ref href="/hk/1995/ln366">L.N. 366 of 1995</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270353_021" name="2" temporalId="s36_2"><num value="2">(2)</num><content>Application for the initial registration of a pharmaceutical product or
                substance shall be made in the specified form and shall be accompanied by the fee
                prescribed in
                    <ref>Schedule
                    9</ref>.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s.
                    58</ref>; <ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270353_029" name="2A" temporalId="s36_2A"><num value="2A">(2A)</num><content>In considering an application for registration of a pharmaceutical product
                which contains as active ingredients any Chinese herbal medicines or proprietary
                Chinese medicines as defined in <ref>section 2</ref> of the Chinese Medicine
                Ordinance (<ref href="/hk/cap549">Cap. 549</ref>) or other materials of herbal,
                animal or mineral origin customarily used by the Chinese for medicinal purpose, the
                Board shall seek advice from the Chinese Medicines Board established under the
                Chinese Medicine Ordinance (<ref href="/hk/cap549">Cap. 549</ref>).
                <sourceNote>(<ref href="/hk/1999/47">47 of 1999 s. 175</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270369_005" name="3" temporalId="s36_3"><num value="3">(3)</num><leadIn>The particulars to be registered shall—</leadIn><paragraph id="ID_1438411270369_013" name="a" temporalId="s36_3_a"><num value="a">(a)</num><leadIn>in the case of a product or substance, be—</leadIn><subparagraph id="ID_1438411270369_021" name="i" temporalId="s36_3_a_i"><num value="i">(i)</num><content>its name;</content></subparagraph><subparagraph id="ID_1438411270369_029" name="ii" temporalId="s36_3_a_ii"><num value="ii">(ii)</num><content>its specifications;</content></subparagraph><subparagraph id="ID_1438411270384_007" name="iii" temporalId="s36_3_a_iii"><num value="iii">(iii)</num><content>its label;</content></subparagraph><subparagraph id="ID_1438411270384_015" name="iv" temporalId="s36_3_a_iv"><num value="iv">(iv)</num><content>its package insert, if any;</content></subparagraph><subparagraph id="ID_1438411270384_023" name="v" temporalId="s36_3_a_v"><num value="v">(v)</num><content>the name and address of the manufacturer; and</content></subparagraph><subparagraph id="ID_1438411270384_031" name="vi" temporalId="s36_3_a_vi"><num value="vi">(vi)</num><content>the name and address of the applicant;</content></subparagraph></paragraph><paragraph id="ID_1438411270384_038" name="b" temporalId="s36_3_b"><num value="b">(b)</num><leadIn>in the case of a product, further be—</leadIn><subparagraph id="ID_1438411270384_046" name="i" temporalId="s36_3_b_i"><num value="i">(i)</num><content>its dose form;</content></subparagraph><subparagraph id="ID_1438411270384_054" name="ii" temporalId="s36_3_b_ii"><num value="ii">(ii)</num><content>the quantity or quantities of the dose form contained in its unit
                        package or unit packages;</content></subparagraph><subparagraph id="ID_1438411270384_062" name="iii" temporalId="s36_3_b_iii"><num value="iii">(iii)</num><content>the name and quantity of all its active ingredients;</content></subparagraph><subparagraph id="ID_1438411270384_070" name="iv" temporalId="s36_3_b_iv"><num value="iv">(iv)</num><content>the name and quantity of all its excipients; and</content></subparagraph><subparagraph id="ID_1438411270384_078" name="v" temporalId="s36_3_b_v"><num value="v">(v)</num><content>its proposed indication, dosage and route of administration.
                        <sourceNote>(<ref href="/hk/1995/ln366">L.N. 366 of 1995</ref>)</sourceNote></content></subparagraph></paragraph></subsection><subsection id="ID_1438411270384_084" name="3A" temporalId="s36_3A"><num value="3A">(3A)</num><leadIn>For the purposes of paragraph (3)—</leadIn><def name="ActiveIngredient"><term>active
                    ingredient</term>
                    (<term xml:lang="zh-Hant-HK">有效成分</term>) means an ingredient of the product
                which is not an excipient;</def><def name="Excipient"><term>excipient</term>
                    (<term xml:lang="zh-Hant-HK">賦形劑</term>) means an ingredient of the product
                which does not contribute to its pharmacological action or which so contributes only
                by regulating the release of an active ingredient;</def><def name="Label"><term>label</term>
                    (<term xml:lang="zh-Hant-HK">標籤</term>) means any statement forming part of or
                affixed to the container or package of the product or substance;</def><def name="PackageInsert"><term>package
                    insert</term>
                    (<term xml:lang="zh-Hant-HK">包裝附頁</term>) means any leaflet, notification or
                other document supplied with the container or package of the product or substance,
                but does not include a label.
                <sourceNote>(<ref href="/hk/1995/ln366">L.N. 366 of 1995</ref>)</sourceNote></def></subsection><subsection id="ID_1626060206570_001" name="4" temporalId="s36_4"><num value="4">(4)</num><content>Prototypes of the sales packs, and proposed wordings of the labels, of the
                product or substance must be made available for inspection by the Committee.
                    <sourceNote>(<ref href="hk/2020/19">19 of 2020 s. 12</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270400_026" name="5" temporalId="s36_5"><num value="5">(5)</num><content>The Committee may, subject to any conditions it thinks fit to impose, register
                a pharmaceutical product or substance by issuing to the applicant a registration
                certificate in the specified form and the certificate is valid for a period of 5
                years from the date of registration on payment of the fee prescribed in
                    <ref>Schedule
                    9</ref>.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s.
                    58</ref>; <ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270416_005" name="6" temporalId="s36_6"><num value="6">(6)</num><content>The Committee shall advise the applicant whether the pharmaceutical product or
                substance appears in the Poisons List and if so, under which
                classification.</content></subsection><subsection id="ID_1453965234998_005" name="7" temporalId="s36_7"><num value="7">(7)</num><leadIn>A registration certificate issued under paragraph (5) shall be renewable
                        on— <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 58</ref>)</sourceNote></leadIn><paragraph id="ID_1438411270416_020" name="a" temporalId="s36_7_a"><num value="a">(a)</num><content>payment of the fee prescribed in
                        <ref>Schedule
                        9</ref>; and
                    <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                    2020</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411270416_028" name="b" temporalId="s36_7_b"><num value="b">(b)</num><content>providing the Committee with the up-to-date information specified by the
                    Committee regarding the pharmaceutical product or substance.
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 58</ref>)</sourceNote></content></paragraph></subsection><subsection id="ID_1438411270416_036" name="7A" temporalId="s36_7A"><num value="7A">(7A)</num><content>A renewal under paragraph (7) is subject to any conditions the Committee thinks
                fit to impose.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 58</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270416_044" name="7B" temporalId="s36_7B"><num value="7B">(7B)</num><content>The Committee may vary a condition imposed under paragraph (5) or (7A) if it
                thinks fit to do so.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 58</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270431_004" name="8" temporalId="s36_8"><num value="8">(8)</num><content>The Committee may deregister a pharmaceutical product or substance, suspend the
                registration of a pharmaceutical product or substance for a period specified by the
                Committee, or issue a warning letter to the holder of a registration certificate, if
                it is of the opinion that a condition of the registration is contravened or if it
                considers it to be in the public interest to do so.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 58</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270431_012" name="8A" temporalId="s36_8A"><num value="8A">(8A)</num><content>Where the Committee refuses to register or deregisters a pharmaceutical product
                or substance it shall forward to the applicant or permit holder, as the case may be,
                a notice of refusal or of deregistration and shall state in such notice its reasons
                for refusal to register or for deregistration.
                <sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270431_020" name="9" temporalId="s36_9"><num value="9">(9)</num><content>Any applicant or holder of a registration certificate aggrieved by a decision
                of the Committee under this regulation may, in the prescribed manner, appeal to the
                Tribunal against that decision.
                <sourceNote>(<ref href="/hk/1980/ln369">L.N. 369 of 1980</ref>; <ref href="/hk/2015/2">2 of
                        2015 s. 58</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270447_005" name="10" temporalId="s36_10"><num value="10">(10)</num><sourceNote>(Repealed <ref href="/hk/1980/ln369">L.N. 369 of 1980</ref>)</sourceNote></subsection><subsection id="ID_1438411270447_013" name="11" temporalId="s36_11"><num value="11">(11)</num><sourceNote>(Repealed <ref href="/hk/1995/ln366">L.N. 366 of 1995</ref>)</sourceNote></subsection><sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>; <ref href="/hk/1980/ln369">L.N. 369 of
            1980</ref>; <ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section><section id="ID_1438402707439_002" name="s36A" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s36A"><num value="36A">36A.</num><heading>Application for approval to change the registered particulars of a registered product or substance</heading><subsection id="ID_1438411270525_004" name="1" temporalId="s36A_1"><num value="1">(1)</num><leadIn>In this regulation—</leadIn><def name="PersonResponsibleForRegisteringARegisteredProductOrSubstance"><term>person
                    responsible for registering a registered product or
                substance</term>
                    (<term xml:lang="zh-Hant-HK">負責將註冊製品或物質註冊的人</term>) means a person who, in
                relation to the product or substance, belongs to any one of the classes of person
                described in <ref>regulation 36(1)(a)</ref>, (b) or (c).</def></subsection><subsection id="ID_1438411270525_018" name="2" temporalId="s36A_2"><num value="2">(2)</num><content>The person responsible for registering a registered product or substance may apply in writing to the Committee for approval to change any of the registrable particulars of the product or substance except the particulars referred to in <ref>regulation 36(3)(a)(i)</ref> and (b)(i) and (iii).</content></subsection><subsection id="ID_1438411270540_005" name="3" temporalId="s36A_3"><num value="3">(3)</num><content>A person responsible for registering a registered product or substance who proposes to change the particulars referred to in <ref>regulation 36(3)(a)(i)</ref> or (b)(i) or (iii) may apply under <ref>regulation 36</ref> for registering, as a separate product or substance, as the case may be, the product or substance with the particulars changed as proposed.</content></subsection><subsection id="ID_1438411270540_013" name="4" temporalId="s36A_4"><num value="4">(4)</num><leadIn>In dealing with an application under paragraph (2)—</leadIn><paragraph id="ID_1438411270540_021" name="a" temporalId="s36A_4_a"><num value="a">(a)</num><content>the Committee shall take into consideration the safety, efficacy and quality of the pharmaceutical product or substance with its particulars changed as proposed, and in considering such safety and efficacy, the Committee shall observe the requirements of <ref>regulation 37(2)</ref>; and</content></paragraph><paragraph id="ID_1438411270556_006" name="b" temporalId="s36A_4_b"><num value="b">(b)</num><content><ref>regulation 37(3)</ref> shall apply to such application as if it were an application for initial registration of the pharmaceutical product or substance with the particulars changed as proposed.</content></paragraph></subsection><subsection id="ID_1438411270556_013" name="5" temporalId="s36A_5"><num value="5">(5)</num><content>The Committee shall advise the applicant in writing whether the change is approved, and where the Committee refuses to approve a change it shall state its reasons for such refusal.</content></subsection><subsection id="ID_1438411270556_021" name="6" temporalId="s36A_6"><num value="6">(6)</num><leadIn>Where the change is approved, it shall be approved to take effect from a certain date, and the following provisions shall apply—</leadIn><paragraph id="ID_1438411270556_029" name="a" temporalId="s36A_6_a"><num value="a">(a)</num><content>as from that date, and without limiting the generality of <ref>regulation
                        36(1B)</ref>, the product or substance having as its registrable particulars
                    the registered particulars which are to be changed (hereinafter referred to as
                    the
                        <term>product
                        or substance to be
                    replaced</term>)
                    shall not be regarded as registered with the Board;</content></paragraph><paragraph id="ID_1438411270556_037" name="b" temporalId="s36A_6_b"><num value="b">(b)</num><content>the applicant shall, prior to that date, recall or cause to be recalled any product or substance to be replaced which may still be in the possession of any person to whom he supplied the product or substance;</content></paragraph><paragraph id="ID_1438411270572_006" name="c" temporalId="s36A_6_c"><num value="c">(c)</num><content>where the product or substance to be replaced is to be recalled, the applicant shall, as soon as reasonably possible, replace or cause to be replaced such product or substance with the product or substance having the particulars changed as approved, or make such alternative arrangements as are agreed with the person to whom he supplied the product or substance.</content></paragraph></subsection><subsection id="ID_1438411270572_013" name="7" temporalId="s36A_7"><num value="7">(7)</num><content>Any person aggrieved by a decision of the Committee under this regulation may, in the prescribed manner, appeal to the Tribunal against that decision.</content></subsection><sourceNote>(<ref href="/hk/1995/ln366">L.N. 366 of 1995</ref>)</sourceNote></section><section id="ID_1438402707470_001" name="s36B" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s36B"><num value="36B">36B.</num><heading>Clinical trials and medicinal tests</heading><subsection id="ID_1438411270618_035" name="1" temporalId="s36B_1"><num value="1">(1)</num><content>A person must not conduct a clinical trial on human beings, or cause or permit
                such a trial to be conducted, except in accordance with a clinical trial certificate
                issued to the person under paragraph (3).
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 59</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270634_005" name="1A" temporalId="s36B_1A"><num value="1A">(1A)</num><content>A person must not conduct a medicinal test on animals, or cause or permit such
                a test to be conducted, except in accordance with a medicinal test certificate
                issued to the person under paragraph (3).
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 59</ref>)</sourceNote></content></subsection><subsection id="ID_1453966040897_001" name="1B" temporalId="s36B_1B"><num value="1B">(1B)</num><content>A person who contravenes paragraph (1) or (1A) commits an offence and is liable
                to a fine at level 2.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 59</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270634_022" name="1C" temporalId="s36B_1C"><num value="1C">(1C)</num><content>For the purpose of conducting a clinical trial on human beings or a medicinal
                test on
                animals,
                application shall be made in writing to the Committee and shall be accompanied by
                the fee prescribed in
                    <ref>Schedule
                    9</ref>.
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270634_030" name="2" temporalId="s36B_2"><num value="2">(2)</num><content>A copy of the protocol for the trial or test shall accompany the
                application.</content></subsection><subsection id="ID_1438411270634_038" name="3" temporalId="s36B_3"><num value="3">(3)</num><content>The Committee may, subject to any conditions it thinks fit to impose, issue a
                clinical trial certificate or medicinal test certificate in the specified form and
                the certificate is valid for a period not exceeding 5 years on payments of the fee
                prescribed in
                    <ref>Schedule
                    9</ref>.
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270650_005" name="3A" temporalId="s36B_3A"><num value="3A">(3A)</num><content>The Committee may vary a condition imposed under paragraph (3) if it thinks fit
                to do so.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 59</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270650_013" name="3B" temporalId="s36B_3B"><num value="3B">(3B)</num><leadIn>The Committee may cancel a clinical trial certificate or medicinal test
                certificate, suspend it for a period specified by the Committee, or issue a warning
                letter to the holder of the certificate, if—</leadIn><paragraph id="ID_1438411270650_021" name="a" temporalId="s36B_3B_a"><num value="a">(a)</num><content>it is of the opinion that the holder of the certificate has contravened a
                    condition of the certificate; or</content></paragraph><paragraph id="ID_1438411270650_029" name="b" temporalId="s36B_3B_b"><num value="b">(b)</num><content>it considers it to be in the public interest to do so.
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 59</ref>)</sourceNote></content></paragraph></subsection><subsection id="ID_1438411270650_036" name="3C" temporalId="s36B_3C"><num value="3C">(3C)</num><content>If the Committee refuses an application under paragraph (1C), the Committee
                must give the applicant a notice of refusal and state in the notice the reasons for refusal.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 59</ref>)</sourceNote></content></subsection><subsection id="ID_1453966041006_002" name="3D" temporalId="s36B_3D"><num value="3D">(3D)</num><content>If the Committee decides to cancel or suspend a certificate under paragraph
                (3B), the Committee must give the holder of the certificate a notice of cancellation
                or suspension (as the case may be) and state in the notice the reasons for its decision.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 59</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270665_005" name="4" temporalId="s36B_4"><num value="4">(4)</num><content>Any applicant or holder of a clinical trial certificate or medicinal test
                certificate aggrieved by a decision of the Committee under this regulation may, in
                the prescribed manner, appeal to the Tribunal against that decision.
                <sourceNote>(<ref href="/hk/1980/ln369">L.N. 369 of 1980</ref>)</sourceNote></content></subsection><sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>; <ref href="/hk/1980/ln369">L.N.
                369
                of 1980</ref>; <ref href="/hk/2015/2">2 of 2015 s.
            59</ref>; <ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section><section id="ID_1438402707470_003" name="s36C" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s36C"><num value="36C">36C.</num><heading>Definition of
                <term>pharmaceutical
                product</term>
            and
                <term>substance</term>
            for the purposes of this Part</heading><content name="PharmaceuticalProduct,Substance">For the purposes of this Part,
            <term>pharmaceutical
                product</term>
                (<term xml:lang="zh-Hant-HK">藥劑製品</term>) and
                <term>substance</term>
                (<term xml:lang="zh-Hant-HK">物質</term>) have the meaning assigned to
                <term>pharmaceutical
                product</term>
            and
                <term>medicine</term>
            in the Ordinance.</content><sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of
            1978</ref>; <ref href="hk/2020/er5">E.R. 5 of 2020</ref>)</sourceNote></section><section id="ID_1438402707486_002" name="s36D" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s36D"><num value="36D">36D.</num><heading>Duplicate certificates</heading><subsection id="ID_1438411270712_018" name="1" temporalId="s36D_1"><num value="1">(1)</num><content>The Committee may issue a duplicate of any certificate issued under this Part
                if the Committee is satisfied that the original certificate has been lost or
                destroyed or that for other good reason such duplicate ought to be issued.</content></subsection><subsection id="ID_1438411270712_026" name="2" temporalId="s36D_2"><num value="2">(2)</num><content>A duplicate certificate issued under this regulation shall be certified in such
                manner as the Committee may determine.</content></subsection><subsection id="ID_1438411270712_034" name="3" temporalId="s36D_3"><num value="3">(3)</num><content>There shall be payable in respect of any duplicate certificate issued under
                this regulation the fee prescribed in respect thereof in
                    <ref>Schedule
                    9</ref>.
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></content></subsection><sourceNote>(<ref href="/hk/1980/ln369">L.N. 369 of
            1980</ref>; <ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section><section id="ID_1438402707486_004" name="s37" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s37"><num value="37">37.</num><heading>Factors relevant to determination of application for registration</heading><subsection id="ID_1438411270743_004" name="1" temporalId="s37_1"><num value="1">(1)</num><leadIn>In dealing with an application for initial registration of a pharmaceutical
                product or substance the Committee shall in particular take into
                consideration—</leadIn><paragraph id="ID_1438411270743_012" name="a" temporalId="s37_1_a"><num value="a">(a)</num><content>the safety of the pharmaceutical product or substance to which the
                    application relates;</content></paragraph><paragraph id="ID_1438411270743_020" name="b" temporalId="s37_1_b"><num value="b">(b)</num><content>the efficacy of the pharmaceutical product or substance for the purposes
                    for which the product or substance is proposed to be administered; and</content></paragraph><paragraph id="ID_1438411270743_028" name="c" temporalId="s37_1_c"><num value="c">(c)</num><content>the quality of the pharmaceutical product or substance according to the
                    specification and the method or proposed method of manufacture of the product or
                    substance, and the provisions proposed for securing that the product or
                    substance as sold or supplied will be of that quality.</content></paragraph></subsection><subsection id="ID_1438411270743_035" name="2" temporalId="s37_2"><num value="2">(2)</num><content>
                <leadIn>In taking into consideration the efficacy for a particular purpose of a
                    pharmaceutical product or substance to which such an application relates, the
                    Committee shall leave out of account any question whether a pharmaceutical
                    product or substance of another description would or might be equally or more
                    efficacious for that purpose:</leadIn>
                
                
                
                <proviso name="proviso" temporalId="s37_2_proviso">Provided that nothing in
                    this
                    paragraph shall be construed as requiring the Committee, in considering the
                    safety of a pharmaceutical product or substance of a particular description, in
                    relation to a purpose for which it is proposed to be administered, to leave out
                    of account any question whether a pharmaceutical product or substance of another
                    description, being equally or more efficacious for that purpose, would or might
                    be safer in relation to that purpose.
                    <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                    2020</ref>)</sourceNote></proviso>
            </content></subsection><subsection id="ID_1453966439347_001" name="3" temporalId="s37_3"><num value="3">(3)</num><leadIn>In dealing with an application made in respect of a pharmaceutical product or
                substance manufactured outside Hong Kong, the Committee shall also take into
                consideration in particular the methods, standards and conditions of manufacture of
                the pharmaceutical product or substance in respect of which application is made and
                may, if it thinks fit, require the applicant to take any or all of the following
                        actions— <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 60</ref>)</sourceNote></leadIn><paragraph id="ID_1438411270759_012" name="a" temporalId="s37_3_a"><num value="a">(a)</num><content>produce an undertaking, given by the manufacturer of any such products or
                    substances, to permit the premises where they are to be manufactured, and the
                    operations carried on or to be carried on in the course of manufacturing them,
                    to be inspected by or on behalf of the Committee;
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 60</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411270774_006" name="b" temporalId="s37_3_b"><num value="b">(b)</num><content>produce a declaration, given by or on behalf of the manufacturer of any
                    such products or substances, that, in relation to the manufacture of these
                    products any requirements imposed by or under the law of the country in which
                    they are or are to be manufactured have been or will be complied with;
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s.
                        60</ref>)</sourceNote><marker role="section-break"></marker></content></paragraph><paragraph id="ID_1438411270774_013" name="c" temporalId="s37_3_c"><num value="c">(c)</num><content>pay a fee determined by the Committee as representing the expenditure
                    incurred, or likely to be incurred, by or on behalf of the Committee in carrying
                    out an inspection mentioned in subparagraph (a).
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 60</ref>)</sourceNote></content></paragraph></subsection><subsection id="ID_1438411270774_021" name="4" temporalId="s37_4"><num value="4">(4)</num><content>The Committee shall make arrangements for the separate processing of an
                application for the registration of a new pharmaceutical product or new substance so
                that its registration shall not be unduly delayed.
                <sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>)</sourceNote></content></subsection><subsection id="ID_1438411270774_029" name="5" temporalId="s37_5"><num value="5">(5)</num><def name="NewPharmaceuticalProduct,NewSubstance">For the purposes of paragraph (4),
                <term>new
                    pharmaceutical
                product</term>
                    (<term xml:lang="zh-Hant-HK">新藥劑製品</term>) and
                    <term>new
                    substance</term>
                    (<term xml:lang="zh-Hant-HK">新物質</term>) mean a medicine containing an active
                ingredient, or a substance, having a chemical formula which has not previously been
                marketed or registered in Hong Kong under some other name or description.
                <sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>; <ref href="/hk/1996/ln235">L.N. 235 of
                    1996</ref>; <ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></def></subsection><sourceNote>(<ref href="/hk/1980/ln369">L.N. 369 of 1980</ref>)</sourceNote></section></part><part id="ID_1438402707501_002" name="P8A" reason="repealed" startPeriod="2015-02-06" status="repealed" temporalId="P8A"><num value="8A">Part VIIIA</num><sourceNote>(Repealed <ref href="/hk/2015/2">2 of 2015 s. 61</ref>)</sourceNote><section id="ID_1438402707517_001" name="s37A" reason="repealed" role="regulation" startPeriod="2015-02-06" status="repealed" temporalId="s37A"><num value="37A">37A.</num><sourceNote>(Repealed <ref href="/hk/2015/2">2 of 2015 s. 61</ref>)</sourceNote></section></part><part id="ID_1438402707517_003" name="P9" reason="inEffect" startPeriod="2015-11-12" status="operational" temporalId="P9"><num value="9">Part
            9</num><heading>Sale of
            Medicines</heading><section id="ID_1438402707533_002" name="s38" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s38"><num value="38">38.</num><heading>Disclosure of composition of medicines</heading><subsection id="ID_1438411270837_004" name="1" temporalId="s38_1"><num value="1">(1)</num><leadIn>Subject to these regulations, no person shall—</leadIn><paragraph id="ID_1438411270837_012" name="a" temporalId="s38_1_a"><num value="a">(a)</num><content>sell any article consisting of or comprising a substance recommended as a medicine; or</content></paragraph><paragraph id="ID_1438411270852_006" name="b" temporalId="s38_1_b"><num value="b">(b)</num><content>supply any such article as a sample for the purpose of inducing persons to buy the substances of which it consists or which it comprises,</content></paragraph><continued>unless—</continued><paragraph id="ID_1438411270852_020" name="i" temporalId="s38_1_i"><num value="i">(i)</num><content>the article is labelled as required under <ref>regulation 31</ref>; or</content></paragraph><paragraph id="ID_1438411270852_028" name="ii" temporalId="s38_1_ii"><num value="ii">(ii)</num><content>the particulars specified under <ref>regulation 31(1)</ref> are printed so
                    as to be clearly legible in English or Chinese on the article or a label affixed thereto.
                    <sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>)</sourceNote></content></paragraph></subsection><subsection id="ID_1438411270852_035" name="2" temporalId="s38_2"><num value="2">(2)</num><leadIn>Nothing in this regulation shall apply to any article—</leadIn><paragraph id="ID_1438411270852_043" name="a" temporalId="s38_2_a"><num value="a">(a)</num><content>made up and supplied for the use of a particular person, being an article prescribed by reference to the needs of that person; or</content></paragraph><paragraph id="ID_1438411270852_051" name="b" temporalId="s38_2_b"><num value="b">(b)</num><leadIn>consisting wholly of either—</leadIn><subparagraph id="ID_1438411270852_059" name="i" temporalId="s38_2_b_i"><num value="i">(i)</num><content>a product resulting solely from the pharmaceutical treatment of natural products as referred to by the Chinese Herbal Materia Medica;</content></subparagraph><subparagraph id="ID_1438411270852_067" name="ii" temporalId="s38_2_b_ii"><num value="ii">(ii)</num><content>a mixture the sole ingredients of which are two or more of such products; or</content></subparagraph><subparagraph id="ID_1438411270852_075" name="iii" temporalId="s38_2_b_iii"><num value="iii">(iii)</num><content>a natural mineral water or an artificial imitation thereof.</content></subparagraph></paragraph></subsection><subsection id="ID_1438411270852_081" name="3" temporalId="s38_3"><num value="3">(3)</num><leadIn>For the purposes of this regulation—</leadIn><def name="Advertisement"><term>advertisement</term>
                    (<term xml:lang="zh-Hant-HK">廣告</term>) includes any notice, circular, pamphlet,
                label, wrapper or other document, and any announcement made orally or by any means
                of producing or transmitting light or sound;</def><def name="ProprietaryDesignation,Proprietor"><term>proprietary
                    designation</term>
                    (<term xml:lang="zh-Hant-HK">所有人稱號</term>), in relation to the sale of an
                article consisting of or comprising a substance recommended as a medicine, means
                words used or proposed to be used in
                connexion
                with the sale of articles consisting of or comprising the substance, for the purpose
                of indicating that they are the goods of a particular person by virtue of
                manufacture, selection, certification, dealing with or offering for sale; and
                    <term>proprietor</term>
                    (<term xml:lang="zh-Hant-HK">所有人</term>) in relation to such a designation means
                the person whose goods are indicated or intended to be indicated by the
                designation;</def><def name="Substance"><term>substance</term>
                    (<term xml:lang="zh-Hant-HK">物質</term>) includes a preparation;</def><def name="SubstanceRecommendedAsAMedicine"><leadIn><term>substance
                        recommended as a
                    medicine</term>
                        (<term xml:lang="zh-Hant-HK">建議作為藥物的物質</term>), in relation to the sale of
                    an article consisting or comprising a substance so recommended, means a
                    substance which is referred to—</leadIn><paragraph id="ID_1438411270868_026" name="a" temporalId="s38_3_a"><num value="a">(a)</num><content>on the article, or on any wrapper or container in which the article is sold, or on any label affixed to, or in any document enclosed in, the article or such wrapper or container; or</content></paragraph><paragraph id="ID_1438411270884_006" name="b" temporalId="s38_3_b"><num value="b">(b)</num><content>in any placard or other document exhibited at the place where the article is sold; or</content></paragraph><paragraph id="ID_1438411270884_014" name="c" temporalId="s38_3_c"><num value="c">(c)</num><content>in any advertisement published after the coming into operation of these regulations by or on behalf of the manufacturer of the article, or the person carrying on the business in the course of which the article was sold, or, in a case where the article was under a proprietary designation, the proprietor of the designation,</content></paragraph><continued>in terms which are calculated to lead to the use of the substance for the prevention or treatment of any ailment, infirmity or injury affecting the human body, not being terms which give a definite indication that the substance is intended to be used as, or as part of, a food or drink, and not as, or as part of, a medicine.</continued></def></subsection></section><section id="ID_1438402707548_002" name="s38A" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s38A"><num value="38A">38A.</num><heading>Labelling of certain medicines</heading><subsection id="ID_1438411270930_004" name="1" temporalId="s38A_1"><num value="1">(1)</num><content>No person shall sell or supply any medicine unless it is labelled with
                particulars printed so as to be clearly legible in English and Chinese, as to dosage
                and the route and frequency of administration.</content></subsection><subsection id="ID_1438411270930_012" name="2" temporalId="s38A_2"><num value="2">(2)</num><content>This regulation shall not apply to medicine that is included in Part
                1
                of the Poisons List or in the
                    <ref>Schedule</ref>
                to the Antibiotics Regulations (<ref href="/hk/cap137A">Cap. 137 sub. leg.
                A</ref>).</content></subsection><sourceNote>(<ref href="/hk/1987/ln85">L.N. 85 of
            1987</ref>; <ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section></part><part id="ID_1438402707564_002" name="P10" reason="inEffect" startPeriod="2015-11-12" status="operational" temporalId="P10"><num value="10">Part
            10</num><heading>Miscellaneous</heading><section id="ID_1438402707564_004" name="s38B" reason="inEffect" role="regulation" startPeriod="2015-11-12" status="operational" temporalId="s38B"><num value="38B">38B.</num><heading>Power to specify forms</heading><subsection id="ID_1438411270962_004" name="1" temporalId="s38B_1"><num value="1">(1)</num><content>An executive committee established under <ref>section 4A</ref> for a provision of these regulations may specify forms to be used for that provision.</content></subsection><subsection id="ID_1438411270962_012" name="2" temporalId="s38B_2"><num value="2">(2)</num><leadIn>If a form is specified under this regulation, the Board must make copies of the form available for inspection by the public free of charge—</leadIn><paragraph id="ID_1438411270962_020" name="a" temporalId="s38B_2_a"><num value="a">(a)</num><content>at the office of the Secretary during normal office hours; and</content></paragraph><paragraph id="ID_1438411270962_028" name="b" temporalId="s38B_2_b"><num value="b">(b)</num><content>in any other manner the Board thinks fit.</content><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 62</ref>)</sourceNote></paragraph></subsection></section><section id="ID_1438402707579_002" name="s39" reason="inEffect" role="regulation" startPeriod="2021-08-01" status="operational" temporalId="s39"><num value="39">39.</num><heading>Keeping
            and transfer
            of records</heading><sourceNote>(<ref href="hk/2020/19">19 of 2020 s. 13</ref>)</sourceNote><subsection id="ID_1626060066252_001" name="1" temporalId="s39_1"><num value="1">(1)</num><leadIn>Subject
                to paragraph (2), all—
                <sourceNote>(<ref href="hk/2020/19">19 of 2020 s. 13</ref>)</sourceNote></leadIn><paragraph id="ID_1438411270977_049" name="a" temporalId="s39_1_a"><num value="a">(a)</num><content>poisons books;</content></paragraph><paragraph id="ID_1438411270977_057" name="b" temporalId="s39_1_b"><num value="b">(b)</num><content>books kept under <ref>section 28(3)</ref>;</content></paragraph><paragraph id="ID_1438411270977_065" name="c" temporalId="s39_1_c"><num value="c">(c)</num><content>certificates
                    given
                    under <ref>section 22(1)(a)</ref> kept by authorized sellers of
                    poisons;</content></paragraph><paragraph id="ID_1438411270977_073" name="d" temporalId="s39_1_d"><num value="d">(d)</num><content>books or other form of records and documents required to be kept or
                    retained by licensed wholesale dealers or licensed manufacturers under
                        <ref>regulation 28</ref>; and
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 63</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411270993_006" name="e" temporalId="s39_1_e"><num value="e">(e)</num><content>records
                    and documents required to be kept or retained by licensed manufacturers under
                        <ref>regulation 35</ref>,
                    <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s.
                        63</ref>; <ref href="hk/2020/19">19 of 2020 s. 13</ref>)</sourceNote></content></paragraph><continued>shall be preserved by the authorized seller of poisons, licensed wholesale
                dealer or licensed manufacturer, as the case may be, in the premises in which the
                transaction recorded took
                        place— <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 63</ref>)</sourceNote></continued><paragraph id="ID_1438411270993_020" name="i" temporalId="s39_1_i"><num value="i">(i)</num><content>for a period of 2 years from the date of the last entry therein;
                    or</content></paragraph><paragraph id="ID_1438411270993_028" name="ii" temporalId="s39_1_ii"><num value="ii">(ii)</num><content>in relation to a certificate or document, for a period of 2 years from the
                    date of the transaction.</content></paragraph></subsection><subsection id="ID_1626060066367_002" name="2" temporalId="s39_2"><num value="2">(2)</num><leadIn>For an advanced therapy product—</leadIn><paragraph id="ID_1626060066368_003" name="a" temporalId="s39_2_a"><num value="a">(a)</num><content>all books, records and documents required to be kept or retained in respect
                    of the product under <ref>regulations 28</ref> and <ref>35(1)(a)</ref>, (b),
                    (c), (ca) and (h) (<i><b>specified documents</b></i>) must be preserved by the
                    relevant licensed wholesale dealer or licensed manufacturer (<b><i>specified
                            person</i></b>) for a period of 30 years after the expiry date of the
                    product;</content></paragraph><paragraph id="ID_1626060066370_004" name="b" temporalId="s39_2_b"><num value="b">(b)</num><leadIn>if, before the period referred to in subparagraph (a) expires—</leadIn><subparagraph id="ID_1626060066371_005" name="1" temporalId="s39_2_b_1"><num value="1">(i)</num><content>for a specified person that is a natural person—the specified person
                        becomes bankrupt or enters into a voluntary arrangement as defined by
                            <ref>section 2</ref> of the Bankruptcy Ordinance (<ref href="/hk/cap6">Cap. 6</ref>) with the person’s creditors; or</content></subparagraph><subparagraph id="ID_1626060066373_006" name="2" temporalId="s39_2_b_2"><num value="2">(ii)</num><content>for a specified person that is a company as defined by <ref>section
                            2(1)</ref> of the Companies Ordinance (<ref href="/hk/cap622">Cap.
                            622</ref>)—the specified person is commenced to be wound up or is
                        dissolved without being wound up,</content></subparagraph><continued>the specified person must transfer the specified documents to the Board
                    as soon as practicable after the event mentioned in sub-subparagraph (i) or (ii)
                    occurs; and</continued></paragraph><paragraph id="ID_1626060066375_007" name="c" temporalId="s39_2_c"><num value="c">(c)</num><content>if, before the period referred to in subparagraph (a) expires, the
                    specified person ceases to operate as a licensed wholesale dealer or licensed
                    manufacturer, the specified person must transfer the specified documents to the
                    Board within 14 days after the cessation. <sourceNote>(<ref href="hk/2020/19">19 of 2020 s. 13</ref>)</sourceNote></content></paragraph></subsection></section><section id="ID_1438402707595_001" name="s40" reason="inEffect" role="regulation" startPeriod="2021-08-01" status="operational" temporalId="s40"><num value="40">40.</num><heading>Penalties</heading><content>Any person who contravenes any of the provisions of <ref>regulation 9(1)</ref> or
            (4),
                <ref>10</ref>,
                <ref>10A</ref>,
                <ref>11</ref>,
                <ref>12</ref>,
                <ref>15</ref>,
                <ref>16(1)</ref>
            or (2),
                <ref>18</ref>,
                <ref>19</ref>,
                <ref>20</ref>,
                <ref>21(1)</ref>
            or (2),
                <ref>22(2)</ref>,
            (3), (4) or (5),
                <ref>23(1)</ref>,
            (2) or (3),
                <ref>24</ref>,
                <ref>25</ref>,
                <ref>27</ref>,
                <ref>28</ref>,
                <ref>29(1)</ref>,
                <ref>30(1)</ref>,
                <ref>31(1)</ref>,
                <ref>32</ref>,
                <ref>33(1)</ref>,
            (2), (3), (4), (4B),
            (4D) or (5),
                <ref>34</ref>,
                <ref>35</ref>,
                <ref>36(1)</ref>,
                <ref>36A(6)(b)</ref>,
                <ref>38(1)</ref>,
                <ref>38A</ref>
            or
                <ref>39</ref>
            commits an offence and is liable on conviction to the penalties specified in
                <ref>section 34</ref> of the Ordinance.</content><sourceNote>(<ref href="/hk/1995/ln262">L.N. 262 of 1995</ref>; <ref href="/hk/1995/ln366">L.N. 366 of 1995</ref>; <ref href="/hk/2015/2">2 of 2015 s.
            64</ref>, <ref href="hk/2020/19">19 of 2020 s. 14</ref>)</sourceNote></section><section id="ID_1438402707595_003" name="s41" reason="inEffect" role="regulation" startPeriod="2020-09-10" status="operational" temporalId="s41"><num value="41">41.</num><heading>Certificates, forms and fees</heading><subsection id="ID_1438411271024_025" name="1" temporalId="s41_1"><num value="1">(1)</num><content>The certificate referred to in <ref>section 22(1)(a)</ref> may be given by any
                person known both to the intending purchaser and the intending seller and shall be
                in the specified form.
                <sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 65</ref>)</sourceNote></content></subsection><subsection id="ID_1438411271040_005" name="2" temporalId="s41_2"><num value="2">(2)</num><sourceNote>(Repealed <ref href="/hk/2015/2">2 of 2015 s. 65</ref>)</sourceNote></subsection><subsection id="ID_1438411271040_013" name="2A" temporalId="s41_2A"><num value="2A">(2A)</num><content>The logo referred to in <ref>section 13A(1)</ref> shall be in the form
                prescribed in
                    <ref>Schedule
                    8</ref>.
                    (<i>See
                        <ref>Schedule
                        8</ref>, Form 17</i>)
                <sourceNote>(<ref href="/hk/1987/ln85">L.N. 85 of
                    1987</ref>; <ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></content></subsection><subsection id="ID_1438411271040_021" name="3" temporalId="s41_3"><num value="3">(3)</num><sourceNote>(Repealed <ref href="/hk/2015/2">2 of 2015 s. 65</ref>)</sourceNote></subsection><subsection id="ID_1438411271040_029" name="4" temporalId="s41_4"><num value="4">(4)</num><content>The fees to be paid under the Ordinance and these regulations shall be those
                prescribed in
                    <ref>Schedule
                    9</ref>.
                <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of
                2020</ref>)</sourceNote></content></subsection><sourceNote>(<ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section><section id="ID_1438402707611_001" name="s42" reason="omittedAsSpent" role="regulation" startPeriod="2015-11-12" status="omitted" temporalId="s42"><num value="42">42.</num><sourceNote>(Omitted as spent—<ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></section></part><schedule name="sch1" reason="inEffect" startPeriod="2025-10-17" status="operational" temporalId="sch1" id="ID_1438402707642_001"><num value="1">Schedule 1</num><note class="align_right" role="crossReferences" type="inline">[<ref href="/hk/cap138A/s3">regs. 3</ref>, <ref href="/hk/cap138A/s5">5</ref>, <ref href="/hk/cap138A/s6">6</ref>, <ref href="/hk/cap138A/s7">7</ref>, <ref href="/hk/cap138A/s17">17</ref>,
                <ref href="/hk/cap138A/s22">22</ref><br></br>&amp; <ref href="/hk/cap138A/s24">24</ref>
            &amp; <ref href="/hk/cap138A/sch5">Sch. 5</ref>]<sourceNote>(<ref href="/hk/2015/2">2 of
                    2015 s. 66</ref>; <ref href="hk/2015/er3">E.R. 3 of
            2015</ref>)</sourceNote></note><heading>Substances to which Certain Restrictions with
            respect to the Sale, Supply, Labelling and Storage Apply under <ref>Regulations 3</ref>,
                <ref>5</ref>, <ref>6</ref>, <ref>22 and 24</ref></heading><sourceNote>(<ref href="/hk/2007/ln41">L.N. 41 of 2007</ref>; <ref href="/hk/2015/2">2 of 2015 s.
                66</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker></sourceNote><crossHeading class="font_size_14">Division A</crossHeading><sourceNote>(<ref href="/hk/2007/ln41">L.N. 41 of
            2007</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker></sourceNote><division name="D0" temporalId="sch1_D0" id="ID_1676952782085_001"><text>Abacavir; its salts</text><text>Abatacept</text><text>Abciximab</text><text>Abemaciclib; its salts</text><text>Abiraterone; its salts</text><text>Abrocitinib; its salts</text><text>Acalabrutinib; its salts</text><text>Acamprosate; its salts</text><text>Acarbose; its salts</text><text>Acebutolol; its salts</text><text>Aceclofenac; its salts</text><text>Acemetacin; its salts</text><text>Acetanilide; alkyl acetanilides</text><text>Acetazolamide; its salts</text><text>Acetohexamide</text><text>Acetorphine; its salts; its esters and ethers; their salts</text><text>Acetylcarbromal</text><text>Acetyldihydrocodeine; its salts</text><text class="left_indent_12 first_line_indent_-12">Aciclovir; its salts; except when
                contained in skin creams packed in a package size of not more than 3 grams and
                labelled for the treatment of cold sores only</text><text>Acipimox; its salts</text><text>Acitretin; its salts; its esters</text><text>Aclidinium; its salts</text><text>Adagrasib; its salts</text><text>Adalimumab</text><text>Adapalene; its salts; its esters</text><text>Adefovir; its salts; its esters; their salts</text><text>Afatinib; its salts</text><text>Aflibercept</text><text>Afoxolaner; its salts</text><text>Agalsidase alfa</text><text>Agalsidase beta</text><text>Agomelatine; its salts</text><text>Alclofenac; its complexes</text><text>Alcuronium; its salts</text><text>Aldesleukin</text><text>Alectinib; its salts</text><text>Alefacept</text><text>Alemtuzumab</text><text>Alendronic acid; its salts</text><text>Alfacalcidol; its salts</text><text>Alfuzosin; its salts</text><text>Alglucosidase alfa</text><text>Alirocumab</text><text>Aliskiren; its salts; its esters; their salts</text><text class="first_line_indent_0">Alizapride; its salts</text><text class="left_indent_12 first_line_indent_-12">Alkaloids, the following; their
                quaternary compounds; any salts, simple or complex, of any substance falling within
                the following—</text><text class="left_indent_36 first_line_indent_-12">Calabar bean, alkaloids of</text><text class="left_indent_36 first_line_indent_-12">Coca, alkaloids of, except substances
                containing less than 0.1% of the alkaloids of coca</text><text class="left_indent_36 first_line_indent_-12">Cocaine, except substances containing
                less than 0.1% of cocaine</text><text class="left_indent_36 first_line_indent_-12">Codeine</text><text class="left_indent_36 first_line_indent_-12">Colchicum, alkaloids of; their
                salts</text><text class="left_indent_36 first_line_indent_-12">Coniine, except substances containing
                less than 0.1% of coniine</text><text class="left_indent_36 first_line_indent_-12">Cotarnine, except substances
                containing less than 0.2% of cotarnine</text><text class="left_indent_36 first_line_indent_-12">Curare, alkaloids of; curare
                bases</text><text class="left_indent_36 first_line_indent_-12">Ecgonine; its esters and ethers;
                except substances containing less than the equivalent of 0.1% of ecgonine</text><text class="left_indent_36 first_line_indent_-12">Emetine, except substances containing
                less than 1% of emetine</text><text class="left_indent_36 first_line_indent_-12">Ephedrine; its optical isomers; their
                salts; when contained in aerosol dispensers</text><text class="left_indent_36 first_line_indent_-12">Ergot, alkaloids of</text><text class="left_indent_36 first_line_indent_-12">Galantamine</text><text class="left_indent_36 first_line_indent_-12">Gelsemium, alkaloids of, except
                substances containing less than 0.1% of the alkaloids of gelsemium</text><text class="left_indent_36 first_line_indent_-12">Morphine; its esters and ethers;
                except substances containing less than 0.2% of morphine calculated as anhydrous
                morphine</text><text class="left_indent_36 first_line_indent_-12">Nicotine
                (except when contained in (a) chewing gum or lozenges, intended to be used in
                nicotine replacement therapy and containing not more than 4 mg of Nicotine per
                piece; or (b) patches for external application, intended to be used in nicotine
                replacement therapy); any compound containing the chemical structure of
                3-(1-methylpyrrolidin-2-yl)pyridine substituted to any degree or without
                substitution</text><text class="left_indent_36 first_line_indent_-12">Pilocarpus, alkaloids of, except
                substances containing less than 0.5% of the alkaloids of pilocarpus</text><text class="left_indent_36 first_line_indent_-12">Rauwolfia, alkaloids of; their
                derivatives</text><text class="left_indent_36 first_line_indent_-12">Sabadilla, alkaloids of, except
                substances containing less than 1% of the alkaloids of sabadilla</text><text class="left_indent_36 first_line_indent_-12">Thebaine, except substances
                containing less than 1% of thebaine</text><text class="left_indent_36 first_line_indent_-12">Veratrum, alkaloids of, except
                substances containing less than 1% of the alkaloids of veratrum</text><text class="left_indent_36 first_line_indent_-12">Vinca, alkaloids of</text><text>Allergen extract of Dermatophagoides farinae</text><text>Allergen extract of Dermatophagoides pteronyssinus</text><text>Allopurinol</text><text>Allylisopropylacetylurea</text><text>Allylprodine; its salts</text><text>Almitrine; its salts</text><text>Alogliptin; its salts</text><text>Alpelisib; its salts</text><text>Alphadolone; its esters</text><text>Alphaxalone</text><text>Alprenolol; its salts</text><text>Alteplase</text><text>Alufibrate</text><text>Amantadine; its salts</text><text>Ambrisentan; its salts; its esters; their salts</text><text>Amidopyrine; its salts</text><text>Amifostine; its salts</text><text>Amiloride; its salts</text><text>Amineptine; its salts</text><text>Aminoglutethimide</text><text class="first_line_indent_0">5-Aminolevulinic acid; its salts; its derivatives;
                their salts</text><text>Aminopterin; its derivatives</text><text>Aminorex; its salts</text><text class="left_indent_12 first_line_indent_-12">para-Aminosalicylic acid; its salts;
                its derivatives; their salts; any compound with any substance falling within this
                item</text><text class="first_line_indent_0">Amiodarone; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Amisulpride; its salts</text><text>Amitriptyline; its salts</text><text>Amivantamab</text><text>Amlodipine; its salts</text><text>Amrinone</text><text>Amsacrine; its salts</text><text>Amylene hydrate</text><text class="first_line_indent_0">Anagrelide; its salts</text><text class="first_line_indent_0">Anastrozole; its salts</text><text class="first_line_indent_0">Andexanet alfa</text><text class="first_line_indent_0">Androgenic, oestrogenic and progestational substances,
                the following—</text><text class="left_indent_0 first_line_indent_24">Benzoestrol</text><text class="left_indent_36 first_line_indent_-12">Derivatives of stilbene, dibenzyl or
                naphthalene with oestrogenic activity; their esters</text><text class="left_indent_36 first_line_indent_-12">Steroid compounds with androgenic or
                oestrogenic or progestational activity; their
                esters; except
                when contained in a preparation intended to be taken orally for contraceptive
                purposes only and each dose of the preparation contains not more than the
                following—</text><text class="left_indent_48">0.15 mg of Desogestrel;</text><text class="left_indent_48">3.00 mg of Drospirenone;</text><text class="left_indent_48">0.05 mg of Ethinyloestradiol;</text><text class="left_indent_48">0.10 mg of Gestodene;</text><text class="left_indent_48">0.25 mg of Levonorgestrel;</text><text class="left_indent_48">2.50 mg of Lynoestrenol;</text><text class="left_indent_48">0.05 mg of Mestranol;</text><text class="left_indent_48">1.00 mg of Norethisterone;</text><text class="left_indent_48">0.25 mg of Norgestimate; and</text><text class="left_indent_48">0.50 mg of Norgestrel</text><text>Anidulafungin; its salts; its esters; their salts</text><text>Anifrolumab</text><text>Anileridine; its salts</text><text>Anistreplase</text><text class="left_indent_12 first_line_indent_-12">Antihistamine substances, the
                following; their salts; any compound with any substance falling within this
                item—</text><text class="left_indent_0 first_line_indent_24">Antazoline</text><text class="left_indent_0 first_line_indent_24">Astemizole</text><text class="left_indent_0 first_line_indent_24">Bilastine</text><text class="left_indent_0 first_line_indent_24">Doxylamine</text><text class="left_indent_0 first_line_indent_24">Mebhydrolin</text><text class="left_indent_0 first_line_indent_24">Terfenadine</text><text class="left_indent_0 first_line_indent_24">Tripelennamine</text><text class="left_indent_12 first_line_indent_-12">Antilymphocyte Immunoglobulins</text><text class="left_indent_12 first_line_indent_-12">Antimonial poisons, except substances
                containing less than the equivalent of 1% of antimony trioxide</text><text>Antisera, antitoxins, immunoglobulins and vaccines—</text><paragraph id="ID_1438411271133_070" name="a" temporalId="sch1_D0_a"><num value="a">(a)</num><content>the following—</content><content class="left_indent_46">Bacillus Calmette-Guérin (BCG)</content><content class="left_indent_46">Meningococcal vaccines</content><content class="left_indent_46">Normal immunoglobulins</content><content class="left_indent_46">Pneumococcal vaccines</content><content class="left_indent_46">Rotavirus vaccines</content><content class="left_indent_46">Snake venom antisera</content><content class="left_indent_46">Staphylococcal vaccines</content><content class="left_indent_46">Streptococcal vaccines;</content></paragraph><paragraph id="ID_1438411271133_142" name="b" temporalId="sch1_D0_b"><num value="b">(b)</num><content>directed against the following diseases, viruses or organisms—</content><content class="left_indent_46">Bordetella species</content><content class="left_indent_46">Botulism</content><content class="left_indent_46">Canine infectious disease</content><content class="left_indent_46">Cholera</content><content class="left_indent_46">Dengue fever</content><content class="left_indent_46">Diphtheria</content><content class="left_indent_46">Feline calicivirus</content><content class="left_indent_46">Feline Chlamydia psittaci</content><content class="left_indent_46">Feline immunodeficiency virus</content><content class="left_indent_46">Feline leukemia virus</content><content class="left_indent_46">Feline panleukopenia virus</content><content class="left_indent_46">Feline rhinotracheitis virus</content><content class="left_indent_46">Haemophilus influenzae type b</content><content class="left_indent_46">Hepatitis A</content><content class="left_indent_46">Hepatitis B</content><content class="left_indent_46">Herpes simplex</content><content class="left_indent_46">Herpes zoster</content><content class="left_indent_46">Human papillomavirus</content><content class="left_indent_46">Influenza</content><content class="left_indent_46">Japanese encephalitis</content><content class="left_indent_46">Measles</content><content class="left_indent_46">Mumps</content><content class="left_indent_46">Pertussis</content><content class="left_indent_46">Plague</content><content class="left_indent_46">Poliomyelitis</content><content class="left_indent_46">Rabies</content><content class="left_indent_46">Respiratory syncytial virus</content><content class="left_indent_46">Rubella</content><content class="left_indent_46">Severe acute respiratory syndrome coronavirus 2
                    (SARS-CoV-2)</content><content class="left_indent_46">Tetanus</content><content class="left_indent_46">Typhoid</content><content class="left_indent_46">Varicella</content><content class="left_indent_46">Yellow fever</content></paragraph><text class="first_line_indent_0">Antithymocyte Immunoglobulin</text><text>Apalutamide; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Apixaban; its salts</text><text class="left_indent_12 first_line_indent_-12">Apomorphine; its salts; its
                quaternary compounds; except substances containing less than 0.2% of
                apomorphine</text><text class="first_line_indent_0">Apremilast; its salts</text><text class="first_line_indent_0">Aprepitant; its salts</text><text class="first_line_indent_0">Aprindine; its salts</text><text class="first_line_indent_0">Aripiprazole</text><text class="first_line_indent_0">Arsenic trioxide when contained in pharmaceutical
                products</text><text class="left_indent_12 first_line_indent_-12">Arsenical poisons, except substances
                containing less than the equivalent of 0.01% of arsenic trioxide and except
                dentifrices containing less than 0.5% of acetarsol </text><text class="first_line_indent_0">Artemether; its salts</text><text class="first_line_indent_0">Articaine; its salts</text><text class="first_line_indent_0">Asciminib; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Asenapine; its salts; its
                isomers</text><text class="first_line_indent_-24 left_indent_24 ">Asfotase alfa</text><text>Asunaprevir; its salts</text><text class="first_line_indent_0">Atazanavir; its salts</text><text class="first_line_indent_0">Atenolol; its salts</text><text class="first_line_indent_0">Atezolizumab</text><text class="first_line_indent_0">Atogepant</text><text class="first_line_indent_0">Atomoxetine; its salts</text><text class="first_line_indent_0">Atorvastatin; its salts</text><text class="first_line_indent_0">Atosiban; its salts</text><text class="first_line_indent_0">Atovaquone</text><text class="first_line_indent_0">Atracurium besylate</text><text class="left_indent_12 first_line_indent_-12">Atropine; its salts; when contained
                in pharmaceutical products for human parenteral administration or pharmaceutical
                products intended to be used for slowing the progression of myopia</text><text class="first_line_indent_0">Auranofin</text><text>Avalglucosidase alfa</text><text class="first_line_indent_0">Avanafil; its salts</text><text class="first_line_indent_0">Avapritinib; its salts</text><text class="first_line_indent_0">Avatrombopag; its salts; its esters; their
                salts</text><text>Avelumab</text><text class="first_line_indent_0">Axitinib; its salts </text><text class="first_line_indent_0">Azacitidine; its salts</text><text class="first_line_indent_0">Azacyclonal; its salts</text><text class="first_line_indent_0">Azapropazone</text><text class="first_line_indent_0">Azauridine; its derivatives</text><text class="first_line_indent_0">Azilsartan; its salts; its esters; their salts</text><text class="first_line_indent_0">Aziridine; its derivatives</text><text class="first_line_indent_0">Baclofen</text><text class="first_line_indent_0">Baloxavir; its salts; its esters and ethers; their
                salts</text><text class="first_line_indent_0">Bambuterol and its salts when contained in aerosol
                dispensers</text><text class="left_indent_12 first_line_indent_-12">Barbituric acid; its salts; its
                derivatives; their salts; any compound with any substance falling within this
                item</text><text class="first_line_indent_0">Baricitinib; its salts</text><text class="first_line_indent_0">Basiliximab; its salts</text><text class="first_line_indent_0">Becaplermin; its salts</text><text class="first_line_indent_0">Bedaquiline; its salts</text><text class="first_line_indent_0">Befunolol; its salts</text><text>Belantamab mafodotin</text><text class="first_line_indent_-24 left_indent_24 ">Belimumab</text><text class="first_line_indent_-24 left_indent_24 ">Belumosudil; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Belzutifan; its salts</text><text class="first_line_indent_0">Bemiparin; its salts</text><text>Bempedoic acid; its salts; its esters; their salts</text><text class="first_line_indent_0">Benactyzine; its salts</text><text class="first_line_indent_0">Benazepril;
                its salts</text><text class="first_line_indent_0">Benmelstobart</text><text class="first_line_indent_0">Benoxaprofen; its salts</text><text>Benralizumab</text><text class="first_line_indent_0">Benserazide; its salts</text><text class="first_line_indent_0">Benzbromarone</text><text class="first_line_indent_0">Benzethidine; its salts</text><text class="first_line_indent_0">Benzhexol; its salts</text><text class="first_line_indent_0">Benzoylmorphine; its salts</text><text class="first_line_indent_0">Benzquinamide</text><text class="first_line_indent_0">Benztropine and its homologues; their salts</text><text class="first_line_indent_0">Benzylmorphine; its salts</text><text class="first_line_indent_0">Besifloxacin; its salts; its esters; their
                salts</text><text class="left_indent_12 first_line_indent_-12">Betahistine; its salts; except when
                contained in pharmaceutical products containing betahistine hydrochloride or
                betahistine mesilate (a) labelled with a maximum recommended daily dose of the
                pharmaceutical product having the equivalent of 48 mg of betahistine hydrochloride
                or 36 mg of betahistine mesilate; (b) stated for use only in patients of 18 years
                old or above for relief of vertigo symptoms only; and (c) to be sold in packs for a
                maximum of 5 days’ use</text><text class="first_line_indent_0">Betaxolol; its salts</text><text class="first_line_indent_0">Bethanidine; its salts</text><text class="first_line_indent_0">Bevacizumab</text><text class="first_line_indent_0">Bexarotene; its salts</text><text class="first_line_indent_0">Bezafibrate</text><text class="first_line_indent_0">Bezitramide; its salts</text><text class="first_line_indent_0">Bicalutamide; its salts</text><text>Bictegravir; its salts</text><text>Bimekizumab</text><text>Binimetinib; its salts</text><text class="left_indent_12 first_line_indent_-12">Biphenylacetic acid; its salts; its
                esters; except when contained in preparations intended for external use only</text><text class="left_indent_12 first_line_indent_-12">N-[4,4-Bis(para-fluorophenyl)butyl]piperidine, 4-substituted derivatives of; their
                salts</text><text class="first_line_indent_0">Bisoprolol; its salts</text><text class="first_line_indent_0">Bitolterol and its salts when contained in aerosol
                dispensers</text><text>Bivalirudin; its salts</text><text>Blinatumomab</text><text class="left_indent_12 first_line_indent_-12">Blood products derived from human
                blood or manufactured by biotechnology, the following—</text><text class="left_indent_0 first_line_indent_24">Albumin</text><text class="left_indent_0 first_line_indent_24">Antithrombins</text><text class="left_indent_0 first_line_indent_24">Blood clotting factors</text><text class="left_indent_0 first_line_indent_24">Fibrin</text><text class="left_indent_0 first_line_indent_24">Fibrinogen</text><text class="left_indent_0 first_line_indent_24">Plasma protein fractions</text><text class="left_indent_0 first_line_indent_24">Thrombin</text><text class="first_line_indent_0">Boceprevir; its salts</text><text class="first_line_indent_0">Bortezomib</text><text class="first_line_indent_0">Bosentan; its salts</text><text class="first_line_indent_0">Botulinum toxin complexes</text><text class="first_line_indent_0">Brentuximab vedotin</text><text class="first_line_indent_0">Bretylium tosylate</text><text>Brexpiprazole; its salts</text><text>Brigatinib; its salts</text><text class="first_line_indent_0">Brimonidine; its salts</text><text class="first_line_indent_0">Brinzolamide; its salts</text><text>Brivaracetam; its salts</text><text>Brodalumab</text><text>Brolucizumab</text><text class="first_line_indent_0">Bromocriptine; its salts</text><text class="first_line_indent_0">Bromvaletone</text><text class="first_line_indent_0">Broncho-Vaxom</text><text class="first_line_indent_0">Brotizolam</text><text class="first_line_indent_0">Bucolome</text><text class="first_line_indent_0">Bufexamac</text><text class="first_line_indent_0">Buformin; its salts</text><text class="first_line_indent_0">Bumadizone; its salts</text><text class="first_line_indent_0">Bumetanide; its salts; its derivatives; their
                salts</text><text class="first_line_indent_0">Bupivacaine; its salts</text><text class="first_line_indent_0">Bupranolol; its salts</text><text class="first_line_indent_0">Buprenorphine; its salts</text><text class="first_line_indent_0">Bupropion; its salts</text><text class="first_line_indent_0">Burosumab</text><text class="first_line_indent_0">Buserelin; its salts</text><text class="first_line_indent_0">Buspirone; its salts</text><text class="first_line_indent_0">Busulphan; its salts</text><text class="first_line_indent_0">Butorphanol; its salts</text><text class="first_line_indent_0">Cabazitaxel; its salts; its esters; their salts</text><text class="first_line_indent_0">Cabergoline; its salts</text><text>Cabotegravir; its salts</text><text class="first_line_indent_0">Cabozantinib; its salts</text><text class="first_line_indent_0">Calcifediol</text><text class="first_line_indent_0">Calcipotriol; its salts</text><text>Calcitriol; its salts</text><text class="first_line_indent_0">Canagliflozin; its salts</text><text class="first_line_indent_0">Canakinumab</text><text class="first_line_indent_0">Candesartan; its salts; its esters; their salts</text><text>Cannabidiol; its salts; when contained in pharmaceutical products</text><text class="left_indent_12 first_line_indent_-12">Cannabinol and its tetrahydro
                or hexahydro
                derivatives; their 3-alkyl homologues; any ester or ether of any
                substance falling within this item</text><text class="left_indent_12 first_line_indent_-12">Cannabis; the resin of cannabis;
                extracts of cannabis; tinctures of cannabis; cannabin tennate</text><text class="first_line_indent_-24 left_indent_24 ">Capecitabine; its salts</text><text class="first_line_indent_0">Capivasertib; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Capmatinib; its salts</text><text class="first_line_indent_0">Captodiamine; its salts</text><text class="first_line_indent_0">Captopril</text><text class="first_line_indent_0">Carbachol</text><text class="first_line_indent_0">Carbamazepine</text><text class="first_line_indent_0">Carbidopa; its salts</text><text class="first_line_indent_0">Carbimazole; its salts</text><text class="first_line_indent_0">Carboplatin</text><text class="first_line_indent_0">Carbromal</text><text class="first_line_indent_0">Carbutamide</text><text class="first_line_indent_0">Carfilzomib; its salts</text><text class="first_line_indent_0">Carglumic acid; its salts; its esters; their
                salts</text><text class="first_line_indent_0">Carisoprodol</text><text class="first_line_indent_0">Carmustine</text><text class="first_line_indent_0">Carperidine; its salts</text><text class="first_line_indent_0">Carprofen; its salts</text><text class="first_line_indent_0">Carteolol; its salts</text><text class="first_line_indent_0">Carvedilol; its salts</text><text class="first_line_indent_0">Casirivimab</text><text class="first_line_indent_0">Caspofungin; its salts</text><text class="first_line_indent_0">Catequentinib (Anlotinib); its salts</text><text class="first_line_indent_0">Cedazuridine; its salts</text><text class="first_line_indent_0">Celecoxib; its salts</text><text class="first_line_indent_0">Celiprolol; its salts</text><text>Cemiplimab</text><text>Cenobamate; its salts</text><text>Ceritinib; its salts</text><text class="first_line_indent_0">Cerivastatin; its salts</text><text class="first_line_indent_0">Certolizumab pegol</text><text class="first_line_indent_0">Cetrorelix; its salts; its esters; their salts</text><text class="first_line_indent_0">Cetuximab</text><text class="first_line_indent_0">Chlofenamic acid; its salts</text><text class="left_indent_12 first_line_indent_-12">Chloral; its addition and its
                condensation products other than alphachloralose; any compound with any substance
                falling within this item, except when contained, in the form of chloral hydrate, in
                preparations intended for external application only</text><text class="first_line_indent_0">Chlordiazepoxide; its salts</text><text class="first_line_indent_0">Chlormethiazole; its salts</text><text class="first_line_indent_0">Chlormezanone</text><text class="left_indent_12 first_line_indent_-12">Chloroform, except substances
                containing not more than 5% of chloroform or when in preparations not intended for
                the internal treatment of human ailments</text><text class="first_line_indent_0">Chloroquine; its salts</text><text class="left_indent_12 first_line_indent_-12">Chlorothiazide and other derivatives
                of benzo-1,2,4-thiadiazine-7-sulphonamide 1,1-dioxide, whether hydrogenated or not;
                their salts</text><text class="first_line_indent_0">Chlorphenoxamine; its salts</text><text class="first_line_indent_0">Chlorphentermine; its salts</text><text class="first_line_indent_0">Chlorpropamide; its salts</text><text class="first_line_indent_-12 left_indent_12">Chlorprothixene and other derivatives
                of 9-methylenethiaxanthen; their salts</text><text class="first_line_indent_0">Chlorthalidone and other derivatives of
                ortho-chlorobenzene-sulphonamide</text><text class="first_line_indent_0">Chlorzoxazone</text><text class="first_line_indent_0">Chorionic Gonadotrophin</text><text class="first_line_indent_0">Chymopapain</text><text class="first_line_indent_0">Cicletanine; its salts</text><text class="first_line_indent_0">Cidofovir; its salts</text><text class="first_line_indent_0">Cilazapril; its salts</text><text class="first_line_indent_0">Cilgavimab</text><text class="first_line_indent_0">Cilostazol; its salts</text><text class="first_line_indent_0">Cinacalcet; its salts</text><text class="first_line_indent_0">Cinepazide; its salts</text><text class="first_line_indent_0">Ciprofibrate; its salts</text><text class="first_line_indent_0">Ciprofloxacin; its salts; its esters</text><text class="first_line_indent_0">Cisapride</text><text class="first_line_indent_0">Cisatracurium besylate</text><text class="first_line_indent_0">Cisplatin</text><text class="first_line_indent_0">Citalopram; its salts</text><text class="left_indent_12 first_line_indent_-12">Citicoline; its salts; when contained
                in pharmaceutical products intended to be used for the treatment of cognitive and
                neurological disorders associated with cerebrovascular disease or brain injury, or
                both</text><text class="first_line_indent_0">Cladribine</text><text class="first_line_indent_0">Clioquinol</text><text class="first_line_indent_0">Clobazam</text><text class="first_line_indent_0">Clodronic acid; its salts; its esters</text><text class="first_line_indent_0">Clofarabine; its salts; its esters; their salts</text><text class="first_line_indent_0">Clofazimine; its salts</text><text class="first_line_indent_0">Clofibrate</text><text class="first_line_indent_0">Clomiphene; its salts</text><text class="first_line_indent_0">Clomipramine; its salts; its derivatives; their
                salts</text><text class="first_line_indent_0">Clonidine; its salts</text><text class="first_line_indent_0">Clonitazene; its salts</text><text class="first_line_indent_0">Clopidogrel; its salts</text><text class="first_line_indent_0">Clorexolone</text><text class="first_line_indent_0">Cloridarol</text><text class="first_line_indent_0">Clorprenaline and its salts when contained in aerosol
                dispensers</text><text class="first_line_indent_0">Clothiapine</text><text class="first_line_indent_-24 left_indent_24 ">Clozapine; its salts</text><text class="first_line_indent_0">Cobicistat; its salts</text><text class="first_line_indent_0">Cobimetinib; its salts</text><text class="first_line_indent_0">Codergocrine mesilate</text><text class="first_line_indent_0">Colaspase</text><text class="first_line_indent_0">Colfosceril; its salts</text><text class="first_line_indent_0">Collagen, purified</text><text class="left_indent_12 first_line_indent_-12">Contrast media, the following; their
                salts; any compound with any substance falling within this item; when contained in
                preparations for parenteral use—</text><text class="left_indent_0 first_line_indent_24">Acetrizoic acid</text><text class="left_indent_0 first_line_indent_24">Diatrizoic acid</text><text class="left_indent_0 first_line_indent_24">Ferucarbotran</text><text class="left_indent_0 first_line_indent_24">Gadobenic acid</text><text class="left_indent_0 first_line_indent_24">Gadobutrol</text><text class="left_indent_0 first_line_indent_24">Gadodiamide</text><text class="left_indent_0 first_line_indent_24">Gadopentetic acid</text><text class="left_indent_0 first_line_indent_24">Gadoteric acid</text><text class="left_indent_0 first_line_indent_24">Iobitridol</text><text class="left_indent_0 first_line_indent_24">Iocarmic acid</text><text class="left_indent_0 first_line_indent_24">Iocetamic acid</text><text class="left_indent_0 first_line_indent_24">Iodamide</text><text class="left_indent_0 first_line_indent_24">Iodipamide</text><text class="left_indent_0 first_line_indent_24">Iodised oil</text><text class="left_indent_0 first_line_indent_24">Iodixanol</text><text class="left_indent_0 first_line_indent_24">Iodoxamic acid</text><text class="left_indent_0 first_line_indent_24">Ioglicic acid</text><text class="left_indent_0 first_line_indent_24">Ioglycamic acid</text><text class="left_indent_0 first_line_indent_24">Iohexol</text><text class="left_indent_0 first_line_indent_24">Iomeprol</text><text class="left_indent_0 first_line_indent_24">Iopamidol</text><text class="left_indent_0 first_line_indent_24">Iopanoic acid</text><text class="left_indent_0 first_line_indent_24">Iophendylate</text><text class="left_indent_0 first_line_indent_24">Iopromide</text><text class="left_indent_0 first_line_indent_24">Iothalamic acid</text><text class="left_indent_0 first_line_indent_24">Iotrolan</text><text class="left_indent_0 first_line_indent_24">Iotroxic acid</text><text class="left_indent_0 first_line_indent_24">Ioversol</text><text class="left_indent_0 first_line_indent_24">Ioxaglic acid</text><text class="left_indent_0 first_line_indent_24">Ioxitalamic acid</text><text class="left_indent_0 first_line_indent_24">Ipodic acid</text><text class="left_indent_0 first_line_indent_24">Metrizamide</text><text class="left_indent_0 first_line_indent_24">Propyliodone</text><text class="left_indent_0 first_line_indent_24">Sulphur hexafluoride</text><text class="left_indent_0 first_line_indent_24">Tyropanoic acid</text><text class="first_line_indent_-24 left_indent_24 ">Corifollitropin alfa</text><text class="first_line_indent_0">Corticorelin; its salts</text><text class="first_line_indent_0">Corticotrophins</text><text class="first_line_indent_0">Corynebacterium parvum</text><text class="first_line_indent_0">Crisaborole; its salts</text><text class="first_line_indent_0">Crizotinib; its salts </text><text class="first_line_indent_0">4-Cyano-2-dimethylamino-4,4-diphenylbutane; its
                salts</text><text class="first_line_indent_0">4-Cyano-1-methyl-4-phenylpiperidine; its salts</text><text class="first_line_indent_0">Cyclarbamate</text><text class="first_line_indent_0">Cyclobenzaprine; its salts</text><text class="first_line_indent_0">Cyclofenil</text><text class="first_line_indent_0">Cyclosporin A</text><text class="first_line_indent_0">Cytarabine; its salts</text><text class="first_line_indent_0">Dabigatran etexilate; its salts</text><text class="first_line_indent_0">Dabrafenib; its salts</text><text class="first_line_indent_0">Dacarbazine</text><text>Daclatasvir; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Daclizumab</text><text>Dacomitinib; its salts</text><text class="first_line_indent_0">Dalteparin; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Danicopan; its salts</text><text class="first_line_indent_0">Dapagliflozin; its salts </text><text class="first_line_indent_0">Dapoxetine; its salts</text><text class="first_line_indent_0">Dapsone</text><text class="first_line_indent_0">Daratumumab</text><text class="first_line_indent_0">Darbepoetin alfa</text><text class="first_line_indent_0">Daridorexant; its salts</text><text class="first_line_indent_0">Darifenacin; its salts</text><text class="first_line_indent_0">Darolutamide; its salts</text><text class="first_line_indent_0">Darunavir; its salts</text><text>Dasabuvir; its salts</text><text class="first_line_indent_0">Dasatinib; its salts</text><text class="first_line_indent_0">Deanol acetamidobenzoate</text><text class="first_line_indent_0">Debrisoquine; its salts</text><text class="first_line_indent_0">Decitabine; its salts</text><text class="first_line_indent_0">Deferasirox; its salts; its esters; their salts</text><text class="first_line_indent_0">Deferiprone; its salts</text><text class="first_line_indent_0">Degarelix; its salts</text><text class="first_line_indent_0">Dehydroemetine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Delafloxacin; its salts; its esters;
                their salts</text><text>Delamanid; its salts</text><text>Delandistrogene moxeparvovec</text><text class="first_line_indent_0">Demecarium bromide</text><text class="first_line_indent_-24 left_indent_24 ">Denosumab</text><text class="first_line_indent_0">Desferrioxamine; its salts</text><text>Desflurane</text><text class="first_line_indent_0">Desipramine; its salts</text><text class="first_line_indent_0">Desomorphine; its salts; its esters and ethers; their
                salts</text><text class="first_line_indent_0">Desvenlafaxine; its salts</text><text class="first_line_indent_0">Deucravacitinib; its salts</text><text class="first_line_indent_0">Dexketoprofen; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Dexlansoprazole; its salts</text><text class="first_line_indent_0">Dexmedetomidine; its salts</text><text class="first_line_indent_0">Dexrazoxane; its salts</text><text class="first_line_indent_0">Diacerein; its salts; its esters</text><text class="first_line_indent_0">Diampromide; its salts</text><text class="left_indent_12 first_line_indent_-12">Diazepam and other compounds
                containing the chemical structure of dihydro-1, 4-benzodiazepine substituted to any
                degree; their salts</text><text class="first_line_indent_0">Diazoxide</text><text class="left_indent_12 first_line_indent_-12">Diclofenac; its salts; except when
                contained in preparations for external application only</text><text class="first_line_indent_0">Didanosine; its salts</text><text class="first_line_indent_0">Digitalis, glycosides of; other active principles of
                digitalis</text><text class="first_line_indent_0">Dihydralazine; its salts</text><text class="first_line_indent_0">Dihydrocodeine; its salts; its esters and ethers;
                their salts</text><text class="first_line_indent_0">Dihydrocodeinone; its salts</text><text class="first_line_indent_0">Dihydrocodeinone O-carboxymethyloxime; its salts; its
                esters; their salts</text><text class="first_line_indent_0">Dihydrocodeinone enol acetate; its salts</text><text class="first_line_indent_0">Dihydroergotamine; its salts, simple or complex</text><text class="first_line_indent_0">Dihydroetorphine; its salts</text><text class="first_line_indent_0">Dihydromorphine; its salts; its esters and ethers;
                their salts</text><text class="first_line_indent_0">3-(3,4-Dihydroxyphenyl)alanine; its salts</text><text class="first_line_indent_0">Diltiazem; its salts</text><text class="first_line_indent_0">Dimefline; its salts</text><text class="first_line_indent_0">Dimenoxadole; its salts</text><text class="first_line_indent_0">Dimepheptanol; its salts; its esters and ethers; their
                salts</text><text class="first_line_indent_0">Dimethyl fumarate when contained in pharmaceutical
                products</text><text class="first_line_indent_0">Dinutuximab beta</text><text class="first_line_indent_0">Dioxaphetyl butyrate; its salts</text><text class="first_line_indent_0">Dipipanone; its salts</text><text class="first_line_indent_0">Diprenorphine; its salts</text><text class="first_line_indent_0">Dipyridamole</text><text class="first_line_indent_0">Diquafosol; its salts</text><text class="first_line_indent_0">Disopyramide; its salts</text><text class="first_line_indent_0">Distigmine; its salts</text><text class="first_line_indent_0">Disulfiram</text><text class="first_line_indent_0">Dithienylallylamines; dithienylalkylallylamines; their
                salts</text><text class="first_line_indent_0">Dobutamine; its salts</text><text class="first_line_indent_0">Docetaxel; its salts</text><text class="first_line_indent_0">Dolutegravir; its salts</text><text class="first_line_indent_0">Domperidone; its salts</text><text>Donanemab</text><text class="first_line_indent_0">Donepezil; its salts</text><text class="first_line_indent_0">Dopamine; its salts</text><text class="first_line_indent_0">Doravirine; its salts</text><text class="first_line_indent_0">Dornase alfa</text><text class="first_line_indent_0">Dorzolamide; its salts</text><text class="first_line_indent_0">Dostarlimab</text><text class="first_line_indent_0">Dothiepin; its salts</text><text class="first_line_indent_0">Doxapram; its salts</text><text class="first_line_indent_0">Doxazosin; its salts</text><text class="first_line_indent_0">Doxepin; its salts; its derivatives; their
                salts</text><text class="first_line_indent_0">Dronedarone; its salts</text><text class="first_line_indent_0">Droperidol</text><text class="first_line_indent_0">Drotrecogin alfa</text><text>Dulaglutide</text><text class="first_line_indent_0">Duloxetine; its salts</text><text>Dupilumab</text><text>Durvalumab</text><text class="first_line_indent_0">Dutasteride</text><text class="first_line_indent_0">Dyflos</text><text class="first_line_indent_0">Ecothiopate iodide</text><text class="first_line_indent_0">Ectylurea</text><text class="first_line_indent_0">Eculizumab</text><text class="first_line_indent_0">Edoxaban; its salts</text><text class="first_line_indent_0">Efalizumab</text><text class="first_line_indent_0">Efanesoctocog alfa</text><text class="first_line_indent_0">Efavirenz; its salts</text><text>Efinaconazole; its salts</text><text class="first_line_indent_0">Elacestrant; its salts</text><text>Eladocagene exuparvovec</text><text class="first_line_indent_0">Elapegademase</text><text class="first_line_indent_0">Elbasvir; its salts</text><text class="first_line_indent_0">Eletriptan; its salts</text><text class="first_line_indent_0">Elosulfase alfa</text><text class="first_line_indent_0">Elotuzumab</text><text class="first_line_indent_0">Elranatamab</text><text class="first_line_indent_0">Eltrombopag; its salts; its esters; their salts</text><text class="first_line_indent_0">Elvitegravir; its salts</text><text class="first_line_indent_0">Embutramide</text><text>Emicizumab</text><text>Empagliflozin; its salts</text><text class="first_line_indent_0">Emtricitabine; its salts</text><text class="first_line_indent_0">Emylcamate</text><text class="first_line_indent_0">Enalapril; its salts</text><text class="first_line_indent_0">Enalaprilat; its salts</text><text class="first_line_indent_0">Encorafenib; its salts</text><text>Enfortumab vedotin</text><text class="first_line_indent_0">Enfuvirtide</text><text class="first_line_indent_0">Enoxacin; its salts; its esters</text><text class="first_line_indent_0">Enoxaparin; its salts</text><text class="first_line_indent_0">Enoximone</text><text class="first_line_indent_0">Enrofloxacin; its salts; its esters</text><text>Ensifentrine; its salts</text><text class="first_line_indent_0">Entacapone; its salts</text><text class="first_line_indent_0">Entecavir; its salts; its esters; their salts</text><text>Entrectinib; its salts</text><text class="first_line_indent_0">Enzalutamide; its salts</text><text class="first_line_indent_0">Epcoritamab</text><text class="first_line_indent_0">Eplerenone</text><text class="first_line_indent_0">Epoetin beta</text><text class="first_line_indent_0">Eprosartan; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Eptifibatide; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Eptinezumab</text><text>Equecabtagene autoleucel</text><text class="first_line_indent_-24 left_indent_24">Erdafitinib; its salts</text><text>Erenumab</text><text class="first_line_indent_-24 left_indent_24 ">Eribulin; its salts</text><text class="first_line_indent_0">Erlotinib; its salts</text><text>Ertugliflozin; its salts</text><text class="first_line_indent_0">Esmolol; its salts</text><text class="first_line_indent_0">Esomeprazole; its salts</text><text class="first_line_indent_0">Etafenone; its salts</text><text class="first_line_indent_0">Etamivan; its salts</text><text class="first_line_indent_0">Etanercept</text><text class="first_line_indent_0">Etelcalcetide; its salts</text><text class="first_line_indent_0">Ethacrynic acid; its salts</text><text class="first_line_indent_0">Ethambutol; its salts</text><text class="first_line_indent_0">Ethchlorvynol</text><text class="first_line_indent_0">Ethinamate</text><text class="first_line_indent_0">Ethionamide</text><text class="first_line_indent_0">Ethoglucid</text><text class="first_line_indent_0">Ethoheptazine; its salts</text><text class="left_indent_12 first_line_indent_-12">Ethosuximide; its salts</text><text class="left_indent_12 first_line_indent_-12">Ethylmorphine; its salts; its esters
                and ethers; their salts; except substances containing less than 0.2% of
                ethylmorphine</text><text class="first_line_indent_0">Etidronic acid; its salts; when contained in
                pharmaceutical products</text><text class="first_line_indent_0">Etilefrine; its salts</text><text class="first_line_indent_0">Etodolac</text><text class="first_line_indent_0">Etofibrate</text><text class="first_line_indent_0">Etomidate; its salts</text><text class="first_line_indent_0">Etonitazene; its salts</text><text class="first_line_indent_0">Etoposide; its esters</text><text class="first_line_indent_0">Etoricoxib; its salts</text><text class="first_line_indent_0">Etorphine; its salts; its esters and ethers; their
                salts</text><text class="first_line_indent_0">Etoxeridine; its salts</text><text class="first_line_indent_0">Etranacogene dezaparvovec</text><text class="first_line_indent_0">Etrasimod; its salts; its esters; their salts</text><text class="first_line_indent_0">Etravirine</text><text class="first_line_indent_0">Etretinate</text><text class="first_line_indent_0">Etryptamine; its salts</text><text class="first_line_indent_0">Everolimus; its salts; its esters; their salts</text><text class="first_line_indent_0">Evocalcet; its salts; its esters; their salts</text><text>Evolocumab</text><text class="first_line_indent_0">Exemestane; its salts</text><text class="first_line_indent_0">Exenatide</text><text class="first_line_indent_0">Ezetimibe</text><text class="first_line_indent_0">Famciclovir; its salts</text><text class="first_line_indent_0">Fampridine; its salts </text><text class="first_line_indent_0">Faricimab</text><text class="first_line_indent_0">Febuxostat; its salts; its esters; their salts</text><text class="first_line_indent_0">Felodipine</text><text class="first_line_indent_0">Fenbufen</text><text class="first_line_indent_0">Fencamfamin; its salts</text><text class="first_line_indent_0">Fenclofenac; its salts</text><text class="first_line_indent_0">Fendiline; its salts</text><text class="first_line_indent_0">Fenfluramine; its salts</text><text class="first_line_indent_0">Fenofibrate</text><text class="first_line_indent_0">Fenoprofen; its salts</text><text class="first_line_indent_0">Fenoterol and its salts when contained in aerosol
                dispensers</text><text class="first_line_indent_0">Fenoxazoline; its salts</text><text class="first_line_indent_0">Fentanyl; its salts</text><text class="first_line_indent_0">Fentiazac; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Fenticonazole; its salts</text><text class="first_line_indent_0">Feprazone</text><text class="first_line_indent_0">Fesoterodine; its salts; its esters; their
                salts</text><text class="first_line_indent_-24 left_indent_24 ">Fezolinetant; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Filgotinib; its salts</text><text class="first_line_indent_0">Filgrastim</text><text class="first_line_indent_0">Finasteride</text><text class="first_line_indent_0">Finerenone; its salts</text><text class="first_line_indent_0">Fingolimod; its salts; its esters; their salts</text><text>Firocoxib; its salts</text><text>Fitusiran; its salts</text><text class="first_line_indent_0">Flavoxate; its salts</text><text class="first_line_indent_0">Flecainide; its salts</text><text class="first_line_indent_0">Fleroxacin; its salts; its esters</text><text class="first_line_indent_0">Fluanisone</text><text class="first_line_indent_0">Fluconazole; its salts</text><text class="first_line_indent_0">Fludarabine; its salts</text><text class="first_line_indent_0">Flufenamic acid; its salts; its esters; their
                salts</text><text class="first_line_indent_0">Flumazenil</text><text class="first_line_indent_0">Flumethrin; its salts</text><text class="first_line_indent_0">Fluorouracil; its derivatives</text><text class="first_line_indent_0">Fluoxetine; its salts</text><text class="first_line_indent_0">Flupenthixol; its salts</text><text>Fluralaner; its salts</text><text class="first_line_indent_0">Flurbiprofen</text><text class="first_line_indent_0">Fluspirilene</text><text class="first_line_indent_0">Flutamide</text><text class="first_line_indent_0">Fluvastatin</text><text class="first_line_indent_0">Fluvoxamine; its salts</text><text class="first_line_indent_0">Folinic acid; its salts</text><text class="first_line_indent_0">Fondaparinux; its salts</text><text class="first_line_indent_0">Formestane</text><text class="first_line_indent_0">Formoterol and its salts when contained in aerosol
                dispensers</text><text class="first_line_indent_0">Fosaprepitant; its salts</text><text class="first_line_indent_0">Foscarnet trisodium hexahydrate</text><text class="first_line_indent_0">Fosinopril; its salts</text><text>Fosnetupitant; its salts</text><text class="first_line_indent_0">Fosphenytoin; its salts</text><text class="first_line_indent_0">Fostamatinib; its salts</text><text class="first_line_indent_0">Fotemustine; its salts</text><text class="first_line_indent_0">Fremanezumab</text><text class="first_line_indent_0">Fruquintinib; its salts</text><text class="first_line_indent_0">Frusemide</text><text class="first_line_indent_0">Fulvestrant</text><text class="first_line_indent_0">Furethidine; its salts</text><text class="first_line_indent_0">Futibatinib; its salts</text><text class="first_line_indent_0">Gabapentin; its salts</text><text class="first_line_indent_0">Gadoxetic acid; its salts</text><text class="first_line_indent_0">Galcanezumab</text><text class="first_line_indent_0">Gallamine; its salts; its quaternary compounds</text><text class="first_line_indent_0">Gallium-68; its salts; when contained in
                pharmaceutical products</text><text class="first_line_indent_0">Gallopamil; its salts</text><text class="first_line_indent_0">Galsulfase</text><text class="first_line_indent_0">Ganciclovir; its salts</text><text class="first_line_indent_0">Ganirelix; its salts</text><text class="first_line_indent_0">Gatifloxacin; its salts; its esters</text><text class="first_line_indent_0">Gefitinib; its salts</text><text class="first_line_indent_0">Gemcitabine; its salts</text><text class="first_line_indent_0">Gemfibrozil</text><text>Gemtuzumab ozogamicin</text><text>Germanium-68; its salts; when contained in pharmaceutical products</text><text>Gilteritinib; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Gimeracil; its salts</text><text class="first_line_indent_0">Glecaprevir; its salts</text><text class="first_line_indent_0">Glibenclamide</text><text class="first_line_indent_0">Glibornuride</text><text class="first_line_indent_0">Gliclazide</text><text class="first_line_indent_0">Glimepiride; its salts</text><text class="first_line_indent_0">Glipizide</text><text class="first_line_indent_0">Gliquidone</text><text class="first_line_indent_0">Glofitamab</text><text class="first_line_indent_0">Glucagon; its salts</text><text class="left_indent_12 first_line_indent_-12">Glutathione; its salts; its
                derivatives; when contained in products for human parenteral administration</text><text class="first_line_indent_0">Glutethimide; its salts</text><text class="first_line_indent_0">Glycerol phenylbutyrate</text><text class="first_line_indent_-60 left_indent_60">Glycopyrronium; its salts</text><text class="first_line_indent_0">Glymidine</text><text class="first_line_indent_0">Golimumab</text><text class="first_line_indent_0">Gonadorelin; its salts</text><text class="first_line_indent_0">Goserelin; its salts</text><text class="first_line_indent_0">Gozetotide; its salts</text><text class="first_line_indent_0">Granisetron; its salts</text><text class="first_line_indent_0">Grazoprevir; its salts</text><text class="first_line_indent_0">Grepafloxacin; its salts; its esters</text><text class="first_line_indent_0">Guanabenz; its salts</text><text class="first_line_indent_0">Guanethidine; its salts</text><text class="first_line_indent_0">Guanfacine; its salts</text><text class="first_line_indent_0">Guanidines, the following—</text><text class="first_line_indent_-12 left_indent_24 ">Polymethylene diguanidines;
                di-para-anisyl-para-phenethylguanidine; their salts</text><text>Guselkumab</text><text class="first_line_indent_0">Halofantrine; its salts</text><text class="left_indent_12 first_line_indent_-12">Haloperidol and other 4-substituted
                derivatives of N-(3-para-fluorobenzoylpropyl) piperidine</text><text class="left_indent_12 first_line_indent_-12">Hemin; its salts; its esters; their
                salts</text><text class="left_indent_12 first_line_indent_-12">Hexachlorophane contained in
                medicinal products except (a) in the case of medicinal products for human use
                substances containing 0.1% or less; and (b) in the case of medicinal products for
                animal use (i) aerosols the contents of the container of which contain 0.1% or less;
                (ii) soaps and shampoos containing 2% or less; (iii) other medicinal products
                containing 0.75% or less; and (c) preparations for oral administration to sheep or
                cattle for liver fluke disease</text><text class="first_line_indent_0">Hexamethylmelamine</text><text class="first_line_indent_0">Hexapropymate</text><text class="first_line_indent_0">Hexobendine; its salts</text><text class="left_indent_12 first_line_indent_-12">Human chondrocytes when contained in
                advanced therapy products indicated for the repair of symptomatic articular
                cartilage defects</text><text class="first_line_indent_0">Human cytomegalovirus immunoglobulin</text><text class="first_line_indent_0">Hydralazine; its salts</text><text class="first_line_indent_0">Hydrazines, the following and their alpha-methyl
                derivatives—</text><text class="left_indent_0 first_line_indent_24">Benzyl hydrazine</text><text class="left_indent_0 first_line_indent_24">Phenethyl hydrazine</text><text class="left_indent_0 first_line_indent_24">Phenoxyethyl hydrazine</text><text class="left_indent_12 first_line_indent_0">their salts; their acyl derivatives;
                their salts</text><text class="left_indent_12 first_line_indent_-12">Hydrocyanic acid, except substances
                containing less than 0.15%, weight in weight, of hydrocyanic acid (HCN); cyanides,
                other than ferrocyanides and ferricyanides, except substances containing less than
                the equivalent of 0.1% weight in weight, of hydrocyanic acid (HCN)</text><text class="first_line_indent_0">Hydromorphinol; its salts; its esters and ethers;
                their salts</text><text class="first_line_indent_0">Hydromorphone; its salts; its esters and ethers; their
                salts</text><text class="first_line_indent_0">Hydroxychloroquine; its salts</text><text class="left_indent_12 first_line_indent_-12">Hydroxy-N,N-dimethyltryptamines;
                their esters and ethers; any salt of any substance falling within this item</text><text class="left_indent_12 first_line_indent_-12">3-Hydroxy-N-methylmorphinan; its
                salts; its optical isomers; their salts</text><text class="left_indent_12 first_line_indent_-12">3-Hydroxymorphinan; its salts; its
                optical isomers; their salts; their esters and ethers; their salts</text><text class="left_indent_12 first_line_indent_-12">3-Hydroxy-N-phenacylmorphinan; its
                salts; its optical isomers; their salts; their esters and ethers; their salts</text><text class="first_line_indent_0">Hydroxypethidine; its salts; its esters and ethers;
                their salts</text><text class="first_line_indent_0">Hydroxyphenamate</text><text class="first_line_indent_0">Hydroxyurea</text><text class="first_line_indent_0">Hydroxyzine; its salts</text><text class="first_line_indent_0">Ibandronic acid; its salts</text><text class="first_line_indent_0">Ibritumomab tiuxetan</text><text>Ibrutinib; its salts</text><text>Icatibant; its salts; its esters; their salts</text><text class="left_indent_12 first_line_indent_-12">Icosapent ethyl when contained in
                pharmaceutical products indicated for the reduction of the risk of myocardial
                infarction, stroke, coronary revascularization, or unstable angina requiring
                hospitalization</text><text>Idarucizumab</text><text>Idelalisib; its salts</text><text class="first_line_indent_0">Idursulfase</text><text class="first_line_indent_0">Idursulfase beta</text><text class="first_line_indent_0">Ifosfamide</text><text class="first_line_indent_0">Iloprost; its salts</text><text class="first_line_indent_0">Imatinib; its salts</text><text class="first_line_indent_0">Imdevimab</text><text class="first_line_indent_0">Imidapril; its salts</text><text class="first_line_indent_0">Imiglucerase</text><text class="first_line_indent_0">Imipramine; its salts</text><text class="first_line_indent_0">Imiquimod; its salts</text><text>Inaticabtagene autoleucel</text><text class="first_line_indent_0">Inclisiran; its salts</text><text class="first_line_indent_0">Indacaterol; its salts; its esters; their salts</text><text class="first_line_indent_0">Indinavir; its salts</text><text class="first_line_indent_0">Indomethacin; its salts</text><text class="first_line_indent_0">Indoprofen; its salts</text><text class="first_line_indent_0">Indoramin; its salts</text><text class="first_line_indent_0">Infliximab</text><text class="first_line_indent_0">Inosine</text><text class="first_line_indent_0">Inosine pranobex</text><text>Inotuzumab ozogamicin</text><text class="first_line_indent_0">Interferons</text><text class="left_indent_12 first_line_indent_-12">Iodine-131; its salts; when contained
                in pharmaceutical products</text><text class="left_indent_12 first_line_indent_-12">Ioflupane Iodine-123; its salts; when
                contained in pharmaceutical products</text><text class="first_line_indent_0">Ipilimumab</text><text class="first_line_indent_0">Iprindole; its salts</text><text class="first_line_indent_0">Iptacopan; its salts</text><text class="first_line_indent_0">Irbesartan; its salts</text><text class="first_line_indent_0">Irinotecan; its salts</text><text>Isatuximab</text><text>Isavuconazole; its salts; its derivatives; their salts</text><text class="first_line_indent_0">Isoaminile; its salts</text><text class="first_line_indent_0">Isoetharine; its salts</text><text>Isoflurane</text><text class="first_line_indent_0">Isomethadone; its salts</text><text class="left_indent_12 first_line_indent_-12">Isoniazid; its salts; its
                derivatives; their salts; any compound with any substance falling within this
                item</text><text class="first_line_indent_0">Isoprenaline; its salts</text><text class="first_line_indent_0">Isopyrin; its salts</text><text class="first_line_indent_0">Isotretinoin</text><text class="first_line_indent_0">Isoxicam; its salts</text><text class="first_line_indent_0">Isradipine</text><text class="first_line_indent_0">Itraconazole; its salts</text><text class="first_line_indent_0">Ivabradine; its salts</text><text>Ivosidenib; its salts</text><text class="first_line_indent_0">Ixazomib; its salts</text><text>Ixekizumab</text><text class="first_line_indent_0">Ketamine; its salts</text><text class="first_line_indent_0">Ketanserin; its salts</text><text class="first_line_indent_0">Ketobemidone; its salts; its esters and ethers; their
                salts</text><text class="left_indent_12 first_line_indent_-12">Ketoconazole, except when contained
                in preparations for external application only</text><text class="first_line_indent_0">Ketophenylbutazone</text><text class="first_line_indent_0">Ketorolac; its salts; its esters</text><text class="first_line_indent_0">Labetalol; its salts</text><text class="first_line_indent_0">Labuvirtide</text><text class="first_line_indent_0">Lacidipine; its salts</text><text class="first_line_indent_0">Lacosamide; its salts</text><text class="first_line_indent_0">Lamivudine; its salts</text><text class="first_line_indent_0">Lamotrigine; its salts</text><text class="first_line_indent_0">Lanadelumab</text><text class="first_line_indent_0">Lanreotide; its salts</text><text class="first_line_indent_0">Lansoprazole</text><text class="first_line_indent_0">Lanthanum carbonate</text><text class="first_line_indent_0">Lapatinib; its salts</text><text class="first_line_indent_0">Laronidase</text><text class="first_line_indent_0">Laropiprant; its salts</text><text>Larotrectinib; its salts</text><text>Latanoprostene bunod; its salts</text><text>Lazertinib; its salts</text><text class="first_line_indent_0">Lead, compounds of, with acids from fixed oils</text><text class="first_line_indent_0">Lebrikizumab</text><text class="first_line_indent_0">Lecanemab</text><text>Ledipasvir; its salts</text><text class="first_line_indent_0">Leflunomide; its salts</text><text class="first_line_indent_0">Lemborexant; its salts</text><text class="first_line_indent_0">Lenacapavir; its salts</text><text class="first_line_indent_0">Lenalidomide; its salts</text><text>Lenvatinib; its salts</text><text class="first_line_indent_0">Lepirudin; its salts</text><text class="first_line_indent_0">Lercanidipine; its salts</text><text>Letermovir; its salts; its esters; their salts</text><text class="first_line_indent_0">Letrozole</text><text class="first_line_indent_0">Leuprorelin; its salts</text><text class="first_line_indent_0">Levallorphan; its salts</text><text class="first_line_indent_0">Levetiracetam; its salts</text><text class="first_line_indent_0">Levosimendan; its salts</text><text class="first_line_indent_0">Lidoflazine</text><text class="left_indent_12 first_line_indent_-12">Lignocaine; its salts; when in
                mixture with prilocaine or in mixture with the salts of prilocaine, and intended to
                be used for the treatment of premature ejaculation</text><text class="left_indent_12 first_line_indent_-12">Lignocaine; its salts; when in
                mixture with tetracaine (being an amino alcohol esterified with a derivative of
                benzoic acid) or in mixture with the salts of tetracaine</text><text>Linaclotide; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Linagliptin; its salts</text><text class="first_line_indent_0">Linezolid; its salts</text><text>Lipegfilgrastim</text><text class="first_line_indent_0">Liraglutide</text><text>Lisdexamfetamine; its salts</text><text class="first_line_indent_0">Lisinopril; its salts</text><text class="first_line_indent_0">Lithium carbonate</text><text class="first_line_indent_0">Lithium sulphate</text><text class="first_line_indent_0">Lixisenatide</text><text class="first_line_indent_0">Lomefloxacin; its salts; its esters</text><text class="first_line_indent_0">Lomustine</text><text class="first_line_indent_0">Lonazolac; its salts</text><text class="first_line_indent_0">Loncastuximab tesirine</text><text class="first_line_indent_0">Lopinavir; its salts</text><text class="first_line_indent_0">Loracarbef; its salts</text><text class="first_line_indent_0">Lorcainide; its salts</text><text>Lorlatinib; its salts</text><text class="first_line_indent_0">Losartan; its salts</text><text class="first_line_indent_0">Lotilaner; its salts</text><text class="first_line_indent_0">Lovastatin when contained in pharmaceutical
                products</text><text class="first_line_indent_0">Loxapine; its salts</text><text class="first_line_indent_0">Lumefantrine; its salts</text><text class="first_line_indent_0">Lurasidone; its salts</text><text class="first_line_indent_0">Lurbinectedin; its salts</text><text class="first_line_indent_0">Luspatercept</text><text class="first_line_indent_0">Lutetium-177; its salts; when contained in
                pharmaceutical products</text><text>Lutetium (177Lu) oxodotreotide; its salts</text><text>Lutetium (177Lu) vipivotide tetraxetan; its salts</text><text class="first_line_indent_0">Lysuride; its salts</text><text>Macitentan; its salts</text><text class="first_line_indent_0">Mangafodipir; its salts</text><text class="first_line_indent_0">Mannomustine; its salts</text><text class="first_line_indent_0">Maprotiline; its salts</text><text class="first_line_indent_0">Maralixibat; its salts</text><text class="first_line_indent_0">Maraviroc; its salts</text><text class="first_line_indent_0">Marbofloxacin; its salts</text><text class="first_line_indent_0">Maribavir; its salts</text><text class="first_line_indent_0">Marstacimab</text><text class="first_line_indent_0">Mavacamten; its salts</text><text class="first_line_indent_0">Mazindol</text><text class="first_line_indent_0">Mebutamate</text><text class="first_line_indent_0">Mecamylamine; its salts</text><text class="first_line_indent_0">Meclofenamic acid; its salts</text><text class="first_line_indent_0">Meclofenoxate; its salts</text><text class="first_line_indent_0">Medigoxin</text><text class="first_line_indent_0">Mefenamic acid; its salts; its esters; their
                salts</text><text class="first_line_indent_0">Mefloquine; its salts</text><text class="first_line_indent_0">Mefruside</text><text class="first_line_indent_0">Melagatran; its salts; its derivatives; their
                salts</text><text class="left_indent_12 first_line_indent_-12">Melatonin; its salts; when contained
                in pharmaceutical products intended to be used for the treatment of insomnia</text><text class="first_line_indent_0">Melitracen; its salts</text><text class="first_line_indent_0">Meloxicam; its salts</text><text class="first_line_indent_0">Memantine; its salts</text><text class="first_line_indent_0">Mephenesin; its esters; their salts</text><text class="first_line_indent_0">Mephenoxalone</text><text class="first_line_indent_0">Mepirizole; its salts</text><text class="first_line_indent_0">Mepivacaine; its salts</text><text class="first_line_indent_0">Mepolizumab</text><text class="first_line_indent_0">Meprobamate</text><text class="first_line_indent_0">alpha-Meprodine; its salts</text><text class="first_line_indent_0">beta-Meprodine; its salts</text><text class="first_line_indent_0">Mercaptopurine; its salts; its derivatives; their
                salts</text><text class="left_indent_12 first_line_indent_-12">Mercuric chloride, except substances
                containing less than 1% of mercuric chloride; mercuric iodide, except substances
                containing less than 2% of mercuric iodide; nitrates of mercury, except substances
                containing less than the equivalent of 3%, weight in weight, of mercury (Hg);
                potassiomercuric iodides, except substances containing less than the equivalent of
                1% of mercuric iodide; organic compounds of mercury, except substances, not being
                aerosols, containing less than the equivalent of 0.3%, weight in weight, of mercury
                (Hg)</text><text class="first_line_indent_0">Meropenem; its salts</text><text class="first_line_indent_0">Mertiatide; its salts; its esters; their salts</text><text class="first_line_indent_0">Mesalazine; its salts</text><text class="left_indent_12 first_line_indent_-12">Mescaline; its salts; other
                derivatives of phenethylamine formed by substitution in the aromatic ring; their
                salts</text><text class="first_line_indent_0">Mesocarb; its salts</text><text class="first_line_indent_0">Metaflumizone; its salts</text><text class="first_line_indent_0">Metaraminol; its salts</text><text class="first_line_indent_0">Metaxalone</text><text class="first_line_indent_0">Metazocine; its salts; its esters and ethers; their
                salts</text><text class="first_line_indent_0">Metergoline</text><text class="first_line_indent_0">Metformin; its salts</text><text class="first_line_indent_0">Methadone; its salts</text><text class="first_line_indent_0">Methadyl acetate; its salts</text><text class="first_line_indent_0">Methaqualone; its salts</text><text class="first_line_indent_0">Methimazole; its salts</text><text class="first_line_indent_0">Methixene; its salts</text><text class="first_line_indent_0">Methocarbamol</text><text class="left_indent_12 first_line_indent_-12">Methorphan; its salts; its optical
                isomers; their salts; except substances containing not more than 0.1% of
                dextromethorphan</text><text class="first_line_indent_0">Methoxsalen</text><text>Methoxyflurane</text><text class="first_line_indent_0">Methyldesorphine; its salts; its esters and ethers;
                their salts</text><text class="first_line_indent_0">Methyldihydromorphine; its salts; its esters and
                ethers; their salts</text><text class="first_line_indent_0">Methyldopa; its esters; their salts</text><text class="left_indent_12 first_line_indent_-12">2-Methyl-3-morpholino-1,1-diphenylpropane carboxylic acid; its salts; its esters;
                their salts</text><text class="first_line_indent_0">Methylnaltrexone; its salts</text><text class="first_line_indent_0">Methylpentynol; its derivatives</text><text class="left_indent_12 first_line_indent_-12">alpha-Methylphenethylamine;
                beta-methylphenethylamine; alpha-ethylphenethylamine; beta-ethylphenethylamine;
                their optical isomers; any synthetic compound structurally derived from any of those
                substances by substitution in the aliphatic part or by ring closure therein (or by
                both such substitution and such closure) or by substitution in the aromatic ring
                (with or without substitution at the nitrogen atom), except hydroxyamphetamine,
                methoxyphenamine, pholedrine and N-substituted derivatives of ephedrine; any salt of
                any substance falling within this item</text><text class="first_line_indent_0">Methylphenidate; its salts</text><text class="left_indent_12 first_line_indent_-12">1-Methyl-4-phenylpiperidine-4-carboxylic acid; its salts; its esters; their
                salts</text><text class="first_line_indent_0">Methyprylone</text><text class="first_line_indent_0">Metipranolol; its salts</text><text class="first_line_indent_0">Metoclopramide; its salts</text><text class="first_line_indent_0">Metolazone</text><text class="first_line_indent_0">Metopon; its salts; its esters and ethers; their
                salts</text><text class="first_line_indent_0">Metoprolol; its salts</text><text class="first_line_indent_0">Metronidazole; its salts; its esters; their
                salts</text><text class="first_line_indent_0">Metyrapone; its salts</text><text class="first_line_indent_0">Mexiletine; its salts</text><text class="first_line_indent_0">Mianserin; its salts</text><text class="first_line_indent_0">Mibefradil; its salts</text><text class="first_line_indent_0">Micafungin; its salts; its esters</text><text class="first_line_indent_0">Midodrine; its salts</text><text class="first_line_indent_0">Midostaurin; its salts</text><text class="first_line_indent_0">Mifepristone; its salts; its esters; their
                salts</text><text>Migalastat; its salts</text><text class="first_line_indent_0">Miglitol; its salts</text><text class="first_line_indent_0">Milnacipran; its salts</text><text class="first_line_indent_0">Milrinone; its salts</text><text class="left_indent_12 first_line_indent_-12">Minoxidil, except when contained in
                preparations intended for external application only and the preparations contain not
                more than 5% of Minoxidil</text><text class="first_line_indent_0">Mirabegron; its salts; its esters; their salts</text><text class="first_line_indent_0">Mirogabalin; its salts; its esters; their salts</text><text class="first_line_indent_0">Mirtazapine; its salts</text><text class="first_line_indent_0">Mitobronitol</text><text class="first_line_indent_0">Mitopodozide; its salts</text><text class="first_line_indent_0">Mitotane</text><text class="first_line_indent_0">Mitoxantrone; its salts</text><text class="first_line_indent_0">Mivacurium; its salts</text><text class="first_line_indent_0">Mizolastine; its salts</text><text>Mobocertinib; its salts</text><text class="first_line_indent_0">Moclobemide; its salts</text><text class="first_line_indent_0">Moexipril; its salts</text><text class="first_line_indent_0">Mofebutazone; its salts</text><text class="first_line_indent_0">Molgramostim</text><text class="first_line_indent_0">Molindone; its salts</text><text class="first_line_indent_0">Molnupiravir; its salts</text><text class="first_line_indent_0">Molybdate (99Mo); its salts; when contained in
                pharmaceutical products</text><text class="first_line_indent_0">Momelotinib; its salts</text><text class="first_line_indent_0">Montelukast; its salts</text><text class="first_line_indent_0">Moracizine; its salts</text><text class="first_line_indent_0">Moramide; its salts; its optical isomers; their
                salts</text><text class="first_line_indent_0">Moroxydine; its salts</text><text class="first_line_indent_0">Morpheridine; its salts</text><text>Mosunetuzumab</text><text class="first_line_indent_0">Moxifloxacin; its salts</text><text class="first_line_indent_0">Moxonidine; its salts</text><text class="first_line_indent_0">Muromonab-CD3</text><text class="left_indent_12 first_line_indent_-12">Mustine and any other N-substituted
                derivative of di-(2-chloroethyl)amine; their salts</text><text class="first_line_indent_0">Muzolimine</text><text class="first_line_indent_0">Mycophenolic acid; its salts; its esters</text><text class="first_line_indent_0">Myrophine; its salts</text><text class="first_line_indent_0">Nabumetone</text><text class="first_line_indent_0">Nadolol; its salts</text><text class="first_line_indent_0">Nadroparin; its salts</text><text class="first_line_indent_0">Nafarelin; its salts</text><text class="first_line_indent_0">Naftidrofuryl; its salts</text><text class="first_line_indent_0">Nalbuphine; its salts</text><text class="first_line_indent_0">Naldemedine; its salts</text><text class="first_line_indent_0">Nalidixic acid</text><text class="first_line_indent_0">Nalmefene; its salts</text><text class="first_line_indent_0">Nalorphine; its salts</text><text class="first_line_indent_0">Naloxone; its salts</text><text class="first_line_indent_0">Naltrexone; its salts</text><text class="first_line_indent_0">alpha-Naphthylacetic acid; its salts</text><text class="first_line_indent_0">Naproxen; its salts</text><text class="first_line_indent_0">Naratriptan; its salts</text><text class="first_line_indent_0">Natalizumab</text><text class="first_line_indent_0">Nateglinide; its salts; its esters</text><text class="first_line_indent_0">Naxitamab</text><text class="first_line_indent_0">Nebivolol; its salts</text><text>Necitumumab</text><text class="first_line_indent_0">Nefazodone; its salts</text><text class="first_line_indent_0">Nefopam; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Nelfinavir; its salts</text><text class="first_line_indent_0">Neostigmine; its salts</text><text class="first_line_indent_0">Nepafenac; its salts</text><text>Neratinib; its salts</text><text class="first_line_indent_0">Nesiritide</text><text>Netarsudil; its salts</text><text>Netupitant; its salts</text><text class="first_line_indent_0">Nevirapine; its salts</text><text>Nicardipine; its salts</text><text class="first_line_indent_0">Nicergoline</text><text class="first_line_indent_0">Nicocodine; its salts</text><text class="left_indent_12 first_line_indent_-12">Nicotinamide mononucleotide when
                contained as an active ingredient in products for human parenteral
                administration</text><text class="left_indent_12 first_line_indent_-12">Nicotinic acid and its salts when
                contained in pharmaceutical products the recommended daily dose of which contains
                more than 200 mg of nicotinic acid</text><text class="left_indent_12 first_line_indent_-12">Nifedipine</text><text class="first_line_indent_0">Nifenazone</text><text class="first_line_indent_0">Niflumic acid; its salts</text><text class="first_line_indent_0">Nifuratel; its salts</text><text class="first_line_indent_0">Nifuroxazide; its salts</text><text class="first_line_indent_0">Nilotinib; its salts</text><text class="first_line_indent_0">Nilvadipine</text><text class="first_line_indent_0">Nimesulide; its salts</text><text class="first_line_indent_0">Nimodipine</text><text>Nintedanib; its salts</text><text>Niraparib; its salts</text><text>Nirmatrelvir; its salts</text><text class="first_line_indent_0">Nirsevimab</text><text class="first_line_indent_0">Nisoldipine</text><text class="first_line_indent_0">Nitrendipine</text><text class="first_line_indent_0">Nitrofural; its salts</text><text class="first_line_indent_0">Nitrofurantoin; its salts</text><text class="first_line_indent_0">Nitromethaqualone; its salts</text><text class="first_line_indent_0">Nitroxoline; its salts</text><text>Nivolumab</text><text class="first_line_indent_0">Nomifensine; its salts</text><text class="first_line_indent_0">Noracymethadol; its salts</text><text class="first_line_indent_0">Noramidopyrine methanesulphonate; its salts</text><text class="first_line_indent_0">Norcodeine; its salts; its esters and ethers; their
                salts</text><text class="first_line_indent_0">Norfloxacin; its salts; its esters</text><text class="first_line_indent_0">Normethadone; its salts</text><text class="first_line_indent_0">Normorphine; its salts; its esters and ethers; their
                salts</text><text class="first_line_indent_0">Norpipanone; its salts</text><text class="first_line_indent_0">Nortriptyline; its salts</text><text>Nusinersen; its salts</text><text>Obinutuzumab; its antibody drug conjugates</text><text>Oclacitinib; its salts</text><text>Ocrelizumab</text><text class="first_line_indent_0">Ocriplasmin</text><text class="first_line_indent_0">Octreotide; its salts</text><text>Odevixibat; its salts; its esters; their salts</text><text>Ofatumumab</text><text class="first_line_indent_0">Ofloxacin; its salts; its esters</text><text class="first_line_indent_0">Olanzapine; its salts</text><text class="first_line_indent_0">Olaparib; its salts</text><text>Olaratumab</text><text class="first_line_indent_0">Olmesartan; its salts; its esters; their salts</text><text class="first_line_indent_0">Olodaterol; its salts</text><text class="first_line_indent_0">Olsalazine; its salts</text><text class="first_line_indent_0">Omalizumab</text><text>Ombitasvir; its salts</text><text class="left_indent_12 first_line_indent_-12">Omega-3 fatty acids; their salts;
                their esters; when contained in pharmaceutical products intended to be used for the
                treatment of hypertriglyceridaemia</text><text class="left_indent_12 first_line_indent_-12">Omidenepag; its salts; its esters;
                their salts</text><text class="first_line_indent_0">Onasemnogene abeparvovec</text><text class="first_line_indent_0">Ondansetron; its salts</text><text class="first_line_indent_0">Opipramol; its salts; its derivatives; their
                salts</text><text class="left_indent_12 first_line_indent_-12">Opium, except substances containing
                less than 0.2% of morphine calculated as anhydrous morphine</text><text class="first_line_indent_0">Orciprenaline; its salts</text><text class="first_line_indent_0">Orgotein</text><text class="left_indent_12 first_line_indent_-12">Orlistat; its salts; except when
                contained in a pharmaceutical product of which the recommended dose is a quantity of
                the product that contains not more than 60 mg of orlistat or its salts, taken 3
                times a day</text><text class="first_line_indent_0">Orphenadrine; its salts</text><text class="first_line_indent_0">Oseltamivir; its salts</text><text class="first_line_indent_0">Osimertinib; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Oteracil; its salts</text><text class="first_line_indent_0">Ouabain</text><text class="first_line_indent_-24 left_indent_24 ">Oxaliplatin; its salts</text><text class="first_line_indent_0">Oxanamide</text><text class="first_line_indent_0">Oxcarbazepine; its salts</text><text class="first_line_indent_0">Oxprenolol; its salts</text><text class="first_line_indent_0">Oxycodone; its salts; its esters and ethers; their
                salts</text><text class="first_line_indent_0">Oxyfedrine; its salts</text><text class="first_line_indent_0">Oxymorphone; its salts; its esters and ethers; their
                salts</text><text class="first_line_indent_0">Oxypertine</text><text class="first_line_indent_0">Oxyphenbutazone</text><text class="first_line_indent_0">Oxytocins</text><text class="first_line_indent_0">Ozanimod; its salts</text><text class="first_line_indent_0">Paclitaxel</text><text class="first_line_indent_0">Palbociclib; its salts</text><text class="first_line_indent_0">Paliperidone; its salts</text><text class="first_line_indent_0">Palivizumab</text><text class="first_line_indent_0">Palonosetron; its salts</text><text class="first_line_indent_0">Pamidronate; its salts</text><text class="first_line_indent_0">Pancuronium; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Panitumumab</text><text class="first_line_indent_-24 left_indent_24 ">Panobinostat; its salts</text><text class="first_line_indent_0">Pantethine; its salts</text><text class="left_indent_12 first_line_indent_-12">Pantoprazole; its salts; except when
                contained in oral preparations with 20 mg or less per solid dosage unit, indicated
                with the maximum daily dose of 20 mg for relief of heartburn symptoms associated
                with acid reflux in patients of 18 years old or above, and in packs with the maximum
                supply of 7 days</text><text class="first_line_indent_0">Paraldehyde</text><text class="first_line_indent_0">Paramethadione</text><text class="first_line_indent_0">Parecoxib; its salts</text><text class="first_line_indent_0">Pargyline; its salts</text><text class="first_line_indent_0">Paricalcitol; its salts; its esters; their
                salts</text><text>Paritaprevir; its salts</text><text class="first_line_indent_0">Paroxetine; its salts</text><text class="first_line_indent_0">Pasireotide; its salts</text><text class="first_line_indent_0">Pazopanib; its salts</text><text class="first_line_indent_0">Pefloxacin; its salts; its esters</text><text class="first_line_indent_0">Pegaptanib; its salts</text><text class="first_line_indent_0">Pegaspargase</text><text class="first_line_indent_0">Pegfilgrastim</text><text class="first_line_indent_0">Pegunigalsidase alfa</text><text class="first_line_indent_0">Pegvisomant; its salts</text><text>Pembrolizumab</text><text class="first_line_indent_0">Pemetrexed; its salts; its esters; their salts</text><text class="first_line_indent_0">Pemigatinib; its salts</text><text class="first_line_indent_0">Pemirolast; its salts</text><text class="first_line_indent_0">Pemoline; its salts</text><text class="first_line_indent_0">Pempidine; its salts</text><text class="first_line_indent_0">Penbutolol; its salts</text><text class="first_line_indent_0">Penciclovir; its salts</text><text class="first_line_indent_0">Penicillamine; its salts</text><text class="first_line_indent_0">Pentamidine; its salts</text><text class="first_line_indent_0">Pentazocine; its salts</text><text class="first_line_indent_0">Pentolinium; its salts</text><text>Pentoxifylline; its salts</text><text class="first_line_indent_0">Perampanel</text><text class="first_line_indent_0">Perflubutane</text><text class="first_line_indent_0">Pergolide; its salts</text><text class="first_line_indent_0">Perindoprilat; its salts; its esters; their
                salts</text><text class="first_line_indent_0">Pertechnetate (99mTc); its salts; when contained in
                pharmaceutical products</text><text class="first_line_indent_0">Pertuzumab</text><text class="left_indent_12 first_line_indent_-12">Pharmaceutical products for human
                parenteral administration containing the following or their salts, as active
                ingredients, except in mixture with insulin—</text><text class="left_indent_24">Acetic acid</text><text class="left_indent_24">Acetylcholine</text><text class="left_indent_24">Acetylcysteine</text><text class="left_indent_24">Adenosine</text><text class="left_indent_24">Adrenaline</text><text class="left_indent_24">Ambroxol</text><text class="left_indent_24">Amino acids</text><text class="left_indent_24">Aminophylline</text><text class="left_indent_24">Anti-D (rho) immunoglobulins</text><text class="left_indent_24">Antihistamine substances</text><text class="left_indent_24">Betiatide</text><text class="left_indent_24">Bicisate</text><text class="left_indent_24">Butetamate</text><text class="left_indent_24">Caffeine</text><text class="left_indent_24">Carnitine</text><text class="left_indent_36 first_line_indent_-12">Cations, the following, except in
                preparations containing any substance to which the Antibiotics Ordinance (<ref href="/hk/cap137">Cap. 137</ref>) applies—</text><text class="left_indent_48">Calcium</text><text class="left_indent_48">Chromium</text><text class="left_indent_48">Copper</text><text class="left_indent_48">Iron</text><text class="left_indent_48">Magnesium</text><text class="left_indent_48">Manganese</text><text class="left_indent_48">Potassium</text><text class="left_indent_48">Selenium</text><text class="left_indent_48">Sodium, except sodium chloride 0.9%</text><text class="left_indent_48">Zinc</text><text class="left_indent_24">Choline</text><text class="left_indent_24">Cimetidine</text><text class="left_indent_24">Citicoline</text><text class="left_indent_24">Deoxycholic acid</text><text class="left_indent_24">Dextromethorphan</text><text class="left_indent_24">Dicycloverine</text><text class="left_indent_24">Difenidol</text><text class="left_indent_24">Diprophylline</text><text class="left_indent_24">Disofenin</text><text class="left_indent_24">Ephedrine</text><text class="left_indent_24">Exametazime</text><text class="left_indent_24">Fish oil</text><text class="left_indent_24">Fluorescein</text><text class="left_indent_24">Gallium</text><text class="left_indent_24">Gelatin</text><text class="left_indent_24">Glucosamine</text><text class="left_indent_24">Glucose</text><text class="left_indent_24">Glycerol</text><text class="left_indent_24">Glyceryl trinitrate</text><text class="left_indent_24">Guaifenesin</text><text class="left_indent_24">Heparin</text><text class="left_indent_24">Hyaluronic acid</text><text class="left_indent_24">Hyaluronidase</text><text class="left_indent_24">Hydroxyethyl starch</text><text class="left_indent_24">Hyoscine</text><text class="left_indent_24">Ibuprofen</text><text class="left_indent_24">Icodextrin</text><text class="left_indent_24">Indigo carmine</text><text class="left_indent_24">Indocyanine green</text><text class="left_indent_24">Iodine norcholesterol</text><text class="left_indent_24">Isosorbide</text><text class="left_indent_24">Lactic acid</text><text class="left_indent_24">Lecithin</text><text class="left_indent_24">Lignocaine</text><text class="left_indent_24">Mannitol</text><text class="left_indent_24">Mebrofenin</text><text class="left_indent_24">Medronic acid</text><text class="left_indent_24">Mesna</text><text class="left_indent_24">Methoxyphenamine</text><text class="left_indent_24">Methylene blue</text><text class="left_indent_24">Methylephedrine</text><text class="left_indent_24">Noradrenaline</text><text class="left_indent_24">Olive oil</text><text class="left_indent_24">Omeprazole</text><text class="left_indent_24">Oxidronate</text><text class="left_indent_24">Papaverine</text><text class="left_indent_24">Paracetamol</text><text class="left_indent_24">Patent blue V</text><text class="left_indent_24">Pentetic acid</text><text class="left_indent_24">Phenol</text><text class="left_indent_24">Phenylephrine</text><text class="left_indent_24">Procaine</text><text class="left_indent_24">Protamine</text><text class="left_indent_24">Ranitidine</text><text class="left_indent_24">Rhenium</text><text class="left_indent_24">Sodium chloride 0.9%</text><text class="left_indent_24">Sodium pyrophosphate</text><text class="left_indent_24">Sodium tetradecyl sulfate</text><text class="left_indent_24">Sodium thiosulfate</text><text class="left_indent_24">Sorbitol</text><text class="left_indent_24">Soya oil</text><text class="left_indent_24">Stonefish antivenom</text><text class="left_indent_24">Succimer</text><text class="left_indent_24">Terbutaline</text><text class="left_indent_24">Tetrakis copper tetrafluoroborate</text><text class="left_indent_24">Tetrofosmin</text><text class="left_indent_24">Thallium</text><text class="left_indent_24">Tin</text><text class="left_indent_24">Triglycerides</text><text class="left_indent_24">Tuberculin</text><text class="left_indent_24">Vitamins</text><text class="left_indent_24">Water</text><text class="left_indent_24">Xantinol nicotinate</text><text class="first_line_indent_0">Phenacemide</text><text class="first_line_indent_0">Phenacetin</text><text class="first_line_indent_0">Phenadoxone; its salts</text><text class="first_line_indent_0">Phenaglycodol</text><text class="first_line_indent_0">Phenampromide; its salts</text><text class="first_line_indent_0">Phenazocine; its salts; its esters and ethers; their
                salts</text><text class="first_line_indent_0">Phenbutrazate</text><text class="first_line_indent_0">Phencyclidine; its salts</text><text class="first_line_indent_0">Phenetidylphenacetin</text><text class="first_line_indent_0">Phenformin; its salts</text><text class="first_line_indent_0">Phenindione</text><text class="first_line_indent_0">Phenomorphan; its salts; its esters and ethers; their
                salts</text><text class="first_line_indent_0">Phenoperidine; its salts; its esters and ethers; their
                salts</text><text class="left_indent_12 first_line_indent_-12">Phenothiazine; its salts; its
                derivatives (except dimethoxanate and promethazine); their salts (except salts of
                dimethoxanate and promethazine); any compound with any substance falling within this
                item</text><text class="first_line_indent_0">Phenoxybenzamine; its salts</text><text class="first_line_indent_0">Phenprenazone</text><text class="first_line_indent_0">Phenprobamate</text><text class="first_line_indent_0">Phentolamine; its salts</text><text class="first_line_indent_0">Phenylbutazone; its salts</text><text class="first_line_indent_-24 left_indent_24 ">2-Phenylcinchoninic acid;
                2-salicylcinchoninic acid; their salts; their esters</text><text class="first_line_indent_-24 left_indent_24 ">5-Phenylhydantoin; its alkyl and
                aryl derivatives; their salts</text><text class="first_line_indent_-24 left_indent_24 ">4-Phenylpiperidine-4-carboxylic acid
                ethyl ester; its salts</text><text class="left_indent_12 first_line_indent_-12">Pholcodine; its salts; its esters and
                ethers; their salts; except substances containing less than 1.5% of
                pholcodine</text><text class="left_indent_12 first_line_indent_-12">Phospholipid fraction; when contained
                in pharmaceutical products intended to be used as pulmonary surfactant for the
                treatment of respiratory distress syndrome</text><text class="first_line_indent_0">Pibrentasvir; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Picrotoxin</text><text class="first_line_indent_-24 left_indent_24 ">Pimecrolimus</text><text class="first_line_indent_-24 left_indent_24 ">Piminodine; its salts</text><text>Pimobendan; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Pioglitazone; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Pipecuronium; its salts</text><text class="first_line_indent_0">Pipemidic acid</text><text class="first_line_indent_-24 left_indent_24 ">Pipobroman</text><text class="first_line_indent_-24 left_indent_24 ">Piracetam; its salts</text><text>Pirfenidone; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Piritramide; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Piromidic acid; its salts</text><text class="left_indent_12 first_line_indent_-12">Piroxicam, except when contained in
                preparations for external application only</text><text class="first_line_indent_-24 left_indent_24 ">Pirprofen; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Pirtobrutinib; its salts</text><text>Pitavastatin; its salts; its esters; their salts</text><text>Pitolisant; its salts</text><text class="left_indent_12 first_line_indent_-12">Pituitary gland, the active
                principles of, other than corticotrophins, oxytocins and vasopressins</text><text class="first_line_indent_0">Pizotifen; its salts</text><text class="first_line_indent_0">Plerixafor; its salts</text><text>Polatuzumab vedotin</text><text class="first_line_indent_-24 left_indent_24 ">Polymethylenebistrimethylammonium
                salts</text><text>Pomalidomide; its salts</text><text>Ponatinib; its salts</text><text class="first_line_indent_0">Ponesimod; its salts</text><text class="first_line_indent_0">Poractant alfa</text><text>Porfimer; its salts</text><text class="first_line_indent_0">Posaconazole; its salts; its esters; their
                salts</text><text class="first_line_indent_0">Pralidoxime; its salts</text><text class="first_line_indent_0">Pralsetinib; its salts</text><text class="first_line_indent_0">Pramipexole; its salts</text><text>Prasterone; its salts; when contained in pharmaceutical products</text><text class="first_line_indent_0">Prasugrel; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Pravastatin; its salts; its
                esters</text><text class="first_line_indent_-24 left_indent_24 ">Prazosin; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Pregabalin; its salts</text><text>Pretomanid; its salts</text><text class="first_line_indent_0">Pridinol; its salts</text><text class="first_line_indent_0">Primaquine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Primidone</text><text class="first_line_indent_-24 left_indent_24 ">Prindolol; its salts</text><text>Probenecid</text><text class="first_line_indent_-24 left_indent_24 ">Probucol</text><text class="first_line_indent_-24 left_indent_24 ">Procainamide; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Procarbazine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Procaterol and its salts when
                contained in aerosol dispensers</text><text class="first_line_indent_-24 left_indent_24 ">Procyclidine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">alpha-Prodine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">beta-Prodine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Proglumetacin; its salts</text><text class="first_line_indent_0">Proguanil; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Proheptazine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Promoxolane</text><text class="first_line_indent_-24 left_indent_24 ">Propafenone; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Propanidid</text><text class="first_line_indent_0">Propiverine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Propofol</text><text class="first_line_indent_0">Propoxur; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Propoxyphene; its salts; its optical
                isomers; their salts</text><text class="first_line_indent_-24 left_indent_24 ">Propranolol; its salts; its
                derivatives; their salts</text><text class="first_line_indent_-24 left_indent_24 ">Propylhexedrine; its salts</text><text class="first_line_indent_0">Propylthiouracil; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Proquazone</text><text class="first_line_indent_0">Prostaglandins, the following and their
                derivatives—</text><text class="left_indent_0 first_line_indent_24">Alprostadil</text><text class="left_indent_0 first_line_indent_24">Bimatoprost</text><text class="left_indent_0 first_line_indent_24">Dinoprost</text><text class="left_indent_0 first_line_indent_24">Dinoprostone</text><text class="left_indent_0 first_line_indent_24">Epoprostenol</text><text class="left_indent_0 first_line_indent_24">Latanoprost</text><text class="left_indent_0 first_line_indent_24">Misoprostol</text><text class="left_indent_0 first_line_indent_24">Travoprost</text><text class="left_indent_0 first_line_indent_24">Unoprostone</text><text class="left_indent_12 first_line_indent_0">their salts; their esters</text><text class="first_line_indent_-24 left_indent_24 ">Prothionamide</text><text class="first_line_indent_-24 left_indent_24 ">Prothipendyl; its salts</text><text class="first_line_indent_0">Protirelin; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Protriptyline; its salts; its
                derivatives; their salts</text><text class="first_line_indent_0">Prucalopride; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Prulifloxacin; its salts; its
                esters; their salts</text><text class="first_line_indent_-24 left_indent_24 ">Pyrazinamide</text><text class="first_line_indent_0">Pyricarbate (Pyridinolcarbamate)</text><text class="first_line_indent_0">Pyridostigmine; its salts</text><text class="first_line_indent_0">Pyrimethamine</text><text>Pyriprole; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Pyrithyldione</text><text class="first_line_indent_0">Quetiapine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Quinagolide; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Quinapril; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Quinethazone</text><text class="first_line_indent_-24 left_indent_24 ">Quinidine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Quinine; its salts; its derivatives;
                their salts</text><text class="first_line_indent_0">Quizartinib; its salts</text><text class="first_line_indent_0">Rabeprazole; its salts</text><text class="first_line_indent_0">Racecadotril; its salts</text><text class="first_line_indent_0">Ractopamine; its salts</text><text class="first_line_indent_0">Radium-223; its salts; when contained in
                pharmaceutical products</text><text class="first_line_indent_0">Raloxifene; its salts</text><text class="first_line_indent_0">Raltegravir; its salts</text><text class="first_line_indent_0">Raltitrexed; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Ramipril; its salts</text><text>Ramucirumab</text><text class="first_line_indent_0">Ranibizumab</text><text class="first_line_indent_0">Ranolazine; its salts </text><text class="first_line_indent_-24 left_indent_24 ">Rasagiline; its salts</text><text class="first_line_indent_0">Rasburicase; its salts</text><text class="first_line_indent_0">Ravulizumab</text><text class="first_line_indent_0">Reboxetine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Recombinant human
                erythropoietin</text><text class="first_line_indent_-24 left_indent_24 ">Regadenoson; its salts</text><text class="first_line_indent_0">Regorafenib; its salts </text><text class="first_line_indent_0">Remdesivir; its salts</text><text class="first_line_indent_0">Remifentanil; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Remoxipride; its salts</text><text class="first_line_indent_0">Repaglinide; its salts; its esters</text><text class="first_line_indent_0">Repotrectinib; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Reproterol and its salts when
                contained in aerosol dispensers</text><text class="first_line_indent_-24 left_indent_24 ">Rescinnamine</text><text class="first_line_indent_0">Reteplase</text><text class="first_line_indent_-24 left_indent_24 ">Retigabine; its salts</text><text>Revefenacin; its salts</text><text class="first_line_indent_0">Reviparin; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Ribavirin; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Ribociclib; its salts</text><text class="first_line_indent_0">Rilmenidine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Rilpivirine; its salts</text><text class="first_line_indent_0">Riluzole; its salts</text><text>Rimegepant; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Rimiterol and its salts when
                contained in aerosol dispensers</text><text class="first_line_indent_0">Rimonabant; its salts</text><text class="first_line_indent_0">Riociguat; its salts</text><text class="first_line_indent_0">Ripretinib; its salts</text><text>Risankizumab</text><text>Risdiplam; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Risedronic acid; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Risperidone</text><text class="first_line_indent_-24 left_indent_24 ">Ritlecitinib; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Ritodrine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Ritonavir; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Rituximab</text><text class="first_line_indent_0">Rivaroxaban; its slats</text><text class="first_line_indent_0">Rivastigmine; its salts</text><text class="first_line_indent_0">Rizatriptan; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Rocuronium; its salts</text><text class="first_line_indent_0">Rofecoxib; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Roflumilast; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Romiplostim</text><text class="first_line_indent_-24 left_indent_24 ">Romosozumab</text><text class="first_line_indent_-24 left_indent_24 ">Ropeginterferon alfa-2b</text><text class="first_line_indent_0">Ropinirole; its salts</text><text class="first_line_indent_0">Ropivacaine; its salts</text><text class="first_line_indent_0">Rosiglitazone; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Rosoxacin; its salts</text><text class="first_line_indent_0">Rosuvastatin; its salts</text><text class="first_line_indent_0">Rotigotine; its salts</text><text class="first_line_indent_0">Roxadustat; its salts</text><text>Rufinamide; its salts</text><text>Rurioctocog alfa pegol</text><text class="first_line_indent_0">Ruxolitinib; its salts </text><text class="first_line_indent_0">Sacituzumab govitecan</text><text class="first_line_indent_0">Sacubitril; its salts</text><text class="first_line_indent_0">Safinamide; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Salbutamol and its salts, except
                when contained in aerosol dispensers</text><text class="first_line_indent_-24 left_indent_24 ">Salmeterol and its salts when
                contained in aerosol dispensers</text><text class="first_line_indent_0">Saquinavir; its salts</text><text class="first_line_indent_0">Sarilumab</text><text class="first_line_indent_0">Satralizumab</text><text class="first_line_indent_0">Savolitinib; its salts</text><text class="first_line_indent_0">Saxagliptin; its salts</text><text class="first_line_indent_0">Sebelipase alfa</text><text>Secukinumab</text><text>Selexipag; its salts</text><text>Selinexor; its salts</text><text>Selpercatinib; its salts</text><text class="first_line_indent_0">Selumetinib; its salts</text><text>Semaglutide</text><text class="first_line_indent_0">Sermorelin; its salts</text><text class="first_line_indent_0">Sertindole; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Sertraline; its salts</text><text class="first_line_indent_0">Sevelamer; its salts</text><text>Sevoflurane</text><text class="left_indent_12 first_line_indent_-12">Sibutramine; its salts; any compound
                containing the chemical structure of
                1-[1-(4-Chlorophenyl)cyclobutyl]-3-methylbutan-1-amine substituted to any degree or
                without substitution; its salts</text><text class="left_indent_12 first_line_indent_-12">Sildenafil; its salts; any compound
                containing the chemical structure of
                    5-(2-ethoxyphenyl)-1-methyl-3-propyl-1<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7(6<i>H</i>)-one
                substituted to any degree or without substitution; its salts</text><text>Silodosin; its salts</text><text>Siltuximab</text><text>Simeprevir; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Simvastatin</text><text>Sintilimab</text><text class="first_line_indent_-24 left_indent_24 ">Siponimod; its salts; its esters;
                their salts</text><text class="first_line_indent_0">Sirolimus; its salts</text><text class="first_line_indent_0">Sitagliptin; its salts</text><text>Socazolimab</text><text class="first_line_indent_0">Sodium aurothiomalate</text><text class="first_line_indent_-24 left_indent_24 ">Sodium nitroprusside</text><text>Sodium zirconium cyclosilicate</text><text class="first_line_indent_-24 left_indent_24 ">Sofosbuvir; its salts</text><text class="first_line_indent_0">Solifenacin; its salts; its esters; their salts</text><text class="first_line_indent_0">Solriamfetol; its salts</text><text class="first_line_indent_0">Somapacitan</text><text class="first_line_indent_0">Somatostatin</text><text>Somatrogon</text><text class="first_line_indent_0">Sorafenib; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Sotalol; its salts</text><text>Sotatercept</text><text class="first_line_indent_-24 left_indent_24 ">Sotorasib; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Sparfloxacin; its salts; its
                esters</text><text class="first_line_indent_-24 left_indent_24 ">Sparteine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Spesolimab</text><text class="first_line_indent_-24 left_indent_24 ">Spinosad</text><text class="first_line_indent_-24 left_indent_24 ">Spironolactone</text><text class="first_line_indent_-24 left_indent_24 ">Stavudine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Stiripentol; its salts</text><text class="first_line_indent_0">Streptokinase</text><text class="first_line_indent_-24 left_indent_24 ">Strontium ranelate</text><text class="first_line_indent_-24 left_indent_24 ">Strophanthus, glycosides of</text><text class="first_line_indent_-24 left_indent_24 ">Styramate</text><text class="first_line_indent_-24 left_indent_24 ">Sucroferric oxyhydroxide</text><text>Sugammadex; its salts; its esters; their salts</text><text class="first_line_indent_-24 left_indent_24 ">Sulindac</text><text class="first_line_indent_-24 left_indent_24 ">Sulphinpyrazone</text><text class="first_line_indent_-24 left_indent_24 ">Sulphonal; alkyl sulphonals</text><text class="first_line_indent_-24 left_indent_24 ">Sulpiride</text><text class="first_line_indent_-24 left_indent_24 ">Sultopride</text><text class="first_line_indent_-24 left_indent_24 ">Sumatriptan; its salts</text><text class="first_line_indent_0">Sunitinib; its salts</text><text class="left_indent_12 first_line_indent_-12">Suprarenal gland, the active
                principles of, except adrenaline and noradrenaline (other than when contained in
                aerosol dispensers); their salts; except salts of adrenaline (other than when
                contained in aerosol dispensers); their derivatives; their salts; except
                hydrocortisone and its salts when contained in preparations intended for external
                application only at not more than 1%; except beclomethasone and its salts when
                contained in aerosol dispensers and except clobetasone butyrate when contained in
                preparations intended for external application only at not more than 0.05%</text><text>Surufatinib; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Sutoprofen; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Suxamethonium; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Syrosingopine</text><text class="first_line_indent_-24 left_indent_24 ">Tacrine; its salts</text><text class="first_line_indent_0">Tacrolimus</text><text class="left_indent_12 first_line_indent_-12 align_justified">Tadalafil; its salts;
                any compound containing the chemical structure of
                    6-(Benzo[1,3]dioxol-5-yl)-2,3,6,7,12,12a-hexahydropyrazino[1’,2’:1,6]<br></br>pyrido[3,4-<i>b</i>]indole-1,4-dione
                substituted to any degree or without substitution; its salts</text><text>Tafamidis; its salts</text><text>Tafasitamab</text><text class="first_line_indent_0">Tafluprost</text><text>Tagraxofusp</text><text class="first_line_indent_0">Talazoparib; its salts</text><text class="first_line_indent_0">Talquetamab</text><text class="first_line_indent_-24 left_indent_24 ">Tamoxifen; its salts</text><text class="first_line_indent_0">Tapentadol; its salts </text><text class="first_line_indent_0">Tarlatamab</text><text class="first_line_indent_0">Tazarotene; its salts</text><text class="first_line_indent_0">Tazemetostat; its salts</text><text>Teclistamab</text><text class="first_line_indent_0">Tegaserod; its salts</text><text class="first_line_indent_0">Telbivudine; its salts</text><text class="first_line_indent_0">Telmisartan; its salts</text><text class="first_line_indent_0">Temozolomide; its salts</text><text class="first_line_indent_0">Temsirolimus; its salts; its esters</text><text>Tenapanor; its salts</text><text class="first_line_indent_0">Tenecteplase; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Teniposide</text><text class="first_line_indent_-24 left_indent_24 ">Tenofovir; its salts; its
                derivatives; their salts</text><text class="first_line_indent_-24 left_indent_24 ">Tenoxicam</text><text class="first_line_indent_0">Tepotinib; its salts</text><text class="first_line_indent_0">Teprotumumab</text><text class="first_line_indent_-24 left_indent_24 ">Terazosin; its salts</text><text class="left_indent_12 first_line_indent_-12">Terbinafine; its salts; except when
                contained in preparations for external application only</text><text class="first_line_indent_0">Terbutaline and its salts when contained in aerosol
                dispensers</text><text class="first_line_indent_0">Teriflunomide; its salts</text><text class="first_line_indent_0">Teriparatide; its salts</text><text class="first_line_indent_0">Terodiline; its salts</text><text class="first_line_indent_0">Tertatolol; its salts</text><text class="first_line_indent_0">Tetrabenazine; its salts</text><text class="left_indent_12 first_line_indent_-12"></text><text class="first_line_indent_0">Tetracosactide; its salts</text><text>Tezepelumab</text><text class="first_line_indent_0">Thalidomide; its salts</text><text class="first_line_indent_0">Thallium, salts of</text><text class="first_line_indent_0">Theofibrate</text><text class="first_line_indent_0">Thiacetazone</text><text class="first_line_indent_0">Thiocarlide; its salts</text><text class="left_indent_12 first_line_indent_-12">Thioctic acid; its salts; its
                derivatives; when contained in pharmaceutical products</text><text class="first_line_indent_0">Thiotepa</text><text class="first_line_indent_0">Thymosin alpha 1</text><text class="first_line_indent_0">Thyroid gland, the active principles of; their
                salts</text><text class="first_line_indent_0">Thyrotropin alfa</text><text class="first_line_indent_0">Tiagabine; its salts; its esters; their salts</text><text class="first_line_indent_0">Tianeptine; its salts; its esters; their salts</text><text class="first_line_indent_0">Tiapride; its salts</text><text class="first_line_indent_0">Ticagrelor; its salts; its esters; their salts</text><text class="first_line_indent_0">Ticlopidine; its salts</text><text class="first_line_indent_0">Tildrakizumab</text><text class="first_line_indent_0">Tiletamine; its salts</text><text class="first_line_indent_0">Tilidate; its salts</text><text class="first_line_indent_0">Tiludronic acid; its salts</text><text class="first_line_indent_0">Timolol; its salts</text><text class="first_line_indent_0">Tinoridine; its salts</text><text class="first_line_indent_0">Tinzaparin; its salts</text><text class="first_line_indent_0">Tiotropium; its salts</text><text class="left_indent_12 first_line_indent_-12">Tipiracil; its salts; when contained
                in pharmaceutical products</text><text class="first_line_indent_0">Tiratricol; its salts</text><text class="first_line_indent_0">Tirofiban; its salts</text><text class="first_line_indent_0">Tirzepatide</text><text class="first_line_indent_0">Tisagenlecleucel</text><text class="first_line_indent_0">Tislelizumab</text><text>Tisotumab vedotin</text><text class="first_line_indent_0">Tixagevimab</text><text class="first_line_indent_0">Tizanidine; its salts</text><text class="first_line_indent_0">Tocainide; its salts</text><text class="first_line_indent_0">Tocilizumab</text><text class="first_line_indent_0">Todralazine; its salts</text><text class="first_line_indent_0">Tofacitinib; its salts </text><text class="first_line_indent_0">Tofenacin; its salts</text><text class="first_line_indent_0">Tolazamide</text><text class="first_line_indent_0">Tolbutamide</text><text class="first_line_indent_0">Tolcapone; its salts</text><text class="first_line_indent_0">Tolfenamic acid; its salts</text><text class="first_line_indent_0">Tolmetin; its salts</text><text class="first_line_indent_0">Tolperisone; its salts</text><text class="first_line_indent_0">Tolterodine; its salts</text><text class="first_line_indent_0">Tolvaptan</text><text class="first_line_indent_0">para-Tolylmethylcarbinol nicotinic acid ester</text><text class="first_line_indent_0">Topiramate; its salts</text><text class="first_line_indent_0">Topotecan; its salts</text><text class="first_line_indent_0">Torasemide</text><text class="first_line_indent_0">Toripalimab</text><text class="first_line_indent_0">Trabectedin; its salts; its esters</text><text class="first_line_indent_0">Tramadol; its salts</text><text class="first_line_indent_0">Trametinib; its salts</text><text class="first_line_indent_0">Trandolapril; its salts</text><text class="first_line_indent_0">Tranexamic acid, except when contained in toothpaste
                at 0.05% by weight</text><text class="first_line_indent_0">Tranylcypromine; its salts</text><text class="first_line_indent_0">Trastuzumab; its antibody drug conjugates</text><text class="first_line_indent_0">Trazodone; its salts</text><text class="first_line_indent_0">Tremelimumab</text><text class="first_line_indent_0">Treosulfan; its salts</text><text>Treprostinil; its salts; its esters; their salts</text><text class="first_line_indent_0">Tretamine; its salts</text><text class="first_line_indent_0">Tretinoin</text><text class="first_line_indent_0">Triamterene; its salts</text><text class="first_line_indent_0">Triaziquone</text><text class="first_line_indent_0">Tribromoethyl alcohol</text><text class="first_line_indent_0">2,2,2-Trichloroethyl alcohol, esters of; their
                salts</text><text class="left_indent_12 first_line_indent_-12">Trientine; its salts; when contained
                in pharmaceutical products</text><text class="first_line_indent_0">Trifarotene; its salts; its esters; their salts</text><text class="first_line_indent_0">Trifluridine; its salts</text><text class="first_line_indent_0">Trilostane</text><text class="first_line_indent_0">Trimeperidine; its salts</text><text class="first_line_indent_0">Trimetaphan; its salts</text><text class="first_line_indent_0">Trimetazidine; its salts</text><text class="first_line_indent_0">Trimethadione</text><text class="first_line_indent_0">Trimethoprim</text><text class="first_line_indent_0">Trimetozine</text><text class="first_line_indent_0">Trimetrexate; its salts</text><text class="first_line_indent_0">Trimipramine; its salts</text><text class="first_line_indent_0">Trioxsalen</text><text class="first_line_indent_0">Triptorelin; its salts</text><text class="left_indent_12 first_line_indent_-12">Tromantadine; its salts; except when
                contained in pharmaceutical products labelled for the treatment of cold sores
                only</text><text class="first_line_indent_0">Tropisetron; its salts</text><text class="first_line_indent_0">Trospium chloride</text><text class="first_line_indent_0">Trovafloxacin; its salts; its derivatives; their
                salts</text><text class="first_line_indent_0">Tucatinib; its salts</text><text class="first_line_indent_0">Tulobuterol and its salts when contained in aerosol
                dispensers</text><text class="first_line_indent_0">Tybamate</text><text class="first_line_indent_0">Umeclidinium; its salts</text><text class="first_line_indent_0">Upadacitinib; its salts</text><text class="first_line_indent_0">Urapidil; its salts</text><text class="first_line_indent_0">Urethane</text><text class="first_line_indent_0">Urokinase</text><text class="first_line_indent_0">Ustekinumab</text><text class="first_line_indent_0">Valaciclovir; its salts</text><text class="first_line_indent_0">Valdecoxib; its salts</text><text class="first_line_indent_0">Valganciclovir; its salts</text><text class="first_line_indent_0">Valnoctamide</text><text class="first_line_indent_0">Valproic acid; its salts; its esters</text><text class="first_line_indent_0">Valsartan; its salts</text><text class="first_line_indent_0">Vandetanib; its salts</text><text class="left_indent_12 first_line_indent_-12">Vardenafil; its salts; any compound
                containing the chemical structure of
                    2-(2-ethoxyphenyl)-5-methyl-7-propylimidazo[5,1-<i>f</i>][1,2,4]triazin-4(3<i>H</i>)-one
                substituted to any degree or without substitution; its salts</text><text class="first_line_indent_0">Varenicline; its salts</text><text class="first_line_indent_0">Vasopressins</text><text class="first_line_indent_0">Vecuronium; its salts</text><text>Vedolizumab</text><text>Velmanase alfa</text><text>Velpatasvir; its salts</text><text class="first_line_indent_0">Vemurafenib; its salts</text><text>Venetoclax; its salts</text><text class="first_line_indent_0">Venlafaxine; its salts</text><text class="first_line_indent_0">Veralipride; its salts</text><text class="first_line_indent_0">Verapamil; its salts</text><text class="first_line_indent_0">Vericiguat; its salts</text><text class="first_line_indent_0">Vernakalant; its salts</text><text class="first_line_indent_0">Verteporfin; its salts</text><text class="first_line_indent_0">Vidarabine; its salts</text><text class="first_line_indent_0">Vigabatrin</text><text class="first_line_indent_0">Vilanterol; its salts</text><text class="first_line_indent_0">Vildagliptin; its salts</text><text class="first_line_indent_0">Viloxazine; its salts</text><text class="first_line_indent_0">Vindesine; its salts</text><text class="first_line_indent_0">Vinorelbine; its salts</text><text class="first_line_indent_0">Vismodegib; its salts</text><text class="left_indent_12 first_line_indent_-12">Vitamin A and its esters when
                contained in pharmaceutical products the recommended daily dose of which contains
                not less than 10,000 international units of vitamin A</text><text class="left_indent_12 first_line_indent_-12">Vitamin D and its salts when
                contained in pharmaceutical products the recommended daily dose of which contains
                more than 1,000 international units of vitamin D</text><text class="left_indent_12 first_line_indent_-12">Vitamin K and its salts when
                contained in pharmaceutical products, except products with recommended daily dose of
                120 mcg or less of vitamin K1 or K2 or its salts</text><text class="first_line_indent_0">Vonoprazan; its salts</text><text class="first_line_indent_0">Voriconazole; its salts</text><text class="first_line_indent_0">Vortioxetine; its salts </text><text class="first_line_indent_0">Vosoritide</text><text>Voxilaprevir; its salts</text><text class="first_line_indent_0">Vutrisiran; its salts</text><text class="first_line_indent_0">Warfarin; its salts</text><text class="first_line_indent_0">Xamoterol; its salts</text><text class="first_line_indent_0">Xylazine; its salts</text><text class="first_line_indent_0">Zafirlukast</text><text class="first_line_indent_0">Zalcitabine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Zaleplon; its salts</text><text class="first_line_indent_0">Zanamivir; its salts</text><text class="first_line_indent_0">Zanubrutinib; its salts</text><text class="first_line_indent_0">Zidovudine</text><text class="first_line_indent_0">Zimelidine; its salts</text><text class="first_line_indent_0">Zipeprol; its salts</text><text class="first_line_indent_0">Ziprasidone; its salts</text><text class="first_line_indent_0">Zofenopril; its salts</text><text class="first_line_indent_0">Zolazepam; its salts</text><text>Zolbetuximab</text><text class="first_line_indent_0">Zoledronic acid; its salts</text><text class="first_line_indent_0">Zolmitriptan; its salts</text><text class="first_line_indent_0">Zolpidem; its salts</text><text class="first_line_indent_0">Zomepirac; its salts</text><text class="first_line_indent_0">Zopiclone</text><text class="first_line_indent_0">Zoxazolamine; its salts</text><sourceNote class="align_justified">(<ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>; <ref href="/hk/1980/ln369">L.N. 369 of 1980</ref>; <ref href="/hk/1984/ln415">L.N. 415 of 1984</ref>; <ref href="/hk/1986/ln129">L.N. 129 of 1986</ref>; <ref href="/hk/1987/ln130">L.N. 130 of 1987</ref>; <ref href="/hk/1989/ln197">L.N.
                    197 of 1989</ref>; <ref href="/hk/1990/ln128">L.N. 128 of 1990</ref>; <ref href="/hk/1992/ln384">L.N. 384 of 1992</ref>; <ref href="/hk/1995/ln262">L.N.
                    262 of 1995</ref>; <ref href="/hk/1998/ln130">L.N. 130 of 1998</ref>; <ref href="/hk/1999/ln22">L.N. 22 of 1999</ref>; <ref href="/hk/1999/ln202">L.N. 202
                    of 1999</ref>; <ref href="/hk/2000/ln30">L.N. 30 of 2000</ref>; <ref href="/hk/2000/ln138">L.N. 138 of 2000</ref>; <ref href="/hk/2000/ln235">L.N.
                    235 of 2000</ref>; <ref href="/hk/2000/ln296">L.N. 296 of 2000</ref>; <ref href="/hk/2001/ln51">L.N. 51 of 2001</ref>; <ref href="/hk/2001/ln143">L.N. 143
                    of 2001</ref>; <ref href="/hk/2001/ln173">L.N. 173 of 2001</ref>; <ref href="/hk/2001/ln287">L.N. 287 of 2001</ref>; <ref href="/hk/2002/ln56">L.N. 56
                    of 2002</ref>; <ref href="/hk/2002/ln112">L.N. 112 of 2002</ref>; <ref href="/hk/2002/ln132">L.N. 132 of 2002</ref>; <ref href="/hk/2002/ln170">L.N.
                    170 of 2002</ref>; <ref href="/hk/2002/ln237">L.N. 237 of 2002</ref>; <ref href="/hk/2003/ln73">L.N. 73 of 2003</ref>; <ref href="/hk/2003/ln179">L.N. 179
                    of 2003</ref>; <ref href="/hk/2003/ln181">L.N. 181 of 2003</ref>; <ref href="/hk/2003/ln273">L.N. 273 of 2003</ref>; <ref href="/hk/2003/ln276">L.N.
                    276 of 2003</ref>; <ref href="/hk/2004/ln74">L.N. 74 of 2004</ref>; <ref href="/hk/2004/ln135">L.N. 135 of 2004</ref>; <ref href="/hk/2004/ln191">L.N.
                    191 of 2004</ref>; <ref href="/hk/2005/ln11">L.N. 11 of 2005</ref>; <ref href="/hk/2005/ln72">L.N. 72 of 2005</ref>; <ref href="/hk/2005/ln114">L.N. 114
                    of 2005</ref>; <ref href="/hk/2005/ln212">L.N. 212 of 2005</ref>; <ref href="/hk/2006/ln25">L.N. 25 of 2006</ref>; <ref href="/hk/2006/ln122">L.N. 122
                    of 2006</ref>; <ref href="/hk/2006/ln178">L.N. 178 of 2006</ref>; <ref href="/hk/2006/ln223">L.N. 223 of 2006</ref>; <ref href="/hk/2006/ln277">L.N.
                    277 of 2006</ref>; <ref href="/hk/2007/ln41">L.N. 41 of 2007</ref>; <ref href="/hk/2007/ln98">L.N. 98 of 2007</ref>; <ref href="/hk/2007/ln143">L.N. 143
                    of 2007</ref>; <ref href="/hk/2007/ln208">L.N. 208 of 2007</ref>; <ref href="/hk/2007/ln239">L.N. 239 of 2007</ref>; <ref href="/hk/2008/ln61">L.N. 61
                    of 2008</ref>; <ref href="/hk/2008/ln113">L.N. 113 of 2008</ref>; <ref href="/hk/2008/ln197">L.N. 197 of 2008</ref>; <ref href="/hk/2008/ln234">L.N.
                    234 of 2008</ref>; <ref href="/hk/2008/ln282">L.N. 282 of 2008</ref>; <ref href="/hk/2009/ln90">L.N. 90 of 2009</ref>; <ref href="/hk/2009/ln147">L.N. 147
                    of 2009</ref>; <ref href="/hk/2009/ln199">L.N. 199 of 2009</ref>; <ref href="/hk/2009/ln258">L.N. 258 of 2009</ref>; <ref href="/hk/2010/ln11">L.N. 11
                    of 2010</ref>; <ref href="/hk/2010/ln32">L.N. 32 of 2010</ref>; <ref href="/hk/2010/ln81">L.N. 81 of 2010</ref>; <ref href="/hk/2010/ln104">L.N. 104
                    of 2010</ref>; <ref href="/hk/2010/ln140">L.N. 140 of 2010</ref>; <ref href="/hk/2011/ln23">L.N. 23 of 2011</ref>; <ref href="/hk/2011/ln127">L.N. 127
                    of 2011</ref>; <ref href="/hk/2012/ln33">L.N. 33 of 2012</ref>; <ref href="/hk/2012/ln124">L.N. 124 of 2012</ref>; <ref href="/hk/2012/ln179">L.N.
                    179 of 2012</ref>; <ref href="/hk/2013/ln19">L.N. 19 of 2013</ref>; <ref href="/hk/2013/ln94">L.N. 94 of 2013</ref>; <ref href="/hk/2013/ln98">L.N. 98 of
                    2013</ref>; <ref href="/hk/2013/ln125">L.N. 125 of 2013</ref>; <ref href="/hk/2013/ln158">L.N. 158 of 2013</ref>; <ref href="/hk/2013/ln195">L.N.
                    195 of 2013</ref>; <ref href="/hk/2014/ln39">L.N. 39 of 2014</ref>; <ref href="/hk/2014/ln134">L.N. 134 of 2014</ref>; <ref href="/hk/2015/2">2 of 2015
                    s. 66</ref>; <ref href="/hk/2015/ln34">L.N. 34 of 2015</ref>; <ref href="/hk/2015/ln67">L.N. 67 of 2015</ref>; <ref href="/hk/2015/ln100">L.N. 100
                    of 2015</ref>; <ref href="hk/2015/ln193">L.N. 193 of 2015</ref>; <ref href="hk/2015/ln235">L.N. 235 of 2015</ref>; <ref href="hk/2016/ln40">L.N. 40 of
                    2016</ref>; <ref href="hk/2016/ln51">L.N. 51 of 2016</ref>; <ref href="hk/2016/ln83">L.N. 83 of 2016</ref>; <ref href="hk/2016/ln119">L.N. 119 of
                    2016</ref>; <ref href="hk/2016/ln172">L.N. 172 of 2016</ref>; <ref href="hk/2017/ln11">L.N. 11 of 2017</ref>; <ref href="hk/2017/ln38">L.N. 38 of
                    2017</ref>; <ref href="hk/2017/ln119">L.N. 119 of 2017</ref>; <ref href="hk/2017/ln140">L.N. 140 of 2017</ref>; <ref href="hk/2017/ln167">L.N. 167
                    of 2017</ref>; <ref href="hk/2018/ln10">L.N. 10 of 2018</ref>; <ref href="hk/2018/ln42">L.N. 42 of 2018</ref>; <ref href="hk/2018/ln80">L.N. 80 of
                    2018</ref>; <ref href="hk/2018/ln136">L.N. 136 of 2018</ref>; <ref href="hk/2018/ln191">L.N. 191 of 2018</ref>; <ref href="hk/2018/ln210">L.N. 210
                    of 2018</ref>; <ref href="hk/2018/ln228">L.N. 228 of 2018</ref>; <ref href="hk/2019/ln3">L.N. 3 of 2019</ref>; <ref href="hk/2019/ln10">L.N. 10 of
                    2019</ref>; <ref href="hk/2019/ln30">L.N. 30 of 2019</ref>; <ref href="hk/2019/ln145">L.N. 145 of 2019</ref>; <ref href="hk/2019/ln184">L.N. 184
                    of 2019</ref>; <ref href="hk/2020/ln14">L.N. 14 of 2020</ref>; <ref href="hk/2020/ln41">L.N. 41 of 2020</ref>; <ref href="hk/2020/ln126">L.N. 126 of
                    2020</ref>; <ref href="/hk/2020/er5">E.R. 5 of 2020</ref>; <ref href="hk/2020/ln212">L.N. 212 of 2020</ref>; <ref href="hk/2020/ln252">L.N. 252
                    of 2020</ref>; <ref href="hk/2021/ln104">L.N. 104 of 2021</ref>; <ref href="hk/2021/ln218">L.N. 218 of 2021</ref>; <ref href="hk/2022/ln1">L.N. 1 of
                    2022</ref>; <ref href="hk/2022/ln19">L.N. 19 of 2022</ref>; <ref href="hk/2022/ln33">L.N. 33 of 2022</ref>; <ref href="hk/2022/ln122">L.N. 122 of
                    2022</ref>; <ref href="hk/2022/ln194">L.N. 194 of
                2022</ref>; <ref href="hk/2022/ln232">L.N. 232 of 2022</ref>; <ref href="hk/2023/ln10">L.N.
                    10 of
                2023</ref>; <ref href="hk/2023/ln108">L.N. 108 of
                2023</ref>; <ref href="hk/2023/ln138">L.N. 138 of
                2023</ref>; <ref href="hk/2024/ln9">L.N. 9 of
                2024</ref>; <ref href="hk/2024/ln73">L.N. 73 of
                2024</ref>; <ref href="hk/2024/ln105">L.N. 105 of
                2024</ref>; <ref href="hk/2024/ln135">L.N. 135 of
                2024</ref>; <ref href="hk/2024/ln177">L.N. 177 of
                2024</ref>; <ref href="hk/2025/ln5">L.N. 5 of 2025</ref>; <ref href="hk/2025/ln38">L.N. 38
                    of
                2025</ref>; <ref href="hk/2025/ln116">L.N. 116 of 2025</ref>; <ref href="hk/2025/ln161">L.N.
                    161 of 2025</ref>; <ref href="hk/2025/ln211">L.N. 211 of
                2025</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker><marker role="blank-line"></marker><marker role="blank-line"></marker></sourceNote></division><crossHeading class="font_size_14">Division B</crossHeading><sourceNote class="align_right">(<ref href="/hk/2007/ln41">L.N. 41 of
            2007</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker></sourceNote><division name="D0" temporalId="sch1_D0" id="ID_1676952784966_002"><text>
                <text>Barium, salts of, except barium sulphate</text>
                <text>Dinitronaphthols; dinitrophenols; dinitrothymols</text>
                <text>meta-Nitrophenol; ortho-nitrophenol; para-nitrophenol</text>
                <text>Phosmet</text>
            </text><sourceNote class="align_right">(<ref href="/hk/1977/ln195">L.N. 195 of 1977</ref>; <ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>; <ref href="/hk/1986/ln129">L.N.
                    129 of 1986</ref>; <ref href="/hk/1995/ln262">L.N. 262 of
                1995</ref>)</sourceNote></division></schedule><schedule id="ID_1438402707735_001" name="sch2" reason="inEffect" startPeriod="2025-06-28" status="operational" temporalId="sch2"><num value="2">Schedule
            2</num><note class="align_right" role="crossReferences" type="inline">[<ref href="/hk/cap138A/s8">reg.
            8</ref>]</note><heading>Articles
            Exempted by <ref>Regulation 8</ref> from the Provisions of the Ordinance and of these
            Regulations</heading><part id="ID_1455507316225_001" name="PI" temporalId="sch2_PI"><num value="I">Group
                I</num><heading>General
                Exemptions</heading></part><text class="align_center font_size_14">
            
            
            <marker role="blank-line"></marker>
            
            
            
            
            <marker role="blank-line"></marker>
            
            
        </text><text class="align_justified"><marker role="blank-line"></marker><marker role="blank-line"></marker>Adhesives;
            anti-fouling compositions; builders’ materials; ceramics; distempers; electrical valves;
            enamels; explosives; fillers; fireworks; fluorescent lamps; glazes; glues; inks; lacquer
            solvents; loading materials; matches; motor fuels and lubricants; paints other than
            pharmaceutical paints; photographic paper; pigments; plastics; propellants; rubber;
            varnishes</text><sourceNote>(<ref href="/hk/1977/ln195">L.N. 195 of 1977</ref>; <ref href="/hk/1995/ln262">L.N. 262 of
            1995</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker><marker role="blank-line"></marker><marker role="blank-line"></marker></sourceNote><part id="ID_1455507316365_002" name="PII" temporalId="sch2_PII"><num value="II">Group
                II</num><heading>Special
                Exemptions</heading><heading>Division A</heading><sourceNote class="align_right font_size_11">(<ref href="/hk/2007/ln41">L.N. 41 of
                    2007</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker></sourceNote></part><division temporalId="sch2_D0" name="D0" id="ID_1586244835805_001"><text><table xmlns="http://www.w3.org/1999/xhtml" width="445" class="repeat_header">
                    <col width="45%"></col>
                    <col width="1%"></col>
                    <col width="54%"></col>
                    <thead>
                        <tr>
                            <td class="align_center">Poison<marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker><marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker></td>
                            <th></th>
                            <td class="align_center">Substance or article in which
                                exempted<marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker><marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker></td>
                        </tr>
                    </thead>
                    <tr>
                        <td>
                            <p>Alkaloids, the following—</p>
                        </td>
                        <td></td>
                        <td></td>
                    </tr>
                    <tr>
                        <td>
                            <p class="left_indent_24">Brucine</p>
                        </td>
                        <td></td>
                        <td>
                            <p class="align_justified left_indent_12 first_line_indent_-12">Surgical
                                spirit containing not more than 0.015% of brucine</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p class="left_indent_24">Emetine</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class=" left_indent_12 first_line_indent_-12">Ipecacuanha; extracts
                                and tinctures of ipecacuanha; substances containing less than 0.05%
                                of emetine</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p class="left_indent_48 first_line_indent_-24">Lobelia, alkaloids
                                of</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Preparations for the
                                relief of asthma in the form of cigarettes, smoking mixtures or
                                fumigants; substances containing less than 0.1% of the alkaloids of
                                lobelia</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p class="left_indent_36 first_line_indent_-12">Pilocarpus, alkaloids
                                <br></br>of</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances containing
                                less than 0.025% of the alkaloids of pilocarpus, preparations
                                containing not more than 2%, weight of the sulphate salt of
                                transpilosine <sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/1978/ln137">L.N. 137 of
                                1978</ref>)</sourceNote></p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p class="left_indent_36 first_line_indent_-12">Pomegranate,<br></br>alkaloids of</p>
                        </td>
                        <td></td>
                        <td>
                            <p class="left_indent_12 first_line_indent_-12">Pomegranate bark</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p class="left_indent_36 first_line_indent_-12">Stavesacre, alkaloids
                                <br></br>of</p>
                        </td>
                        <td></td>
                        <td>
                            <p class="left_indent_12 first_line_indent_-12">Soaps; ointments;
                                lotions for external use</p>
                        </td>
                    </tr>
                    <tr>
                        <td></td>
                        <td></td>
                        <td></td>
                    </tr>
                    <tr>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">para-Aminobenzene-sulphonamide; its salts; derivatives of
                                para-aminobenzene-sulphonamide having any of the hydrogen atoms of
                                the para amino group or of the sulphonamide group substituted by
                                another radical; their salts</p>
                        </td>
                        <td></td>
                        <td>
                            <p class="left_indent_12 first_line_indent_-12">Feeding stuffs
                                containing not more than 0.5% of total sulphonamides</p>
                        </td>
                    </tr>
                    <tr>
                        <td align="char"></td>
                        <td></td>
                        <td></td>
                    </tr>
                    <tr>
                        <td align="char" rowspan="3">
                            <p class="left_indent_12 first_line_indent_-12">Androgenic, oestrogenic
                                and progestational substances, the following—</p>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                            <p class="left_indent_36 first_line_indent_-12">Benzoestrol</p>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                            <p class="left_indent_36 first_line_indent_-12">Derivatives of stilbene,
                                dibenzyl or naphthalene with oestrogenic activity; their esters</p>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td rowspan="2" align="char">
                            <p class="left_indent_12 first_line_indent_-12">Preparations intended
                                for external application only; except preparations containing more
                                than 4 milligrams of oestrogenic substance per 100 grams of inert
                                substance and preparations containing testosterone or its esters
                                    <sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/2009/ln90">L.N. 90 of
                                    2009</ref>; <ref href="/hk/2020/er5">E.R. 5 of
                                    2020</ref>)</sourceNote></p>
                        </td>
                    </tr>
                    <tr>
                        <td></td>
                    </tr>
                    <tr>
                        <td></td>
                        <td></td>
                    </tr>
                    <tr>
                        <td align="char">
                            <p class="left_indent_36 first_line_indent_-12">Steroid
                                compounds<br></br>with androgenic or <br></br>oestrogenic or
                                <br></br>progestational<br></br>activity; their <br></br>esters</p>
                        </td>
                        <td></td>
                        
                        
                        <td class="align_left">
                            
                            <p class="left_indent_12 first_line_indent_-12">Multivitamin
                                preparations (with or without minerals) containing not more than the
                                following in each dosage form—</p>
                            
                            <p class="left_indent_24">0.01 mg of Ethinyloestradiol; and</p>
                            
                            <p class="left_indent_24">2.50 mg of Methyltestosterone <sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/2024/ln105">L.N. 105 of
                                2024</ref>)</sourceNote></p>
                            
                            
                        </td>
                        
                    </tr>
                    <tr>
                        <td align="char"></td>
                        <td></td>
                        
                        
                        
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Antihistamine
                                substances; their salts; any compound with any substance falling
                                within this item</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Preparations intended
                                for external application only and preparations containing not more
                                than 1% of antihistamine substances for application in the nose or
                                    eye<inline xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" class="width_6"> </inline><sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/2020/er5">E.R. 5 of 2020</ref>)</sourceNote></p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Arsenical poisons</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Poultry or pig feeding
                                stuffs containing not more than 0.005% of
                                4-hydroxy-3-nitrophenylarsonic acid and not containing any other
                                arsenical poison; animal feeding stuffs containing not more than
                                0.01% of arsenilic acid and not containing any other arsenical
                                poison; poultry feeding stuffs containing not more than 0.0375% of
                                carbarsone and not containing any other arsenical poison;</p>
                            <p class="left_indent_12 first_line_indent_-12">medicines containing
                                arsenic in a non-assimilable form</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Barbituric acid; its
                                salts; its derivatives; their salts; any compound with
                                any<br></br>substance
                                falling
                                within<br></br>this
                                item</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Self-heating
                                preparations, in aerosol dispensers intended for external
                                application only, containing 1, 5-diethyl-2-thio-4,
                                6-pyrimidine-dione and not containing any other substance mentioned
                                opposite hereto in the first column</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Chloroform</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances containing
                                less than 1% of chloroform; solid preparations; toothpaste</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Clioquinol</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Preparations intended
                                for external application only <sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/1978/ln137">L.N. 137 of
                                1978</ref>)</sourceNote></p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p class="left_indent_12 first_line_indent_-12">Creosote obtained
                                from<br></br>wood</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="align_justified left_indent_12 first_line_indent_-11">Substances containing less than 50% of creosote obtained from
                                wood</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Diperodon; its salts</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Preparations intended
                                for external application only, containing not more than 1% of
                                diperodon, calculated as anhydrous base</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Hydrocyanic acid</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Preparations of wild
                                cherry; in reagent kits supplied for medical or veterinary purposes;
                                substances containing less than the equivalent of 0.1%, weight in
                                weight, of hydrocyanic acid (HCN)</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Lead acetate</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances containing
                                less than 4% of lead acetate</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Lead, compounds of</p>
                        </td>
                        <td></td>
                        <td>
                            <p>Machine-spread plasters</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p class="left_indent_12 first_line_indent_-12">Lignocaine; its
                                salts</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Preparations intended
                                for external application only, containing not more than 0.7% of
                                Lignocaine or its salts <sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/1980/ln369">L.N. 369 of
                                1980</ref>)</sourceNote></p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p class="left_indent_12 first_line_indent_-12">Mercury, nitrates of</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="align_justified left_indent_12 first_line_indent_-11">Ointments containing less than the equivalent of 3%, weight in
                                weight, of mercury (Hg)</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Mescaline; its salts</p>
                        </td>
                        <td></td>
                        <td>
                            <p>Living plants</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Phenols</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Butylated
                                hydroxytoluene, carvacrol, creosote obtained from coal tar;</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">essential oils in which
                                phenols occur naturally;</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">medicines containing
                                less than 1% of phenols;</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">nasal sprays, mouth
                                washes, pastilles, lozenges, capsules, pessaries, ointments or
                                suppositories containing less than 2.5% of phenols, in reagent kits
                                supplied for medical or veterinary purposes;</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <p>smelling bottles;</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <p>soaps for washing;</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">solid substances, other
                                than pastilles, lozenges, capsules, pessaries, ointments and
                                suppositories, containing less than 60% of phenols;</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td align="char">
                            <p>Tar (coal or wood), crude or refined;</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td align="char">
                            <p>para-tertiary amylphenol;</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td align="char">
                            <p>tertiary butylcresol;</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td align="char">
                            <p>para-tertiary butylphenol;</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">para-(1, 1, 3,
                                3-tetramethylbutyl) phenol;</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <p class="align_justified left_indent_12 first_line_indent_-11">thymol</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Phenyl mercuric salts</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Toilet, cosmetic and
                                therapeutic preparations containing not more than 0.01% of phenyl
                                mercuric salts as preservative; antiseptic dressings on
                                toothbrushes; in textiles containing not more than 0.01% of phenyl
                                mercuric salts as a bacteriostat and fungicide</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Picric acid</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances containing
                                less than 5% of picric acid</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p class="left_indent_12 first_line_indent_-12">Podophyllum resin</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Preparations containing
                                not more than 1.5%, weight in weight, of podophyllum resin</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Procaine</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Feeding stuffs
                                containing any substance to which the Antibiotics Ordinance (<ref xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" href="/hk/cap137">Cap. 137</ref>) for the time being applies</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Quinine; its salts;
                                its<br></br>derivatives; their salts</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Preparations containing
                                not more than 1% of quinine, its salts, its derivatives or their
                                salts; soft drinks, wines or tonic wines; preparations containing
                                not more than 15% of quinine, its salts, its derivatives or their
                                salts for use in the manufacture of soft drinks, wines, tonic wines,
                                or confectionery <sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/1987/ln130">L.N. 130 of
                                1987</ref>)</sourceNote></p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Sodium ethyl
                                mercurithio-salicylate</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Therapeutic substances
                                containing less than 0.1% of sodium ethyl mercurithiosalicylate as a
                                preservative</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Sodium fluoride</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances containing
                                less than 3% of sodium fluoride as a preservative; dentifrices
                                containing not more than 0.33% of sodium fluoride; mouth wash
                                tablets containing not more than 0.2% of sodium fluoride and liquid
                                mouth washes containing not more than 0.05% thereof; tablets
                                containing not more than 0.016%, weight in weight, of sodium
                                fluoride and intended, when chewed to prevent tooth decay
                                    <sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/1999/ln202">L.N. 202 of 1999</ref>; <ref href="/hk/2015/er1">E.R. 1 of 2015</ref>)</sourceNote></p>
                        </td>
                    </tr>
                    
                    
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td align="char">
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Tranexamic acid</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Topical preparations
                                containing not more than 3% of tranexamic acid as cosmetic products
                                not intended for the treatment of human ailments <sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="hk/2022/ln19">L.N. 19 of 2022</ref>)</sourceNote></p>
                        </td>
                    </tr>
                    
                    
                </table><sourceNote>(<ref href="/hk/2000/ln138">L.N. 138 of
                    2000</ref>)<marker role="blank-line"></marker><marker role="section-break"></marker></sourceNote></text></division><division name="D0" temporalId="sch2_D0" id="ID_1586244836102_003"><text><crossHeading class="font_size_14">Division B</crossHeading><sourceNote class="align_right">(<ref href="/hk/2007/ln41">L.N. 41 of
                    2007</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker></sourceNote>
                
                
                
                <marker role="blank-line"></marker>
                
                
                <table xmlns="http://www.w3.org/1999/xhtml" width="445" class="repeat_header">
                    <col width="45%"></col>
                    <col width="1%"></col>
                    <col width="54%"></col>
                    <thead>
                        <tr>
                            <td class="align_center">Poison<marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker><marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker></td>
                            <th></th>
                            <td class="align_center">Substance or article in which
                                exempted<marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker><marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker></td>
                        </tr>
                    </thead>
                    
                    
                    <tr>
                        <td>
                            <p class="left_indent_12 first_line_indent_-12">Acetanilide;
                                alkyl<br></br>acetanilides</p>
                        </td>
                        <td></td>
                        <td>
                            <p class="left_indent_12 first_line_indent_-12">Substances not being
                                preparations for the treatment of human ailments</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    
                    
                    <tr>
                        <td>
                            <p>Ammonia</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances not being
                                solutions of ammonia or preparations containing solutions of
                                ammonia; substances containing less than 5%, weight in weight, of
                                ammonia (NH<sub>3</sub>); refrigerators; smelling bottles</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Antimony, chlorides of</p>
                        </td>
                        <td></td>
                        <td>
                            <p>Polishes</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Arsenical poisons</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Pyrites ores or
                                sulphuric acid containing arsenical poisons as natural
                                impurities</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Barium, salts of</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Witherite other than
                                finely ground witherite; barium carbonate bonded to charcoal for
                                case hardening; fire extinguishers containing barium chloride</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">gamma-Benzene<br></br>hexachloride</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances containing
                                not more than 5% by weight of gamma-benzene hexachloride; when used
                                in agriculture or horticulture <sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/1977/ln195">L.N. 195 of
                                1977</ref>)</sourceNote></p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Diamines, the following;
                                their salts—phenylene diamines; toluene diamines; other
                                alkylated-benzene diamines</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances other than
                                preparations for the dyeing of hair</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Dinitrophenols</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances not being
                                preparations for the treatment of human ailments</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Disulfiram</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances not being
                                preparations for the treatment of human ailments</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Formaldehyde</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances containing
                                less than 5%, weight in weight, of formaldehyde (H. CHO);
                                photographic glazing or hardening solutions</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Formic acid</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances containing
                                less than 5%, weight in weight, of formic acid<br></br>(H. COOH)</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Hydrochloric acid</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances containing
                                less than 9%, weight in weight, of hydrochloric acid (HCl)</p>
                        </td>
                    </tr>
                    
                    
                    
                    <tr>
                        <td>
                            <p>Mercuric chloride</p>
                        </td>
                        <td></td>
                        <td>
                            <p>Batteries</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Mercuric chloride;
                                mercuric iodide; organic compounds of mercury</p>
                        </td>
                        <td></td>
                        <td>
                            <p>Dressings on seeds or bulbs</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Mercury, oxides of</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Canker and wound paints
                                (for trees) containing not more than 3%, weight in weight, of yellow
                                mercuric oxide</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p class="left_indent_12 first_line_indent_-11">Nicotine</p>
                        </td>
                        <td></td>
                        
                        <td align="char">
                            
                            <p class="left_indent_12 first_line_indent_-12">Tobacco
                                in any conventional smoking product (as defined by section 2(1) of
                                the Smoking (Public Health) Ordinance (<ref xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" href="/hk/cap371">Cap. 371</ref>)) <sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="hk/2024/ln177">L.N. 177 of
                                2024</ref>)</sourceNote></p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Nitric acid</p>
                        </td>
                        <td></td>
                        
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances containing
                                less than 9%, weight in weight, of nitric acid (HNO<sub>2</sub>)</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Nitrobenzene</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances containing
                                less than 0.1% of nitrobenzene; soaps containing less than 1% of
                                nitrobenzene; polishes</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>para-Nitrobenzyl cyanide</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Photographic solutions
                                containing less than the equivalent of 0.1%, weight in weight, of
                                hydrocyanic acid (HCN)</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                            
                        </td>
                        <td></td>
                        <td>
                            
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                            
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>para-Nitrophenol</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Preparations for use in
                                agriculture or horticulture containing not more than 0.5% of
                                para-Nitrophenol as preservative</p>
                        </td>
                    </tr>
                    
                    
                    
                    <tr>
                        <td>
                            <p class="left_indent_12 first_line_indent_-12">Oxalic acid;
                                metallic<br></br>oxalates</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Laundry blue; polishes;
                                cleaning powders or scouring products containing the equivalent of
                                not more than 10% of oxalic acid dihydrate</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Phosphoric acid</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances containing
                                phosphoric acid, not being descaling preparations containing more
                                than 50%, weight in weight, of ortho-phosphoric acid <sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/1978/ln137">L.N. 137 of
                                1978</ref>)</sourceNote></p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Potassium hydroxide</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances containing
                                the equivalent of less than 17% of total caustic alkalinity
                                expressed as potassium hydroxide; accumulators, batteries</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Sodium hydroxide</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances containing
                                the equivalent of less than 12% of total caustic alkalinity
                                expressed as sodium hydroxide</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Sodium nitrite</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances other than
                                preparations containing more than 0.1% of sodium nitrite for the
                                destruction of rats or mice</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Sodium silicofluoride</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances containing
                                less than 3% of sodium silicofluoride as preservative</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <p>Sulphaquinoxaline; its salts</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Preparations for the
                                destruction of mice and rats containing not more than the equivalent
                                of 0.5% of sulphaquinoxaline</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td></td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td></td>
                        <td></td>
                        <td></td>
                    </tr>
                    <tr>
                        <td>
                            <p>Sulphuric acid</p>
                        </td>
                        <td></td>
                        <td align="char">
                            <p class="left_indent_12 first_line_indent_-12">Substances containing
                                less than 9%, weight in weight, of sulphuric acid
                                    (H<sub>2</sub>SO<sub>4</sub>); accumulators; batteries and
                                sealed containers in which sulphuric acid is packed together with
                                car batteries for use in those batteries; fire extinguishers</p>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3" class="align_right"><sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/1977/ln195">L.N. 195 of 1977</ref>; <ref href="/hk/1995/ln262">L.N. 262 of 1995</ref>)</sourceNote></td>
                    </tr>
                </table>
            </text></division></schedule><schedule name="sch3" reason="inEffect" startPeriod="2025-10-17" status="operational" temporalId="sch3" id="ID_1438402707798_001"><num value="3">Schedule 3</num><note class="align_right" role="crossReferences" type="inline">[<ref href="/hk/cap138A/s3">regs. 3</ref> &amp; <ref href="/hk/cap138A/s9">9</ref> &amp; <ref href="/hk/cap138A/sch5">Schs. 5</ref> &amp; <ref href="/hk/cap138A/sch10">10</ref>]<sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 67</ref>; <ref href="hk/2015/er3">E.R. 3 of 2015</ref>)</sourceNote></note><heading>Substances
            Required by <ref>Regulation 9</ref> to be Sold by Retail only upon a Prescription Given
            by a Registered Medical Practitioner, Registered Dentist or Registered Veterinary
            Surgeon</heading><sourceNote>(<ref href="/hk/1997/ln614">L.N. 614 of
            1997</ref>)<marker role="blank-line"></marker></sourceNote><crossHeading class="font_size_14">Division A</crossHeading><sourceNote class="align_right">(<ref href="/hk/2014/ln39">L.N. 39 of 2014</ref>)<marker role="blank-line"></marker></sourceNote><division name="D0" temporalId="sch3_D0" id="ID_1676952876516_001"><text>Abacavir; its salts</text><text>Abatacept</text><text class="first_line_indent_0">Abciximab</text><text>Abemaciclib; its salts</text><text>Abiraterone; its salts</text><text>Abrocitinib; its salts</text><text>Acalabrutinib; its salts</text><text class="first_line_indent_0">Acamprosate; its salts</text><text>Acarbose; its salts</text><text>Acebutolol; its salts</text><text>Aceclofenac; its salts</text><text class="first_line_indent_0">Acemetacin; its salts</text><text>Acetanilide; alkyl acetanilides</text><text>Acetazolamide; its salts</text><text>Acetohexamide</text><text>Acetorphine; its salts; its esters and ethers; their salts</text><text>Acetylcarbromal</text><text>Acetyldihydrocodeine; its salts</text><text class="left_indent_12 first_line_indent_-12">Aciclovir; its salts; except when
                contained in skin creams packed in a package size of not more than 3 grams and
                labelled for the treatment of cold sores only</text><text>Acipimox; its salts</text><text>Acitretin; its salts; its esters</text><text>Aclidinium; its salts</text><text class="first_line_indent_0">Adagrasib; its salts</text><text>Adalimumab</text><text class="first_line_indent_0">Adapalene; its salts; its esters</text><text>Adefovir; its salts; its esters; their salts</text><text>Afatinib; its salts</text><text class="first_line_indent_0">Aflibercept</text><text>Afoxolaner; its salts</text><text>Agalsidase alfa</text><text>Agalsidase beta</text><text class="first_line_indent_0">Agomelatine; its salts</text><text>Alclofenac; its complexes</text><text>Alcuronium; its salts</text><text class="first_line_indent_0">Aldesleukin</text><text class="first_line_indent_0">Alectinib; its salts</text><text>Alefacept</text><text>Alemtuzumab</text><text>Alendronic acid; its salts</text><text>Alfacalcidol; its salts</text><text>Alfuzosin; its salts</text><text>Alglucosidase alfa</text><text>Alirocumab</text><text>Aliskiren; its salts; its esters; their salts</text><text>Alizapride; its salts</text><text class="left_indent_12 first_line_indent_-12">Alkaloids, the following; their
                quaternary compounds; any salt, simple or complex, of any substance falling within
                the following—</text><text class="left_indent_0 first_line_indent_24">Calabar bean, alkaloids of</text><text class="left_indent_0 first_line_indent_24">Codeine, except substances containing
                less than 0.2% of codeine</text><text class="left_indent_0 first_line_indent_24">Colchicum, alkaloids of; their
                salts</text><text class="left_indent_0 first_line_indent_24">Coniine, except substances containing
                less than 0.1% of coniine</text><text class="left_indent_0 first_line_indent_24">Cotarnine, except substances containing
                less than 0.2% of cotarnine</text><text class="left_indent_0 first_line_indent_24">Curare, alkaloids of; curare
                bases</text><text class="left_indent_36 first_line_indent_-12">Emetine, except substances containing
                less than 1% of emetine</text><text class="left_indent_36 first_line_indent_-12">Ephedrine; its optical isomers; their
                salts; when contained in aerosol dispensers</text><text class="left_indent_0 first_line_indent_24">Ergot, alkaloids of</text><text class="left_indent_0 first_line_indent_24">Galantamine</text><text class="left_indent_36 first_line_indent_-12">Gelsemium, alkaloids of, except
                substances containing less than 0.1% of the alkaloids of gelsemium</text><text class="left_indent_36 first_line_indent_-12">Pilocarpus, alkaloids of, except
                substances containing less than 0.5% of the alkaloids of pilocarpus</text><text class="left_indent_36 first_line_indent_-12">Rauwolfia, alkaloids of; their salts;
                derivatives of the alkaloids of rauwolfia; their salts</text><text class="left_indent_36 first_line_indent_-12">Sabadilla, alkaloids of, except
                substances containing less than 1% of the alkaloids of sabadilla</text><text class="left_indent_36 first_line_indent_-12">Veratrum, alkaloids of, except
                substances containing less than 1% of the alkaloids of veratrum</text><text class="left_indent_36 first_line_indent_-12">Vinca, alkaloids of</text><text>Allergen extract of Dermatophagoides farinae</text><text class="first_line_indent_0">Allergen extract of Dermatophagoides
                pteronyssinus</text><text>Allopurinol</text><text>Allylisopropylacetylurea</text><text>Almitrine; its salts</text><text>Alogliptin; its salts</text><text>Alpelisib; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Alphadolone; its esters</text><text>Alphaxalone</text><text>Alprenolol; its salts</text><text>Alteplase</text><text>Alufibrate</text><text>Amantadine; its salts</text><text>Ambrisentan; its salts; its esters; their salts </text><text>Amidopyrine; its salts</text><text>Amifostine; its salts</text><text>Amiloride; its salts</text><text>Amineptine; its salts</text><text class="left_indent_12 first_line_indent_-12">para-Aminobenzenesulphonamide; its
                salts; derivatives of para-aminobenzenesulphonamide having any of the hydrogen atoms
                of the para-amino group or of the sulphonamide group substituted by another radical;
                their salts; except when contained in preparations intended for external application
                or surgical dressings or in preparations for the prevention and treatment of
                diseases in poultry</text><text>Aminoglutethimide</text><text class="first_line_indent_0">5-Aminolevulinic acid; its salts; its derivatives;
                their salts</text><text class="first_line_indent_-24 left_indent_24 ">Aminopterin; its derivatives</text><text class="first_line_indent_-24 left_indent_24 ">Aminorex; its salts</text><text class="left_indent_12 first_line_indent_-12">para-Aminosalicylic acid; its salts;
                its derivatives; their salts; any compound with any substance falling within this
                item</text><text class="first_line_indent_-24 left_indent_24 ">Amiodarone; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Amisulpride; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Amitriptyline; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Amivantamab</text><text class="first_line_indent_-24 left_indent_24 ">Amlodipine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Amrinone</text><text class="first_line_indent_-24 left_indent_24 ">Amsacrine; its salts</text><text class="first_line_indent_-24 left_indent_24 ">Amylene hydrate</text><text>Anagrelide; its salts</text><text>Anastrozole; its salts</text><text>Andexanet alfa</text><text class="first_line_indent_-24 left_indent_24 ">Androgenic, oestrogenic and
                progestational substances, the following—</text><text class="left_indent_0 first_line_indent_24">Benzoestrol</text><text class="left_indent_36 first_line_indent_-12">Derivatives of stilbene, dibenzyl or
                naphthalene with oestrogenic activity; their esters</text><text class="left_indent_36 first_line_indent_-12">Steroid compounds with androgenic or
                oestrogenic or progestational activity; their esters; except when contained in a
                preparation intended to be taken orally for contraceptive purposes only and each
                dose of the preparation contains not more than the following—</text><text class="left_indent_50">0.15 mg of Desogestrel;</text><text class="left_indent_50">3.00 mg of Drospirenone;</text><text class="left_indent_50">0.05 mg of Ethinyloestradiol;</text><text class="left_indent_50">0.10 mg of Gestodene;</text><text class="left_indent_50">0.25 mg of Levonorgestrel;</text><text class="left_indent_50">2.50 mg of Lynoestrenol;</text><text class="left_indent_50">0.05 mg of Mestranol;</text><text class="left_indent_50">1.00 mg of Norethisterone;</text><text class="left_indent_50">0.25 mg of Norgestimate; and</text><text class="left_indent_50">0.50 mg of Norgestrel</text><text class="first_line_indent_0">Anidulafungin; its salts; its esters; their
                salts</text><text>Anifrolumab</text><text class="first_line_indent_-24 left_indent_24 ">Anistreplase</text><text class="left_indent_12 first_line_indent_-12">Antihistamine substances, the
                following; their salts; any compound with any substance falling within this
                item—</text><text class="left_indent_0 first_line_indent_24">Antazoline</text><text class="left_indent_0 first_line_indent_24">Astemizole</text><text class="left_indent_0 first_line_indent_24">Bilastine</text><text class="left_indent_0 first_line_indent_24">Doxylamine</text><text class="left_indent_0 first_line_indent_24">Mebhydrolin</text><text class="left_indent_0 first_line_indent_24">Terfenadine</text><text class="left_indent_0 first_line_indent_24">Tripelennamine</text><text class="first_line_indent_-24 left_indent_24 ">Antilymphocyte
                Immunoglobulins</text><text class="first_line_indent_0">Antisera, antitoxins, immunoglobulins and
                vaccines—</text><paragraph id="ID_1438411272787_150" name="a" temporalId="sch3_D0_a"><num value="a">(a)</num><content>the following—</content><content class="left_indent_0 first_line_indent_46">Bacillus Calmette-Guérin
                    (BCG)</content><content class="left_indent_0 first_line_indent_46">Meningococcal vaccines</content><content class="left_indent_0 first_line_indent_46">Normal immunoglobulins</content><content class="left_indent_0 first_line_indent_46">Pneumococcal vaccines</content><content class="left_indent_0 first_line_indent_46">Rotavirus vaccines</content><content class="left_indent_0 first_line_indent_46">Snake venom antisera</content><content class="left_indent_0 first_line_indent_46">Staphylococcal
                    vaccines</content><content class="left_indent_0 first_line_indent_46">Streptococcal
                    vaccines;</content></paragraph><paragraph id="ID_1456472530443_001" name="b" temporalId="sch3_D0_b"><num value="b">(b)</num><content>directed against the following diseases, viruses or organisms—</content><content class="left_indent_0 first_line_indent_46">Bordetella species</content><content class="left_indent_0 first_line_indent_46">Botulism</content><content class="left_indent_0 first_line_indent_46">Canine infectious
                    disease</content><content class="left_indent_0 first_line_indent_46">Cholera</content><content class="left_indent_0 first_line_indent_46">Dengue fever</content><content class="left_indent_0 first_line_indent_46">Diphtheria</content><content class="left_indent_0 first_line_indent_46">Feline calicivirus</content><content class="left_indent_0 first_line_indent_46">Feline Chlamydia
                    psittaci</content><content class="left_indent_0 first_line_indent_46">Feline immunodeficiency
                    virus</content><content class="left_indent_0 first_line_indent_46">Feline leukemia virus</content><content class="left_indent_0 first_line_indent_46">Feline panleukopenia
                    virus</content><content class="left_indent_0 first_line_indent_46">Feline rhinotracheitis
                    virus</content><content class="left_indent_0 first_line_indent_46">Haemophilus influenzae type
                    b</content><content class="left_indent_0 first_line_indent_46">Hepatitis A</content><content class="left_indent_0 first_line_indent_46">Hepatitis B</content><content class="left_indent_0 first_line_indent_46">Herpes simplex</content><content class="left_indent_0 first_line_indent_46">Herpes zoster</content><content class="left_indent_0 first_line_indent_46">Human papillomavirus</content><content class="left_indent_0 first_line_indent_46">Influenza</content><content class="left_indent_0 first_line_indent_46">Japanese encephalitis</content><content class="left_indent_0 first_line_indent_46">Measles</content><content class="left_indent_0 first_line_indent_46">Mumps</content><content class="left_indent_0 first_line_indent_46">Pertussis</content><content class="left_indent_0 first_line_indent_46">Plague</content><content class="left_indent_0 first_line_indent_46">Poliomyelitis</content><content class="left_indent_0 first_line_indent_46">Rabies</content><content class="left_indent_0 first_line_indent_46">Respiratory syncytial
                    virus</content><content class="left_indent_0 first_line_indent_46">Rubella</content><content class="left_indent_0 first_line_indent_46">Severe acute respiratory
                    syndrome coronavirus 2 (SARS-CoV-2)</content><content class="left_indent_0 first_line_indent_46">Tetanus</content><content class="left_indent_0 first_line_indent_46">Typhoid</content><content class="left_indent_0 first_line_indent_46">Varicella</content><content class="left_indent_0 first_line_indent_46">Yellow fever</content></paragraph><text>Antithymocyte Immunoglobulin</text><text>Apalutamide; its salts</text><text>Apixaban; its salts</text><text class="left_indent_12 first_line_indent_-12">Apomorphine; its salts; its
                quaternary compounds; except substances containing less than 0.2% of
                apomorphine</text><text class="first_line_indent_0">Apremilast; its salts</text><text>Aprepitant; its salts</text><text>Aprindine; its salts</text><text>Aripiprazole</text><text>Arsenic trioxide when contained in pharmaceutical products</text><text>Artemether; its salts</text><text>Articaine; its salts</text><text>Asciminib; its salts</text><text>Asenapine; its salts; its isomers</text><text>Asfotase alfa</text><text>Asunaprevir; its salts</text><text>Atazanavir; its salts</text><text>Atenolol; its salts</text><text>Atezolizumab</text><text>Atogepant</text><text>Atomoxetine; its salts</text><text>Atorvastatin; its salts</text><text>Atosiban; its salts</text><text>Atovaquone</text><text>Atracurium besylate</text><text class="left_indent_12 first_line_indent_-12">Atropine; its salts; when contained
                in pharmaceutical products for human parenteral administration or pharmaceutical
                products intended to be used for slowing the progression of myopia</text><text>Auranofin</text><text>Avalglucosidase alfa</text><text>Avanafil; its salts</text><text>Avapritinib; its salts</text><text class="left_indent_12 first_line_indent_-12">Avatrombopag; its salts; its esters;
                their salts</text><text>Avelumab</text><text>Axitinib; its salts </text><text>Azacitidine; its salts</text><text>Azacyclonol; its salts</text><text>Azapropazone</text><text>Azauridine; its derivatives</text><text>Azilsartan; its salts; its esters; their salts</text><text>Aziridine; its derivatives</text><text>Baclofen</text><text>Baloxavir; its salts; its esters and ethers; their salts</text><text>Bambuterol and its salts when contained in aerosol dispensers</text><text class="left_indent_12 first_line_indent_-12">Barbituric acid; its salts; its
                derivatives; their salts; any compound with any substance falling within this
                item</text><text class="first_line_indent_0">Baricitinib; its salts</text><text>Basiliximab; its salts</text><text>Becaplermin; its salts</text><text>Bedaquiline; its salts</text><text>Befunolol; its salts</text><text>Belantamab mafodotin</text><text>Belimumab</text><text>Belumosudil; its salts</text><text>Belzutifan; its salts</text><text>Bemiparin; its salts</text><text>Bempedoic acid; its salts; its esters; their salts</text><text>Benactyzine; its salts</text><text>Benazepril; its salts</text><text>Benmelstobart</text><text>Benoxaprofen; its salts</text><text>Benralizumab</text><text>Benserazide; its salts</text><text>Benzbromarone</text><text>Benzhexol; its salts</text><text>Benzquinamide</text><text>Benztropine and its homologues; their salts</text><text>Besifloxacin; its salts; its esters; their salts</text><text class="left_indent_12 first_line_indent_-12">Betahistine; its salts; except when
                contained in pharmaceutical products containing betahistine hydrochloride or
                betahistine mesilate (a) labelled with a maximum recommended daily dose of the
                pharmaceutical product having the equivalent of 48 mg of betahistine hydrochloride
                or 36 mg of betahistine mesilate; (b) stated for use only in patients of 18 years
                old or above for relief of vertigo symptoms only; and (c) to be sold in packs for a
                maximum of 5 days’ use</text><text>Betaxolol; its salts</text><text>Bethanidine; its salts</text><text>Bevacizumab</text><text>Bexarotene; its salts</text><text>Bezafibrate</text><text>Bicalutamide; its salts</text><text>Bictegravir; its salts</text><text>Bimekizumab</text><text>Binimetinib; its salts</text><text class="left_indent_12 first_line_indent_-12">Biphenylacetic acid; its salts; its
                esters; except when contained in preparations intended for external use only</text><text class="left_indent_12 first_line_indent_-12">N-[4,4-Bis(para-fluorophenyl)butyl]piperidine,4-substituted derivatives of; their
                salts</text><text>Bisoprolol; its salts</text><text>Bitolterol and its salts when contained in aerosol dispensers</text><text>Bivalirudin; its salts</text><text>Blinatumomab</text><text class="left_indent_12 first_line_indent_-12">Blood products derived from human
                blood or manufactured by biotechnology, the following—</text><text class="left_indent_0 first_line_indent_24">Albumin</text><text class="left_indent_0 first_line_indent_24">Antithrombins</text><text class="left_indent_0 first_line_indent_24">Blood clotting factors</text><text class="left_indent_0 first_line_indent_24">Fibrin</text><text class="left_indent_0 first_line_indent_24">Fibrinogen</text><text class="left_indent_0 first_line_indent_24">Plasma protein fractions</text><text class="left_indent_0 first_line_indent_24">Thrombin</text><text>Boceprevir; its salts</text><text>Bortezomib</text><text>Bosentan; its salts</text><text>Botulinum toxin complexes</text><text>Brentuximab vedotin</text><text>Bretylium tosylate</text><text>Brexpiprazole; its salts</text><text>Brigatinib; its salts</text><text>Brimonidine; its salts</text><text>Brinzolamide; its salts</text><text>Brivaracetam; its salts</text><text>Brodalumab</text><text>Brolucizumab</text><text>Bromocriptine; its salts</text><text>Bromvaletone</text><text>Broncho-Vaxom</text><text>Brotizolam</text><text>Bucolome</text><text>Bufexamac</text><text>Buformin; its salts</text><text>Bumadizone; its salts</text><text>Bumetanide; its salts; its derivatives; their salts</text><text>Bupivacaine; its salts</text><text>Bupranolol; its salts</text><text>Buprenorphine; its salts</text><text>Bupropion; its salts</text><text>Burosumab</text><text>Buserelin; its salts</text><text>Buspirone; its salts</text><text>Busulphan; its salts</text><text>Butorphanol; its salts</text><text>Cabazitaxel; its salts; its esters; their salts</text><text>Cabergoline; its salts</text><text>Cabotegravir; its salts</text><text>Cabozantinib; its salts</text><text>Calcifediol</text><text>Calcipotriol; its salts</text><text>Calcitriol; its salts</text><text>Canagliflozin; its salts</text><text>Canakinumab</text><text>Candesartan; its salts; its esters; their salts</text><text>Cannabidiol; its salts; when contained in pharmaceutical products</text><text class="left_indent_12 first_line_indent_-12">Cannabinol and its tetrahydro or
                hexahydro derivatives; their 3-alkyl homologues; any ester or ether of any substance
                falling within this item</text><text>Capecitabine; its salts</text><text>Capivasertib; its salts</text><text>Capmatinib; its salts</text><text>Captodiamine; its salts</text><text>Captopril</text><text class="left_indent_12 first_line_indent_-12">Caramiphen; its salts; except tablets
                containing not more than the equivalent of 7.5 milligrams of caramiphen base and
                liquid preparations containing not more than the equivalent of 0.1% of caramiphen
                base</text><text>Carbachol</text><text>Carbamazepine</text><text>Carbidopa; its salts</text><text>Carbimazole; its salts</text><text>Carboplatin</text><text>Carbromal</text><text>Carbutamide</text><text>Carfilzomib; its salts</text><text>Carglumic acid; its salts; its esters; their salts</text><text>Carisoprodol</text><text>Carmustine</text><text>Carperidine; its salts</text><text>Carprofen; its salts</text><text>Carteolol; its salts</text><text>Carvedilol; its salts</text><text>Casirivimab</text><text>Caspofungin; its salts</text><text>Catequentinib (Anlotinib); its salts</text><text>Cedazuridine; its salts</text><text>Celecoxib; its salts</text><text>Celiprolol; its salts</text><text>Cemiplimab</text><text>Cenobamate; its salts</text><text>Ceritinib; its salts</text><text>Cerivastatin; its salts</text><text>Certolizumab pegol</text><text>Cetrorelix; its salts; its esters; their salts</text><text>Cetuximab</text><text>Chlofenamic acid; its salts</text><text class="left_indent_12 first_line_indent_-12">Chloral; its addition and its
                condensation products other than alphachloralose; any compound with any substance
                falling within this item, except when contained, in the form of chloral hydrate, in
                preparations intended for external application only</text><text>Chlordiazepoxide; its salts</text><text>Chlormethiazole; its salts</text><text>Chlormezanone</text><text>Chloroquine; its salts</text><text class="left_indent_12 first_line_indent_-12">Chlorothiazide and other derivatives
                of benzo-1,2,4-thiadiazine-7-sulphonamide 1, 1-dioxide, whether hydrogenated or not;
                their salts</text><text>Chlorphenoxamine; its salts</text><text>Chlorphentermine; its salts</text><text>Chlorpropamide; its salts</text><text class="left_indent_12 first_line_indent_-12">Chlorprothixene and other derivatives
                of 9-methylenethiaxanthen; their salts</text><text class="left_indent_12 first_line_indent_-12">Chlorthalidone and other derivatives
                of ortho-chlorobenzene sulphonamide</text><text>Chlorzoxazone</text><text>Chorionic Gonadotrophin</text><text>Chymopapain</text><text>Cicletanine; its salts</text><text>Cidofovir; its salts</text><text>Cilazapril; its salts</text><text>Cilgavimab</text><text>Cilostazol; its salts</text><text>Cinacalcet; its salts</text><text>Cinepazide; its salts</text><text>Ciprofibrate; its salts</text><text>Ciprofloxacin; its salts; its esters</text><text>Cisapride</text><text>Cisatracurium besylate</text><text>Cisplatin</text><text>Citalopram; its salts</text><text class="left_indent_12 first_line_indent_-12">Citicoline; its salts; when contained
                in pharmaceutical products intended to be used for the treatment of cognitive and
                neurological disorders associated with cerebrovascular disease or brain injury, or
                both</text><text>Cladribine</text><text>Clioquinol</text><text>Clobazam</text><text>Clodronic acid; its salts; its esters</text><text>Clofarabine; its salts; its esters; their salts</text><text>Clofazimine; its salts</text><text>Clofibrate</text><text>Clomiphene; its salts</text><text>Clomipramine; its salts; its derivatives; their salts</text><text>Clonidine; its salts</text><text>Clopidogrel; its salts</text><text>Clorexolone</text><text>Cloridarol</text><text>Clorprenaline and its salts when contained in aerosol dispensers</text><text>Clothiapine</text><text>Clozapine; its salts</text><text>Cobicistat; its salts</text><text>Cobimetinib; its salts</text><text>Codergocrine mesilate</text><text>Colaspase</text><text>Colfosceril; its salts</text><text>Collagen, purified</text><text class="left_indent_12 first_line_indent_-12">Contrast media, the following; their
                salts; and compound with any substance falling within this item; when contained in
                preparations for parenteral use—</text><text class="left_indent_24">Acetrizoic acid</text><text class="left_indent_24">Diatrizoic acid</text><text class="left_indent_24">Ferucarbotran</text><text class="left_indent_24">Gadobenic acid</text><text class="left_indent_24">Gadobutrol</text><text class="left_indent_24">Gadodiamide</text><text class="left_indent_24">Gadopentetic acid</text><text class="left_indent_24">Gadoteric acid</text><text class="left_indent_24">Iobitridol</text><text class="left_indent_24">Iocarmic acid</text><text class="left_indent_24">Iocetamic acid</text><text class="left_indent_24">Iodamide</text><text class="left_indent_24">Iodipamide</text><text class="left_indent_24">Iodised oil</text><text class="left_indent_24">Iodixanol</text><text class="left_indent_24">Iodoxamic acid</text><text class="left_indent_24">Ioglicic acid</text><text class="left_indent_24">Ioglycamic acid</text><text class="left_indent_24">Iohexol</text><text class="left_indent_24">Iomeprol</text><text class="left_indent_24">Iopamidol</text><text class="left_indent_24">Iopanoic acid</text><text class="left_indent_24">Iophendylate</text><text class="left_indent_24">Iopromide</text><text class="left_indent_24">Iothalamic acid</text><text class="left_indent_24">Iotrolan</text><text class="left_indent_24">Iotroxic acid</text><text class="left_indent_24">Ioversol</text><text class="left_indent_24">Ioxaglic acid</text><text class="left_indent_24">Ioxitalamic acid</text><text class="left_indent_24">Ipodic acid</text><text class="left_indent_24">Metrizamide</text><text class="left_indent_24">Propyliodone</text><text class="left_indent_24">Sulphur hexafluoride</text><text class="left_indent_24">Tyropanoic acid</text><text>Corifollitropin alfa</text><text>Corticorelin; its salts</text><text>Corticotrophins</text><text>Corynebacterium parvum</text><text>Crisaborole; its salts</text><text>Crizotinib; its salts</text><text>Cyclarbamate</text><text>Cyclobenzaprine; its salts</text><text>Cyclofenil</text><text>Cyclosporin A</text><text>Cytarabine; its salts</text><text>Dabigatran etexilate; its salts</text><text>Dabrafenib; its salts</text><text>Dacarbazine</text><text>Daclatasvir; its salts</text><text>Daclizumab</text><text>Dacomitinib; its salts</text><text>Dalteparin; its salts</text><text>Danicopan; its salts</text><text>Dapagliflozin; its salts</text><text>Dapoxetine; its salts</text><text>Dapsone</text><text>Daratumumab</text><text>Darbepoetin alfa</text><text>Daridorexant; its salts</text><text>Darifenacin; its salts</text><text>Darolutamide; its salts</text><text>Darunavir; its salts</text><text>Dasabuvir; its salts</text><text>Dasatinib; its salts</text><text>Deanol acetamidobenzoate</text><text>Debrisoquine; its salts</text><text>Decitabine; its salts</text><text>Deferasirox; its salts; its esters; their salts</text><text>Deferiprone; its salts</text><text>Degarelix; its salts</text><text>Dehydroemetine; its salts</text><text class="first_line_indent_0">Delafloxacin; its salts; its esters; their
                salts</text><text>Delamanid; its salts</text><text>Delandistrogene moxeparvovec</text><text>Demecarium bromide</text><text>Denosumab</text><text>Desferrioxamine; its salts</text><text>Desflurane</text><text>Desipramine; its salts</text><text>Desvenlafaxine; its salts</text><text>Deucravacitinib; its salts</text><text>Dexketoprofen; its salts</text><text>Dexlansoprazole; its salts</text><text>Dexmedetomidine; its salts</text><text>Dexrazoxane; its salts</text><text>Diacerein; its salts; its esters</text><text class="left_indent_12 first_line_indent_-12">Diazepam and other compounds
                containing the chemical structure of dihydro-1,4-benzodiazepine substituted to any
                degree; their salts</text><text class="first_line_indent_0">Diazoxide</text><text class="left_indent_12 first_line_indent_-12">Diclofenac; its salts; except when
                contained in preparations for external application only</text><text>Didanosine; its salts</text><text>Digitalis, glycosides of; other active principles of digitalis</text><text>Dihydralazine; its salts</text><text>Dihydroergotamine; its salts, simple or complex</text><text>Dihydroetorphine; its salts</text><text class="first_line_indent_0">3-(3,4-Dihydroxyphenyl)alanine; its salts</text><text>Diltiazem; its salts</text><text>Dimefline; its salts</text><text>Dimethyl fumarate when contained in pharmaceutical products</text><text>Dinutuximab beta</text><text>Diprenorphine; its salts</text><text>Dipyridamole</text><text>Diquafosol; its salts</text><text class="first_line_indent_0">Disopyramide; its salts</text><text>Distigmine; its salts<text class="first_line_indent_0">Disulfiram</text></text><text class="left_indent_12 first_line_indent_-12">Dithienylallylamines;
                dithienylalkylallylamines; their salts; except diethylthiambutene,
                dimethylthiambutene and ethylmethylthiambutene</text><text>Dobutamine; its salts</text><text>Docetaxel; its salts</text><text>Dolutegravir; its salts</text><text class="first_line_indent_0">Domperidone; its salts</text><text>Donanemab</text><text>Donepezil; its salts</text><text>Dopamine; its salts</text><text>Doravirine; its salts</text><text>Dornase alfa</text><text>Dorzolamide; its salts</text><text class="first_line_indent_0">Dostarlimab</text><text class="first_line_indent_0">Dothiepin; its salts</text><text>Doxapram; its salts</text><text>Doxazosin; its salts</text><text>Doxepin; its salts; its derivatives; their salts</text><text>Dronedarone; its salts</text><text>Droperidol</text><text class="first_line_indent_0">Drotrecogin alfa</text><text>Dulaglutide</text><text>Duloxetine; its salts</text><text>Dupilumab</text><text class="first_line_indent_0">Durvalumab</text><text>Dutasteride</text><text>Ecothiopate iodide</text><text>Ectylurea</text><text>Eculizumab</text><text>Edoxaban; its salts</text><text class="first_line_indent_0">Efalizumab</text><text class="first_line_indent_0">Efanesoctocog alfa</text><text>Efavirenz; its salts</text><text>Efinaconazole; its salts</text><text class="first_line_indent_0">Elacestrant; its salts</text><text>Eladocagene exuparvovec</text><text class="first_line_indent_0">Elapegademase</text><text>Elbasvir; its salts</text><text>Eletriptan; its salts</text><text>Elosulfase alfa</text><text class="first_line_indent_0">Elotuzumab</text><text class="first_line_indent_0">Elranatamab</text><text>Eltrombopag; its salts; its esters; their salts</text><text>Elvitegravir; its salts</text><text>Embutramide</text><text class="first_line_indent_0">Emicizumab</text><text>Empagliflozin; its salts</text><text>Emtricitabine; its salts</text><text>Emylcamate</text><text>Enalapril; its salts</text><text>Enalaprilat; its salts</text><text>Encorafenib; its salts</text><text>Enfortumab vedotin</text><text class="first_line_indent_0">Enfuvirtide</text><text>Enoxacin; its salts; its esters</text><text>Enoxaparin; its salts</text><text>Enoximone</text><text>Enrofloxacin; its salts; its esters</text><text>Ensifentrine; its salts</text><text>Entacapone; its salts</text><text class="first_line_indent_0">Entecavir; its salts; its esters; their salts</text><text>Entrectinib; its salts</text><text>Enzalutamide; its salts</text><text>Epcoritamab</text><text>Eplerenone</text><text class="first_line_indent_0">Epoetin beta</text><text>Eprosartan; its salts</text><text>Eptifibatide; its salts</text><text>Eptinezumab</text><text>Equecabtagene autoleucel</text><text>Erdafitinib; its salts</text><text>Erenumab</text><text>Eribulin; its salts</text><text class="first_line_indent_0">Erlotinib; its salts</text><text>Ertugliflozin; its salts</text><text>Esmolol; its salts</text><text>Esomeprazole; its salts</text><text>Etafenone; its salts</text><text>Etamivan; its salts</text><text class="first_line_indent_0">Etanercept</text><text>Etelcalcetide; its salts</text><text>Ethacrynic acid; its salts</text><text>Ethambutol; its salts</text><text class="first_line_indent_0">Ethchlorvynol</text><text>Ethinamate</text><text>Ethionamide</text><text>Ethoglucid</text><text>Ethoheptazine; its salts</text><text>Ethosuximide; its salts</text><text class="left_indent_12 first_line_indent_-12">Ethylnoradrenaline and its salts when
                contained in aerosol dispensers</text><text class="first_line_indent_0">Etidronic acid; its salts; when contained in
                pharmaceutical products</text><text>Etilefrine; its salts</text><text>Etodolac</text><text>Etofibrate</text><text>Etomidate; its salts</text><text>Etoposide; its esters</text><text class="first_line_indent_0">Etoricoxib; its salts</text><text class="first_line_indent_0">Etranacogene dezaparvovec</text><text>Etrasimod; its salts; its esters; their salts</text><text>Etravirine</text><text>Etretinate</text><text>Etryptamine; its salts</text><text class="first_line_indent_0">Everolimus; its salts; its esters; their salts</text><text class="first_line_indent_0">Evocalcet; its salts; its esters; their salts</text><text>Evolocumab</text><text>Exemestane; its salts</text><text>Exenatide</text><text>Ezetimibe</text><text>Famciclovir; its salts</text><text class="first_line_indent_0">Fampridine; its salts </text><text class="first_line_indent_0">Faricimab</text><text>Febuxostat; its salts; its esters; their salts</text><text>Felodipine</text><text>Fenbufen</text><text>Fencamfamin; its salts</text><text>Fenclofenac; its salts</text><text class="first_line_indent_0">Fendiline; its salts</text><text>Fenfluramine; its salts</text><text>Fenofibrate</text><text class="first_line_indent_0">Fenoprofen; its salts</text><text class="left_indent_12 first_line_indent_-12">Fenoterol and its salts when
                contained in aerosol dispensers</text><text>Fenoxazoline; its salts</text><text>Fentiazac; its salts</text><text>Fenticonazole; its salts</text><text>Feprazone</text><text>Fesoterodine; its salts; its esters; their salts</text><text>Fezolinetant; its salts</text><text>Filgotinib; its salts</text><text class="first_line_indent_0">Filgrastim</text><text>Finasteride</text><text>Finerenone; its salts</text><text>Fingolimod; its salts; its esters; their salts</text><text>Firocoxib; its salts</text><text>Fitusiran; its salts</text><text>Flavoxate; its salts</text><text>Flecainide; its salts</text><text class="first_line_indent_0">Fleroxacin; its salts; its esters</text><text class="first_line_indent_0">Fluanisone</text><text>Fluconazole; its salts</text><text>Fludarabine; its salts</text><text>Flufenamic acid; its salts; its esters; their salts</text><text>Flumazenil</text><text>Flumethrin; its salts</text><text class="first_line_indent_0">Fluorouracil; its derivatives</text><text>Fluoxetine; its salts</text><text>Flupenthixol; its salts</text><text>Fluralaner; its salts</text><text class="first_line_indent_0">Flurbiprofen</text><text>Fluspirilene</text><text>Flutamide</text><text>Fluvastatin</text><text>Fluvoxamine; its salts</text><text>Folinic acid; its salts</text><text class="first_line_indent_0">Fondaparinux; its salts</text><text>Formestane</text><text class="left_indent_12 first_line_indent_-12">Formoterol and its salts when
                contained in aerosol dispensers</text><text>Fosaprepitant; its salts</text><text>Foscarnet trisodium hexahydrate</text><text>Fosinopril; its salts</text><text>Fosnetupitant; its salts</text><text class="first_line_indent_0">Fosphenytoin; its salts</text><text class="first_line_indent_0">Fostamatinib; its salts</text><text>Fotemustine; its salts</text><text>Fremanezumab</text><text>Fruquintinib; its salts</text><text>Frusemide</text><text>Fulvestrant</text><text>Futibatinib; its salts</text><text class="first_line_indent_0">Gabapentin; its salts</text><text>Gadoxetic acid; its salts</text><text>Galcanezumab</text><text>Gallamine; its salts; its quaternary compounds</text><text>Gallium-68; its salts; when contained in pharmaceutical products</text><text>Gallopamil; its salts</text><text>Galsulfase</text><text class="first_line_indent_0">Ganciclovir; its salts</text><text>Ganirelix; its salts</text><text>Gatifloxacin; its salts; its esters</text><text>Gefitinib; its salts</text><text>Gemcitabine; its salts</text><text>Gemfibrozil</text><text class="first_line_indent_0">Gemtuzumab ozogamicin</text><text class="first_line_indent_0">Germanium-68; its salts; when contained in
                pharmaceutical products</text><text class="first_line_indent_0">Gilteritinib; its salts</text><text class="first_line_indent_0">Gimeracil; its salts</text><text>Glecaprevir; its salts</text><text>Glibenclamide</text><text>Glibornuride</text><text>Gliclazide</text><text>Glimepiride; its salts</text><text class="first_line_indent_0">Glipizide</text><text>Gliquidone</text><text>Glofitamab</text><text>Glucagon; its salts</text><text class="left_indent_12 first_line_indent_-12">Glutathione; its salts; its
                derivatives; when contained in products for human parenteral administration</text><text>Glutethimide; its salts</text><text>Glycerol phenylbutyrate</text><text class="first_line_indent_0">Glycopyrronium; its salts</text><text>Glymidine</text><text>Golimumab</text><text>Gonadorelin; its salts</text><text>Goserelin; its salts</text><text>Gozetotide; its salts</text><text>Granisetron; its salts</text><text class="first_line_indent_0">Grazoprevir; its salts</text><text>Grepafloxacin; its salts; its esters</text><text>Guanabenz; its salts</text><text>Guanethidine; its salts</text><text>Guanfacine; its salts</text><text>Guselkumab</text><text class="first_line_indent_0">Halofantrine; its salts</text><text class="left_indent_12 first_line_indent_-12">Halofuginone; its salts; except for
                incorporation in feed for chickens for fattening at levels not exceeding 3 parts per
                million</text><text class="left_indent_12 first_line_indent_-12">Haloperidol and other 4-substituted
                derivatives of N-(3-para-fluorobenzoylpropyl) piperidine</text><text class="left_indent_12 first_line_indent_-12">Hemin; its salts; its esters; their
                salts</text><text>Hexamethylmelamine</text><text>Hexapropymate</text><text>Hexobendine; its salts</text><text class="left_indent_12 first_line_indent_-12">Human chondrocytes when contained in
                advanced therapy products indicated for the repair of symptomatic articular
                cartilage defects</text><text>Human cytomegalovirus immunoglobulin</text><text>Hydralazine; its salts</text><text class="left_indent_12 first_line_indent_-12">Hydrazines, the following and their
                alpha-methyl derivatives—</text><text class="left_indent_24">Benzyl hydrazine</text><text class="left_indent_24">Phenethyl hydrazine</text><text class="left_indent_24">Phenoxyethyl hydrazine</text><text class="left_indent_0 first_line_indent_12">their salts; their acyl derivatives;
                their salts</text><text class="first_line_indent_0">Hydroxychloroquine; its salts</text><text class="left_indent_12 first_line_indent_-12">Hydroxy-N,N-dimethyltryptamines;
                their esters and ethers; any salt of any substance falling within this item</text><text>Hydroxyphenamate</text><text>Hydroxyurea</text><text>Hydroxyzine; its salts</text><text>Ibandronic acid; its salts</text><text class="first_line_indent_0">Ibritumomab tiuxetan</text><text>Ibrutinib; its salts</text><text>Icatibant; its salts; its esters; their salts</text><text class="left_indent_12 first_line_indent_-12">Icosapent ethyl when contained in
                pharmaceutical products indicated for the reduction of the risk of myocardial
                infarction, stroke, coronary revascularization, or unstable angina requiring
                hospitalization</text><text>Idarucizumab</text><text>Idelalisib; its salts</text><text>Idursulfase</text><text>Idursulfase beta</text><text>Ifosfamide</text><text class="first_line_indent_0">Iloprost; its salts</text><text>Imatinib; its salts</text><text>Imdevimab</text><text>Imidapril; its salts</text><text>Imiglucerase</text><text>Imipramine; its salts</text><text class="first_line_indent_0">Imiquimod; its salts</text><text>Inaticabtagene autoleucel</text><text>Inclisiran; its salts</text><text>Indacaterol; its salts; its esters; their salts</text><text>Indinavir; its salts</text><text>Indomethacin; its salts</text><text>Indoprofen; its salts</text><text>Indoramin; its salts</text><text class="first_line_indent_0">Infliximab</text><text>Inosine</text><text>Inosine pranobex</text><text>Inotuzumab ozogamicin</text><text>Interferons</text><text class="first_line_indent_0">Iodine-131; its salts; when contained in
                pharmaceutical products</text><text class="left_indent_12 first_line_indent_-12">Ioflupane Iodine-123; its salts; when
                contained in pharmaceutical products</text><text>Ipilimumab</text><text>Iprindole; its salts</text><text>Iptacopan; its salts</text><text>Irbesartan; its salts</text><text>Irinotecan; its salts</text><text>Isatuximab</text><text class="first_line_indent_0">Isavuconazole; its salts; its derivatives; their
                salts</text><text>Isoaminile; its salts</text><text>Isoetharine; its salts</text><text>Isoflurane</text><text class="left_indent_12 first_line_indent_-12">Isoniazid; its salts; its
                derivatives; their salts; any compound with any substance falling within this
                item</text><text>Isoprenaline; its salts</text><text>Isopyrin; its salts</text><text class="first_line_indent_0">Isotretinoin</text><text>Isoxicam; its salts</text><text>Isradipine</text><text>Itraconazole; its salts</text><text>Ivabradine; its salts</text><text>Ivosidenib; its salts</text><text>Ixazomib; its salts</text><text class="first_line_indent_0">Ixekizumab</text><text>Ketamine; its salts</text><text>Ketanserin; its salts</text><text class="left_indent_12 first_line_indent_-12">Ketoconazole, except when contained
                in preparations for external application only</text><text class="first_line_indent_0">Ketophenylbutazone</text><text>Ketoprofen; its salts</text><text>Ketorolac; its salts; its esters</text><text>Labetalol; its salts</text><text class="first_line_indent_0">Labuvirtide</text><text>Lacidipine; its salts</text><text>Lacosamide; its salts</text><text class="first_line_indent_0">Lamivudine; its salts</text><text>Lamotrigine; its salts</text><text>Lanadelumab</text><text>Lanreotide; its salts</text><text class="first_line_indent_0">Lansoprazole</text><text>Lanthanum carbonate</text><text>Lapatinib; its salts</text><text>Laronidase</text><text>Laropiprant; its salts</text><text>Larotrectinib; its salts</text><text class="first_line_indent_0">Latanoprostene bunod; its salts</text><text class="first_line_indent_0">Lazertinib; its salts</text><text class="first_line_indent_0">Lebrikizumab</text><text class="first_line_indent_0">Lecanemab</text><text class="first_line_indent_0">Ledipasvir; its salts</text><text>Leflunomide; its salts</text><text>Lemborexant; its salts</text><text>Lenacapavir; its salts</text><text>Lenalidomide; its salts</text><text>Lenvatinib; its salts</text><text>Lepirudin; its salts</text><text>Lercanidipine; its salts</text><text class="first_line_indent_0">Letermovir; its salts; its esters; their salts</text><text>Letrozole</text><text>Leuprorelin; its salts</text><text class="first_line_indent_0">Levallorphan; its salts</text><text>Levetiracetam; its salts</text><text>Levosimendan; its salts</text><text>Lidoflazine</text><text class="left_indent_12 first_line_indent_-12">Lignocaine; its salts; when in
                mixture with prilocaine or in mixture with the salts of prilocaine, and intended to
                be used for the treatment of premature ejaculation</text><text class="left_indent_12 first_line_indent_-12">Lignocaine; its salts; when in
                mixture with tetracaine (being an amino alcohol esterified with a derivative of
                benzoic acid) or in mixture with the salts of tetracaine</text><text>Linaclotide; its salts</text><text>Linagliptin; its salts</text><text>Linezolid; its salts</text><text class="first_line_indent_0">Lipegfilgrastim</text><text class="first_line_indent_0">Liraglutide</text><text>Lisdexamfetamine; its salts</text><text>Lisinopril; its salts</text><text>Lithium carbonate</text><text>Lithium sulphate</text><text>Lixisenatide</text><text class="first_line_indent_0">Lomefloxacin; its salts; its esters</text><text>Lomustine</text><text>Lonazolac; its salts</text><text class="first_line_indent_0">Loncastuximab tesirine</text><text class="first_line_indent_0">Lopinavir; its salts</text><text>Loracarbef; its salts</text><text>Lorcainide; its salts</text><text>Lorlatinib; its salts</text><text>Losartan; its salts</text><text>Lotilaner; its salts</text><text>Lovastatin when contained in pharmaceutical products</text><text class="first_line_indent_0">Loxapine; its salts</text><text>Lumefantrine; its salts</text><text>Lurasidone; its salts</text><text>Lurbinectedin; its salts</text><text class="first_line_indent_0">Luspatercept</text><text>Lutetium-177; its salts; when contained in pharmaceutical products</text><text class="first_line_indent_0">Lutetium (177Lu) oxodotreotide; its salts</text><text class="first_line_indent_0">Lutetium (177Lu) vipivotide tetraxetan; its
                salts</text><text class="first_line_indent_0">Lysuride; its salts</text><text>Macitentan; its salts</text><text>Mangafodipir; its salts</text><text>Mannomustine; its salts</text><text>Maprotiline; its salts</text><text>Maralixibat; its salts</text><text>Maraviroc; its salts</text><text class="first_line_indent_0">Marbofloxacin; its salts</text><text class="first_line_indent_0">Maribavir; its salts</text><text class="first_line_indent_0">Marstacimab</text><text>Mavacamten; its salts</text><text>Mazindol</text><text>Mebutamate</text><text class="first_line_indent_0">Mecamylamine; its salts</text><text>Meclofenamic acid; its salts</text><text>Meclofenoxate; its salts</text><text>Medigoxin</text><text>Mefenamic acid; its salts; its esters; their salts</text><text>Mefloquine; its salts</text><text>Mefruside</text><text>Melagatran; its salts; its derivatives; their salts</text><text class="left_indent_12 first_line_indent_-12">Melatonin; its salts; when contained
                in pharmaceutical products intended to be used for the treatment of insomnia</text><text>Melitracen; its salts</text><text class="first_line_indent_0">Meloxicam; its salts</text><text>Memantine; its salts</text><text class="first_line_indent_0">Mephenesin; its esters; their salts</text><text>Mephenoxalone</text><text class="first_line_indent_0">Mepirizole; its salts</text><text>Mepivacaine; its salts</text><text class="first_line_indent_0">Mepolizumab</text><text>Meprobamate</text><text class="first_line_indent_0">Mercaptopurine; its salts; its derivatives; their
                salts</text><text>Meropenem; it salts</text><text class="first_line_indent_0">Mertiatide; its salts; its esters; their salts</text><text>Mesalazine; its salts</text><text class="left_indent_12 first_line_indent_-12">Mescaline; its salts; other
                derivatives of phenethylamine formed by substitution in the aromatic ring; their
                salts</text><text class="first_line_indent_0">Mesocarb; its salts</text><text>Metaflumizone; its salts</text><text class="first_line_indent_0">Metaraminol; its salts</text><text>Metaxalone</text><text class="first_line_indent_0">Metergoline</text><text>Metformin; its salts</text><text class="first_line_indent_0">Methaqualone; its salts</text><text>Methimazole; its salts</text><text class="first_line_indent_0">Methixene; its salts</text><text class="first_line_indent_0">Methocarbamol</text><text>Methoxsalen</text><text class="first_line_indent_0">Methoxyflurane</text><text class="left_indent_12 first_line_indent_-12">Methoxyphenamine and its salts when
                contained in aerosol dispensers</text><text class="left_indent_12 first_line_indent_-12">Methylaminoheptane and its salts when
                contained in aerosol dispensers</text><text>Methyldopa; its esters; their salts</text><text class="first_line_indent_0">Methylnaltrexone; its salts</text><text>Methylpentynol; its derivatives</text><text class="left_indent_12 first_line_indent_-12">alpha-Methylphenethylamine;
                beta-methylphenethylamine; alpha-ethylphenethylamine; beta-ethylphenethylamine;
                their optical isomers; any synthetic compound structurally derived from any of those
                substances by substitution in the aliphatic part or by ring closure therein (or by
                both such substitution and such closure) or by substitution in the aromatic ring
                (with or without substitution at the nitrogen atom), except hydroxyamphetamine,
                methoxy-phenamine, phenylpropanolamine, pholedrine and N-substituted derivatives of
                ephedrine; any salt of any substance falling within this item</text><text class="first_line_indent_0">Methylphenidate; its salts</text><text>Methyprylone</text><text class="first_line_indent_0">Metipranolol; its salts</text><text>Metoclopramide; its salts</text><text class="first_line_indent_0">Metolazone</text><text>Metoprolol; its salts</text><text>Metronidazole; its salts; its esters; their salts</text><text class="first_line_indent_0">Metyrapone; its salts</text><text>Mexiletine; its salts</text><text class="first_line_indent_0">Mianserin; its salts</text><text>Mibefradil; its salts</text><text class="first_line_indent_0">Micafungin; its salts; its esters</text><text class="first_line_indent_0">Midodrine; its salts</text><text>Midostaurin; its salts</text><text class="first_line_indent_0">Mifepristone; its salts; its esters; their
                salts</text><text>Migalastat; its salts</text><text>Miglitol; its salts</text><text class="first_line_indent_0">Milnacipran; its salts</text><text>Milrinone; its salts</text><text class="left_indent_12 first_line_indent_-12">Minoxidil, except when contained in
                preparations intended for external application only and the preparations contain not
                more than 5% of Minoxidil</text><text class="first_line_indent_0">Mirabegron; its salts; its esters; their salts</text><text class="first_line_indent_0">Mirogabalin; its salts; its esters; their salts</text><text>Mirtazapine; its salts</text><text class="first_line_indent_0">Mitobronitol</text><text>Mitopodozide; its salts</text><text class="first_line_indent_0">Mitotane</text><text class="first_line_indent_0">Mitoxantrone; its salts</text><text>Mivacurium; its salts</text><text class="first_line_indent_0">Mizolastine; its salts</text><text>Mobocertinib; its salts</text><text>Moclobemide; its salts</text><text class="first_line_indent_0">Moexipril; its salts</text><text>Mofebutazone; its salts</text><text class="first_line_indent_0">Molgramostim</text><text>Molindone; its salts</text><text class="first_line_indent_0">Molnupiravir; its salts</text><text>Molybdate (99Mo); its salts; when contained in pharmaceutical products</text><text>Momelotinib; its salts</text><text class="first_line_indent_0">Montelukast; its salts</text><text>Moracizine; its salts</text><text class="first_line_indent_0">Moroxydine; its salts</text><text>Mosunetuzumab</text><text class="first_line_indent_0">Moxifloxacin; its salts</text><text>Moxonidine; its salts</text><text class="first_line_indent_0">Muromonab-CD3</text><text class="left_indent_12 first_line_indent_-12">Mustine and any other N-substituted
                derivative of di-(2-chloroethyl) amine; their salts</text><text>Muzolimine</text><text class="first_line_indent_0">Mycophenolic acid; its salts; its esters</text><text>Nabumetone</text><text class="first_line_indent_0">Nadolol; its salts</text><text>Nadroparin; its salts</text><text class="first_line_indent_0">Nafarelin; its salts</text><text>Naftidrofuryl; its salts</text><text class="first_line_indent_0">Nalbuphine; its salts</text><text>Naldemedine; its salts</text><text>Nalidixic acid</text><text class="first_line_indent_0">Nalmefene; its salts</text><text>Nalorphine; its salts</text><text class="first_line_indent_0">Naloxone; its salts</text><text>Naltrexone; its salts</text><text class="first_line_indent_0">alpha-Naphthylacetic acid; its salts</text><text>Naproxen; its salts</text><text class="first_line_indent_0">Naratriptan; its salts</text><text>Natalizumab</text><text class="first_line_indent_0">Nateglinide; its salts; its esters</text><text class="first_line_indent_0">Naxitamab</text><text>Nebivolol; its salts</text><text class="first_line_indent_0">Necitumumab</text><text>Nefazodone; its salts</text><text class="first_line_indent_0">Nefopam; its salts</text><text class="first_line_indent_0">Nelfinavir; its salts</text><text>Neostigmine; its salts</text><text class="first_line_indent_0">Nepafenac; its salts</text><text>Neratinib; its salts</text><text class="first_line_indent_0">Nesiritide</text><text>Netarsudil; its salts</text><text>Netupitant; its salts</text><text class="first_line_indent_0">Nevirapine; its salts</text><text>Nicardipine; its salts</text><text class="first_line_indent_0">Nicergoline</text><text>Nicocodine; its salts</text><text class="left_indent_12 first_line_indent_-12">Nicotinamide mononucleotide when
                contained as an active ingredient in products for human parenteral
                administration</text><text class="left_indent_12 first_line_indent_-12">Nicotinic acid and its salts when
                contained in pharmaceutical products the recommended daily dose of which contains
                more than 200 mg of nicotinic acid</text><text class="first_line_indent_0">Nifedipine</text><text>Nifenazone</text><text class="first_line_indent_0">Niflumic acid; its salts</text><text class="first_line_indent_0">Nifuratel; its salts</text><text class="first_line_indent_0">Nifuroxazide; its salts</text><text class="first_line_indent_0">Nilotinib; its salts</text><text>Nilvadipine</text><text class="first_line_indent_0">Nimesulide; its salts</text><text class="first_line_indent_0">Nimodipine</text><text>Nintedanib; its salts</text><text class="first_line_indent_0">Niraparib; its salts</text><text class="first_line_indent_0">Nirmatrelvir; its salts</text><text>Nirsevimab</text><text class="first_line_indent_0">Nisoldipine</text><text>Nitrendipine</text><text class="first_line_indent_0">Nitrofural; its salts</text><text class="first_line_indent_0">Nitrofurantoin; its salts</text><text class="first_line_indent_0">Nitromethaqualone; its salts</text><text class="first_line_indent_0">Nitroxoline; its salts</text><text class="first_line_indent_0">Nivolumab</text><text>Nomifensine; its salts</text><text class="left_indent_12 first_line_indent_-12">Noramidopyrine methanesulphonate; its
                salts</text><text class="left_indent_12 first_line_indent_-12">Norcodeine; its salts; its esters and
                ethers; their salts</text><text class="first_line_indent_0">Norfloxacin; its salts; its esters</text><text class="first_line_indent_0">Nortriptyline; its salts</text><text>Nusinersen; its salts</text><text class="first_line_indent_0">Obinutuzumab; its antibody drug conjugates</text><text class="first_line_indent_0">Oclacitinib; its salts</text><text>Ocrelizumab</text><text class="first_line_indent_0">Ocriplasmin</text><text>Octreotide; its salts</text><text class="first_line_indent_0">Odevixibat; its salts; its esters; their salts</text><text>Ofatumumab</text><text class="first_line_indent_0">Ofloxacin; its salts; its esters</text><text class="first_line_indent_0">Olanzapine; its salts</text><text>Olaparib; its salts</text><text class="first_line_indent_0">Olaratumab</text><text class="first_line_indent_0">Olmesartan; its salts; its esters; their salts</text><text>Olodaterol; its salts</text><text class="first_line_indent_0">Olsalazine; its salts</text><text class="first_line_indent_0">Omalizumab</text><text>Ombitasvir; its salts</text><text class="left_indent_12 first_line_indent_-12">Omega-3 fatty acids; their salts;
                their esters; when contained in pharmaceutical products intended to be used for the
                treatment of hypertriglyceridaemia</text><text class="first_line_indent_0">Omidenepag; its salts; its esters; their salts</text><text class="first_line_indent_0">Onasemnogene abeparvovec</text><text class="first_line_indent_0">Ondansetron; its salts</text><text class="left_indent_12 first_line_indent_-12">Opipramol; its salts; its
                derivatives; their salts</text><text class="left_indent_12 first_line_indent_-12">Orciprenaline and its salts when
                contained in aerosol dispensers</text><text class="first_line_indent_0">Orgotein</text><text class="left_indent_12 first_line_indent_-12">Orlistat; its salts; except when
                contained in a pharmaceutical product of which the recommended dose is a quantity of
                the product that contains not more than 60 mg of orlistat or its salts, taken 3
                times a day</text><text class="first_line_indent_0">Orphenadrine; its salts</text><text>Oseltamivir; its salts</text><text class="first_line_indent_0">Osimertinib; its salts</text><text>Oteracil; its salts</text><text class="first_line_indent_0">Ouabain</text><text class="first_line_indent_0">Oxaliplatin; its salts</text><text>Oxanamide</text><text class="first_line_indent_0">Oxcarbazepine; its salts</text><text class="first_line_indent_0">Oxprenolol; its salts</text><text>Oxyfedrine; its salts</text><text class="first_line_indent_0">Oxypertine</text><text class="first_line_indent_0">Oxyphenbutazone</text><text>Oxytocins</text><text>Ozanimod; its salts</text><text class="first_line_indent_0">Paclitaxel</text><text class="first_line_indent_0">Palbociclib; its salts</text><text>Paliperidone; its salts</text><text class="first_line_indent_0">Palivizumab</text><text class="first_line_indent_0">Palonosetron; its salts</text><text>Pamidronate; its salts</text><text class="first_line_indent_0">Pancuronium; its salts</text><text>Panitumumab</text><text class="first_line_indent_0">Panobinostat; its salts</text><text class="first_line_indent_0">Pantethine; its salts</text><text class="left_indent_12 first_line_indent_-12">Pantoprazole; its salts; except when
                contained in oral preparations with 20 mg or less per solid dosage unit, indicated
                with the maximum daily dose of 20 mg for relief of heartburn symptoms associated
                with acid reflux in patients of 18 years old or above, and in packs with the maximum
                supply of 7 days</text><text>Paraldehyde</text><text class="first_line_indent_0">Paramethadione</text><text class="first_line_indent_0">Parecoxib; its salts</text><text>Pargyline; its salts</text><text class="first_line_indent_0">Paricalcitol; its salts; its esters; their
                salts</text><text class="first_line_indent_0">Paritaprevir; its salts</text><text>Paroxetine; its salts</text><text class="first_line_indent_0">Pasireotide; its salts</text><text class="first_line_indent_0">Pazopanib; its salts</text><text>Pefloxacin; its salts; its esters</text><text class="first_line_indent_0">Pegaptanib; its salts</text><text class="first_line_indent_0">Pegaspargase</text><text class="first_line_indent_0">Pegfilgrastim</text><text class="first_line_indent_0">Pegunigalsidase alfa</text><text>Pegvisomant; its salts</text><text class="first_line_indent_0">Pembrolizumab</text><text>Pemetrexed; its salts; its esters; their salts</text><text class="first_line_indent_0">Pemigatinib; its salts</text><text class="first_line_indent_0">Pemirolast; its salts</text><text class="first_line_indent_0">Pemoline; its salts</text><text>Pempidine; its salts</text><text class="first_line_indent_0">Penbutolol; its salts</text><text class="first_line_indent_0">Penciclovir; its salts</text><text>Penicillamine; its salts</text><text class="first_line_indent_0">Pentamidine; its salts</text><text class="first_line_indent_0">Pentazocine; its salts</text><text>Pentolinium; its salts</text><text>Pentoxifylline; its salts</text><text class="first_line_indent_0">Perampanel</text><text class="first_line_indent_0">Perflubutane</text><text class="first_line_indent_0">Pergolide; its salts</text><text>Perindoprilat; its salts; its esters; their salts</text><text>Pertechnetate (99mTc); its salts; when contained in pharmaceutical products</text><text>Pertuzumab</text><text class="left_indent_12 first_line_indent_-12">Pharmaceutical products for human
                parenteral administration containing the following or their salts, as active
                ingredients, except in mixture with insulin—</text><text class="left_indent_24">Acetic acid</text><text class="left_indent_24">Acetylcholine</text><text class="left_indent_24">Acetylcysteine</text><text class="left_indent_24">Adenosine</text><text class="left_indent_24">Adrenaline</text><text class="left_indent_24">Ambroxol</text><text class="left_indent_24">Amino acids</text><text class="left_indent_24">Aminophylline</text><text class="left_indent_24">Anti-D (rho) immunoglobulins</text><text class="left_indent_24">Antihistamine substances</text><text class="left_indent_24">Betiatide</text><text class="left_indent_24">Bicisate</text><text class="left_indent_24">Butetamate</text><text class="left_indent_24">Caffeine</text><text class="left_indent_24">Carnitine</text><text class="left_indent_36 first_line_indent_-12">Cations, the following, except in
                preparations containing any substance to which the Antibiotics Ordinance (<ref href="/hk/cap137">Cap. 137</ref>) applies—</text><text class="left_indent_48">Calcium</text><text class="left_indent_48">Chromium</text><text class="left_indent_48">Copper</text><text class="left_indent_48">Iron</text><text class="left_indent_48">Magnesium</text><text class="left_indent_48">Manganese</text><text class="left_indent_48">Potassium</text><text class="left_indent_48">Selenium</text><text class="left_indent_48">Sodium, except sodium chloride 0.9%</text><text class="left_indent_48">Zinc</text><text class="left_indent_24">Choline</text><text class="left_indent_24">Cimetidine</text><text class="left_indent_24">Citicoline</text><text class="left_indent_24">Deoxycholic acid</text><text class="left_indent_24">Dextromethorphan</text><text class="left_indent_24">Dicycloverine</text><text class="left_indent_24">Difenidol</text><text class="left_indent_24">Diprophylline</text><text class="left_indent_24">Disofenin</text><text class="left_indent_24">Ephedrine</text><text class="left_indent_24">Exametazime</text><text class="left_indent_24">Fish oil</text><text class="left_indent_24">Fluorescein</text><text class="left_indent_24">Gallium</text><text class="left_indent_24">Gelatin</text><text class="left_indent_24">Glucosamine</text><text class="left_indent_24">Glucose</text><text class="left_indent_24">Glycerol</text><text class="left_indent_24">Glyceryl trinitrate</text><text class="left_indent_24">Guaifenesin</text><text class="left_indent_24">Heparin</text><text class="left_indent_24">Hyaluronic acid</text><text class="left_indent_24">Hyaluronidase</text><text class="left_indent_24">Hydroxyethyl starch</text><text class="left_indent_24">Hyoscine</text><text class="left_indent_24">Ibuprofen</text><text class="left_indent_24">Icodextrin</text><text class="left_indent_24">Indigo carmine</text><text class="left_indent_24">Indocyanine green</text><text class="left_indent_24">Iodine norcholesterol</text><text class="left_indent_24">Isosorbide</text><text class="left_indent_24">Lactic acid</text><text class="left_indent_24">Lecithin</text><text class="left_indent_24">Lignocaine</text><text class="left_indent_24">Mannitol</text><text class="left_indent_24">Mebrofenin</text><text class="left_indent_24">Medronic acid</text><text class="left_indent_24">Mesna</text><text class="left_indent_24">Methoxyphenamine</text><text class="left_indent_24">Methylene blue</text><text class="left_indent_24">Methylephedrine</text><text class="left_indent_24">Noradrenaline</text><text class="left_indent_24">Olive oil</text><text class="left_indent_24">Omeprazole</text><text class="left_indent_24">Oxidronate</text><text class="left_indent_24">Papaverine</text><text class="left_indent_24">Paracetamol</text><text class="left_indent_24">Patent blue V</text><text class="left_indent_24">Pentetic acid</text><text class="left_indent_24">Phenol</text><text class="left_indent_24">Phenylephrine</text><text class="left_indent_24">Procaine</text><text class="left_indent_24">Protamine</text><text class="left_indent_24">Ranitidine</text><text class="left_indent_24">Rhenium</text><text class="left_indent_24">Sodium chloride 0.9%</text><text class="left_indent_24">Sodium pyrophosphate</text><text class="left_indent_24">Sodium tetradecyl sulfate</text><text class="left_indent_24">Sodium thiosulfate</text><text class="left_indent_24">Sorbitol</text><text class="left_indent_24">Soya oil</text><text class="left_indent_24">Stonefish antivenom</text><text class="left_indent_24">Succimer</text><text class="left_indent_24">Terbutaline</text><text class="left_indent_24">Tetrakis copper tetrafluoroborate</text><text class="left_indent_24">Tetrofosmin</text><text class="left_indent_24">Thallium</text><text class="left_indent_24">Tin</text><text class="left_indent_24">Triglycerides</text><text class="left_indent_24">Tuberculin</text><text class="left_indent_24">Vitamins</text><text class="left_indent_24">Water</text><text class="left_indent_24">Xantinol nicotinate</text><text>Phenacemide</text><text>Phenacetin</text><text>Phenaglycodol</text><text>Phenbutrazate</text><text>Phencyclidine; its salts</text><text>Phenetidylphenacetin</text><text>Phenformin; its salts</text><text>Phenindione</text><text class="left_indent_12 first_line_indent_-12">Phenothiazine; its salts; its
                derivatives (except dimethoxanate and promethazine); their salts (except salts of
                dimethoxanate and promethazine); any compound with any substance falling within this
                item</text><text>Phenoxybenzamine; its salts</text><text>Phenprenazone</text><text>Phenprobamate</text><text>Phentolamine; its salts</text><text>Phenylbutazone; its salts</text><text class="left_indent_12 first_line_indent_-12">2-Phenylcinchoninic acid;
                2-salicylcinchoninic acid; their salts; their esters</text><text class="left_indent_12 first_line_indent_-12">5-Phenylhydantoin; its alkyl and aryl
                derivatives; their salts</text><text class="left_indent_12 first_line_indent_-12">Phospholipid fraction; when contained
                in pharmaceutical products intended to be used as pulmonary surfactant for the
                treatment of respiratory distress syndrome</text><text>Pibrentasvir; its salts</text><text>Picrotoxin</text><text>Pimecrolimus</text><text>Pimobendan; its salts</text><text>Pioglitazone; its salts</text><text>Pipecuronium; its salts</text><text>Pipemidic acid</text><text>Pipobroman</text><text class="first_line_indent_-24 left_indent_24 ">Piracetam; its salts</text><text>Pirfenidone; its salts</text><text>Piromidic acid; its salts</text><text class="left_indent_12 first_line_indent_-12">Piroxicam, except when contained in
                preparations for external application only</text><text class="first_line_indent_0">Pirprofen; its salts</text><text class="first_line_indent_0">Pirtobrutinib; its salts</text><text>Pitavastatin; its salts; its esters; their salts</text><text>Pitolisant; its salts</text><text class="left_indent_12 first_line_indent_-12">Pituitary gland, the active
                principles of, other than corticotrophins, oxytocins and vasopressins, except when
                contained in inhalants or in preparations intended for external application
                only</text><text>Pizotifen; its salts</text><text>Plerixafor; its salts</text><text>Polatuzumab vedotin</text><text>Polymethylenebistrimethylammonium salts</text><text>Pomalidomide; its salts</text><text>Ponatinib; its salts</text><text class="first_line_indent_0">Ponesimod; its salts</text><text>Poractant alfa</text><text>Porfimer; its salts</text><text>Posaconazole; its salts; its esters; their salts</text><text>Pralidoxime; its salts</text><text>Pralsetinib; its salts </text><text>Pramipexole; its salts</text><text>Prasterone; its salts; when contained in pharmaceutical products</text><text>Prasugrel; its salt</text><text>Pravastatin; its salts; its esters</text><text>Prazosin; its salts</text><text>Pregabalin; its salts</text><text>Pretomanid; its salts</text><text>Pridinol; its salts</text><text>Primaquine; its salts</text><text>Primidone</text><text>Prindolol; its salts</text><text>Probenecid</text><text>Probucol</text><text>Procainamide; its salts</text><text>Procarbazine; its salts</text><text class="left_indent_12 first_line_indent_-12">Procaterol and its salts when
                contained in aerosol dispensers</text><text>Proglumetacin; its salts</text><text>Proguanil; its salts</text><text>Promoxolane</text><text>Propafenone; its salts</text><text>Propanidid</text><text>Propiverine; its salts</text><text>Propofol</text><text>Propoxur; its salts</text><text class="left_indent_12 first_line_indent_-12">Propranolol; its salts; its
                derivatives; their salts</text><text class="left_indent_12 first_line_indent_-12">Propylhexedrine and its salts, except
                when contained in inhalers</text><text>Propylthiouracil; its salts</text><text>Proquazone</text><text></text><text></text><text></text><text></text><text class="left_indent_12 first_line_indent_-12">Prostaglandins, the following and
                their derivatives—</text><text class="left_indent_24">Alprostadil</text><text class="left_indent_24">Bimatoprost</text><text class="left_indent_24">Dinoprost</text><text class="left_indent_24">Dinoprostone</text><text class="left_indent_24">Epoprostenol</text><text class="left_indent_24">Latanoprost</text><text class="left_indent_24">Misoprostol</text><text class="left_indent_24">Travoprost</text><text class="left_indent_24">Unoprostone</text><text class="left_indent_0 first_line_indent_12">their salts; their esters</text><text>Prothionamide</text><text>Prothipendyl; its salts</text><text>Protirelin; its salts</text><text class="left_indent_12 first_line_indent_-12">Protriptyline; its salts; its
                derivatives; their salts</text><text class="first_line_indent_0">Prucalopride; its salts</text><text>Prulifloxacin; its salts; its esters; their salts</text><text>Pyrazinamide</text><text>Pyricarbate (Pyridinolcarbamate)</text><text>Pyridostigmine; its salts</text><text>Pyrimethamine</text><text>Pyriprole; its salts</text><text>Pyrithyldione</text><text>Quetiapine; its salts</text><text>Quinagolide; its salts</text><text>Quinapril; its salts</text><text>Quinethazone</text><text>Quinidine; its salts</text><text class="left_indent_12 first_line_indent_-12">Quinine; its salts; its derivatives;
                their salts; except in preparations containing less than 10% of quinine, its salts,
                its derivatives or their salts</text><text>Quizartinib; its salts</text><text>Rabeprazole; its salts</text><text>Racecadotril; its salts</text><text>Ractopamine; its salts</text><text class="left_indent_12 first_line_indent_-12">Radium-223; its salts; when contained
                in pharmaceutical products</text><text>Raloxifene; its salts</text><text>Raltegravir; its salts</text><text>Raltitrexed; its salts</text><text>Ramipril; its salts</text><text>Ramucirumab</text><text>Ranibizumab</text><text>Ranolazine; its salts</text><text>Rasagiline; its salts</text><text>Rasburicase; its salts</text><text>Ravulizumab</text><text>Reboxetine; its salts</text><text>Recombinant human erythropoietin</text><text>Regadenoson; its salts</text><text>Regorafenib; its salts</text><text>Remdesivir; its salts</text><text>Remifentanil; its salts</text><text>Remoxipride; its salts</text><text>Repaglinide; its salts; its esters</text><text>Repotrectinib; its salts</text><text class="left_indent_12 first_line_indent_-12">Reproterol and its salts when
                contained in aerosol dispensers</text><text>Rescinnamine</text><text>Reteplase</text><text>Retigabine; its salts</text><text>Revefenacin; its salts</text><text>Reviparin; its salts</text><text>Ribavirin; its salts</text><text>Ribociclib; its salts</text><text>Rilmenidine; its salts</text><text>Rilpivirine; its salts</text><text>Riluzole; its salts</text><text>Rimegepant; its salts</text><text class="left_indent_12 first_line_indent_-12">Rimiterol and its salts when
                contained in aerosol dispensers</text><text>Rimonabant; its salts</text><text>Riociguat; its salts</text><text>Ripretinib; its salts</text><text>Risankizumab</text><text>Risdiplam; its salts</text><text>Risedronic acid; its salts</text><text>Risperidone</text><text>Ritlecitinib; its salts</text><text>Ritodrine; its salts</text><text>Ritonavir; its salts</text><text>Rituximab</text><text>Rivaroxaban; its salts</text><text>Rivastigmine; its salts</text><text>Rizatriptan; its salts</text><text>Rocuronium; its salts</text><text>Rofecoxib; its salts</text><text>Roflumilast; its salts</text><text>Romiplostim</text><text>Romosozumab</text><text>Ropeginterferon alfa-2b</text><text>Ropinirole; its salts</text><text>Ropivacaine; its salts</text><text>Rosiglitazone; its salts</text><text>Rosoxacin; its salts</text><text>Rosuvastatin; its salts</text><text>Rotigotine; its salts</text><text>Roxadustat; its salts</text><text>Rufinamide; its salts</text><text>Rurioctocog alfa pegol</text><text>Ruxolitinib; its salts</text><text>Sacituzumab govitecan</text><text class="left_indent_12 first_line_indent_-12">Sacubitril; its salts</text><text class="left_indent_12 first_line_indent_-12">Safinamide; its salts</text><text class="left_indent_12 first_line_indent_-12">Salbutamol and its salts, except when
                contained in aerosol dispensers</text><text class="left_indent_12 first_line_indent_-12">Salmeterol and its salts when
                contained in aerosol dispensers</text><text>Saquinavir; its salts</text><text>Sarilumab</text><text>Satralizumab</text><text>Savolitinib; its salts</text><text>Saxagliptin; its salts</text><text>Sebelipase alfa</text><text>Secukinumab</text><text>Selexipag; its salts</text><text>Selinexor; its salts</text><text>Selpercatinib; its salts</text><text class="first_line_indent_0">Selumetinib; its salts</text><text>Semaglutide</text><text>Sermorelin; its salts</text><text>Sertindole; its salts</text><text>Sertraline; its salts</text><text>Sevelamer; its salts</text><text>Sevoflurane</text><text class="left_indent_12 first_line_indent_-12">Sibutramine; its salts; any compound
                containing the chemical structure of
                1-[1-(4-Chlorophenyl)cyclobutyl]-3-methylbutan-1-amine substituted to any degree or
                without substitution; its salts</text><text class="left_indent_12 first_line_indent_-12">Sildenafil; its salts; any compound
                containing the chemical structure of
                    5-(2-ethoxyphenyl)-1-methyl-3-propyl-1<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7(6<i>H</i>)-one
                substituted to any degree or without substitution; its salts</text><text>Silodosin; its salts</text><text>Siltuximab</text><text>Simeprevir; its salts</text><text>Simvastatin</text><text>Sintilimab</text><text>Siponimod; its salts; its esters; their salts</text><text>Sirolimus; its salts</text><text>Sitagliptin; its salts</text><text>Socazolimab</text><text>Sodium aurothiomalate</text><text>Sodium nitroprusside</text><text>Sodium zirconium cyclosilicate</text><text>Sofosbuvir; its salts</text><text>Solifenacin; its salts; its esters; their salts</text><text>Solriamfetol; its salts</text><text>Somapacitan</text><text>Somatostatin</text><text>Somatrogon</text><text>Sorafenib; its salts</text><text>Sotalol; its salts</text><text>Sotatercept</text><text>Sotorasib; its salts</text><text>Sparfloxacin; its salts; its esters</text><text>Sparteine; its salts</text><text>Spesolimab</text><text>Spinosad</text><text>Spironolactone</text><text>Stavudine; its salts</text><text>Stiripentol; its salts</text><text>Streptokinase</text><text>Strontium ranelate</text><text>Strophanthus, glycosides of </text><text>Styramate</text><text>Sucroferric oxyhydroxide</text><text>Sugammadex; its salts; its esters; their salts</text><text>Sulindac</text><text>Sulphinpyrazone</text><text>Sulphonal; alkyl sulphonals</text><text>Sulpiride</text><text>Sultopride</text><text>Sumatriptan; its salts</text><text>Sunitinib; its salts</text><text class="left_indent_12 first_line_indent_-12">Suprarenal gland, the active
                principles of, except adrenaline and noradrenaline (other than when contained in
                aerosol dispensers); their salts; except salts of adrenaline (other than when
                contained in aerosol dispensers); their derivatives; their salts; except
                hydrocortisone and its salts when contained in preparations intended for external
                application only at not more than 1%; except beclomethasone and its salts when
                contained in aerosol dispensers and except clobetasone butyrate when contained in
                preparations intended for external application only at not more than 0.05%</text><text>Surufatinib; its salts</text><text>Sutoprofen; its salts</text><text>Suxamethonium; its salts</text><text>Syrosingopine</text><text>Tacrine; its salts</text><text>Tacrolimus</text><text class="left_indent_12 first_line_indent_-12">Tadalafil; its salts; any compound
                containing the chemical structure of
                6-(Benzo[1,3]dioxol-5-yl)-2,3,6,7,12,12a-hexahydropyrazino[1’,2’:1,6]
                    pyrido[3,4-<i>b</i>]indole-1,4-dione substituted to any degree or without
                substitution; its salts</text><text>Tafamidis; its salts</text><text>Tafasitamab</text><text>Tafluprost</text><text>Tagraxofusp</text><text>Talazoparib; its salts</text><text>Talquetamab</text><text>Tamoxifen; its salts</text><text>Tapentadol; its salts </text><text>Tarlatamab</text><text>Tazarotene; its salts</text><text>Tazemetostat; its salts</text><text>Teclistamab</text><text>Tegaserod; its salts</text><text>Telbivudine; its salts</text><text>Telmisartan; its salts</text><text>Temozolomide; its salts</text><text>Temsirolimus; its salts; its esters</text><text>Tenapanor; its salts</text><text>Tenecteplase; its salts</text><text>Teniposide</text><text>Tenofovir; its salts; its derivatives; their salts</text><text>Tenoxicam</text><text class="first_line_indent_0">Tepotinib; its salts</text><text class="first_line_indent_0">Teprotumumab</text><text>Terazosin; its salts</text><text class="left_indent_12 first_line_indent_-12">Terbinafine; its salts; except when
                contained in preparations for external application only</text><text class="left_indent_12 first_line_indent_-12">Terbutaline and its salts when
                contained in aerosol dispensers</text><text>Teriflunomide; its salts</text><text>Teriparatide; its salts</text><text>Terodiline; its salts</text><text>Tertatolol; its salts</text><text>Tetrabenazine; its salts</text><text>Tetracosactide; its salts</text><text>Tezepelumab</text><text>Thalidomide; its salts</text><text>Theofibrate</text><text>Thiacetazone</text><text>Thiocarlide; its salts</text><text class="left_indent_12 first_line_indent_-12">Thioctic acid; its salts; its
                derivatives; when contained in pharmaceutical products</text><text>Thiotepa</text><text>Thymosin alpha 1</text><text class="left_indent_12 first_line_indent_-12">Thyroid gland, the active principles
                of; their salts</text><text>Thyrotropin alfa</text><text>Tiagabine; its salts; its esters; their salts</text><text>Tianeptine; its salts; its esters; their salts</text><text>Tiapride; its salts</text><text>Ticagrelor; its salts; its esters; their salts</text><text>Ticlopidine; its salts</text><text>Tildrakizumab</text><text>Tiletamine; its salts</text><text>Tilidate; its salts</text><text>Tiludronic acid; its salts</text><text>Timolol; its salts</text><text>Tinoridine; its salts</text><text>Tinzaparin; its salts</text><text>Tiotropium; its salts</text><text class="left_indent_12 first_line_indent_-12">Tipiracil; its salts; when contained
                in pharmaceutical products</text><text>Tiratricol; its salts</text><text>Tirofiban; its salts</text><text>Tirzepatide</text><text>Tisagenlecleucel</text><text>Tislelizumab</text><text>Tisotumab vedotin</text><text>Tixagevimab</text><text>Tizanidine; its salts</text><text>Tocainide; its salts</text><text>Tocilizumab</text><text>Todralazine; its salts</text><text>Tofacitinib; its salts</text><text>Tofenacin; its salts</text><text>Tolazamide</text><text>Tolbutamide</text><text>Tolcapone; its salts</text><text>Tolfenamic acid; its salts</text><text>Tolmetin; its salts</text><text>Tolperisone; its salts</text><text>Tolterodine; its salts</text><text>Tolvaptan</text><text class="left_indent_12 first_line_indent_-12">para-Tolylmethylcarbinol nicotinic
                acid ester</text><text>Topiramate; its salts</text><text>Topotecan; its salts</text><text>Torasemide</text><text>Toripalimab</text><text>Trabectedin; its salts; its esters</text><text>Tramadol; its salts</text><text>Trametinib; its salts</text><text>Trandolapril; its salts</text><text class="left_indent_12 first_line_indent_-12">Tranexamic acid, except when
                contained in toothpaste at 0.05% by weight</text><text>Tranylcypromine; its salts</text><text>Trastuzumab; its antibody drug conjugates</text><text>Trazodone; its salts</text><text>Tremelimumab</text><text>Treosulfan; its salts</text><text>Treprostinil; its salts; its esters; their salts</text><text>Tretamine; its salts</text><text>Tretinoin</text><text>Triamterene; its salts</text><text>Triaziquone</text><text>Tribromoethyl alcohol</text><text>2,2,2-Trichloroethyl alcohol, esters of; their salts</text><text class="left_indent_12 first_line_indent_-12">Trientine; its salts; when contained
                in pharmaceutical products</text><text>Trifarotene; its salts; its esters; their salts</text><text>Trifluridine; its salts</text><text>Trilostane</text><text>Trimetaphan; its salts</text><text>Trimetazidine; its salts</text><text>Trimethadione</text><text>Trimethoprim</text><text>Trimetozine</text><text>Trimetrexate; its salts</text><text>Trimipramine; its salts</text><text>Trioxsalen</text><text>Triptorelin; its salts</text><text class="left_indent_12 first_line_indent_-12">Tromantadine; its salts; except when
                contained in pharmaceutical products labelled for the treatment of cold sores
                only</text><text class="first_line_indent_0">Tropisetron; its salts</text><text class="first_line_indent_0">Trospium chloride</text><text class="left_indent_12 first_line_indent_-12">Trovafloxacin; its salts; its
                derivatives; their salts</text><text class="left_indent_12 first_line_indent_-12">Tucatinib; its salts</text><text class="left_indent_12 first_line_indent_-12">Tulobuterol and its salts when
                contained in aerosol dispensers</text><text>Tybamate</text><text>Umeclidinium; its salts</text><text>Upadacitinib; its salts</text><text>Urapidil; its salts</text><text>Urethane</text><text>Urokinase</text><text>Ustekinumab</text><text>Valaciclovir; its salts</text><text>Valdecoxib; its salts</text><text>Valganciclovir; its salts</text><text>Valnoctamide</text><text>Valproic acid; its salts; its esters</text><text>Valsartan; its salts</text><text>Vandetanib; its salts</text><text class="left_indent_12 first_line_indent_-12">Vardenafil; its salts; any compound
                containing the chemical structure of
                    2-(2-ethoxyphenyl)-5-methyl-7-propylimidazo[5,1-<i>f</i>][1,2,4]triazin-4(3<i>H</i>)-one
                substituted to any degree or without substitution; its salts</text><text>Varenicline; its salts</text><text>Vasopressins</text><text>Vecuronium; its salts</text><text>Vedolizumab</text><text>Velmanase alfa</text><text>Velpatasvir; its salts</text><text>Vemurafenib; its salts</text><text>Venetoclax; its salts</text><text>Venlafaxine; its salts</text><text>Veralipride; its salts</text><text>Verapamil; its salts</text><text>Vericiguat; its salts</text><text>Vernakalant; its salts</text><text>Verteporfin; its salts</text><text>Vidarabine; its salts</text><text>Vigabatrin</text><text>Vilanterol; its salts</text><text>Vildagliptin; its salts</text><text>Viloxazine; its salts</text><text>Vindesine; its salts</text><text>Vinorelbine; its salts</text><text>Vismodegib; its salts</text><text class="left_indent_12 first_line_indent_-12">Vitamin A and its esters when
                contained in pharmaceutical products the recommended daily dose of which contains
                not less than 10,000 international units of vitamin A</text><text class="left_indent_12 first_line_indent_-12">Vitamin D and its salts when
                contained in pharmaceutical products the recommended daily dose of which contains
                more than 1,000 international units of vitamin D</text><text class="left_indent_12 first_line_indent_-12">Vitamin K and its salts when
                contained in pharmaceutical products, except products with recommended daily dose of
                120 mcg or less of vitamin K1 or K2 or its salts</text><text>Vonoprazan; its salts</text><text>Voriconazole; its salts</text><text>Vortioxetine; its salts</text><text>Vosoritide</text><text>Voxilaprevir; its salts</text><text>Vutrisiran; its salts</text><text>Warfarin; its salts</text><text>Xamoterol; its salts</text><text>Xylazine; its salts</text><text>Zafirlukast</text><text>Zalcitabine; its salts</text><text>Zaleplon; its salts</text><text>Zanamivir; its salts</text><text>Zanubrutinib; its salts</text><text>Zidovudine</text><text>Zimelidine; its salts</text><text>Zipeprol; its salts</text><text>Ziprasidone; its salts</text><text>Zofenopril; its salts</text><text>Zolazepam; its salts</text><text>Zolbetuximab</text><text>Zoledronic acid; its salts</text><text>Zolmitriptan; its salts</text><text>Zolpidem; its salts</text><text>Zomepirac; its salts</text><text>Zopiclone</text><text>Zoxazolamine; its salts</text><sourceNote class="align_justified">(<ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>; <ref href="/hk/1980/ln369">L.N. 369 of 1980</ref>; <ref href="/hk/1984/ln415">L.N. 415 of 1984</ref>; <ref href="/hk/1986/ln129">L.N. 129 of 1986</ref>; <ref href="/hk/1987/ln130">L.N. 130 of 1987</ref>; <ref href="/hk/1989/ln197">L.N.
                    197 of 1989</ref>; <ref href="/hk/1990/ln128">L.N. 128 of 1990</ref>; <ref href="/hk/1995/ln262">L.N. 262 of 1995</ref>; <ref href="/hk/1998/ln130">L.N.
                    130 of 1998</ref>; <ref href="/hk/1999/ln22">L.N. 22 of 1999</ref>; <ref href="/hk/1999/ln202">L.N. 202 of 1999</ref>; <ref href="/hk/2000/ln30">L.N. 30
                    of 2000</ref>; <ref href="/hk/2000/ln138">L.N. 138 of 2000</ref>; <ref href="/hk/2000/ln235">L.N. 235 of 2000</ref>; <ref href="/hk/2000/ln296">L.N.
                    296 of 2000</ref>; <ref href="/hk/2001/ln51">L.N. 51 of 2001</ref>; <ref href="/hk/2001/ln143">L.N. 143 of 2001</ref>; <ref href="/hk/2001/ln173">L.N.
                    173 of 2001</ref>; <ref href="/hk/2001/ln287">L.N. 287 of 2001</ref>; <ref href="/hk/2002/ln56">L.N. 56 of 2002</ref>; <ref href="/hk/2002/ln112">L.N. 112
                    of 2002</ref>; <ref href="/hk/2002/ln132">L.N. 132 of 2002</ref>; <ref href="/hk/2002/ln170">L.N. 170 of 2002</ref>; <ref href="/hk/2002/ln237">L.N.
                    237 of 2002</ref>; <ref href="/hk/2003/ln73">L.N. 73 of 2003</ref>; <ref href="/hk/2003/ln179">L.N. 179 of 2003</ref>; <ref href="/hk/2003/ln181">L.N.
                    181 of 2003</ref>; <ref href="/hk/2003/ln273">L.N. 273 of 2003</ref>; <ref href="/hk/2003/ln276">L.N. 276 of 2003</ref>; <ref href="/hk/2004/ln74">L.N. 74
                    of 2004</ref>; <ref href="/hk/2004/ln135">L.N. 135 of 2004</ref>; <ref href="/hk/2004/ln191">L.N. 191 of 2004</ref>; <ref href="/hk/2005/ln11">L.N. 11
                    of 2005</ref>; <ref href="/hk/2005/ln72">L.N. 72 of 2005</ref>; <ref href="/hk/2005/ln114">L.N. 114 of 2005</ref>; <ref href="/hk/2005/ln212">L.N.
                    212 of 2005</ref>; <ref href="/hk/2006/ln25">L.N. 25 of 2006</ref>; <ref href="/hk/2006/ln122">L.N. 122 of 2006</ref>; <ref href="/hk/2006/ln178">L.N.
                    178 of 2006</ref>; <ref href="/hk/2006/ln223">L.N. 223 of 2006</ref>; <ref href="/hk/2006/ln277">L.N. 277 of 2006</ref>; <ref href="/hk/2007/ln41">L.N. 41
                    of 2007</ref>; <ref href="/hk/2007/ln98">L.N. 98 of 2007</ref>; <ref href="/hk/2007/ln143">L.N. 143 of 2007</ref>; <ref href="/hk/2007/ln208">L.N.
                    208 of 2007</ref>; <ref href="/hk/2007/ln239">L.N. 239 of 2007</ref>; <ref href="/hk/2008/ln61">L.N. 61 of 2008</ref>; <ref href="/hk/2008/ln113">L.N. 113
                    of 2008</ref>; <ref href="/hk/2008/ln197">L.N. 197 of 2008</ref>; <ref href="/hk/2008/ln234">L.N. 234 of 2008</ref>; <ref href="/hk/2008/ln282">L.N.
                    282 of 2008</ref>; <ref href="/hk/2009/ln90">L.N. 90 of 2009</ref>; <ref href="/hk/2009/ln147">L.N. 147 of 2009</ref>; <ref href="/hk/2009/ln199">L.N.
                    199 of 2009</ref>; <ref href="/hk/2009/ln258">L.N. 258 of 2009</ref>; <ref href="/hk/2010/ln11">L.N. 11 of 2010</ref>; <ref href="/hk/2010/ln32">L.N. 32 of
                    2010</ref>; <ref href="/hk/2010/ln81">L.N. 81 of 2010</ref>; <ref href="/hk/2010/ln104">L.N. 104 of 2010</ref>; <ref href="/hk/2010/ln140">L.N.
                    140 of 2010</ref>; <ref href="/hk/2011/ln23">L.N. 23 of 2011</ref>; <ref href="/hk/2011/ln127">L.N. 127 of 2011</ref>; <ref href="/hk/2012/ln33">L.N. 33
                    of 2012</ref>; <ref href="/hk/2012/ln124">L.N. 124 of 2012</ref>; <ref href="/hk/2012/ln179">L.N. 179 of 2012</ref>; <ref href="/hk/2013/ln19">L.N. 19
                    of 2013</ref>; <ref href="/hk/2013/ln94">L.N. 94 of 2013</ref>; <ref href="/hk/2013/ln98">L.N. 98 of 2013</ref>; <ref href="/hk/2013/ln125">L.N. 125
                    of 2013</ref>; <ref href="/hk/2013/ln158">L.N. 158 of 2013</ref>; <ref href="/hk/2013/ln195">L.N. 195 of 2013</ref>; <ref href="/hk/2014/ln39">L.N. 39
                    of 2014</ref>; <ref href="/hk/2014/ln134">L.N. 134 of 2014</ref>; <ref href="/hk/2015/2">2 of 2015 s. 67</ref>; <ref href="/hk/2015/ln34">L.N. 34 of
                    2015</ref>; <ref href="/hk/2015/ln67">L.N. 67 of 2015</ref>; <ref href="/hk/2015/ln100">L.N. 100 of 2015</ref>; <ref href="hk/2015/ln193">L.N. 193
                    of 2015</ref>; <ref href="hk/2015/ln235">L.N. 235 of 2015</ref>; <ref href="hk/2016/ln40">L.N. 40 of 2016</ref>; <ref href="hk/2016/ln51">L.N. 51 of
                    2016</ref>; <ref href="hk/2016/ln83">L.N. 83 of 2016</ref>; <ref href="hk/2016/ln119">L.N. 119 of 2016</ref>; <ref href="hk/2016/ln172">L.N. 172
                    of 2016</ref>; <ref href="hk/2017/ln11">L.N. 11 of 2017</ref>; <ref href="hk/2017/ln38">L.N. 38 of 2017</ref>; <ref href="hk/2017/ln119">L.N. 119 of
                    2017</ref>; <ref href="hk/2017/ln140">L.N. 140 of 2017</ref>; <ref href="hk/2017/ln167">L.N. 167 of 2017</ref>; <ref href="hk/2018/ln10">L.N. 10 of
                    2018</ref>; <ref href="hk/2018/ln42">L.N. 42 of 2018</ref>; <ref href="hk/2018/ln80">L.N. 80 of 2018</ref>; <ref href="hk/2018/ln136">L.N. 136 of
                    2018</ref>; <ref href="hk/2018/ln191">L.N. 191 of 2018</ref>; <ref href="hk/2018/ln210">L.N. 210 of 2018</ref>; <ref href="hk/2018/ln228">L.N. 228
                    of 2018</ref>; <ref href="hk/2019/ln3">L.N. 3 of 2019</ref>; <ref href="hk/2019/ln10">L.N. 10 of 2019</ref>; <ref href="hk/2019/ln30">L.N. 30 of
                    2019</ref>; <ref href="hk/2019/ln145">L.N. 145 of 2019</ref>; <ref href="hk/2019/ln184">L.N. 184 of 2019</ref>; <ref href="hk/2020/ln14">L.N. 14 of
                    2020</ref>; <ref href="hk/2020/ln41">L.N. 41 of 2020</ref>; <ref href="hk/2020/ln126">L.N. 126 of 2020</ref>; <ref href="/hk/2020/er5">E.R. 5 of
                    2020</ref>; <ref href="hk/2020/ln212">L.N. 212 of 2020</ref>; <ref href="hk/2020/ln252">L.N. 252 of 2020</ref>; <ref href="hk/2021/ln104">L.N. 104
                    of 2021</ref>; <ref href="hk/2021/ln218">L.N. 218 of 2021</ref>; <ref href="hk/2022/ln1">L.N. 1 of 2022</ref>; <ref href="hk/2022/ln19">L.N. 19 of
                    2022</ref>; <ref href="hk/2022/ln33">L.N. 33 of 2022</ref>; <ref href="hk/2022/ln122">L.N. 122 of
                2022</ref>; <ref href="hk/2022/ln194">L.N. 194 of
                2022</ref>; <ref href="hk/2022/ln232">L.N. 232 of 2022</ref>; <ref href="hk/2023/ln10">L.N.
                    10 of
                2023</ref>; <ref href="hk/2023/ln108">L.N. 108 of
                2023</ref>; <ref href="hk/2023/ln138">L.N. 138 of
                2023</ref>; <ref href="hk/2024/ln9">L.N. 9 of
                2024</ref>; <ref href="hk/2024/ln73">L.N. 73 of
                2024</ref>; <ref href="hk/2024/ln105">L.N. 105 of
                2024</ref>; <ref href="hk/2024/ln135">L.N. 135 of
                2024</ref>; <ref href="hk/2024/ln177">L.N. 177 of
                2024</ref>; <ref href="hk/2025/ln5">L.N. 5 of 2025</ref>; <ref href="hk/2025/ln38">L.N. 38
                    of
                2025</ref>; <ref href="hk/2025/ln116">L.N. 116 of 2025</ref>; <ref href="hk/2025/ln161">L.N.
                    161 of 2025</ref>; <ref href="hk/2025/ln211">L.N. 211 of
                2025</ref>)</sourceNote></division><crossHeading class="font_size_14">Division B</crossHeading><sourceNote class="align_right">(<ref href="/hk/2007/ln41">L.N. 41 of
            2007</ref>)<marker role="blank-line"></marker></sourceNote><division name="D0" temporalId="sch3_D0" id="ID_1676952879313_002"><text class="first_line_indent_0">Dinitronaphthols; dinitrophenols;
                dinitrothymols</text><text class="left_indent_12 first_line_indent_-12">Hexachlorophane; preparations
                containing more than 0.1% for human or animal use in aerosol containers;
                preparations in the form of a cake, tablet or bar of soap for human use containing
                more than 2%; preparations in the form of soaps or shampoos for animal use
                containing more than 2%; medicinal preparations for human or animal use (except
                those for oral administration to sheep or cattle for liver fluke disease) containing
                more than
                0.75%.</text><sourceNote>(<ref href="/hk/1995/ln262">L.N. 262 of 1995</ref>)</sourceNote></division></schedule><schedule id="ID_1438402707907_001" name="sch4" reason="inEffect" startPeriod="2015-11-12" status="operational" temporalId="sch4"><num value="4">Schedule
            4</num><note class="align_right" role="crossReferences" type="inline">[<ref href="/hk/cap138A/s14">reg.
            14</ref>]</note><heading>Statement
            of Particulars as to Proportion of Poison in Certain Cases Permitted by <ref>Regulation
                14(a)</ref><marker role="blank-line"></marker></heading><crossHeading class="font_size_14">Division
            A</crossHeading><sourceNote>(<ref href="/hk/2007/ln41">L.N. 41 of
            2007</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker></sourceNote><text><table xmlns="http://www.w3.org/1999/xhtml" width="100%" class="left_indent_0 repeat_header">
                <colgroup>
                    <col width="42%"></col>
                    <col width="4%"></col>
                    <col width="7%"></col>
                    <col width="47%"></col>
                </colgroup>
                <thead>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_center">Name of Poison</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_center">Particulars</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_justified left_indent_1 first_line_indent_0">Alkaloids</p>
                            <p class="align_justified left_indent_1 first_line_indent_9">Aconite,
                                alkaloids of </p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">The
                                proportion of any one alkaloid of aconite that the preparation would
                                be calculated to contain on the assumption that all the alkaloids of
                                aconite in the preparation were that alkaloid.</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_left left_indent_34 first_line_indent_-11">Belladonna,
                                alkaloids of</p>
                            <p class="align_left left_indent_34 first_line_indent_-11">Calabar bean,
                                alkaloids of</p>
                            <p class="align_left left_indent_34 first_line_indent_-11">Coca,
                                alkaloids of</p>
                            <p class="align_left left_indent_34 first_line_indent_-11">Colchicum,
                                alkaloids of</p>
                            <p class="align_left left_indent_34 first_line_indent_-11">Ephedra,
                                alkaloids of </p>
                            <p class="align_left left_indent_34 first_line_indent_-11">Ergot,
                                alkaloids of </p>
                            <p class="align_left left_indent_34 first_line_indent_-11">Gelsemium,
                                alkaloids of </p>
                            <p class="align_left left_indent_34 first_line_indent_-11">Lobelia,
                                alkaloids of </p>
                            <p class="align_left left_indent_34 first_line_indent_-11">Pilocarpus,
                                alkaloids of</p>
                            <p class="align_left left_indent_34 first_line_indent_-11">Pomegranate,
                                alkaloids of</p>
                            <p class="align_left left_indent_34 first_line_indent_-11">Quebracho,
                                alkaloids of, other than the alkaloids of red quebracho</p>
                            <p class="align_left left_indent_34 first_line_indent_-11">Sabadilla,
                                alkaloids of
                                </p>
                            
                            
                            <p class="align_left left_indent_34 first_line_indent_-11">Stavesacre,
                                alkaloids of</p>
                            
                            
                            <p class="align_left left_indent_34 first_line_indent_-11">Veratrum,
                                alkaloids of </p>
                            <p class="align_left left_indent_34 first_line_indent_-11">Yohimba,
                                alkaloids of </p>
                        </td>
                        
                        <td>
                            
                            
                            
                            <span class="right_brace align_center brace_scale_1500">}</span>
                            
                            
                            
                            
                        </td>
                        
                        <td class="valign_center align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            
                            
                            
                            <p class="align_justified left_indent_12 first_line_indent_-10">The same
                                as above, with the substitution for the reference to aconite of a
                                reference to balladonna, calabar bean or such other of the said
                                poisons as the case may require.
                                <sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/1978/ln137">L.N. 137 of
                                1978</ref>)</sourceNote></p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_justified left_indent_1 first_line_indent_0">Antimonial
                                poisons</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">The
                                proportion of antimony trioxide (Sb<sub>2</sub>O<sub>3</sub>) or
                                antimony pentoxide (Sb<sub>2</sub>O<sub>5</sub>) that the
                                preparation would be calculated to contain on the assumption that
                                the antimony (Sb) in the poison had been wholly converted into
                                antimony trioxide or antimony pentoxide as the case may be.</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_justified left_indent_1 first_line_indent_0">Arsenical
                                poisons</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">The
                                proportion of arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) or
                                arsenic pentoxide (As<sub>2</sub>O<sub>5</sub>) that the preparation
                                would be calculated to contain on the assumption that the arsenic
                                (As) in the poison had been wholly
                                converted
                                into arsenic trioxide or arsenic pentoxide as the case may be.</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Digitalis, glycosides of; other active principles of digitalis</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">The
                                number of units of activity as defined in the British Pharmacopoeia
                                contained in a specified quantity of the preparation.</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Hydrocyanic acid ; cyanides other than ferrocyanides and
                                ferricyanides</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">The
                                proportion of hydrocyanic acid (HCN) that the preparation would be
                                calculated to contain on the assumption that the cyanides in the
                                poison had been wholly converted into hydrocyanic acid.</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_justified left_indent_1 first_line_indent_0">Insulin</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">The
                                number of units of activity as defined in the British Pharmacopoeia
                                contained in a specified quantity of the preparation.</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Lead,
                                compounds of, with acids from fixed oils</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">The
                                proportion of lead oxide (PbO) that the preparation would be
                                calculated to contain on the assumption that the lead in the poison
                                had been wholly converted into lead oxide.</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Mercury,
                                organic compounds of</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">The
                                proportion of organically-combined mercury (Hg) contained in the
                                preparation.</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Nux
                                Vomica</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">The
                                proportion of strychnine contained in the preparation.</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Opium</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">The
                                proportion of morphine contained in the preparation.</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Phenols</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">The
                                proportion of phenols (added together) contained in the
                                preparation.</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Compounds of a phenol with a metal</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">The
                                proportion of phenols (added together) that the preparation would be
                                calculated to contain on the assumption that the compounds of
                                phenols with a metal had been wholly converted into the
                                corresponding phenols.</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td rowspan="4">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Pituitary gland, the active principles of</p>
                        </td>
                        <td></td>
                        <td colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Either—</p>
                        </td>
                    </tr>
                    <tr>
                        <td></td>
                        <td class="align_right cellpadding_left_5 cellpadding_right_5">
                            <p>(a)</p>
                        </td>
                        <td class="align_left cellpadding_left_2 cellpadding_right_5">
                            <p class="align_justified">The number of units of activity as defined in
                                the British Pharmacopoeia contained in a specified quantity of the
                                preparation; or</p>
                        </td>
                    </tr>
                    <tr>
                        <td></td>
                        <td class="align_right cellpadding_left_5 cellpadding_right_5">
                            <p>(b)</p>
                        </td>
                        <td class="align_left cellpadding_left_2 cellpadding_right_5">
                            <p class="align_justified">the proportion of pituitary gland, or of
                                anterior or of posterior lobe of the gland, as the case may be,
                                contained in the preparation; or</p>
                        </td>
                    </tr>
                    <tr>
                        <td></td>
                        <td class="align_right cellpadding_left_5 cellpadding_right_5">
                            <p>(c)</p>
                        </td>
                        <td class="align_left cellpadding_left_2 cellpadding_right_5">
                            <p class="align_justified">the amount of pituitary gland, or of anterior
                                or of posterior lobe of the gland, as the case may be, from which a
                                specified quantity of the preparation was obtained, together with an
                                indication whether the amount relates to fresh or to dried gland
                                substance.</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Strophanthus, glycosides of</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">The
                                amount of Standard Tincture of Strophanthus as defined in the
                                British Pharmacopoeia 1948 which possesses the same activity as a
                                specified quantity of the preparation when assayed by the method
                                described in the said Pharmacopoeia.</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td rowspan="3">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Suprarenal gland, the active principles of; their salts; their
                                derivatives; their salts</p>
                        </td>
                        <td></td>
                        <td colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Either—</p>
                        </td>
                    </tr>
                    <tr>
                        <td></td>
                        <td class="align_right cellpadding_left_5 cellpadding_right_5">
                            <p>(a)</p>
                        </td>
                        <td class="align_left cellpadding_left_2 cellpadding_right_5">
                            <p class="align_justified">the proportion of Suprarenal
                                gland
                                or
                                of
                                the cortex or of the medulla of the gland, as the case may be,
                                contained in the preparation; or</p>
                        </td>
                    </tr>
                    <tr>
                        <td></td>
                        <td class="align_right cellpadding_left_5 cellpadding_right_5">
                            <p>(b)</p>
                        </td>
                        <td class="align_left cellpadding_left_2 cellpadding_right_5">
                            <p class="align_justified">the amount of Suprarenal gland, or of the
                                cortex or of the medulla of the gland, as the case may be, from
                                which a specified quantity of the preparation was obtained, together
                                with an indication whether the amount relates to fresh or to dried
                                gland substance.</p>
                        </td>
                    </tr>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" rowspan="3">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Thyroid
                                gland, the active principles of; their salts</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Either—</p>
                        </td>
                    </tr>
                    <tr>
                        <td></td>
                        <td class="align_right cellpadding_left_5 cellpadding_right_5">
                            <p>(a)</p>
                        </td>
                        <td class="align_left cellpadding_left_2 cellpadding_right_5">
                            <p class="align_justified">the proportion of thyroid gland contained in
                                the preparation; or</p>
                        </td>
                    </tr>
                    <tr>
                        <td></td>
                        <td class="align_right cellpadding_left_5 cellpadding_right_5">
                            <p>(b)</p>
                        </td>
                        <td class="align_left cellpadding_left_2 cellpadding_right_5">
                            <p class="align_justified">the amount of thyroid gland from which a
                                specified quantity of the preparation was obtained together with an
                                indication whether the amount relates to fresh or to dried
                                gland.</p>
                        </td>
                    </tr>
                </tbody>
            </table><marker role="blank-line"></marker><marker role="blank-line"></marker><marker role="blank-line"></marker><marker role="blank-line"></marker><marker role="section-break"></marker></text><crossHeading class="font_size_14">Division
            B</crossHeading><sourceNote>(<ref href="/hk/2007/ln41">L.N. 41 of
            2007</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker></sourceNote><text>
            <table xmlns="http://www.w3.org/1999/xhtml" width="452" class="left_indent_0">
                <colgroup>
                    <col width="42%"></col>
                    <col width="4%"></col>
                    <col width="7%"></col>
                    <col width="47%"></col>
                </colgroup>
                <tbody>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_center">Name of Poison</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_center">Particulars</p>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Barium,
                                salts of</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">The
                                proportion of one particular barium salt which the preparation would
                                be calculated to contain on the assumption that the barium (Ba) in
                                the preparation had been wholly converted into that salt.</p>
                        </td>
                    </tr>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Potassium hydroxide</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">The
                                proportion of potassium monoxide (K<sub>2</sub>O) which the
                                preparation would be calculated to contain on the assumption that
                                the potassium hydroxide in the preparation had been wholly converted
                                into potassium monoxide.</p>
                        </td>
                    </tr>
                    <tr>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p class="align_justified left_indent_12 first_line_indent_-10">Sodium
                                hydroxide</p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5">
                            <p></p>
                        </td>
                        <td class="align_left cellpadding_left_5 cellpadding_right_5" colspan="2">
                            <p class="align_justified left_indent_12 first_line_indent_-10">The
                                proportion of sodium monoxide (Na<sub>2</sub>O) which the
                                preparation would be calculated to contain on the assumption that
                                the sodium hydroxide in the preparation had been wholly converted
                                into sodium monoxide.</p>
                        </td>
                    </tr>
                </tbody>
            </table>
        </text></schedule><schedule id="ID_1438402707938_001" name="sch5" reason="inEffect" startPeriod="2020-09-10" status="operational" temporalId="sch5"><num value="5">Schedule 5</num><note class="align_right" role="crossReferences" type="inline">[<ref href="/hk/cap138A/s15">reg. 15</ref>]</note><sourceNote>(<ref href="hk/2015/2">2 of 2015 s.
            68</ref>)</sourceNote><heading>Texts
            Prescribed by Regulation 15 for Purposes of Section 27(c) or
                (ca)</heading><sourceNote>(<ref href="hk/2015/2">2 of 2015 s.
                68</ref>)</sourceNote><sourceNote>(Format changes—<ref href="/hk/2016/er1">E.R. 1 of
            2016</ref>)</sourceNote><section id="ID_1438411274113_012" name="s1" temporalId="sch5_s1" class="no_header"><num value="1">1.</num><leadIn>To be labelled with the text “Caution. It is dangerous to take this preparation
                except under medical supervision.” 「注意：非經醫生指示，服食此藥有危險。」——</leadIn><paragraph id="ID_1469692506569_001" name="0" temporalId="sch5_s1_0"><content class="first_line_indent_-11 left_indent_70">Medicines made up ready for
                    the internal treatment of human ailments and containing
                    insulin<marker role="blank-line"></marker><marker role="blank-line"></marker></content></paragraph></section><section id="ID_1438411274113_028" name="s2" temporalId="sch5_s2" class="no_header"><num value="2">2.</num><leadIn>To be labelled with the text “Caution. It is dangerous to exceed the stated
                dose.” 「注意：服食過量有危險。」——</leadIn><paragraph id="ID_1469692506569_002" name="0" temporalId="sch5_s2_0"><content class="first_line_indent_-11 left_indent_70">Medicines (other than
                    medicines containing insulin and medicines mentioned in <ref>paragraph 8</ref>
                    of this <ref>Schedule</ref>) made up ready for the internal treatment of human
                    ailments except in the case of a substance included in
                        <ref>Schedule
                        1</ref>
                    <sourceNote>(<ref href="hk/2015/er3">E.R. 3 of
                        2015</ref>; <ref href="hk/2020/er5">E.R. 5 of
                        2020</ref>)</sourceNote><marker role="blank-line"></marker><marker role="blank-line"></marker></content></paragraph></section><section id="ID_1438411274128_002" name="s3" temporalId="sch5_s3" class="no_header"><num value="3">3.</num><leadIn>To be labelled with the text “Poison. For animal treatment only.”
                「毒藥：祇限醫治禽畜用。」——</leadIn><paragraph id="ID_1469692506569_003" name="0" temporalId="sch5_s3_0"><content class="first_line_indent_-11 left_indent_70">Medicines made up ready for
                    the treatment of
                    animals<marker role="blank-line"></marker><marker role="blank-line"></marker></content></paragraph></section><section id="ID_1438411274128_018" name="s4" temporalId="sch5_s4" class="no_header"><num value="4">4.</num><leadIn>To be labelled with the text “Caution. This preparation may cause serious
                inflammation of the skin in certain persons and should be used only in accordance
                with expert advice.” 「注意：此藥可使某些人士皮膚嚴重發炎，須照專家指示使用。」——</leadIn><paragraph id="ID_1469692506569_004" name="0" temporalId="sch5_s4_0"><content class="first_line_indent_-11 left_indent_70">Preparations for the dyeing of
                    hair containing phenylene diamines, toluene diamines or other
                    alkylated-benzene
                    diamines or their
                    salts<marker role="blank-line"></marker><marker role="blank-line"></marker></content></paragraph></section><section id="ID_1438411274128_034" name="s5" temporalId="sch5_s5" class="no_header"><num value="5">5.</num><leadIn>To be labelled with the text “Caution. This substance is caustic.”
                「注意：此物質有腐蝕作用。」——</leadIn><paragraph id="ID_1469692506569_005" name="0" temporalId="sch5_s5_0"><content class="first_line_indent_-11 left_indent_70">Potassium hydroxide, sodium
                    hydroxide, and articles containing either of those
                    substances<marker role="blank-line"></marker><marker role="blank-line"></marker></content></paragraph></section><section id="ID_1438411274128_050" name="s6" temporalId="sch5_s6" class="no_header"><num value="6">6.</num><leadIn>To be labelled with the text “Caution. This substance is poisonous. The
                inhalation of its vapour, mist, spray or dust may have harmful consequences. It may
                also be dangerous to let it contact the skin or clothing.”
                「注意：此物質有毒。吸入其蒸氣、煙霧、噴霧或粉末，可能有害。如觸及皮膚或衣服，亦可能有危險。」——</leadIn><paragraph id="ID_1469692506569_006" name="0" temporalId="sch5_s6_0"><content class="first_line_indent_-11 left_indent_70">Diethyl para-nitrophenyl
                    phosphate</content><content class="first_line_indent_-11 left_indent_70">Organic compounds of mercury
                    in aerosols <sourceNote>(<ref href="/hk/1977/ln195">L.N. 195 of 1977</ref>; <ref href="/hk/1995/ln262">L.N. 262 of
                    1995</ref>)</sourceNote><marker role="blank-line"></marker><marker role="blank-line"></marker></content></paragraph></section><section id="ID_1438411274128_074" name="s7" temporalId="sch5_s7" class="no_header"><num value="7">7.</num><leadIn>To be labelled with the text “Caution. This preparation should be administered
                only under medical supervision. The vapour is dangerous.”
                「注意：此藥之蒸氣有危險，須經醫生指示，方可使用。」——</leadIn><paragraph id="ID_1469692506585_007" name="0" temporalId="sch5_s7_0"><content class="first_line_indent_-11 left_indent_70">Medicines made up ready for
                    the internal or external treatment of human ailments and containing
                    dyflos<marker role="blank-line"></marker><marker role="blank-line"></marker></content></paragraph></section><section id="ID_1438411274128_090" name="s8" temporalId="sch5_s8" class="no_header"><num value="8">8.</num><leadIn>To be labelled with the text “Caution. This may cause drowsiness. If affected,
                do not drive or operate machinery.” 「注意：此藥可使人昏昏欲睡，服後如有此情形，不得駕駛或動用機械。」——</leadIn><paragraph id="ID_1469692506585_008" name="0" temporalId="sch5_s8_0"><content class="first_line_indent_-11 left_indent_70">Medicines made up ready for
                    the internal treatment of human ailments containing any of the antihistamine
                    substances (except Astemizole, Bilastine, Cetirizine, Desloratadine,
                    Fexofenadine, Loratadine and Terfenadine), their salts or their compounds with
                    any other substance <sourceNote>(<ref href="/hk/1995/ln262">L.N. 262 of
                            1995</ref>; <ref href="/hk/1999/ln202">L.N. 202 of 1999</ref>; <ref href="/hk/2002/ln132">L.N. 132 of 2002</ref>; <ref href="/hk/2015/ln66">L.N. 66 of
                    2015</ref>)</sourceNote><marker role="blank-line"></marker><marker role="blank-line"></marker></content></paragraph></section><section id="ID_1438411274144_004" name="s9" temporalId="sch5_s9" class="no_header"><num value="9">9.</num><leadIn>To be labelled with the text “Caution. Not to be taken internally.”
                「注意：忌食。」——</leadIn><paragraph id="ID_1469692506585_009" name="0" temporalId="sch5_s9_0"><content class="first_line_indent_-11 left_indent_70">Preparations for external use
                    containing mercuric ammonium
                    chlorides<marker role="blank-line"></marker><marker role="blank-line"></marker></content></paragraph></section><section id="ID_1438411274144_020" name="s10" temporalId="sch5_s10" class="no_header"><num value="10">10.</num><subsection id="ID_1438411274144_025" name="a" temporalId="sch5_s10_a"><num value="a">(a)</num><leadIn>To be labelled with the text “Not to be used for babies” 「嬰兒禁用。」 or “This
                    preparation should not be administered, except on medical advice, to a child
                    under 2 years of age.”
                    「非經醫生指示，此藥不可用於兩歲以下兒童。」——<marker role="blank-line"></marker></leadIn><paragraph id="ID_1469692506585_010" name="0" temporalId="sch5_s10_a_0"><content class="align_center ">Hexachlorophane<marker role="blank-line"></marker></content></paragraph></subsection><subsection id="ID_1438411274144_038" name="b" temporalId="sch5_s10_b"><num value="b">(b)</num><leadIn>To be labelled with the text “Not to be used for whole body bathing except
                    on medical advice.” 「非經醫生指示不可用作全身沐浴。」——<marker role="blank-line"></marker></leadIn><paragraph id="ID_1469692506585_011" name="0" temporalId="sch5_s10_b_0"><content class="first_line_indent_-11 left_indent_90">Soap for human use
                        containing 2% or more of
                        hexachlorophane<marker role="blank-line"></marker><marker role="blank-line"></marker></content></paragraph></subsection><subsection id="ID_1438411274144_054" name="c" temporalId="sch5_s10_c"><num value="c">(c)</num><leadIn>To be labelled with the text “For animal treatment only.”
                    「祇限醫治禽畜用。」——<marker role="blank-line"></marker></leadIn><paragraph id="ID_1469692506585_012" name="0" temporalId="sch5_s10_c_0"><content class="first_line_indent_-11 left_indent_90">Medicine containing
                        hexachlorophane for the treatment of
                        animal<marker role="blank-line"></marker><marker role="blank-line"></marker></content></paragraph></subsection><subsection id="ID_1456474975126_001" name="d" temporalId="sch5_s10_d"><num value="d">(d)</num><leadIn>To be labelled with the text “Not for use for lactating cattle.”
                    「不得用於授乳牛隻。」——<marker role="blank-line"></marker></leadIn><paragraph id="ID_1469692506585_013" name="0" temporalId="sch5_s10_d_0"><content class="first_line_indent_-11 left_indent_90">Medicine containing
                        hexachlorophane for oral administration for the prevention or treatment of
                        liver fluke disease in
                        cattle<marker role="blank-line"></marker><marker role="blank-line"></marker></content></paragraph></subsection><subsection id="ID_1456474975126_002" name="e" temporalId="sch5_s10_e"><num value="e">(e)</num><leadIn>To be labelled with the text “Protective clothing must be worn by the
                    operator when this product is being administered.”
                    「使用此藥之人員必須穿着防護性衣服。」——<marker role="blank-line"></marker></leadIn><paragraph id="ID_1469692506585_014" name="0" temporalId="sch5_s10_e_0"><content class="first_line_indent_-11 left_indent_90">Medicine containing
                        hexachlorophane for oral administration for the prevention or treatment of
                        liver fluke disease in sheep or
                        cattle<marker role="blank-line"></marker><marker role="blank-line"></marker></content></paragraph></subsection></section><section id="ID_1438411274144_101" name="s11" temporalId="sch5_s11" class="no_header"><num value="11"><inline class="not_bold">11.</inline></num><sourceNote>(Repealed <ref href="/hk/1995/ln262">L.N. 262 of 1995</ref>)</sourceNote></section><section id="ID_1469692506585_015" name="s12" temporalId="sch5_s12" class="no_header"><num value="12">12.</num><leadIn>To be labelled with the text “Prescription Drug 處方藥物”—</leadIn><paragraph id="ID_1469692506585_016" name="0" temporalId="sch5_s12_0"><content class="first_line_indent_-11 left_indent_70">Medicine containing a poison
                    included in
                        <ref>Schedule
                        3</ref>
                    <sourceNote>(<ref href="hk/2015/2">2 of 2015 s.
                        68</ref>; <ref href="hk/2016/er1">E.R. 1 of
                        2016</ref>)</sourceNote></content></paragraph></section><section id="ID_1469692506601_017" name="s13" temporalId="sch5_s13" class="no_header"><num value="13">13.</num><leadIn>To be labelled with the text “Drug under Supervised Sales 監督售賣藥物”—</leadIn><paragraph id="ID_1469692506601_018" name="0" temporalId="sch5_s13_0"><content class="first_line_indent_-11 left_indent_70">Medicine containing a poison
                    included in <ref>Part
                        1</ref>
                    of the Poisons List but not containing a poison included in
                        <ref>Schedule
                        3</ref>
                    <sourceNote>(<ref href="hk/2015/2">2 of 2015 s.
                        68</ref>; <ref href="hk/2016/er1">E.R. 1 of
                        2016</ref>)</sourceNote></content></paragraph></section><sourceNote>(<ref href="hk/2015/2">2 of 2015 s. 68</ref>)</sourceNote></schedule><schedule id="ID_1438402707985_001" name="sch6" reason="inEffect" startPeriod="2020-09-10" status="operational" temporalId="sch6"><num value="6">Schedule
            6</num><note class="align_right" role="crossReferences" type="inline">[<ref href="/hk/cap138A/s4">reg.
            4(2)</ref>]</note><heading>Poisons
            Exempted by <ref>Regulation 4</ref> from Labelling Provisions when Sold or Supplied in
            Certain
            Circumstances<marker role="blank-line"></marker></heading><crossHeading class="font_size_14">Division
            A</crossHeading><sourceNote>(<ref href="/hk/2007/ln41">L.N. 41 of
            2007</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker></sourceNote><text class="first_line_indent_0">Antimony, chlorides of; oxides of; sulphides of;
            antimonates;
            antimonites<marker role="blank-line"></marker><marker role="blank-line"></marker>Chloroform<marker role="blank-line"></marker><marker role="blank-line"></marker>Glyceryl
            trinitrate<marker role="blank-line"></marker><marker role="blank-line"></marker>Lead acetates; compounds
            of lead with acids from fixed
            oils<marker role="blank-line"></marker><marker role="blank-line"></marker>Mercuric chloride; mercuric
            iodide; organic compounds of
            mercury<marker role="blank-line"></marker><marker role="blank-line"></marker>Mercury, nitrates of;
            oxides of<marker role="blank-line"></marker><marker role="blank-line"></marker>Oxalic acid; metallic
            oxalates<marker role="blank-line"></marker><marker role="blank-line"></marker>Phenols; compounds of
            phenol with a metal<marker role="blank-line"></marker><marker role="blank-line"></marker>Picric
            acid<marker role="blank-line"></marker><marker role="blank-line"></marker><marker role="blank-line"></marker><marker role="blank-line"></marker><marker role="section-break"></marker></text><crossHeading class="font_size_14">Division
            B</crossHeading><sourceNote>(<ref href="/hk/2007/ln41">L.N. 41 of
            2007</ref>)</sourceNote><text class="first_line_indent_0">Alkali
            fluorides<marker role="blank-line"></marker><marker role="blank-line"></marker>Ammonia<marker role="blank-line"></marker><marker role="blank-line"></marker>Dinitronaphthols;
            dinitrophenols;
            dinitrothymols<marker role="blank-line"></marker><marker role="blank-line"></marker>Formaldehyde<marker role="blank-line"></marker><marker role="blank-line"></marker>Formic
            acid<marker role="blank-line"></marker><marker role="blank-line"></marker>Hydrochloric
            acid<marker role="blank-line"></marker><marker role="blank-line"></marker>Hydrofluoric acid; sodium
            silicofluoride<marker role="blank-line"></marker><marker role="blank-line"></marker>Nitric
            acid<marker role="blank-line"></marker><marker role="blank-line"></marker>Nitrobenzene<marker role="blank-line"></marker><marker role="blank-line"></marker>meta-Nitrophenol;
            ortho-nitrophenol;
            para-nitrophenol<marker role="blank-line"></marker><marker role="blank-line"></marker>Phosphorus,
            yellow<marker role="blank-line"></marker><marker role="blank-line"></marker>Potassium
            hydroxide<marker role="blank-line"></marker><marker role="blank-line"></marker>Sodium
            hydroxide<marker role="blank-line"></marker><marker role="blank-line"></marker>Sulphuric
                acid</text><sourceNote>(<ref href="/hk/1995/ln262">L.N. 262 of
            1995</ref>; <ref href="hk/2020/er5">E.R. 5 of
            2020</ref>)</sourceNote></schedule><schedule id="ID_1438402708001_002" name="sch7" reason="inEffect" startPeriod="2015-11-12" status="operational" temporalId="sch7"><num value="7">Schedule
            7</num><note class="align_right" role="crossReferences" type="inline">[<ref href="/hk/cap138A/s21">reg.
            21</ref>]</note><heading>Poisons
            Required by <ref>Regulation 21</ref> to be Specially Labelled for
            Transport<marker role="blank-line"></marker></heading><crossHeading class="font_size_14">Division
            A</crossHeading><sourceNote>(<ref href="/hk/2007/ln41">L.N. 41 of
            2007</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker></sourceNote><text class="first_line_indent_0">Arsenical
            poisons<marker role="blank-line"></marker><marker role="blank-line"></marker>Diethyl para-nitrophenyl
            phosphate<marker role="blank-line"></marker><marker role="blank-line"></marker></text><text class="first_line_indent_-8 left_indent_8">Hydrocyanic acid; cyanides, other than
            ferrocyanides and ferricyanides, except preparations containing less than the equivalent
            of 0.1%, weight in weight, of hydrocyanic acid
            (HCN)<marker role="blank-line"></marker><marker role="blank-line"></marker></text><text class="first_line_indent_0">Nicotine<marker role="blank-line"></marker><marker role="blank-line"></marker>Strychnine; its
            salts<marker role="blank-line"></marker><marker role="blank-line"></marker>Thallium, salts
                of</text><sourceNote>(<ref href="/hk/1977/ln195">L.N. 195 of
            1977</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker><marker role="blank-line"></marker><marker role="blank-line"></marker><marker role="section-break"></marker></sourceNote><crossHeading class="font_size_14">Division
            B</crossHeading><sourceNote>(<ref href="/hk/2007/ln41">L.N. 41 of
            2007</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker></sourceNote><text class="first_line_indent_0">Barium, salts of, except barium
            sulphate<marker role="blank-line"></marker><marker role="blank-line"></marker></text><sourceNote>(<ref href="/hk/1978/ln137">L.N. 137 of 1978</ref>; <ref href="/hk/1995/ln262">L.N. 262 of
                1995</ref>)</sourceNote></schedule><schedule id="ID_1438402708032_001" name="sch8" reason="inEffect" startPeriod="2015-11-12" status="operational" temporalId="sch8"><num value="8">Schedule
            8</num><text>
            
            <text>
                <marker role="blank-line"></marker>
                <marker role="blank-line"></marker>
                <table xmlns="http://www.w3.org/1999/xhtml" class="font_size_11" width="450">
                    <col width="33.3333%"></col>
                    <col width="33.3333%"></col>
                    <col width="33.3333%"></col>
                    <tr>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        <td>
                            <center xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">Forms
                                1—5</center>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                    </tr>
                </table>
            </text>
            
            
            <sourceNote> <center>(Repealed <ref href="/hk/2015/2">2 of 2015 s. 69</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker><text>
                        <fillIn class=" width_70">_</fillIn>
                    </text><marker role="blank-line"></marker></center> </sourceNote></text><text></text><text>
            
            <table xmlns="http://www.w3.org/1999/xhtml" class="font_size_11" width="450">
                <col width="33.3333%"></col>
                <col width="33.3333%"></col>
                <col width="33.3333%"></col>
                <tr>
                    <td>
                        <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                    </td>
                    <td>
                        <center xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">Form
                            5A</center>
                    </td>
                    <td>
                        <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                    </td>
                </tr>
            </table>
            
            
        </text><sourceNote> <center>(Repealed <ref href="/hk/2015/2">2 of 2015 s. 69</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker><text>
                    <fillIn class="width_70">_</fillIn>
                </text><marker role="blank-line"></marker></center> </sourceNote><text><table xmlns="http://www.w3.org/1999/xhtml" class="font_size_11" width="450">
                <col width="33.3333%"></col>
                <col width="33.3333%"></col>
                <col width="33.3333%"></col>
                <tr>
                    <td>
                        <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                    </td>
                    <td>
                        <center xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">Forms
                            6—10</center>
                    </td>
                    <td>
                        <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                    </td>
                </tr>
            </table><sourceNote> <center>(Repealed <ref href="/hk/2015/2">2 of 2015 s. 69</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker><text>
                        <fillIn class="width_70">_</fillIn>
                    </text><marker role="blank-line"></marker><marker role="blank-line"></marker></center> </sourceNote></text><text class="align_center">Form
            11<marker role="blank-line"></marker></text><sourceNote> <center>(Spent)<marker role="blank-line"></marker><marker role="blank-line"></marker></center> </sourceNote><text class="align_center">
            <fillIn class=" width_42">_</fillIn>
            <marker role="blank-line"></marker>
            
            
            
        </text><text><table xmlns="http://www.w3.org/1999/xhtml" class="font_size_11" width="450">
                <col width="33.3333%"></col>
                <col width="33.3333%"></col>
                <col width="33.3333%"></col>
                <tr>
                    <td>
                        <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                    </td>
                    <td>
                        <center xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">Forms
                            
                            12—16</center>
                    </td>
                    <td>
                        <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                    </td>
                </tr>
            </table><sourceNote> <center>(Repealed <ref href="/hk/2015/2">2 of 2015 s.
                        69</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker><text class="width_70">
                        <fillIn class="width_70">_</fillIn>
                    </text><marker role="blank-line"></marker></center> </sourceNote></text><text>
            
            <table xmlns="http://www.w3.org/1999/xhtml" class="font_size_11" width="450">
                <col width="33.3333%"></col>
                <col width="33.3333%"></col>
                <col width="33.3333%"></col>
                <tr>
                    <td>
                        <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                    </td>
                    <td>
                        <center xmlns="http://www.xml.gov.hk/schemas/hklm/1.0"><b>Form
                                17</b></center>
                    </td>
                    <td>
                        <p class="align_right">[<ref xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" href="/hk/cap138A/s41">reg.
                                41</ref>]</p>
                    </td>
                </tr>
            </table>
            
            
            
            <marker role="blank-line"></marker>
            <marker role="blank-line"></marker>
            
        </text><text class="align_center"><b>Form of Logo Prescribed for <ref>Section
            13A</ref></b><marker role="blank-line"></marker><marker role="blank-line"></marker></text><text class="align_center"><img alt="This image is the form of logo prescribed for section 13A of the Pharmacy and Poisons Ordinance (Cap. 138)." height="190" src="images/CAP138A_en_sch8_20151112_000000_0001.jpg" width="185" title="This image is the form of logo prescribed for section 13A of the Pharmacy and Poisons Ordinance (Cap. 138)."></img><marker role="blank-line"></marker><marker role="blank-line"></marker></text><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s. 69</ref>)</sourceNote></schedule><schedule name="sch9" reason="inEffect" startPeriod="2023-07-01" status="operational" temporalId="sch9" id="ID_1438402708079_001"><num value="9">Schedule
            9</num><note class="align_right first_line_indent_0 left_indent_24" role="crossReferences" type="inline">[<ref href="/hk/cap138A/s24A">regs. 24A</ref>, <ref href="/hk/cap138A/s26">26</ref>, <ref href="/hk/cap138A/s29">29</ref>, <ref href="/hk/cap138A/s30D">30D</ref>, <ref href="/hk/cap138A/s30E">30E</ref>,
                <ref href="/hk/cap138A/s36">36</ref>,
                <br></br><ref href="/hk/cap138A/s36B">36B</ref>, <ref href="/hk/cap138A/s36D">36D</ref> &amp; <ref href="/hk/cap138A/s41">41</ref>]</note><sourceNote>(<ref href="/hk/2015/2">2 of 2015 s.
            70</ref>)</sourceNote><heading>Fees</heading><text>
            
            <table xmlns="http://www.w3.org/1999/xhtml" class="font_size_11 repeat_header" width="100%">
                
                <col width="8%"></col>
                
                <col width="82%"></col>
                
                <col width="8%"></col>
                
                <col width="2%"></col>
                
                <thead>
                    <tr>
                        <td>
                            <center xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">Item</center>
                        </td>
                        <td>
                            <center xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">Particular</center>
                        </td>
                        <td>
                            
                            <p class="align_right">Fee</p>
                            
                            <p class="left_indent_17">$</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>
                            <p class="align_right">1.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Examination
                                in each subject prescribed by the Board<inline xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" class="width_3"> </inline><sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/2001/ln60">L.N. 60 of 2001</ref>)</sourceNote></p>
                        </td>
                        <td>
                            <p class="align_right">1,110</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">2.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Issue of a
                                certificate of registration as a pharmacist<inline xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" class="width_3"> </inline><sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/2001/ln60">L.N. 60 of 2001</ref>)</sourceNote></p>
                        </td>
                        <td>
                            <p class="align_right">790</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">3.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Issue of a
                                duplicate certificate of registration as a pharmacist</p>
                        </td>
                        <td>
                            <p class="align_right">395</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">4.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Registration of premises of an authorized seller of poisons</p>
                        </td>
                        <td>
                            <p class="align_right">1,000</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">5.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Renewal of
                                registration of premises of an authorized seller of poisons<inline xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" class="width_3"> </inline><sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/2015/2">2 of 2015 s. 70</ref>)</sourceNote></p>
                        </td>
                        <td>
                            <p class="align_right">1,310</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">6.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Application
                                for entry on the list of listed sellers of poisons</p>
                        </td>
                        <td>
                            <p class="align_right">455</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">7.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Retention
                                on the list of listed sellers of poisons, each year</p>
                        </td>
                        <td>
                            <p class="align_right">430</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">8.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Any
                                alteration to the register of premises or to the list of listed
                                sellers</p>
                        </td>
                        <td>
                            <p class="align_right">250</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">9.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">An annual
                                wholesale dealer licence<inline xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" class="width_3"> </inline><sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/2015/2">2 of 2015 s. 70</ref>)</sourceNote></p>
                        </td>
                        <td>
                            <p class="align_right">625</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">10.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Annual
                                licence for manufacturers</p>
                        </td>
                        <td>
                            <p class="align_right">2,680</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">10A.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Certificate
                                of registration of an authorized person<inline xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" class="width_3"> </inline><sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/2015/2">2 of 2015 s. 70</ref>)</sourceNote></p>
                        </td>
                        <td>
                            <p class="align_right">1,420</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">10B.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Renewed
                                certificate of registration of an authorized person<inline xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" class="width_3"> </inline><sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/2015/2">2 of 2015 s. 70</ref>)</sourceNote></p>
                        </td>
                        <td>
                            <p class="align_right">1,420</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">11.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Application
                                for registration of a product</p>
                        </td>
                        <td>
                            <p class="align_right">1,100</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">12.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Certificate
                                of registration of a product</p>
                        </td>
                        <td>
                            <p class="align_right">1,370</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">13.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Renewal of
                                a certificate of registration of a product</p>
                        </td>
                        <td>
                            <p class="align_right">575</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">14.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Free Sale
                                Certificate of Pharmaceutical Product</p>
                        </td>
                        <td>
                            <p class="align_right">180</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">15.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Certificate
                                of Pharmaceutical Product</p>
                        </td>
                        <td>
                            <p class="align_right">140</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">16.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Certificate
                                and Interim Certificate for Manufacturer</p>
                        </td>
                        <td>
                            <p class="align_right">2,020</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">17.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Annual
                                practising certificate for a registered pharmacist<inline xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" class="width_3"> </inline><sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/1995/34">34 of 1995 s. 43</ref>; <ref href="/hk/2001/ln60">L.N. 60 of 2001</ref>)</sourceNote></p>
                        </td>
                        <td>
                            <p class="align_right">520</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">18.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Application
                                for a clinical trial or medicinal test</p>
                        </td>
                        <td>
                            <p class="align_right">1,420</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">19.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Certificate
                                for clinical trial or medicinal test</p>
                        </td>
                        <td>
                            <p class="align_right">1,420</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">20.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified"><sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(Repealed <ref href="/hk/2015/2">2 of 2015 s. 70</ref>)</sourceNote></p>
                        </td>
                        <td>
                            <marker xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" role="blank-line"></marker>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">21.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Duplicate
                                of any certificate</p>
                        </td>
                        <td>
                            <p class="align_right">220</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                    <tr>
                        <td>
                            <p class="align_right">22.</p>
                        </td>
                        
                        <td class="cellpadding_right_5">
                            
                            <p class="left_indent_8 first_line_indent_0 align_justified">Issue of a
                                certificate of good standing<inline xmlns="http://www.xml.gov.hk/schemas/hklm/1.0" class="width_3"> </inline><sourceNote xmlns="http://www.xml.gov.hk/schemas/hklm/1.0">(<ref href="/hk/2001/ln60">L.N. 60 of 2001</ref>)</sourceNote></p>
                        </td>
                        <td>
                            <p class="align_right">415</p>
                        </td>
                        
                        <td></td>
                        
                    </tr>
                </tbody>
            </table>
        </text><sourceNote>(<ref href="/hk/1994/ln597">L.N. 597 of 1994</ref>; <ref href="/hk/1997/ln214">L.N. 214 of 1997</ref>; <ref href="/hk/2006/ln126">L.N. 126 of
                2006</ref>)</sourceNote></schedule><schedule name="sch10" reason="inEffect" startPeriod="2025-10-17" status="operational" temporalId="sch10" id="ID_1438402708125_001"><num value="10">Schedule 10</num><note class="align_right" role="crossReferences" type="inline">[<ref href="/hk/cap138A/s2A">reg. 2A</ref>]</note><heading>Poisons List</heading><section name="s1" temporalId="sch10_s1" class="no_header" id="ID_1676952993755_001"><num value="1">1.</num><heading>Interpretation</heading><subsection name="1" temporalId="sch10_s1_1" id="ID_1676952993756_002"><num value="1">(1)</num><leadIn>In the Poisons List, a reference to a substance includes—</leadIn><paragraph id="ID_1438411274394_038" name="a" temporalId="sch10_s1_1_a"><num value="a">(a)</num><content>that substance prepared either from natural sources or artificially;
                        and</content></paragraph><paragraph id="ID_1438411274394_047" name="b" temporalId="sch10_s1_1_b"><num value="b">(b)</num><content>that substance when contained as such in a preparation, solution,
                        mixture or natural substance.</content></paragraph></subsection><subsection id="ID_1438411274394_055" name="2" temporalId="sch10_s1_2"><num value="2">(2)</num><leadIn>In the Poisons List—</leadIn><def name="Derivative">
                    <leadIn><term>derivative</term> (<term xml:lang="zh-Hant-HK">衍生物</term>) means
                        an organic compound of the following descriptions—</leadIn>
                    <paragraph id="ID_1438411274394_072" name="a" temporalId="sch10_s1_2_a"><num value="a">(a)</num><def name="ParentCompound">
                            <leadIn>it is related to another organic compound (<term>parent
                                    compound</term>) because it has—</leadIn>
                            <subparagraph id="ID_1438411274394_081" name="i" temporalId="sch10_s1_2_a_i"><num value="i">(i)</num><content>the same elemental ring, chain, nucleus or skeleton;
                                    and</content></subparagraph>
                            <subparagraph id="ID_1438411274394_090" name="ii" temporalId="sch10_s1_2_a_ii"><num value="ii">(ii)</num><content>similar pharmaceutical activity;</content></subparagraph>
                        </def></paragraph>
                    <paragraph id="ID_1438411274394_098" name="b" temporalId="sch10_s1_2_b"><num value="b">(b)</num><content>it may have a molecular weight which may be the same as, or higher
                            or lower (for example, after formation of a derivative by the process
                            commonly known as dehydrogenation) than that of the parent compound;
                            and</content></paragraph>
                    <paragraph id="ID_1438411274394_107" name="c" temporalId="sch10_s1_2_c"><num value="c">(c)</num><content>its preparation may or may not require the presence of the parent
                            compound.</content></paragraph>
                </def></subsection><subsection id="ID_1438411274394_115" name="3" temporalId="sch10_s1_3"><num value="3">(3)</num><leadIn>In the Poisons List—</leadIn><paragraph id="ID_1438411274409_006" name="a" temporalId="sch10_s1_3_a"><num value="a">(a)</num><content>substances listed in Divisions A are those whose uses are essentially
                        medicinal; and</content></paragraph><paragraph id="ID_1438411274409_015" name="b" temporalId="sch10_s1_3_b"><num value="b">(b)</num><content>substances listed in Divisions B are not normally used
                        medicinally.<marker role="blank-line"></marker><marker role="blank-line"></marker></content></paragraph></subsection></section><section name="s2" temporalId="sch10_s2" class="no_header" id="ID_1676952993757_003"><num value="2">2.</num><heading>Poisons List</heading><text>The Poisons List is set out in the
                Table.<marker role="blank-line"></marker><marker role="blank-line"></marker></text><crossHeading>Table</crossHeading><part id="ID_1438411274409_042" name="P0" temporalId="sch10_s2_P0" class="no_header"><heading class="no_header">
                    <crossHeading>Part 1</crossHeading>
                    <crossHeading>Division A<marker role="blank-line"></marker></crossHeading>
                </heading><division name="D0" temporalId="sch10_s2_P0_D0" id="ID_1676952993759_004"><text class="tied-tag-leadIn-text">Abacavir; its salts</text><text>Abatacept</text><text>Abciximab</text><text>Abemaciclib; its salts</text><text>Abiraterone; its salts</text><text>Abrocitinib; its salts</text><text>Acalabrutinib; its salts</text><text>Acamprosate; its salts</text><text>Acarbose; its salts</text><text>Acebutolol; its salts</text><text>Aceclofenac; its salts</text><text>Acemetacin; its salts</text><text>Acetanilide; alkyl acetanilides</text><text>Acetazolamide; its salts</text><text>Acetohexamide</text><text>Acetorphine; its salts; its esters and ethers; their salts</text><text>Acetylcarbromal</text><text>Acetyldihydrocodeine; its salts</text><text>Aciclovir; its salts</text><text>Acipimox; its salts</text><text>Acitretin; its salts; its esters</text><text>Aclidinium; its salts</text><text>Adagrasib; its salts</text><text>Adalimumab</text><text>Adapalene; its salts; its esters</text><text>Adefovir; its salts; its esters; their salts</text><text>Afatinib; its salts</text><text>Aflibercept</text><text>Afoxolaner; its salts</text><text>Agalsidase alfa</text><text>Agalsidase beta</text><text>Agomelatine; its salts</text><text>Alclofenac; its complexes</text><text>Alcuronium; its salts</text><text>Aldesleukin</text><text>Alectinib; its salts</text><text>Alefacept</text><text>Alemtuzumab</text><text>Alendronic acid; its salts</text><text>Alfacalcidol; its salts</text><text>Alfuzosin; its salts</text><text>Alglucosidase alfa</text><text>Alirocumab</text><text>Aliskiren; its salts; its esters; their salts</text><text>Alizapride; its salts</text><text class="left_indent_48 first_line_indent_-11">Alkaloids, the following;
                        their quaternary compounds; any salt, simple or complex, of any substance
                        falling within the following—</text><text class="left_indent_72 first_line_indent_-11">Aconite, alkaloids of</text><text class="left_indent_72 first_line_indent_-11">Atropine</text><text class="left_indent_72 first_line_indent_-11">Belladonna, alkaloids
                        of</text><text class="left_indent_72 first_line_indent_-11">Brucine</text><text class="left_indent_72 first_line_indent_-11">Calabar bean, alkaloids
                        of</text><text class="left_indent_72 first_line_indent_-11">Coca, alkaloids of</text><text class="left_indent_72 first_line_indent_-11">Cocaine</text><text class="left_indent_72 first_line_indent_-11">Codeine; its esters and
                        ethers</text><text class="left_indent_72 first_line_indent_-11">Colchicum, alkaloids of;
                        their salts</text><text class="left_indent_72 first_line_indent_-11">Coniine</text><text class="left_indent_72 first_line_indent_-11">Cotarnine</text><text class="left_indent_72 first_line_indent_-11">Curare, alkaloids of; curare
                        bases</text><text class="left_indent_72 first_line_indent_-11">Ecgonine; its esters and
                        ethers</text><text class="left_indent_72 first_line_indent_-11">Emetine</text><text class="left_indent_72 first_line_indent_-11">Ephedra, alkaloids of</text><text class="left_indent_72 first_line_indent_-11">Ergot, alkaloids of</text><text class="left_indent_72 first_line_indent_-11">Galantamine</text><text class="left_indent_72 first_line_indent_-11">Gelsemium, alkaloids
                        of</text><text class="left_indent_72 first_line_indent_-11">Homatropine</text><text class="left_indent_72 first_line_indent_-11">Hyoscine</text><text class="left_indent_72 first_line_indent_-11">Hyoscyamine</text><text class="left_indent_72 first_line_indent_-11">Lobelia, alkaloids of</text><text class="left_indent_72 first_line_indent_-11">Morphine; its esters and
                        ethers</text><text class="left_indent_72 first_line_indent_-11">Nicotine
                        (except when contained in (a) chewing gum or lozenges, intended to be used
                        in nicotine replacement therapy and containing not more than 4 mg of
                        Nicotine per piece; or (b) patches for external application, intended to be
                        used in nicotine replacement therapy); any compound containing the chemical
                        structure of 3-(1-methylpyrrolidin-2-yl)pyridine substituted to any degree
                        or without substitution</text><text class="left_indent_72 first_line_indent_-11">Nux Vomica, alkaloids
                        of</text><text class="left_indent_72 first_line_indent_-11">Papaverine</text><text class="left_indent_72 first_line_indent_-11">Pilocarpus, alkaloids
                        of</text><text class="left_indent_72 first_line_indent_-11">Pomegranate, alkaloids
                        of</text><text class="left_indent_72 first_line_indent_-11">Quebracho, alkaloids
                        of</text><text class="left_indent_72 first_line_indent_-11">Rauwolfia, alkaloids of;
                        their derivatives</text><text class="left_indent_72 first_line_indent_-11">Sabadilla, alkaloids
                        of</text><text class="left_indent_72 first_line_indent_-11">Stavesacre, alkaloids
                        of</text><text class="left_indent_72 first_line_indent_-11">Strychnine</text><text class="left_indent_72 first_line_indent_-11">Thebaine</text><text class="left_indent_72 first_line_indent_-11">Veratrum, alkaloids of</text><text class="left_indent_72 first_line_indent_-11">Vinca, alkaloids of</text><text class="left_indent_72 first_line_indent_-11">Yohimba, alkaloids of</text><text>Allergen extract of Dermatophagoides farinae</text><text>Allergen extract of Dermatophagoides pteronyssinus</text><text>Allopurinol</text><text>Allylisopropylacetylurea</text><text>Allylprodine; its salts</text><text>Almitrine; its salts</text><text>Alogliptin; its salts</text><text>Alpelisib; its salts</text><text>Alphadolone; its esters</text><text>Alphaxalone</text><text>Alprenolol; its salts</text><text>Alteplase</text><text>Alufibrate</text><text>Amantadine; its salts</text><text>Ambrisentan; its salts; its esters; their salts </text><text>Amidopyrine; its salts</text><text>Amifostine; its salts</text><text>Amiloride; its salts</text><text>Amineptine; its salts</text><text class="left_indent_48 first_line_indent_-11">Amino-alcohols esterified
                        with benzoic acid, phenylacetic acid, phenylpropionic acid, cinnamic acid or
                        the derivatives of these acids; their salts (except procaine when in a
                        preparation containing any substance to which the Antibiotics Ordinance
                            (<ref href="/hk/cap137">Cap. 137</ref>) for the time being
                        applies)</text><text class="left_indent_48 first_line_indent_-11">para-Aminobenzenesulphonamide; its salts; derivatives of
                        para-aminobenzenesulphonamide having any of the hydrogen atoms of the
                        para-amino group or of the sulphonamide group substituted by another
                        radical; their salts</text><text class="left_indent_48 first_line_indent_-11">para-Aminobenzoic acid,
                        esters of; their salts; except benzocaine when contained in condoms</text><text>Aminoglutethimide</text><text>5-Aminolevulinic acid; its salts; its derivatives; their salts</text><text>Aminophylline; its salts</text><text>Aminopterin; its derivatives</text><text>Aminorex; its salts</text><text class="left_indent_48 first_line_indent_-11">para-Aminosalicylic acid; its
                        salts; its derivatives; their salts; any compound with any substance falling
                        within this item</text><text>Amiodarone; its salts</text><text>Amisulpride; its salts</text><text>Amitriptyline; its salts</text><text>Amivantamab</text><text>Amlodipine; its salts</text><text>Amrinone</text><text>Amsacrine; its salts</text><text>Amyl nitrite</text><text>Amylene hydrate</text><text>Anagrelide; its salts</text><text>Anastrozole; its salts</text><text>Andexanet alfa</text><text class="left_indent_48 first_line_indent_-11">Androgenic, oestrogenic and
                        progestational substances, the following—</text><text class="left_indent_72 first_line_indent_-11">Benzoestrol</text><text class="left_indent_72 first_line_indent_-11">Derivatives of stilbene,
                        dibenzyl or naphthalene with oestrogenic activity; their esters</text><text class="left_indent_72 first_line_indent_-11">Steroid compounds with
                        androgenic or oestrogenic or progestational activity; their
                        esters;
                        except when contained in a preparation intended to be taken orally for
                        contraceptive purposes only and each dose of the preparation contains not
                        more than the following—</text><text class="left_indent_85">0.15 mg of Desogestrel;</text><text class="left_indent_85">3.00 mg of Drospirenone;</text><text class="left_indent_85">0.05 mg of Ethinyloestradiol;</text><text class="left_indent_85">0.10 mg of Gestodene;</text><text class="left_indent_85">0.25 mg of Levonorgestrel;</text><text class="left_indent_85">2.50 mg of Lynoestrenol;</text><text class="left_indent_85">0.05 mg of Mestranol;</text><text class="left_indent_85">1.00 mg of Norethisterone;</text><text class="left_indent_85">0.25 mg of Norgestimate; and</text><text class="left_indent_85">0.50 mg of Norgestrel</text><text>Anidulafungin; its salts; its esters; their salts</text><text>Anifrolumab</text><text>Anileridine; its salts</text><text>Anistreplase</text><text class="left_indent_48 first_line_indent_-11">Antihistamine substances, the
                        following; their salts; any compound with any substance falling within this
                        item—</text><text class="left_indent_72 first_line_indent_-11">Acrivastine</text><text class="left_indent_72 first_line_indent_-11">Antazoline</text><text class="left_indent_72 first_line_indent_-11">Astemizole</text><text class="left_indent_72 first_line_indent_-11">Azelastine</text><text class="left_indent_72 first_line_indent_-11">Bilastine</text><text class="left_indent_72 first_line_indent_-11">Bromodiphenhydramine</text><text class="left_indent_72 first_line_indent_-11">Buclizine</text><text class="left_indent_72 first_line_indent_-11">Chlorcyclizine</text><text class="left_indent_72 first_line_indent_-11">Cyclizine</text><text class="left_indent_72 first_line_indent_-11">Desloratadine</text><text class="left_indent_72 first_line_indent_-11">3-Di-n-butylaminomethyl-4,5,6-trihydroxyphthalide</text><text class="left_indent_72 first_line_indent_-11">Dimethothiazine</text><text class="left_indent_72 first_line_indent_-11">Diphenhydramine</text><text class="left_indent_72 first_line_indent_-11">Doxylamine</text><text class="left_indent_72 first_line_indent_-11">Ebastine</text><text class="left_indent_72 first_line_indent_-11">Fexofenadine</text><text class="left_indent_72 first_line_indent_-11">Isothipendyl</text><text class="left_indent_72 first_line_indent_-11">Ketotifen</text><text class="left_indent_72 first_line_indent_-11">Loratadine (except
                        Loratadine; its salts; when contained in pharmaceutical products labelled
                        for the relief of the symptoms of allergic rhinitis only)</text><text class="left_indent_72 first_line_indent_-11">Mebhydrolin</text><text class="left_indent_72 first_line_indent_-11">Meclozine</text><text class="left_indent_72 first_line_indent_-11">Methdilazine</text><text class="left_indent_72 first_line_indent_-11">Phenindamine</text><text class="left_indent_72 first_line_indent_-11">Promethazine</text><text class="left_indent_72 first_line_indent_-11">Terfenadine</text><text class="left_indent_72 first_line_indent_-11">Thenalidine</text><text class="left_indent_72 first_line_indent_-11">Trimeprazine</text><text class="left_indent_72 first_line_indent_-11">Tripelennamine</text><text class="left_indent_72 first_line_indent_-11">Substances being
                        tetra-substituted N derivatives of ethylene-diamine or
                        propylenediamine</text><text class="left_indent_72 first_line_indent_-11">Antihistamine substances
                        other than the above; their salts; any compounds with such substances; when
                        contained in preparations for parenteral use</text><text>Antilymphocyte Immunoglobulins</text><text class="left_indent_48 first_line_indent_-11">Antimony, chlorides of;
                        organic compounds of; antimonates; antimonites</text><text>Antisera, antitoxins, immunoglobulins and vaccines—</text><paragraph id="ID_1438411274503_078" name="a" temporalId="sch10_s2_P0_D0_a" class="left_indent_71 first_line_indent_-54"><num value="a">(a)</num><content>the following—</content><content>Bacillus Calmette-Guérin (BCG)</content><content>Meningococcal vaccines</content><content>Normal immunoglobulins</content><content>Pneumococcal vaccines</content><content>Rotavirus vaccines</content><content>Snake venom antisera</content><content>Staphylococcal vaccines</content><content>Streptococcal vaccines;</content></paragraph><paragraph id="ID_1438411274503_150" name="b" temporalId="sch10_s2_P0_D0_b" class="left_indent_71 first_line_indent_-54"><num value="b">(b)</num><content>directed against the following diseases, viruses or
                            organisms—</content><content>Bordetella species</content><content>Botulism</content><content>Canine infectious disease</content><content>Cholera</content><content>Dengue fever</content><content>Diphtheria</content><content>Feline calicivirus</content><content>Feline Chlamydia psittaci</content><content>Feline immunodeficiency virus</content><content>Feline leukemia virus</content><content>Feline panleukopenia virus</content><content>Feline rhinotracheitis virus</content><content>Haemophilus influenzae type b</content><content>Hepatitis A</content><content>Hepatitis B</content><content>Herpes simplex</content><content>Herpes zoster</content><content>Human papillomavirus</content><content>Influenza</content><content>Japanese encephalitis</content><content>Measles</content><content>Mumps</content><content>Pertussis</content><content>Plague</content><content>Poliomyelitis</content><content>Rabies</content><content>Respiratory syncytial virus</content><content>Rubella</content><content class="left_indent_84 first_line_indent_-13">Severe acute
                            respiratory syndrome coronavirus 2 (SARS-CoV-2)</content><content>Tetanus</content><content>Typhoid</content><content>Varicella</content><content>Yellow fever</content></paragraph><text>Antithymocyte Immunoglobulin </text><text>Apalutamide; its salts </text><text>Apixaban; its salts </text><text>Apomorphine; its salts; its quaternary compounds </text><text>Apraclonidine; its salts </text><text>Apremilast; its salts </text><text>Aprepitant; its salts </text><text>Aprindine; its salts </text><text>Aripiprazole </text><text class="left_indent_48 first_line_indent_-11">Arsenic trioxide when
                        contained in pharmaceutical products</text><text class="left_indent_48 first_line_indent_-11">Arsenical substances, the
                        following: halides of arsenic; organic compounds of arsenic; oxides of
                        arsenic; sulphides of arsenic; arsenates; arsenites; thioarsenates</text><text>Artemether; its salts </text><text>Articaine; its salts </text><text>Asciminib; its salts</text><text>Asenapine; its salts; its isomers </text><text>Asfotase alfa</text><text>Asunaprevir; its salts </text><text>Atazanavir; its salts </text><text>Atenolol; its salts </text><text>Atezolizumab </text><text>Atogepant</text><text>Atomoxetine; its salts </text><text>Atorvastatin; its salts </text><text>Atosiban; its salts </text><text>Atovaquone </text><text>Atracurium besylate </text><text>Auranofin </text><text>Avalglucosidase alfa</text><text>Avanafil; its salts </text><text>Avapritinib; its salts</text><text>Avatrombopag; its salts; its esters; their salts</text><text>Avelumab </text><text>Axitinib; its salts </text><text>Azacitidine; its salts </text><text>Azacyclonol; its salts </text><text>Azapropazone </text><text>Azauridine; its derivatives </text><text>Azelaic acid</text><text>Azilsartan; its salts; its esters; their salts </text><text>Aziridine; its derivatives </text><text>Baclofen </text><text>Baloxavir; its salts; its esters and ethers; their salts </text><text>Bambuterol; its salts </text><text class="left_indent_48 first_line_indent_-11">Barbituric acid; its salts;
                        its derivatives; their salts; any compound with any substance falling within
                        this item</text><text>Baricitinib; its salts </text><text>Basiliximab; its salts </text><text>Becaplermin; its salts </text><text>Bedaquiline; its salts </text><text>Befunolol; its salts </text><text>Belantamab mafodotin</text><text>Belimumab </text><text>Belumosudil; its salts</text><text>Belzutifan; its salts</text><text>Bemiparin; its salts </text><text>Bempedoic acid; its salts; its esters; their salts</text><text>Benactyzine; its salts </text><text>Benazepril; its salts </text><text>Benmelstobart</text><text>Benoxaprofen; its
                        salts</text><text>Benralizumab </text><text>Benserazide; its salts </text><text>Benzbromarone </text><text>Benzethidine; its salts </text><text>Benzhexol; its salts </text><text>Benzoylmorphine; its salts </text><text>Benzquinamide </text><text>Benztropine and its homologues; their salts </text><text>Benzydamine; its salts </text><text>Benzylmorphine; its salts </text><text>Besifloxacin; its salts; its esters; their salts </text><text>Betahistine; its salts</text><text>Betaxolol; its salts </text><text>Bethanidine; its salts </text><text>Bevacizumab </text><text>Bexarotene; its salts</text><text>Bezafibrate </text><text>Bezitramide; its salts</text><text>Bicalutamide; its salts </text><text>Bictegravir; its salts </text><text>Bifonazole; its salts </text><text>Bimekizumab</text><text>Binimetinib; its salts</text><text>Biperiden; its salts </text><text>Biphenylacetic acid; its salts; its esters </text><text class="left_indent_48 first_line_indent_-11">N-[4,4-Bis(para-fluorophenyl)butyl]piperidine,4-substituted derivatives of;
                        their salts</text><text>Bisoprolol; its salts</text><text>Bitolterol; its salts</text><text>Bivalirudin; its salts</text><text>Blinatumomab</text><text class="left_indent_48 first_line_indent_-11">Blood products derived from
                        human blood or manufactured by biotechnology, the following—</text><text class="left_indent_60">Albumin </text><text class="left_indent_60">Antithrombins </text><text class="left_indent_60">Blood clotting factors </text><text class="left_indent_60">Fibrin </text><text class="left_indent_60">Fibrinogen </text><text class="left_indent_60">Plasma protein fractions </text><text class="left_indent_60">Thrombin </text><text>Boceprevir; its salts </text><text>Bortezomib </text><text>Bosentan; its salts </text><text>Botulinum toxin complexes </text><text>Brentuximab vedotin </text><text>Bretylium tosylate </text><text>Brexpiprazole; its salts </text><text>Brigatinib; its salts </text><text>Brimonidine; its salts </text><text>Brinzolamide; its salts </text><text>Brivaracetam; its salts </text><text>Brodalumab </text><text>Brolucizumab</text><text>Bromocriptine; its salts </text><text>Bromvaletone </text><text>Broncho-Vaxom </text><text>Brotizolam </text><text>Bucolome </text><text>Bufexamac </text><text>Buformin; its salts </text><text>Bumadizone; its salts </text><text>Bumetanide; its salts; its derivatives; their salts </text><text>Bupivacaine; its salts </text><text>Bupranolol; its salts </text><text>Buprenorphine; its salts </text><text>Bupropion; its salts </text><text>Burosumab </text><text>Buserelin; its salts </text><text>Buspirone; its salts </text><text>Busulphan; its salts </text><text>Butorphanol; its salts </text><text>Butylchloral hydrate </text><text>Cabazitaxel; its salts; its esters; their salts </text><text>Cabergoline; its salts </text><text>Cabotegravir; its salts</text><text>Cabozantinib; its salts </text><text>Calcifediol</text><text>Calcipotriol; its salts </text><text>Calcitriol; its salts </text><text>Canagliflozin; its salts </text><text>Canakinumab </text><text>Candesartan; its salts; its esters; their salts </text><text>Cannabidiol; its salts; when contained in pharmaceutical products</text><text class="left_indent_48 first_line_indent_-11">Cannabinol and its
                        tetrahydro
                        or hexahydro derivatives; their 3-alkyl homologues; any
                        ester or ether of any substance falling within this item</text><text class="left_indent_48 first_line_indent_-11">Cannabis; the resin of
                        cannabis; extracts of cannabis; tinctures of cannabis; cannabin
                        tannate</text><text>Cantharidin; cantharidates </text><text>Capecitabine; its salts </text><text>Capivasertib; its salts</text><text>Capmatinib; its salts</text><text>Captodiamine; its salts </text><text>Captopril </text><text>Caramiphen; its salts </text><text>Carbachol </text><text>Carbamazepine </text><text>Carbidopa; its salts </text><text>Carbimazole; its salts </text><text>Carboplatin </text><text>Carbromal </text><text>Carbutamide </text><text>Carfilzomib; its salts </text><text>Carglumic acid; its salts; its esters; their salts</text><text>Carisoprodol </text><text>Carmustine </text><text>Carperidine; its salts </text><text>Carprofen; its salts </text><text>Carteolol; its salts </text><text>Carvedilol; its salts </text><text>Casirivimab</text><text>Caspofungin; its salts </text><text>Catequentinib (Anlotinib); its salts</text><text>Cedazuridine; its salts</text><text>Celecoxib; its salts </text><text>Celiprolol; its salts </text><text>Cemiplimab</text><text>Cenobamate; its salts</text><text>Ceritinib; its salts </text><text>Cerivastatin; its salts </text><text>Certolizumab pegol </text><text>Cetrorelix; its salts; its esters; their salts </text><text>Cetuximab </text><text>Chlofenamic acid; its salts </text><text class="left_indent_48 first_line_indent_-11">Chloral; its addition and its
                        condensation products; any compound with any substance falling within this
                        item</text><text>Chlordiazepoxide; its salts</text><text>Chlormethiazole; its salts</text><text>Chlormezanone</text><text>Chloroform</text><text>Chloroquine; its salts; its derivatives; their salts</text><text class="left_indent_48 first_line_indent_-11">Chlorothiazide and other
                        derivatives of benzo-1,2,4-thiadiazine-7-sulphonamide 1,1-dioxide, whether
                        hydrogenated or not; their salts</text><text>Chlorphenoxamine; its salts</text><text>Chlorphentermine; its salts</text><text>Chlorpropamide; its salts</text><text class="left_indent_48 first_line_indent_-11">Chlorprothixene and other
                        derivatives of 9-methylenethiaxanthen; their salts</text><text class="left_indent_48 first_line_indent_-11">Chlorthalidone and other
                        derivatives of ortho-chlorobenzenesulphonamide</text><text>Chlorzoxazone </text><text>Chorionic Gonadotrophin </text><text>Chymopapain </text><text>Cicletanine; its salts </text><text>Cidofovir; its salts </text><text>Cilazapril; its salts </text><text>Cilgavimab</text><text>Cilostazol; its salts </text><text>Cinacalcet; its salts </text><text>Cinepazide; its salts </text><text>Ciprofibrate; its salts </text><text>Ciprofloxacin; its salts; its esters </text><text>Cisapride </text><text>Cisatracurium besylate </text><text>Cisplatin </text><text>Citalopram; its salts </text><text class="left_indent_48 first_line_indent_-11">Citicoline; its salts; when
                        contained in pharmaceutical products intended to be used for the treatment
                        of cognitive and neurological disorders associated with cerebrovascular
                        disease or brain injury, or both</text><text>Cladribine </text><text>Clioquinol </text><text>Clobazam </text><text>Clodronic acid; its salts; its esters </text><text>Clofarabine; its salts; its esters; their salts </text><text>Clofazimine; its salts </text><text>Clofibrate </text><text>Clomiphene; its salts </text><text>Clomipramine; its salts; its derivatives; their salts </text><text>Clonidine; its salts </text><text>Clonitazene; its salts </text><text>Clopidogrel; its salts </text><text>Clorexolone </text><text>Cloridarol </text><text>Clorprenaline; its salts </text><text>Clothiapine </text><text class="left_indent_48 first_line_indent_-11">Clotrimazole; its salts;
                        except when contained in pharmaceutical products labelled only for the
                        treatment of tinea pedis or tinea cruris, or both</text><text>Clozapine; its salts </text><text>Cobicistat; its salts </text><text>Cobimetinib; its salts </text><text>Codergocrine mesilate</text><text>Colaspase </text><text>Colfosceril; its salts </text><text>Collagen, purified </text><text class="left_indent_48 first_line_indent_-11">Contrast media, the
                        following; their salts; any compound with any substance falling within this
                        item; when contained in preparations for parenteral use—</text><text class="left_indent_60">Acetrizoic acid </text><text class="left_indent_60">Diatrizoic acid </text><text class="left_indent_60">Ferucarbotran </text><text class="left_indent_60">Gadobenic acid </text><text class="left_indent_60">Gadobutrol </text><text class="left_indent_60">Gadodiamide </text><text class="left_indent_60">Gadopentetic acid </text><text class="left_indent_60">Gadoteric acid </text><text class="left_indent_60">Iobitridol </text><text class="left_indent_60">Iocarmic acid </text><text class="left_indent_60">Iocetamic acid </text><text class="left_indent_60">Iodamide </text><text class="left_indent_60">Iodipamide </text><text class="left_indent_60">Iodised oil </text><text class="left_indent_60">Iodixanol </text><text class="left_indent_60">Iodoxamic acid </text><text class="left_indent_60">Ioglicic acid </text><text class="left_indent_60">Ioglycamic acid </text><text class="left_indent_60">Iohexol </text><text class="left_indent_60">Iomeprol </text><text class="left_indent_60">Iopamidol </text><text class="left_indent_60">Iopanoic acid </text><text class="left_indent_60">Iophendylate </text><text class="left_indent_60">Iopromide </text><text class="left_indent_60">Iothalamic acid </text><text class="left_indent_60">Iotrolan </text><text class="left_indent_60">Iotroxic acid </text><text class="left_indent_60">Ioversol </text><text class="left_indent_60">Ioxaglic acid </text><text class="left_indent_60">Ioxitalamic acid </text><text class="left_indent_60">Ipodic acid </text><text class="left_indent_60">Metrizamide </text><text class="left_indent_60">Propyliodone </text><text class="left_indent_60">Sulphur hexafluoride </text><text class="left_indent_60">Tyropanoic acid </text><text>Corifollitropin alfa</text><text>Corticorelin; its salts</text><text>Corticotrophins</text><text>Corynebacterium parvum</text><text>Creosote obtained from wood</text><text>Crisaborole; its salts</text><text>Crizotinib; its salts</text><text>Croton, oil of</text><text class="left_indent_48 first_line_indent_-11">4-Cyano-2-dimethylamino-4,4-diphenylbutane; its salts</text><text class="left_indent_48 first_line_indent_-11">4-Cyano-1-methyl-4-phenylpiperidine; its salts</text><text>Cyclarbamate</text><text>Cyclobenzaprine; its salts</text><text>Cyclofenil</text><text class="left_indent_48 first_line_indent_-11">1-Cyclohexyl-3-para-toluenesulphonylurea (tolcyclamide)</text><text>Cyclosporin A </text><text>Cycrimine; its salts </text><text>Cytarabine; its salts </text><text>Dabigatran etexilate; its salts </text><text>Dabrafenib; its salts </text><text>Dacarbazine </text><text>Daclatasvir; its salts </text><text>Daclizumab </text><text>Dacomitinib; its salts </text><text>Dalteparin; its salts </text><text>Danicopan; its salts</text><text>Dapagliflozin; its salts </text><text>Dapoxetine; its salts </text><text>Dapsone </text><text>Daratumumab </text><text>Darbepoetin alfa </text><text>Daridorexant; its salts </text><text>Darifenacin; its salts </text><text>Darolutamide; its salts</text><text>Darunavir; its salts </text><text>Dasabuvir; its salts </text><text>Dasatinib; its salts </text><text>Deanol acetamidobenzoate </text><text>Debrisoquine; its salts </text><text>Decitabine; its salts </text><text>Deferasirox; its salts; its esters; their salts </text><text>Deferiprone; its salts </text><text>Degarelix; its salts </text><text>Dehydroemetine; its salts </text><text>Delafloxacin; its salts; its esters; their salts</text><text>Delamanid; its salts </text><text>Delandistrogene moxeparvovec</text><text>Demecarium bromide </text><text>Denosumab </text><text>Desferrioxamine; its salts </text><text>Desflurane </text><text>Desipramine; its salts </text><text>Desomorphine; its salts; its esters and ethers; their salts </text><text>Desvenlafaxine; its salts </text><text>Deucravacitinib; its salts</text><text>Dexketoprofen; its salts </text><text>Dexlansoprazole; its salts </text><text>Dexmedetomidine; its salts </text><text>Dexrazoxane; its salts </text><text>Diacerein; its salts; its esters </text><text>Diacetylnalorphine; its salts </text><text>Diampromide; its salts </text><text class="left_indent_48 first_line_indent_-11">Diazepam and other compounds
                        containing the chemical structure of dihydro-1,4-benzodiazepine substituted
                        to any degree; their salts</text><text>Diazoxide </text><text>Diclofenac; its salts </text><text>Didanosine; its salts </text><text>Diethylaminoethylephedrine; its salts </text><text>Diethyl para-nitrophenyl phosphate </text><text>Difenoxin; its salts </text><text>Diflunisal </text><text>Digitalis, glycosides of; other active principles of digitalis </text><text>Dihydralazine; its salts </text><text>Dihydrocodeine; its salts; its esters and ethers; their salts </text><text>Dihydrocodeinone; its salts </text><text class="left_indent_48 first_line_indent_-11">Dihydrocodeinone
                        O-carboxymethyloxime; its salts; its esters; their salts</text><text>Dihydrocodeinone enol acetate; its salts </text><text>Dihydroergotamine; its salts, simple or complex </text><text>Dihydroetorphine; its salts </text><text>Dihydromorphine; its salts; its esters and ethers; their salts </text><text>3-(3,4-Dihydroxyphenyl)alanine; its salts</text><text>Diltiazem; its salts </text><text>Dimefline; its salts </text><text>Dimenoxadole; its salts </text><text>Dimepheptanol; its salts; its esters and ethers; their salts </text><text class="left_indent_48 first_line_indent_-11">Dimethyl fumarate when
                        contained in pharmaceutical products</text><text class="left_indent_48 first_line_indent_-11">Dinutuximab beta</text><text>Dioxaphetyl butyrate; its salts</text><text>Diperodon; its salts</text><text>Diphenoxylate; its salts</text><text>Dipipanone; its salts</text><text>Diprenorphine; its salts</text><text>Diprophylline; its salts</text><text>Dipyridamole</text><text>Diquafosol; its salts</text><text>Disopyramide; its salts</text><text>Distigmine; its salts</text><text>Disulfiram</text><text class="left_indent_48 first_line_indent_-11">Dithienylallylamines;
                        dithienylalkylallylamines; their salts</text><text>Dobutamine; its salts </text><text>Docetaxel; its salts </text><text>Dolutegravir; its salts </text><text>Domperidone; its salts </text><text>Donanemab</text><text>Donepezil; its salts </text><text>Dopamine; its salts </text><text>Doravirine; its salts </text><text>Dornase alfa </text><text>Dorzolamide; its salts </text><text class="first_line_indent_0">Dostarlimab</text><text>Dothiepin; its salts </text><text>Doxapram; its salts </text><text>Doxazosin; its salts </text><text>Doxepin; its salts; its derivatives; their salts </text><text>Dronedarone; its salts </text><text>Droperidol </text><text>Drotrecogin alfa </text><text>Dulaglutide </text><text>Duloxetine; its salts </text><text>Dupilumab </text><text>Durvalumab </text><text>Dutasteride </text><text>Dyflos </text><text>Econazole; its salts </text><text>Ecothiopate iodide </text><text>Ectylurea </text><text>Eculizumab </text><text>Edoxaban; its salts </text><text>Efalizumab </text><text>Efanesoctocog alfa</text><text>Efavirenz; its salts </text><text>Efinaconazole; its salts </text><text>Elacestrant; its salts</text><text>Eladocagene exuparvovec</text><text>Elapegademase</text><text>Elaterin </text><text>Elbasvir; its salts </text><text>Eletriptan; its salts </text><text>Elosulfase alfa </text><text>Elotuzumab </text><text>Elranatamab</text><text>Eltrombopag; its salts; its esters; their salts </text><text>Elvitegravir; its salts </text><text>Embutramide </text><text>Emicizumab </text><text>Empagliflozin; its salts </text><text>Emtricitabine; its salts </text><text>Emylcamate </text><text>Enalapril; its salts </text><text>Enalaprilat; its salts </text><text>Encorafenib; its salts</text><text>Enfortumab vedotin</text><text>Enfuvirtide </text><text>Enoxacin; its salts; its esters </text><text>Enoxaparin; its salts </text><text>Enoximone </text><text>Enrofloxacin; its salts; its esters </text><text>Ensifentrine; its salts</text><text>Entacapone; its salts </text><text>Entecavir; its salts; its esters; their salts </text><text>Entrectinib; its salts </text><text>Enzalutamide; its salts </text><text>Epcoritamab</text><text>Eplerenone </text><text>Epoetin beta </text><text>Eprosartan; its salts </text><text>Eptifibatide; its salts </text><text>Eptinezumab</text><text>Equecabtagene autoleucel</text><text>Erdafitinib; its salts </text><text>Erenumab </text><text>Eribulin; its salts </text><text>Erlotinib; its salts </text><text>Ertugliflozin; its salts </text><text>Erythrityl tetranitrate </text><text>Esmolol; its salts </text><text>Esomeprazole; its salts </text><text>Etafedrine; its salts </text><text>Etafenone; its salts </text><text>Etamivan; its salts </text><text>Etanercept </text><text>Etelcalcetide; its salts </text><text>Ethacrynic acid; its salts </text><text>Ethambutol; its salts </text><text>Ethchlorvynol </text><text>Ethinamate </text><text>Ethionamide </text><text>Ethoglucid </text><text>Ethoheptazine; its salts </text><text>Ethosuximide; its salts </text><text>Ethylmorphine; its salts; its esters and ethers; their salts </text><text>Ethylnoradrenaline; its salts </text><text>Etidronic acid; its salts; when contained in pharmaceutical products </text><text>Etilefrine; its salts </text><text>Etodolac </text><text>Etofibrate</text><text>Etomidate; its salts </text><text>Etonitazene; its salts </text><text>Etoposide; its esters </text><text>Etoricoxib; its salts </text><text>Etorphine; its salts; its esters and ethers; their salts </text><text>Etoxeridine; its salts</text><text>Etranacogene dezaparvovec</text><text>Etrasimod; its salts; its esters; their salts</text><text>Etravirine </text><text>Etretinate </text><text>Etryptamine; its salts </text><text>Everolimus; its salts; its esters; their salts </text><text>Evocalcet; its salts; its esters; their salts</text><text>Evolocumab </text><text>Exemestane; its salts </text><text>Exenatide </text><text>Ezetimibe </text><text>Famciclovir; its salts </text><text>Fampridine; its salts </text><text>Faricimab</text><text>Febuxostat; its salts; its esters; their salts </text><text>Felodipine </text><text>Fenbufen </text><text>Fencamfamin; its salts </text><text>Fenclofenac; its salts </text><text>Fendiline; its salts </text><text>Fenfluramine; its salts </text><text>Fenofibrate </text><text>Fenoprofen; its salts </text><text>Fenoterol; its salts </text><text>Fenoxazoline; its salts </text><text>Fentanyl; its salts </text><text>Fentiazac; its salts </text><text>Fenticonazole; its salts </text><text>Feprazone </text><text>Fesoterodine; its salts; its esters; their salts </text><text>Fezolinetant; its salts</text><text>Filgotinib; its salts</text><text>Filgrastim </text><text>Finasteride </text><text>Finerenone; its salts</text><text>Fingolimod; its salts; its esters; their salts </text><text>Firocoxib; its salts </text><text>Fitusiran; its salts </text><text>Flavoxate; its salts </text><text>Flecainide; its salts </text><text>Fleroxacin; its salts; its esters </text><text>Fluanisone </text><text>Fluconazole; its salts </text><text>Flucytosine </text><text>Fludarabine; its salts </text><text>Flufenamic acid; its salts; its esters; their salts </text><text>Flumazenil </text><text>Flumethrin; its salts </text><text>Fluorouracil; its derivatives </text><text>Fluoxetine; its salts </text><text>Flupenthixol; its salts </text><text>Fluralaner; its salts </text><text>Flurbiprofen </text><text>Fluspirilene </text><text>Flutamide </text><text>Fluvastatin </text><text>Fluvoxamine; its salts </text><text>Folinic acid; its salts </text><text>Fondaparinux; its salts </text><text>Formestane </text><text>Formoterol; its salts </text><text>Fosaprepitant; its salts </text><text>Foscarnet trisodium hexahydrate </text><text>Fosinopril; its salts </text><text>Fosnetupitant; its salts</text><text>Fosphenytoin; its salts </text><text>Fostamatinib; its salts</text><text>Fotemustine; its salts </text><text>Fremanezumab</text><text>Fruquintinib; its salts</text><text>Frusemide </text><text>Fulvestrant </text><text>Furethidine; its salts </text><text>Futibatinib; its salts</text><text>Gabapentin; its salts </text><text>Gadoxetic acid; its salts </text><text>Galcanezumab </text><text>Gallamine; its salts; its quaternary compounds </text><text>Gallium-68; its salts; when contained in pharmaceutical products</text><text>Gallopamil; its salts </text><text>Galsulfase </text><text>Ganciclovir; its salts </text><text>Ganirelix; its salts </text><text>Gatifloxacin; its salts; its esters </text><text>Gefitinib; its salts </text><text>Gemcitabine; its salts </text><text>Gemfibrozil </text><text>Gemtuzumab ozogamicin </text><text class="left_indent_48 first_line_indent_-11">Germanium-68; its salts; when
                        contained in pharmaceutical products</text><text>Gilteritinib; its salts</text><text>Gimeracil; its salts </text><text>Glecaprevir; its salts </text><text>Glibenclamide </text><text>Glibornuride </text><text>Gliclazide</text><text>Glimepiride; its salts </text><text>Glipizide </text><text>Gliquidone </text><text>Glofitamab</text><text>Glucagon; its salts </text><text class="left_indent_48 first_line_indent_-11">Glutathione; its salts; its
                        derivatives; when contained in products for human parenteral
                        administration</text><text>Glutethimide; its salts </text><text>Glycerol phenylbutyrate</text><text>Glyceryl trinitrate </text><text>Glycopyrronium; its salts </text><text>Glymidine </text><text>Golimumab </text><text>Gonadorelin; its salts </text><text>Goserelin; its salts </text><text>Gozetotide; its salts</text><text>Granisetron; its salts </text><text>Grazoprevir; its salts </text><text>Grepafloxacin; its salts; its esters </text><text>Guanabenz; its salts </text><text>Guanethidine; its salts </text><text>Guanfacine; its salts </text><text>Guanidines, the following—</text><text class="left_indent_72 first_line_indent_-11">Polymethylene diguanidines;
                        di-para-anisyl-para-phenethylguanidine; their salts</text><text>Guselkumab</text><text>Halofantrine; its salts</text><text>Halofuginone; its salts</text><text class="left_indent_48 first_line_indent_-11">Haloperidol and other
                        4-substituted derivatives of N-(3-para-fluorobenzoylpropyl)
                        piperidine</text><text class="left_indent_48 first_line_indent_-11">Hemin; its salts; its esters;
                        their salts</text><text>Hexamethylmelamine</text><text>Hexapropymate</text><text>Hexobendine; its salts</text><text class="left_indent_48 first_line_indent_-11">Human chondrocytes when
                        contained in advanced therapy products indicated for the repair of
                        symptomatic articular cartilage defects</text><text>Human cytomegalovirus immunoglobulin</text><text>Hydralazine; its salts</text><text>Hydrazines, the following and their alpha-methyl derivatives—</text><text class="left_indent_60">Benzyl hydrazine</text><text class="left_indent_60">Phenethyl hydrazine</text><text class="left_indent_60">Phenoxyethyl hydrazine</text><text class="left_indent_48">their salts; their acyl derivatives; their
                        salts</text><text class="left_indent_48 first_line_indent_-11">Hydrocyanic acid; cyanides,
                        other than ferrocyanides and ferricyanides</text><text class="left_indent_48 first_line_indent_-11">Hydromorphinol; its salts;
                        its esters and ethers; their salts</text><text class="left_indent_48 first_line_indent_-11">Hydromorphone; its salts; its
                        esters and ethers; their salts</text><text class="left_indent_48 first_line_indent_-11">Hydroxycinchoninic acids;
                        derivatives of; their salts; their esters</text><text class="left_indent_48 first_line_indent_-11">Hydroxy-N,N-dimethyltryptamines; their esters and ethers; any salt of any
                        substance falling within this item</text><text class="left_indent_48 first_line_indent_-11">3-Hydroxy-N-methylmorphinan;
                        its salts; its optical isomers; their salts</text><text class="left_indent_48 first_line_indent_-11">3-Hydroxymorphinan; its
                        salts; its optical isomers; their salts; their esters and ethers; their
                        salts</text><text class="left_indent_48 first_line_indent_-11">3-Hydroxy-N-phenacylmorphinan; its salts; its optical isomers; their salts;
                        their esters and ethers; their salts</text><text class="left_indent_48 first_line_indent_-11">Hydroxypethidine; its salts;
                        its esters and ethers; their salts</text><text>Hydroxyphenamate </text><text>Hydroxyurea </text><text>Hydroxyzine; its salts </text><text>Ibandronic acid; its salts </text><text>Ibritumomab tiuxetan </text><text>Ibrutinib; its salts </text><text>Ibuprofen; its salts </text><text>Icatibant; its salts; its esters; their salts</text><text class="left_indent_48 first_line_indent_-11">Icosapent ethyl when
                        contained in pharmaceutical products indicated for the reduction of the risk
                        of myocardial infarction, stroke, coronary revascularization, or unstable
                        angina requiring hospitalization</text><text>Idarucizumab </text><text>Idelalisib; its salts </text><text>Idursulfase </text><text>Idursulfase beta</text><text>Ifosfamide </text><text>Iloprost; its salts </text><text>Imatinib; its salts </text><text>Imdevimab</text><text>Imidapril; its salts </text><text>Imiglucerase </text><text>Imipramine; its salts </text><text>Imiquimod; its salts </text><text>Inaticabtagene autoleucel</text><text>Inclisiran; its salts</text><text>Indacaterol; its salts; its esters; their salts </text><text>Indinavir; its salts </text><text>Indomethacin; its salts </text><text>Indoprofen; its salts </text><text>Indoramin; its salts </text><text>Infliximab </text><text>Inosine </text><text>Inosine pranobex </text><text>Inotuzumab ozogamicin </text><text>Insulin </text><text>Interferons </text><text>Iodine-131; its salts; when contained in pharmaceutical products </text><text class="left_indent_48 first_line_indent_-11">Ioflupane Iodine-123; its
                        salts; when contained in pharmaceutical products</text><text>Ipilimumab </text><text>Iprindole; its salts </text><text>Iptacopan; its salts</text><text>Irbesartan; its salts </text><text>Irinotecan; its salts </text><text>Isatuximab</text><text>Isavuconazole; its salts; its derivatives; their salts </text><text>Isoaminile; its salts </text><text>Isoconazole; its salts </text><text>Isoetharine; its salts </text><text>Isoflurane </text><text>Isomethadone; its salts </text><text class="left_indent_48 first_line_indent_-11">Isoniazid; its salts; its
                        derivatives; their salts; any compound with any substance falling within
                        this item</text><text>Isoprenaline; its salts </text><text>Isopyrin; its salts </text><text>Isosorbide; its nitrates </text><text>Isotretinoin </text><text>Isoxicam; its salts </text><text>Isradipine </text><text>Itraconazole; its salts </text><text>Ivabradine; its salts </text><text>Ivosidenib; its salts</text><text>Ixazomib; its salts </text><text>Ixekizumab </text><text>Ketamine; its salts </text><text>Ketanserin; its salts </text><text>Ketobemidone; its salts; its esters and ethers; their salts </text><text>Ketoconazole </text><text>Ketophenylbutazone </text><text>Ketoprofen; its salts </text><text>Ketorolac; its salts; its esters </text><text>Labetalol; its salts </text><text>Labuvirtide</text><text>Lacidipine; its salts </text><text>Lacosamide; its salts </text><text>Lamivudine; its salts </text><text>Lamotrigine; its salts </text><text>Lanadelumab</text><text>Lanreotide; its salts </text><text>Lansoprazole </text><text>Lanthanum carbonate </text><text>Lapatinib; its salts </text><text>Laronidase </text><text>Laropiprant; its salts </text><text>Larotrectinib; its salts </text><text>Latanoprostene bunod; its salts </text><text>Laudexium; its salts </text><text>Lazertinib; its salts</text><text>Lead acetates; compounds of lead with acids from fixed oils </text><text>Lebrikizumab</text><text>Lecanemab</text><text>Ledipasvir; its salts </text><text>Leflunomide; its salts </text><text>Lemborexant; its salts</text><text>Lenacapavir; its salts</text><text>Lenalidomide; its salts </text><text>Lenvatinib; its salts </text><text>Lepirudin; its salts </text><text>Lercanidipine; its salts </text><text>Letermovir; its salts; its esters; their salts </text><text>Letrozole </text><text>Leuprorelin; its salts </text><text>Levallorphan; its salts </text><text>Levetiracetam; its salts </text><text>Levodropropizine; its salts </text><text>Levosimendan; its salts </text><text>Lidoflazine </text><text>Lignocaine; its salts </text><text>Linaclotide; its salts </text><text>Linagliptin; its salts </text><text>Linezolid; its salts </text><text>Lipegfilgrastim </text><text>Liraglutide </text><text>Lisdexamfetamine; its salts </text><text>Lisinopril; its salts </text><text>Lithium carbonate </text><text>Lithium sulphate </text><text>Lixisenatide </text><text>Lodoxamide tromethamine </text><text>Lomefloxacin; its salts; its esters </text><text>Lomustine </text><text>Lonazolac; its salts </text><text class="first_line_indent_0">Loncastuximab tesirine</text><text>Lopinavir; its salts </text><text>Loracarbef; its salts </text><text>Lorcainide; its salts </text><text>Lorlatinib; its salts </text><text>Losartan; its salts </text><text>Lotilaner; its salts</text><text>Lovastatin when contained in pharmaceutical products </text><text>Loxapine; its salts </text><text>Lumefantrine; its salts </text><text>Lurasidone; its salts </text><text>Lurbinectedin; its salts</text><text class="first_line_indent_0">Luspatercept</text><text>Lutetium-177; its salts; when contained in pharmaceutical products</text><text class="left_indent_48 first_line_indent_-11">Lutetium (177Lu)
                        oxodotreotide; its salts</text><text class="left_indent_48 first_line_indent_-11">Lutetium (177Lu) vipivotide
                        tetraxetan; its salts</text><text class="left_indent_48 first_line_indent_-11">Lysergamide; its salts,
                        simple or complex; its quaternary compounds</text><text class="left_indent_48 first_line_indent_-11">Lysergic acid; its salts,
                        simple or complex; its quaternary compounds</text><text class="left_indent_48 first_line_indent_-11">Lysergide; its salts, simple
                        or complex; its quaternary compounds</text><text>Lysuride; its salts </text><text>Macitentan; its salts </text><text>Mangafodipir; its salts </text><text>Mannityl hexanitrate </text><text>Mannomustine; its salts </text><text>Maprotiline; its salts </text><text>Maralixibat; its salts</text><text>Maraviroc; its salts </text><text>Marbofloxacin; its salts </text><text>Maribavir; its salts</text><text>Marstacimab</text><text>Mavacamten; its salts</text><text>Mazindol </text><text>Mebezonium iodide </text><text>Mebutamate </text><text>Mecamylamine; its salts </text><text>Meclofenamic acid; its salts </text><text>Meclofenoxate; its salts </text><text>Medigoxin </text><text>Mefenamic acid; its salts; its esters; their salts </text><text>Mefloquine; its salts </text><text>Mefruside </text><text>Melagatran; its salts; its derivatives; their salts </text><text class="left_indent_48 first_line_indent_-11">Melatonin; its salts; when
                        contained in pharmaceutical products intended to be used for the treatment
                        of insomnia</text><text>Melitracen; its salts </text><text>Meloxicam; its salts </text><text>Memantine; its salts</text><text>Mephenesin; its esters; their salts </text><text>Mephenoxalone </text><text>Mepirizole; its salts </text><text>Mepivacaine; its salts </text><text>Mepolizumab </text><text>Meprobamate </text><text>alpha-Meprodine; its salts </text><text>beta-Meprodine; its salts </text><text>Mercaptopurine; its salts; its derivatives; their salts </text><text class="left_indent_48 first_line_indent_-11">Mercury, nitrates of; organic
                        compounds of; oxides of; mercuric ammonium chloride; mercuric chloride;
                        mercuric iodide; mercuric oxycyanide; mercuric thiocyanate; potassiomercuric
                        iodides</text><text>Meropenem; its salts</text><text>Mertiatide; its salts; its esters; their salts</text><text>Mesalazine; its salts</text><text class="left_indent_48 first_line_indent_-11">Mescaline; its salts; other
                        derivatives of phenethylamine formed by substitution in the aromatic ring;
                        their salts</text><text>Mesocarb; its salts </text><text>Metaflumizone; its salts </text><text>Metaraminol; its salts </text><text>Metaxalone </text><text>Metazocine; its salts; its esters and ethers; their salts </text><text>Metergoline </text><text>Metformin; its salts </text><text>Methadone; its salts </text><text>Methadyl acetate; its salts </text><text>Methaqualone; its salts </text><text>Methimazole; its salts </text><text>Methixene; its salts </text><text>Methocarbamol </text><text>Methorphan; its salts; its optical isomers; their salts </text><text>Methoxsalen </text><text>Methoxyflurane </text><text>Methoxyphenamine; its salts </text><text>Methylaminoheptane; its salts </text><text class="left_indent_48 first_line_indent_-11">Methyldesorphine; its salts;
                        its esters and ethers; their salts</text><text class="left_indent_48 first_line_indent_-11">Methyldihydromorphine; its
                        salts; its esters and ethers; their salts</text><text>Methyldopa; its esters; their salts</text><text class="left_indent_48 first_line_indent_-11">2-Methyl-3-morpholino-1,1-diphenylpropane carboxylic acid; its salts; its
                        esters; their salts</text><text>Methylnaltrexone; its salts</text><text>Methylpentynol; its derivatives</text><text class="left_indent_48 first_line_indent_-11">alpha-Methylphenethylamine;
                        beta-methylphenethylamine; alpha-ethylphenethylamine;
                        beta-ethylphenethylamine; their optical isomers; any synthetic compound
                        structurally derived from any of those substances by substitution in the
                        aliphatic part or by ring closure therein (or by both such substitution and
                        such closure) or by substitution in the aromatic ring (with or without
                        substitution at the nitrogen atom), except hydroxyamphetamine,
                        methoxyphenamine, pholedrine and N-substituted derivatives of ephedrine; any
                        salt of any substance falling within this item</text><text>Methylphenidate; its salts</text><text class="left_indent_48 first_line_indent_-11">1-Methyl-4-phenylpiperidine-4-carboxylic acid; its salts; its esters; their
                        salts</text><text>Methyprylone </text><text>Metipranolol; its salts </text><text>Metoclopramide; its salts </text><text>Metolazone </text><text>Metopon; its salts; its esters and ethers; their salts </text><text>Metoprolol; its salts </text><text>Metronidazole; its salts; its esters; their salts</text><text>Metyrapone; its salts </text><text>Mexiletine; its salts </text><text>Mianserin; its salts </text><text>Mibefradil; its salts </text><text>Micafungin; its salts; its esters </text><text>Miconazole; its salts </text><text>Midodrine; its salts </text><text>Midostaurin; its salts </text><text>Mifepristone; its salts; its esters; their salts </text><text>Migalastat; its salts</text><text>Miglitol; its salts </text><text>Milnacipran; its salts </text><text>Milrinone; its salts </text><text>Minoxidil </text><text>Mirabegron; its salts; its esters; their salts </text><text>Mirogabalin; its salts; its esters; their salts</text><text>Mirtazapine; its salts </text><text>Mitobronitol </text><text>Mitopodozide; its salts </text><text>Mitotane </text><text>Mitoxantrone; its salts </text><text>Mivacurium; its salts </text><text>Mizolastine; its salts </text><text>Mobocertinib; its salts</text><text>Moclobemide; its salts </text><text>Moexipril; its salts </text><text>Mofebutazone; its salts </text><text>Molgramostim </text><text>Molindone; its salts </text><text>Molnupiravir; its salts</text><text class="left_indent_48 first_line_indent_-11">Molybdate (99Mo); its salts;
                        when contained in pharmaceutical products</text><text>Momelotinib; its salts</text><text>Montelukast; its salts </text><text>Moracizine; its salts </text><text>Moramide; its salts; its optical isomers; their salts </text><text>Moroxydine; its salts </text><text>Morpheridine; its salts </text><text>Mosunetuzumab</text><text>Moxifloxacin; its salts </text><text>Moxonidine; its salts </text><text>Muromonab-CD3 </text><text class="left_indent_48 first_line_indent_-11">Mustine and any other
                        N-substituted derivative of di-(2- chloroethyl)amine; their salts</text><text>Muzolimine </text><text>Mycophenolic acid; its salts; its esters </text><text>Myrophine; its salts </text><text>Myrtecaine; its salts </text><text>Nabumetone </text><text>Nadolol; its salts </text><text>Nadroparin; its salts </text><text>Nafarelin; its salts </text><text>Naftidrofuryl; its salts </text><text>Nalbuphine; its salts </text><text>Naldemedine; its salts</text><text>Nalidixic acid </text><text>Nalmefene; its salts </text><text>Nalorphine; its salts </text><text>Naloxone; its salts </text><text>Naltrexone; its salts </text><text>alpha-Naphthylacetic acid; its salts </text><text>Naproxen; its salts </text><text>Naratriptan; its salts </text><text>Natalizumab </text><text>Nateglinide; its salts; its esters </text><text>Naxitamab</text><text>Nebivolol; its salts </text><text>Necitumumab </text><text>Nedocromil; its salts </text><text>Nefazodone; its salts </text><text>Nefopam; its salts </text><text>Nelfinavir; its salts </text><text>Neostigmine; its salts </text><text>Nepafenac; its salts </text><text>Neratinib; its salts </text><text>Nesiritide </text><text>Netarsudil; its salts</text><text>Netupitant; its salts </text><text>Nevirapine; its salts </text><text>Nicardipine; its salts </text><text>Nicergoline </text><text>Niclofolan </text><text>Nicocodine; its salts </text><text class="left_indent_48 first_line_indent_-11">Nicotinamide mononucleotide
                        when contained as an active ingredient in products for human parenteral
                        administration</text><text class="left_indent_48 first_line_indent_-11">Nicotinic acid and its salts
                        when contained in pharmaceutical products the recommended daily dose of
                        which contains more than 200 mg of nicotinic acid</text><text>Nifedipine </text><text>Nifenazone </text><text>Niflumic acid; its salts </text><text class="first_line_indent_0">Nifuratel; its salts</text><text class="first_line_indent_0">Nifuroxazide; its salts</text><text>Nilotinib; its salts </text><text>Nilvadipine </text><text>Nimesulide; its salts </text><text>Nimodipine </text><text>Nintedanib; its salts </text><text>Niraparib; its salts </text><text>Nirmatrelvir; its salts</text><text>Nirsevimab</text><text>Nisoldipine </text><text>Nitrendipine </text><text class="first_line_indent_0">Nitrofural; its salts</text><text class="first_line_indent_0">Nitrofurantoin; its salts</text><text>Nitromethaqualone; its salts </text><text class="first_line_indent_0">Nitroxoline; its salts</text><text>Nivolumab </text><text>Nomifensine; its salts </text><text>Noracymethadol; its salts </text><text>Noramidopyrine methanesulphonate; its salts </text><text>Norcodeine; its salts; its esters and ethers; their salts </text><text>Norfloxacin; its salts; its esters </text><text>Normethadone; its salts </text><text>Normorphine; its salts; its esters and ethers; their salts </text><text>Norpipanone; its salts </text><text>Nortriptyline; its salts </text><text>Nusinersen; its salts </text><text>Obinutuzumab; its antibody drug conjugates </text><text>Oclacitinib; its salts</text><text>Ocrelizumab</text><text>Ocriplasmin </text><text>Octreotide; its salts </text><text>Odevixibat; its salts; its esters; their salts</text><text>Ofatumumab</text><text>Ofloxacin; its salts; its esters </text><text>Olanzapine; its salts </text><text>Olaparib; its salts </text><text>Olaratumab </text><text>Olmesartan; its salts; its esters; their salts </text><text>Olodaterol; its salts </text><text>Olsalazine; its salts </text><text>Omalizumab </text><text>Ombitasvir; its salts </text><text class="left_indent_48 first_line_indent_-11">Omega-3 fatty acids; their
                        salts; their esters; when contained in pharmaceutical products intended to
                        be used for the treatment of hypertriglyceridaemia</text><text>Omeprazole; its salts </text><text>Omidenepag; its salts; its esters; their salts</text><text>Omoconazole; its salts </text><text>Onasemnogene abeparvovec</text><text>Ondansetron; its salts </text><text>Opipramol; its salts; its derivatives; their salts </text><text>Opium </text><text>Orciprenaline; its salts </text><text>Orgotein </text><text>Orlistat; its salts </text><text>Orphenadrine; its salts </text><text>Orthocaine; its salts </text><text>Oseltamivir; its salts </text><text>Osimertinib; its salts </text><text>Oteracil; its salts </text><text>Ouabain </text><text>Oxalic acid; its salts other than quadroxalates </text><text>Oxaliplatin; its salts </text><text>Oxanamide </text><text>Oxcarbazepine; its salts </text><text>Oxethazaine; its salts </text><text>Oxiconazole; its salts </text><text>Oxolamine; its salts </text><text>Oxprenolol; its salts </text><text>Oxycinchoninic acid; its derivatives; their salts; their esters </text><text>Oxycodone; its salts; its esters and ethers; their salts </text><text>Oxyfedrine; its salts </text><text>Oxymorphone; its salts; its esters and ethers; their salts </text><text>Oxypertine </text><text>Oxyphenbutazone </text><text>Oxytocins </text><text>Ozanimod; its salts</text><text>Paclitaxel </text><text>Palbociclib; its salts </text><text>Paliperidone; its salts </text><text>Palivizumab </text><text>Palonosetron; its salts </text><text>Pamidronate; its salts </text><text>Pancuronium; its salts </text><text>Panitumumab </text><text>Panobinostat; its salts </text><text>Pantethine; its salts </text><text>Pantoprazole; its salts </text><text>Paraldehyde </text><text>Paramethadione </text><text>Parecoxib; its salts </text><text>Pargyline; its salts </text><text>Paricalcitol; its salts; its esters; their salts </text><text>Paritaprevir; its salts </text><text>Paroxetine; its salts </text><text>Pasireotide; its salts </text><text>Pazopanib; its salts </text><text>Pefloxacin; its salts; its esters </text><text>Pegaptanib; its salts </text><text>Pegaspargase</text><text>Pegfilgrastim </text><text>Pegunigalsidase alfa </text><text>Pegvisomant; its salts </text><text>Pembrolizumab </text><text>Pemetrexed; its salts; its esters; their salts </text><text class="first_line_indent_0">Pemigatinib; its salts</text><text>Pemirolast; its salts </text><text>Pemoline; its salts </text><text>Pempidine; its salts </text><text>Penbutolol; its salts </text><text>Penciclovir; its salts </text><text>Penicillamine; its salts </text><text>Pentaerythritol tetranitrate </text><text>Pentamidine; its salts </text><text>Pentazocine; its salts </text><text>Pentolinium; its salts </text><text>Pentoxifylline; its salts</text><text>Perampanel </text><text>Perflubutane</text><text>Pergolide; its salts </text><text>Perindoprilat; its salts; its esters; their salts </text><text class="left_indent_48 first_line_indent_-11">Pertechnetate (99mTc); its
                        salts; when contained in pharmaceutical products</text><text>Pertuzumab </text><text class="left_indent_48 first_line_indent_-11">Pharmaceutical products for
                        human parenteral administration containing the following or their salts, as
                        active ingredients, except in mixture with insulin—</text><text class="left_indent_60">Acetic acid</text><text class="left_indent_60">Acetylcholine</text><text class="left_indent_60">Acetylcysteine</text><text class="left_indent_60">Adenosine</text><text class="left_indent_60">Adrenaline</text><text class="left_indent_60">Ambroxol</text><text class="left_indent_60">Amino acids</text><text class="left_indent_60">Aminophylline</text><text class="left_indent_60">Anti-D (rho) immunoglobulins</text><text class="left_indent_60">Antihistamine substances</text><text class="left_indent_60">Betiatide</text><text class="left_indent_60">Bicisate</text><text class="left_indent_60">Butetamate</text><text class="left_indent_60">Caffeine</text><text class="left_indent_60">Carnitine</text><text class="left_indent_71 first_line_indent_-11">Cations, the following,
                        except in preparations containing any substance to which the Antibiotics
                        Ordinance (<ref href="/hk/cap137">Cap. 137</ref>) applies—</text><text class="left_indent_82">Calcium</text><text class="left_indent_82">Chromium</text><text class="left_indent_82">Copper</text><text class="left_indent_82">Iron</text><text class="left_indent_82">Magnesium</text><text class="left_indent_82">Manganese</text><text class="left_indent_82">Potassium</text><text class="left_indent_82">Selenium</text><text class="left_indent_82">Sodium, except sodium chloride 0.9%</text><text class="left_indent_82">Zinc</text><text class="left_indent_60">Choline</text><text class="left_indent_60">Cimetidine</text><text class="left_indent_60">Citicoline</text><text class="left_indent_60">Deoxycholic acid</text><text class="left_indent_60">Dextromethorphan</text><text class="left_indent_60">Dicycloverine</text><text class="left_indent_60">Difenidol</text><text class="left_indent_60">Disofenin</text><text class="left_indent_60">Ephedrine</text><text class="left_indent_60">Exametazime</text><text class="left_indent_60">Fish oil</text><text class="left_indent_60">Fluorescein</text><text class="left_indent_60">Gallium</text><text class="left_indent_60">Gelatin</text><text class="left_indent_60">Glucosamine</text><text class="left_indent_60">Glucose</text><text class="left_indent_60">Glycerol</text><text class="left_indent_60">Glyceryl trinitrate</text><text class="left_indent_60">Guaifenesin</text><text class="left_indent_60">Heparin</text><text class="left_indent_60">Hyaluronic acid</text><text class="left_indent_60">Hyaluronidase</text><text class="left_indent_60">Hydroxyethyl starch</text><text class="left_indent_60">Hyoscine</text><text class="left_indent_60">Icodextrin</text><text class="left_indent_60">Indigo carmine</text><text class="left_indent_60">Indocyanine green</text><text class="left_indent_60">Iodine norcholesterol</text><text class="left_indent_60">Isosorbide</text><text class="left_indent_60">Lactic acid</text><text class="left_indent_60">Lecithin</text><text class="left_indent_60">Lignocaine</text><text class="left_indent_60">Mannitol</text><text class="left_indent_60">Mebrofenin</text><text class="left_indent_60">Medronic acid</text><text class="left_indent_60">Mesna</text><text class="left_indent_60">Methoxyphenamine</text><text class="left_indent_60">Methylene blue</text><text class="left_indent_60">Methylephedrine</text><text class="left_indent_60">Noradrenaline</text><text class="left_indent_60">Olive oil</text><text class="left_indent_60">Omeprazole</text><text class="left_indent_60">Oxidronate</text><text class="left_indent_60">Papaverine</text><text class="left_indent_60">Paracetamol</text><text class="left_indent_60">Patent blue V</text><text class="left_indent_60">Pentetic acid</text><text class="left_indent_60">Phenol</text><text class="left_indent_60">Phenylephrine</text><text class="left_indent_60">Procaine</text><text class="left_indent_60">Protamine</text><text class="left_indent_60">Ranitidine</text><text class="left_indent_60">Rhenium</text><text class="left_indent_60">Sodium chloride 0.9%</text><text class="left_indent_60">Sodium pyrophosphate</text><text class="left_indent_60">Sodium tetradecyl sulfate</text><text class="left_indent_60">Sodium thiosulfate</text><text class="left_indent_60">Sorbitol</text><text class="left_indent_60">Soya oil</text><text class="left_indent_60">Stonefish antivenom</text><text class="left_indent_60">Succimer</text><text class="left_indent_60">Terbutaline</text><text class="left_indent_60">Tetrakis copper tetrafluoroborate</text><text class="left_indent_60">Tetrofosmin</text><text class="left_indent_60">Thallium</text><text class="left_indent_60">Tin</text><text class="left_indent_60">Triglycerides</text><text class="left_indent_60">Tuberculin</text><text class="left_indent_60">Vitamins</text><text class="left_indent_60">Water</text><text class="left_indent_60">Xantinol nicotinate</text><text>Phenacemide </text><text>Phenacetin </text><text>Phenadoxone; its salts </text><text>Phenaglycodol </text><text>Phenampromide; its salts </text><text>Phenazocine; its salts; its esters and ethers; their salts </text><text>Phenazopyridine; its salts</text><text>Phenbutrazate </text><text>Phencyclidine; its salts </text><text>Phenetidylphenacetin </text><text>Phenformin; its salts </text><text>Phenindione </text><text class="left_indent_48 first_line_indent_-11">Phenols (any member of the
                        series of phenols of which the first member is phenol and of which the
                        molecular composition varies from member to member by 1 atom of carbon and 2
                        atoms of hydrogen) except in substances containing less than 60%, weight in
                        weight, of phenols; compounds of phenol with a metal, except in substances
                        containing less than the equivalent of 60%, weight in weight, of
                        phenols</text><text>Phenomorphan; its salts; its esters and ethers; their salts</text><text>Phenoperidine; its salts; its esters and ethers; their salts</text><text class="left_indent_48 first_line_indent_-11">Phenothiazine; its salts; its
                        derivatives (except dimethoxanate); their salts (except salts of
                        dimethoxanate); any compound with any substance falling within this
                        item</text><text>Phenoxybenzamine; its salts</text><text>Phenprenazone</text><text>Phenprobamate</text><text>Phentolamine; its salts</text><text>Phenylbutazone; its salts</text><text class="left_indent_48 first_line_indent_-11">2-Phenylcinchoninic acid;
                        2-salicylcinchoninic acid; their salts; their esters</text><text class="left_indent_48 first_line_indent_-11">5-Phenylhydantoin; its alkyl
                        and aryl derivatives; their salts</text><text class="left_indent_48 first_line_indent_-11">4-Phenylpiperidine-4-carboxylic acid ethyl ester; its salts</text><text class="left_indent_48 first_line_indent_-11">Pholcodine; its salts; its
                        esters and ethers; their salts</text><text class="left_indent_48 first_line_indent_-11">Phospholipid fraction; when
                        contained in pharmaceutical products intended to be used as pulmonary
                        surfactant for the treatment of respiratory distress syndrome</text><text>Pibrentasvir; its salts </text><text>Picric acid </text><text>Picrotoxin </text><text>Pimecrolimus </text><text>Piminodine; its salts </text><text>Pimobendan; its salts </text><text>Pioglitazone; its salts </text><text>Pipecuronium; its salts </text><text>Pipemidic acid </text><text>Pipobroman </text><text>Piracetam; its salts</text><text>Pirfenidone; its salts </text><text>Piritramide; its salts </text><text>Piromidic acid; its salts </text><text>Piroxicam </text><text>Pirprofen; its salts </text><text>Pirtobrutinib; its salts</text><text>Pitavastatin; its salts; its esters; their salts</text><text>Pitolisant; its salts</text><text class="left_indent_48 first_line_indent_-11">Pituitary gland, the active
                        principles of, other than corticotrophins, oxytocins and vasopressins</text><text>Pizotifen; its salts </text><text>Plerixafor; its salts </text><text>Podophyllum resin </text><text>Polatuzumab vedotin </text><text>Polymethylenebistrimethylammonium salts </text><text>Pomalidomide; its salts </text><text>Ponatinib; its salts </text><text class="first_line_indent_0">Ponesimod; its salts</text><text>Poractant alfa </text><text>Porfimer; its salts </text><text>Posaconazole; its salts; its esters; their salts </text><text>Pralidoxime; its salts </text><text>Pralsetinib; its salts</text><text>Pramipexole; its salts </text><text>Pramoxine; its salts </text><text>Prasterone; its salts; when contained in pharmaceutical products </text><text>Prasugrel; its salts </text><text>Pravastatin; its salts; its esters </text><text>Prazosin; its salts </text><text>Pregabalin; its salts </text><text>Pretomanid; its salts</text><text>Pridinol; its salts </text><text>Primaquine; its salts </text><text>Primidone </text><text>Prindolol; its salts </text><text>Probenecid</text><text>Probucol </text><text>Procainamide; its salts </text><text>Procarbazine; its salts </text><text>Procaterol; its salts </text><text>Procyclidine; its salts </text><text>alpha-Prodine; its salts </text><text>beta-Prodine; its salts </text><text>Proglumetacin; its salts </text><text>Proguanil; its salts </text><text>Proheptazine; its salts </text><text>Promoxolane </text><text>Propafenone; its salts </text><text>Propanidid </text><text>Propiverine; its salts </text><text>Propofol </text><text>Propoxur; its salts </text><text>Propoxyphene; its salts; its optical isomers; their salts </text><text>Propranolol; its salts; its derivatives; their salts </text><text>Propylhexedrine; its salts </text><text>Propylthiouracil; its salts </text><text>Proquazone </text><text>Prostaglandins, the following and their derivatives—</text><text class="left_indent_60">Alprostadil</text><text class="left_indent_60">Bimatoprost</text><text class="left_indent_60">Dinoprost</text><text class="left_indent_60">Dinoprostone </text><text class="left_indent_60">Epoprostenol </text><text class="left_indent_60">Latanoprost </text><text class="left_indent_60">Misoprostol </text><text class="left_indent_60">Travoprost </text><text class="left_indent_60">Unoprostone </text><text class="left_indent_48">their salts; their esters</text><text>Prothionamide </text><text>Prothipendyl; its salts </text><text>Protirelin; its salts </text><text>Protriptyline; its salts; its derivatives; their salts </text><text>Prucalopride; its salts </text><text>Prulifloxacin; its salts; its esters; their salts </text><text>Pseudoephedrine; its salts </text><text>Pyrazinamide </text><text>Pyricarbate (Pyridinolcarbamate) </text><text>Pyridostigmine; its salts </text><text>Pyrimethamine </text><text>Pyriprole; its salts </text><text>Pyrithyldione </text><text>Quetiapine; its salts </text><text>Quinagolide; its salts </text><text>Quinapril; its salts </text><text>Quinethazone </text><text>Quinidine; its salts </text><text>Quinine; its salts; its derivatives; their salts </text><text>Quizartinib; its salts</text><text>Rabeprazole; its salts </text><text>Racecadotril; its salts </text><text>Ractopamine; its salts </text><text class="left_indent_48 first_line_indent_-12">Radium-223; its salts; when
                        contained in pharmaceutical products</text><text>Raloxifene; its salts </text><text>Raltegravir; its salts </text><text>Raltitrexed; its salts </text><text>Ramipril; its salts </text><text>Ramucirumab </text><text>Ranibizumab </text><text>Ranolazine; its salts </text><text>Rasagiline; its salts </text><text>Rasburicase; its salts </text><text>Ravulizumab</text><text>Reboxetine; its salts </text><text>Recombinant human erythropoietin </text><text>Regadenoson; its salts </text><text>Regorafenib; its salts </text><text>Remdesivir; its salts</text><text>Remifentanil; its salts </text><text>Remoxipride; its salts </text><text>Repaglinide; its salts; its esters </text><text>Repotrectinib; its salts</text><text>Reproterol; its salts </text><text>Rescinnamine </text><text>Reteplase </text><text>Retigabine; its salts </text><text>Revefenacin; its salts</text><text>Reviparin; its salts </text><text>Ribavirin; its salts </text><text>Ribociclib; its salts </text><text>Rilmenidine; its salts </text><text>Rilpivirine; its salts </text><text>Riluzole; its salts </text><text>Rimegepant; its salts</text><text>Rimiterol; its salts </text><text>Rimonabant; its salts </text><text>Riociguat; its salts </text><text>Ripretinib; its salts</text><text>Risankizumab</text><text>Risdiplam; its salts</text><text>Risedronic acid; its salts </text><text>Risperidone </text><text>Ritlecitinib; its salts</text><text>Ritodrine; its salts </text><text>Ritonavir; its salts </text><text>Rituximab </text><text>Rivaroxaban; its salts </text><text>Rivastigmine; its salts </text><text>Rizatriptan; its salts </text><text>Rocuronium; its salts </text><text>Rofecoxib; its salts </text><text>Roflumilast; its salts </text><text>Romiplostim </text><text>Romosozumab </text><text>Ropeginterferon alfa-2b</text><text>Ropinirole; its salts </text><text>Ropivacaine; its salts </text><text>Rosiglitazone; its salts </text><text>Rosoxacin; its salts </text><text>Rosuvastatin; its salts </text><text>Rotigotine; its salts </text><text>Roxadustat; its salts</text><text>Rufinamide; its salts </text><text>Rurioctocog alfa pegol</text><text>Ruxolitinib; its salts </text><text>Sacituzumab govitecan</text><text>Sacubitril; its salts </text><text>Safinamide; its salts</text><text>Salbutamol; its salts </text><text>Salmeterol; its salts </text><text>Saquinavir; its salts </text><text>Sarilumab </text><text>Satralizumab</text><text>Savin, oil of </text><text>Savolitinib; its salts</text><text>Saxagliptin; its salts </text><text>Sebelipase alfa</text><text>Secukinumab </text><text>Selexipag; its salts </text><text>Selinexor; its salts</text><text>Selpercatinib; its salts</text><text class="first_line_indent_0">Selumetinib; its salts</text><text>Semaglutide </text><text>Sermorelin; its salts </text><text>Sertaconazole; its salts </text><text>Sertindole; its salts </text><text>Sertraline; its salts </text><text>Sevelamer; its salts </text><text>Sevoflurane</text><text class="left_indent_48 first_line_indent_-11">Sibutramine; its salts; any
                        compound containing the chemical structure of
                        1-[1-(4-Chlorophenyl)cyclobutyl]-3-methylbutan-1-amine substituted to any
                        degree or without substitution; its salts</text><text class="left_indent_48 first_line_indent_-11">Sildenafil; its salts; any
                        compound containing the chemical structure of
                            5-(2-ethoxyphenyl)-1-methyl-3-propyl-1<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7(6<i>H</i>)-one
                        substituted to any degree or without substitution; its salts</text><text>Silodosin; its salts</text><text>Siltuximab</text><text>Simeprevir; its salts</text><text>Simvastatin </text><text>Sintilimab</text><text>Siponimod; its salts; its esters; their salts</text><text>Sirolimus; its salts </text><text>Sitagliptin; its salts </text><text>Socazolimab</text><text>Sodium aurothiomalate </text><text>Sodium cromoglycate </text><text>Sodium nitroprusside </text><text>Sodium zirconium cyclosilicate </text><text>Sofosbuvir; its salts </text><text>Solifenacin; its salts; its esters; their salts </text><text>Solriamfetol; its salts</text><text>Somapacitan</text><text>Somatostatin </text><text>Somatrogon</text><text>Sorafenib; its salts </text><text>Sotalol; its salts </text><text>Sotatercept</text><text>Sotorasib; its salts</text><text>Sparfloxacin; its salts; its esters </text><text>Sparteine; its salts </text><text>Spesolimab</text><text>Spinosad </text><text>Spironolactone </text><text>Stavudine; its salts </text><text>Stiripentol; its salts</text><text>Streptokinase </text><text>Strontium ranelate </text><text>Strophanthus, glycosides of </text><text>Styramate </text><text>Sucroferric oxyhydroxide </text><text>Sugammadex; its salts; its esters; their salts </text><text>Sulconazole; its salts </text><text>Sulindac </text><text>Sulphinpyrazone </text><text>Sulphonal; alkyl sulphonals </text><text>Sulpiride </text><text>Sultopride </text><text>Sumatriptan; its salts </text><text>Sunitinib; its salts </text><text class="left_indent_48 first_line_indent_-11">Suprarenal gland, the active
                        principles of; their salts; their derivatives; their salts</text><text>Surufatinib; its salts</text><text>Sutoprofen; its salts</text><text>Suxamethonium; its salts</text><text>Syrosingopine</text><text>Tacrine; its salts</text><text>Tacrolimus</text><text class="left_indent_48 first_line_indent_-11">Tadalafil; its salts; any
                        compound containing the chemical structure of
                        6-(Benzo[1,3]dioxol-5-yl)-2,3,6,7,12,12a-hexahydropyrazino
                            [1’,2’:1,6]pyrido[3,4-<i>b</i>]indole-1,4-dione substituted to any
                        degree or without substitution; its salts </text><text>Tafamidis; its salts </text><text>Tafasitamab</text><text>Tafluprost </text><text>Tagraxofusp</text><text>Talazoparib; its salts </text><text>Talquetamab</text><text>Tamoxifen; its salts </text><text>Tapentadol; its salts </text><text>Tarlatamab</text><text>Tazarotene; its salts </text><text>Tazemetostat; its salts</text><text>Teclistamab</text><text>Tegaserod; its salts </text><text>Telbivudine; its salts </text><text>Telmisartan; its salts </text><text>Temozolomide; its salts </text><text>Temsirolimus; its salts; its esters </text><text>Tenapanor; its salts</text><text>Tenecteplase; its salts </text><text>Teniposide </text><text>Tenofovir; its salts; its derivatives; their salts </text><text>Tenoxicam </text><text class="first_line_indent_0">Tepotinib; its salts</text><text class="first_line_indent_0">Teprotumumab</text><text>Terazosin; its salts </text><text class="left_indent_48 first_line_indent_-11">Terbinafine; its salts;
                        except when contained in preparations for external application only with no
                        more than 1% of Terbinafine and not to be administered as a single
                        application and when labelled only for the treatment of tinea pedis or tinea
                        cruris, or both</text><text>Terbutaline; its salts </text><text>Terconazole; its salts </text><text>Teriflunomide; its salts </text><text>Teriparatide; its salts </text><text>Terodiline; its salts </text><text>Tertatolol; its salts </text><text>Tetrabenazine; its salts </text><text>Tetracosactide; its salts </text><text>Tezepelumab</text><text>Thalidomide; its salts </text><text>Thallium, salts of </text><text>Theofibrate </text><text>Theophylline; its salts </text><text>Thiacetazone </text><text>Thiocarlide; its salts </text><text class="left_indent_48 first_line_indent_-11">Thioctic acid; its salts; its
                        derivatives; when contained in pharmaceutical products</text><text>Thiotepa </text><text>Thymosin alpha 1 </text><text>Thyroid gland, the active principles of; their salts </text><text>Thyrotropin alfa </text><text>Tiagabine; its salts; its esters; their salts </text><text>Tianeptine; its salts; its esters; their salts </text><text>Tiapride; its salts </text><text>Ticagrelor; its salts; its esters; their salts </text><text>Ticlopidine; its salts </text><text>Tildrakizumab</text><text>Tiletamine; its salts </text><text>Tilidate; its salts </text><text>Tiludronic acid; its salts </text><text>Timolol; its salts </text><text>Tinidazole; its salts </text><text>Tinoridine; its salts </text><text>Tinzaparin; its salts </text><text>Tioconazole; its salts </text><text>Tiotropium; its salts </text><text class="left_indent_48 first_line_indent_-11">Tipiracil; its salts; when
                        contained in pharmaceutical products</text><text>Tiratricol; its salts </text><text>Tirofiban; its salts </text><text>Tirzepatide</text><text>Tisagenlecleucel </text><text>Tislelizumab</text><text>Tisotumab vedotin</text><text>Tixagevimab</text><text>Tizanidine; its salts </text><text>Tocainide; its salts </text><text>Tocilizumab </text><text>Todralazine; its salts </text><text>Tofacitinib; its salts </text><text>Tofenacin; its salts </text><text>Tolazamide </text><text>Tolbutamide </text><text>Tolcapone; its salts </text><text>Tolfenamic acid; its salts </text><text>Tolmetin; its salts </text><text>Tolperisone; its salts </text><text>Tolterodine; its salts </text><text>Tolvaptan </text><text>para-Tolylmethylcarbinol nicotinic acid ester </text><text>Topiramate; its salts </text><text>Topotecan; its salts </text><text>Torasemide </text><text>Toripalimab</text><text>Trabectedin; its salts; its esters </text><text>Tramadol; its salts </text><text>Trametinib; its salts </text><text>Trandolapril; its salts </text><text>Tranexamic acid </text><text>Tranylcypromine; its salts </text><text>Trastuzumab; its antibody drug conjugates </text><text>Trazodone; its salts </text><text>Tremelimumab</text><text>Treosulfan; its salts</text><text>Treprostinil; its salts; its esters; their salts</text><text>Tretamine; its salts </text><text>Tretinoin </text><text>Tretoquinol; its salts </text><text>Triamterene; its salts </text><text>Triaziquone </text><text>Tribromoethyl alcohol </text><text>2,2,2-Trichloroethyl alcohol, esters of; their salts </text><text>Trientine; its salts; when contained in pharmaceutical products</text><text>Trifarotene; its salts; its esters; their salts</text><text>Trifluridine; its salts </text><text>Trilostane </text><text>Trimeperidine; its salts </text><text>Trimetaphan; its salts </text><text>Trimetazidine; its salts </text><text>Trimethadione </text><text>Trimethoprim </text><text>Trimetozine </text><text>Trimetrexate; its salts </text><text>Trimipramine; its salts </text><text>Trioxsalen </text><text>Triptorelin; its salts </text><text>Tromantadine; its salts </text><text>Tropisetron; its salts </text><text>Trospium chloride</text><text>Trovafloxacin; its salts; its derivatives; their salts </text><text>Tucatinib; its salts</text><text>Tulobuterol; its salts </text><text>Tybamate </text><text>Umeclidinium; its salts </text><text>Upadacitinib; its salts</text><text>Urapidil; its salts </text><text>Urethane </text><text>Urokinase </text><text>Ustekinumab </text><text>Valaciclovir; its salts </text><text>Valdecoxib; its salts </text><text>Valganciclovir; its salts </text><text>Valnoctamide </text><text>Valproic acid; its salts; its esters </text><text>Valsartan; its salts </text><text>Vandetanib; its salts </text><text class="left_indent_48 first_line_indent_-11">Vardenafil; its salts; any
                        compound containing the chemical structure of
                            2-(2-ethoxyphenyl)-5-methyl-7-propylimidazo[5,1-<i>f</i>][1,2,4]triazin-4(3<i>H</i>)-one
                        substituted to any degree or without substitution; its salts</text><text>Varenicline; its salts </text><text>Vasopressins </text><text>Vecuronium; its salts </text><text>Vedolizumab </text><text>Velmanase alfa</text><text>Velpatasvir; its salts </text><text>Vemurafenib; its salts </text><text>Venetoclax; its salts </text><text>Venlafaxine; its salts </text><text>Veralipride; its salts </text><text>Verapamil; its salts </text><text>Vericiguat; its salts</text><text>Vernakalant; its salts </text><text>Verteporfin; its salts </text><text>Vidarabine; its salts </text><text>Vigabatrin </text><text>Vilanterol; its salts </text><text>Vildagliptin; its salts </text><text>Viloxazine; its salts </text><text>Vindesine; its salts </text><text>Vinorelbine; its salts </text><text>Vismodegib; its salts </text><text class="left_indent_48 first_line_indent_-11">Vitamin A and its esters when
                        contained in pharmaceutical products the recommended daily dose of which
                        contains not less than 10 000 international units of vitamin A</text><text class="left_indent_48 first_line_indent_-11">Vitamin D and its salts when
                        contained in pharmaceutical products the recommended daily dose of which
                        contains more than 1 000 international units of vitamin D</text><text class="left_indent_48 first_line_indent_-11">Vitamin K and its salts when
                        contained in pharmaceutical products, except products with recommended daily
                        dose of 120 mcg or less of vitamin K1 or K2 or its salts</text><text>Vonoprazan; its salts</text><text>Voriconazole; its salts </text><text>Vortioxetine; its salts </text><text>Vosoritide</text><text>Voxilaprevir; its salts </text><text>Vutrisiran; its salts</text><text>Warfarin; its salts </text><text>Xamoterol; its salts </text><text>Xylazine; its salts </text><text>Zafirlukast </text><text>Zalcitabine; its salts </text><text>Zaleplon; its salts </text><text>Zanamivir; its salts </text><text>Zanubrutinib; its salts</text><text>Zidovudine </text><text>Zimelidine; its salts </text><text>Zipeprol; its salts </text><text>Ziprasidone; its salts </text><text>Zofenopril; its salts </text><text>Zolazepam; its salts </text><text>Zolbetuximab</text><text>Zoledronic acid; its salts </text><text>Zolmitriptan; its salts </text><text>Zolpidem; its salts </text><text>Zomepirac; its salts </text><text>Zopiclone </text><text>Zoxazolamine; its salts </text><sourceNote class="align_justified">(<ref href="/hk/2015/ln34">L.N. 34 of
                            2015</ref>; <ref href="/hk/2015/ln67">L.N. 67 of 2015</ref>; <ref href="/hk/2015/ln100">L.N. 100 of 2015</ref>; <ref href="hk/2015/ln193">L.N. 193 of 2015</ref>; <ref href="hk/2015/ln235">L.N. 235 of
                            2015</ref>; <ref href="hk/2016/ln40">L.N. 40 of 2016</ref>; <ref href="hk/2016/ln51">L.N. 51 of 2016</ref>; <ref href="hk/2016/ln83">L.N. 83 of 2016</ref>; <ref href="hk/2016/ln119">L.N. 119 of 2016</ref>; <ref href="hk/2016/ln172">L.N. 172 of 2016</ref>; <ref href="hk/2017/ln11">L.N. 11 of 2017</ref>; <ref href="hk/2017/ln38">L.N. 38 of 2017</ref>; <ref href="hk/2017/ln119">L.N. 119 of 2017</ref>; <ref href="hk/2017/ln140">L.N. 140 of 2017</ref>; <ref href="hk/2017/ln167">L.N. 167 of 2017</ref>; <ref href="hk/2018/ln10">L.N. 10 of 2018</ref>; <ref href="hk/2018/ln42">L.N. 42 of 2018</ref>; <ref href="hk/2018/ln80">L.N. 80 of 2018</ref>; <ref href="hk/2018/ln136">L.N. 136 of
                        2018</ref>; <ref href="hk/2018/ln191">L.N. 191 of 2018</ref>; <ref href="hk/2018/ln210">L.N. 210 of 2018</ref>; <ref href="hk/2018/ln228">L.N. 228 of 2018</ref>; <ref href="hk/2019/ln3">L.N. 3 of 2019</ref>; <ref href="hk/2019/ln10">L.N. 10 of 2019</ref>; <ref href="hk/2019/ln30">L.N. 30 of 2019</ref>; <ref href="hk/2019/ln145">L.N. 145 of
                        2019</ref>; <ref href="hk/2019/ln184">L.N. 184 of 2019</ref>; <ref href="hk/2020/ln14">L.N. 14 of 2020</ref>; <ref href="hk/2020/ln41">L.N.
                            41 of 2020</ref>; <ref href="hk/2020/ln126">L.N. 126 of 2020</ref>; <ref href="hk/2020/er5">E.R. 5 of 2020</ref>; <ref href="hk/2020/ln212">L.N.
                            212 of 2020</ref>; <ref href="hk/2020/ln252">L.N. 252 of 2020</ref>; <ref href="hk/2021/ln104">L.N. 104 of 2021</ref>; <ref href="hk/2021/ln218">L.N. 218 of 2021</ref>; <ref href="hk/2022/ln1">L.N. 1 of 2022</ref>; <ref href="hk/2022/ln19">L.N. 19 of 2022</ref>; <ref href="hk/2022/ln33">L.N. 33 of 2022</ref>; <ref href="hk/2022/ln122">L.N. 122 of
                        2022</ref>; <ref href="hk/2022/ln194">L.N. 194 of
                        2022</ref>; <ref href="hk/2022/ln232">L.N. 232 of 2022</ref>; <ref href="hk/2023/ln10">L.N. 10 of
                            2023</ref>; <ref href="hk/2023/ln108">L.N. 108 of
                        2023</ref>; <ref href="hk/2023/ln138">L.N. 138 of
                        2023</ref>; <ref href="hk/2024/ln9">L.N. 9 of
                        2024</ref>; <ref href="hk/2024/ln73">L.N. 73 of
                        2024</ref>; <ref href="hk/2024/ln105">L.N. 105 of
                        2024</ref>; <ref href="hk/2024/ln135">L.N. 135 of
                        2024</ref>; <ref href="hk/2024/ln177">L.N. 177 of
                        2024</ref>; <ref href="hk/2025/ln5">L.N. 5 of 2025</ref>; <ref href="hk/2025/ln38">L.N. 38 of
                        2025</ref>; <ref href="hk/2025/ln116">L.N. 116 of 2025</ref>; <ref href="hk/2025/ln161">L.N. 161 of 2025</ref>; <ref href="hk/2025/ln211">L.N. 211 of
                        2025</ref>)<marker role="blank-line"></marker><marker role="blank-line"></marker></sourceNote></division><crossHeading><b>Division B</b><marker role="blank-line"></marker></crossHeading><division name="D0-1" temporalId="sch10_s2_P0_D0-1" id="ID_1676952994651_005"><text>Alkali fluorides other than those specified in Part 2 of this List</text><text>Barium, salts of, except barium sulphate</text><text>alpha-Chlorohydrin (3-chloro-1,2-Propanediol)</text><text>Dinitronaphthols; dinitrophenols; dinitrothymols</text><text>Hexachlorophane, the following—</text><paragraph id="ID_1597130606242_001" name="0" temporalId="sch10_s2_P0_D0-1_0"><subparagraph id="ID_1438411275205_006" name="a" temporalId="sch10_s2_P0_D0-1_0_a"><num value="a">(a)</num><content>medicinal products for human use containing more than 0.1%
                                hexachlorophane;</content></subparagraph><subparagraph id="ID_1438411275205_015" name="b" temporalId="sch10_s2_P0_D0-1_0_b"><num value="b">(b)</num><leadIn>preparations for animal use—</leadIn><subparagraph id="ID_1438411275205_024" name="i" temporalId="sch10_s2_P0_D0-1_0_b_i"><num value="i">(i)</num><content>aerosols the contents of the container of which contain
                                    more than 0.1% hexachlorophane;</content></subparagraph><subparagraph id="ID_1438411275205_033" name="ii" temporalId="sch10_s2_P0_D0-1_0_b_ii"><num value="ii">(ii)</num><content>soaps and shampoos containing more than 2%
                                    hexachlorophane;</content></subparagraph><subparagraph id="ID_1438411275205_042" name="iii" temporalId="sch10_s2_P0_D0-1_0_b_iii"><num value="iii">(iii)</num><content>other medicinal products (except those for oral
                                    administration to sheep or cattle for liver fluke disease)
                                    containing more than 0.75% hexachlorophane</content></subparagraph></subparagraph></paragraph><text>meta-Nitrophenol; ortho-nitrophenol; para-nitrophenol</text><text>Phosmet</text><text>Phosphorus, yellow</text><text class="left_indent_48 first_line_indent_-11">Sulphuric acid, except
                        substances containing not more than 70%, weight in weight, of sulphuric
                        acid<marker role="blank-line"></marker><marker role="blank-line"></marker></text></division></part><part id="ID_1438411275205_076" name="P0-1" temporalId="sch10_s2_P0-1" class="no_header"><heading class="no_header">
                    <crossHeading>Part 2</crossHeading>
                    <crossHeading>Division A<marker role="blank-line"></marker></crossHeading>
                </heading><division name="D0" temporalId="sch10_s2_P0-1_D0" id="ID_1676952994652_006"><text class="left_indent_48 first_line_indent_-11">Antihistamine substances not
                        included in Part 1 of this List; their salts; their compounds with any other
                        substance</text><text class="left_indent_48 first_line_indent_-11">Aspirin; its salts; when
                        contained in pharmaceutical products</text><text>Benzocaine when contained in condoms</text><text>alpha-Chloralose</text><text class="left_indent_48 first_line_indent_-11">Clotrimazole; its salts; when
                        contained in pharmaceutical products labelled only for the treatment of
                        tinea pedis or tinea cruris, or both</text><text class="left_indent_48 first_line_indent_-11">Ethenzamide; its salts</text><text class="left_indent_48 first_line_indent_-11">Loratadine; its salts; when
                        contained in pharmaceutical products labelled for the relief of the symptoms
                        of allergic rhinitis only</text><text class="left_indent_48 first_line_indent_-11">Nicotine when contained in
                        (a) chewing gum or lozenges, intended to be used in nicotine replacement
                        therapy and containing not more than 4 mg of Nicotine per piece; or (b)
                        patches for external application, intended to be used in nicotine
                        replacement therapy</text><text class="left_indent_48 first_line_indent_-11">Paracetamol; its salts; when
                        contained in pharmaceutical products</text><text class="left_indent_48 first_line_indent_-11">Pharmaceutical products
                        retailed in the form as supplied by the manufacturer, containing a poison
                        included in Division A of Part 1 of this List, where the proportion of the
                        poison does not exceed the equivalent of—</text><paragraph id="ID_1438411275220_014" name="a" temporalId="sch10_s2_P0-1_D0_a" class="left_indent_72 first_line_indent_-54"><num value="a">(a)</num><content>0.01% by weight of arsenic trioxide, cantharidin, cocaine, coniine,
                            ecgonine, hydrocyanic acid, strychnine, alkaloids of aconite, alkaloids
                            of coca or alkaloids of gelsemium;</content></paragraph><paragraph id="ID_1438411275220_023" name="b" temporalId="sch10_s2_P0-1_D0_b" class="left_indent_72 first_line_indent_-54"><num value="b">(b)</num><content>2%, weight in volume, of mercurochrome when contained in solutions
                            for external use only; and</content></paragraph><paragraph id="ID_1438411275220_032" name="c" temporalId="sch10_s2_P0-1_D0_c" class="left_indent_72 first_line_indent_-54"><num value="c">(c)</num><content>0.1% by weight in the case of other poisons,</content></paragraph><text class="left_indent_48">except pharmaceutical products containing any
                        poison—</text><paragraph id="ID_1438411275220_048" name="d" temporalId="sch10_s2_P0-1_D0_d" class="left_indent_72 first_line_indent_-54"><num value="d">(d)</num><content>included in <ref>Schedule 3</ref>; or <sourceNote>(<ref href="hk/2020/er5">E.R. 5 of 2020</ref>)</sourceNote></content></paragraph><paragraph id="ID_1438411275220_057" name="e" temporalId="sch10_s2_P0-1_D0_e" class="left_indent_72 first_line_indent_-54"><num value="e">(e)</num><content>in the following list—</content><content>Acetyldihydrocodeine; its salts</content><content>Alkaloids of belladonna; their salts</content><content>Alkaloids of ephedra; their salts</content><content>Atropine; its salts</content><content>Bambuterol; its salts</content><content>Benzydamine; its salts</content><content>Butropium; its salts</content><content>Codeine; its salts</content><content>Dextromethorphan; its salts</content><content>Diclofenac; its salts</content><content>Dihydrocodeine; its salts</content><content>Ethylmorphine; its salts</content><content>Fenoterol; its salts</content><content>Formoterol; its salts</content><content>Homatropine; its salts</content><content>Hyoscine; its salts</content><content>Hyoscyamine; its salts</content><content>Ipratropium; its salts</content><content>Methylaminoheptane; its salts</content><content>Morphine; its salts</content><content>Nicocodine; its salts</content><content class="left_indent_84 first_line_indent_-11">Nicotine
                            (except when contained in (a) chewing gum or lozenges, intended to be
                            used in nicotine replacement therapy and containing not more than 4 mg
                            of Nicotine per piece; or (b) patches for external application, intended
                            to be used in nicotine replacement therapy); any compound containing the
                            chemical structure of 3-(1-methylpyrrolidin-2-yl)pyridine substituted to
                            any degree or without substitution</content><content>Norcodeine; its salts</content><content>Orciprenaline; its salts</content><content>Papaverine; its salts</content><content>Phenylpropanolamine; its salts</content><content>Pholcodine; its salts</content><content>Procaterol; its salts</content><content>Salmeterol; its salts</content><content>Terbutaline; its salts</content><content>Tretoquinol; its salts</content></paragraph><text class="left_indent_48 first_line_indent_-11">Phenazone; its salts</text><text class="left_indent_48 first_line_indent_-11">Phenols as defined in Part 1
                        of this List in substances containing less than 60%, weight in weight, of
                        phenols; compounds of phenol with a metal in substances containing less than
                        the equivalent of 60%, weight in weight, of phenols</text><text class="left_indent_48 first_line_indent_-11">Propyphenazone; its
                        salts</text><text class="left_indent_48 first_line_indent_-11">Salicylamide; its salts; when
                        contained in pharmaceutical products</text><text class="left_indent_48 first_line_indent_-11">Steroid compounds with
                        androgenic or oestrogenic or progestational activity; their esters; when
                        contained in a preparation intended to be taken orally for contraceptive
                        purposes only and each dose of the preparation contains not more than the
                        following—</text><text class="left_indent_60">0.15 mg of Desogestrel;</text><text class="left_indent_60">3.00 mg of Drospirenone;</text><text class="left_indent_60">0.05 mg of Ethinyloestradiol;</text><text class="left_indent_60">0.10 mg of Gestodene;</text><text class="left_indent_60">0.25 mg of Levonorgestrel;</text><text class="left_indent_60">2.50 mg of Lynoestrenol;</text><text class="left_indent_60">0.05 mg of Mestranol;</text><text class="left_indent_60">1.00 mg of Norethisterone;</text><text class="left_indent_60">0.25 mg of Norgestimate; and</text><text class="left_indent_60">0.50 mg of Norgestrel</text><text class="left_indent_48 first_line_indent_-11">Terbinafine; its salts; when
                        contained in preparations for external application only with no more than 1%
                        of Terbinafine and not to be administered as a single application and when
                        labelled only for the treatment of tinea pedis or tinea cruris, or
                        both</text><sourceNote>(<ref href="hk/2015/ln234">L.N. 234 of 2015</ref>; <ref href="hk/2015/ln235">L.N. 235 of
                        2015</ref>; <ref href="hk/2022/ln194">L.N. 194 of
                        2022</ref>; <ref href="hk/2024/ln105">L.N. 105 of
                        2024</ref>; <ref href="hk/2024/ln177">L.N. 177 of
                        2024</ref>)</sourceNote></division><crossHeading>Division B<marker role="blank-line"></marker></crossHeading><division name="D0-1" temporalId="sch10_s2_P0-1_D0-1" id="ID_1676952994701_007"><text>Ammonia</text><text class="left_indent_48 first_line_indent_-11">gamma-Benzene hexachloride
                        (1,2,3,4,5,6-hexachlorocyclo-hexane)</text><text>Diamines, the following; their salts—</text><text class="left_indent_72 first_line_indent_-11">Phenylene diamines; toluene
                        diamines; other alkylated-benzene diamines</text><text>Formaldehyde</text><text>Formic acid</text><text>Hydrochloric acid</text><text class="left_indent_48 first_line_indent_-11">Hydrofluoric acid; alkali
                        fluorides; alkali metal bifluorides; ammonium bifluorides; sodium
                        silicofluoride</text><text>Metallic oxalates</text><text>Nitric acid</text><text>Nitrobenzene</text><text>Phosphoric acid</text><text>Potassium hydroxide</text><text class="left_indent_48 first_line_indent_-11">Products retailed in the form
                        as supplied by the manufacturer, containing a poison included in Division B
                        of Part 1 of this List, where the proportion of such poison does not exceed
                        the equivalent of 0.1%</text><text>Sodium hydroxide</text><text>Sodium nitrite</text><sourceNote class="align_right">(<ref>Schedule 10</ref> added <ref href="/hk/2015/2">2 of 2015 s. 71</ref>. <ref href="hk/2015/er3">E.R. 3
                            of 2015</ref>)</sourceNote></division></part></section></schedule></main></subLeg>